<SEC-DOCUMENT>0001703057-23-000008.txt : 20230504
<SEC-HEADER>0001703057-23-000008.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504165745
ACCESSION NUMBER:		0001703057-23-000008
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbCellera Biologics Inc.
		CENTRAL INDEX KEY:			0001703057
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39781
		FILM NUMBER:		23889747

	BUSINESS ADDRESS:	
		STREET 1:		2215 YUKON STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Y 0A1
		BUSINESS PHONE:		(604) 559-9005

	MAIL ADDRESS:	
		STREET 1:		2215 YUKON STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Y 0A1
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abcl-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:650343a1-ca86-4cd1-b410-9b387e72615d,g:7bff7bb1-4386-4395-9d16-110d609544b1,d:25d26736ba6e4b0989ccc984f8a74878--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:abcl="http://www.abcellera.com/20230331" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abcl-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF8yLTEtMS0xLTYyNQ_b2b453e9-0c10-47bf-96a7-544e598e5e19">0001703057</ix:nonNumeric><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF8zLTEtMS0xLTYyNQ_b7bf18f5-7b0b-48ad-a5df-a2c93ad3a5d4">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF80LTEtMS0xLTYyNQ_fdbc682c-f528-4104-9c05-390df847fc71">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF81LTEtMS0xLTYyNQ_19964943-ceda-47f0-a707-0f5b8653709b">2023</ix:nonNumeric><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF82LTEtMS0xLTYyNQ_114cdad7-b9c9-467d-8d57-f9eb840ecad5">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abcl-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1073262526243f4a574de999c567cbb_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i737052aafe7343188b2138b8a10bd9ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iafcf79187f5d43869ccc9becf7aeccc4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:ResearchFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c835c1ffc64e5f833ad6c4e166b620_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:ResearchFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483c9c91d20d4152999b9b47124960fa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf11690d32474d71aec19ceb33d3618d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab73ed844c554fa19226ae861475ca07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf0bf68b36f4153b40b11c6cbdcbeb0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:MilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1eb70ee5544c889039a3a33f6a3ca1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70268a9464e4e829f619d4233df421f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbafe87c3597488486483c87064dca70_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248effdeb0124e28aff3eb04055b2003_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2aa801be5c4f8790c550d3f085d3f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2795c9a5ca65468f89a3330586c261c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f8fc50fe69495fbd3d33c5d2974485_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9aa34c517e046d7ab19dbcb1dd308f2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780148e6ee1845b8ae18bb190fa364c0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba57c3ec41b7436fa87687bff535045e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78911cd59bb34e02911e888b48446aaa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4c8a76d406402399f79719acbd035e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d27bab226214438b0d7f573c20ee26e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea9ff625cec4672a5d93fbfed8791f3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ea95c9d57e45c98f3caedf608c417f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0decdf41be2e4a30ae97c1a91fa5b593_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6682fd53d24996a9444b260c02f16e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95249fd386d947d39d33c4ef4a83d14e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i861d96426dca41259dd492868210425f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6732b5466cb84d3c9b86f94b68a032d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae52bf585f2406684f9101c92e3ed0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82fb29d006754942a2f5913a08541ed7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91864d811230449ab2c770081bffde09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a2304c602314a149a3829e4bb16839d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63526f8d447e49f5851992c00795cb56_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c1534cce0324615ba2ea393852c6c61_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9615a195ad1a4b138c452ec64af6a8b7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e59f6941600414cacd5ce35743135eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4889d91d341e4ab8b818801f569b0d96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a0bae74c9743ff8ff66ad8ff963146_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6139469318d432e82d6baefdf566dce_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e371e7d54148dbba3063693fd8a2d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e470366e74a442c8d52acc2a9f1b5f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf93e4e7dd64c7e839faca3ad8410d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406b6a1622cd4dff99832c9462b6e4a7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1c38a1157c413c866c668dd92b9a77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d27a736c37340be83efab3ba99a8bc0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c66215525a40069a548e7bd3025c84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a403b1fa38d47ada5644a9f4c1fff58_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853afd911efa4258a08a6952094096cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d0ae58e07dc4eb983249c3c61c1ad45_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if039c44ad3504f63aa1ec431499bafec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">abcl:LicenseBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5caae842c49f4155ad44dff34efdb797_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jointventure"><xbrli:measure>abcl:jointVenture</xbrli:measure></xbrli:unit><xbrli:context id="ia507651da5b4472a9bda28dcdad3b575_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0148f1e33c6b4510b7104f707a9f1015_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a7c5f735ad47f2ad483da48085449d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7dd7959a16f4e469b26e2d1a0a91144_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i6bfea07b5a744d6596d3882f182d5906_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5e482b7eb34446b5095f10b3fbcd1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47a8affab5e347a4b46782717c4df146_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcee6e4ab663465bac83ebdfecfc71e5_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:NewDayluLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:NewDayluLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ffacd78e54c008bb62a070d409d8e_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:NewDayluLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib925185cbb614e71b24a62dc39dc9707_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb8630f96284448a0ad62c00db72975_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a27eee6bb20488893688edd304543db_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21720092b1fd485a91d701040dc8eaf4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:PreInitialPublicOfferingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:PreInitialPublicOfferingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7615a3703fc444c5bf358dc8748655b8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:PreInitialPublicOfferingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a61c2a4c454272afe77744cf55c9ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2858e48f05f04827941d142a021d6fad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f5814bf79942159d756fd4d496dc6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5c3602feb942b29d99d1347ccefffa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4cf5d989e9741afb07a70513b1e2a5b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4fd149aa8c46f3800472cd46fa49e2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7c7469d9e04930b97b96e58ef2f063_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if605d90125084846a2a1044b2692e5de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic528446a6c1c4f6d8b57c3c9e62fb472_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf8dcc696b24c26bf569ab099f74655_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib84a76c6a7d040048417a102641bdd98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22756f6454b64f73afb36c0c807ea9d5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df4d4b94b884162a2e0a0a1c655b8a8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a81d06f8df44d5835bbc3c04f6a927_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5b507a22fd14249969fb3270137dd02_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974a95ee817c4dfaa7fe8e4fd9971189_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c6977e90834eb3bd8b3526452e9e35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1de9aa8ab44841868c7d65c602095235_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87414b0fe0f34080ae5ec5e948eafda6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d15a4aeba64cd299c7371834bb7abf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441987f8eb1e43f5b29f11eb02f70403_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ad3bc7b19842bea7e2bec41c9cce9d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f397da2a35b4cce8dcf8e1c494f9789_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cae519cf0de46818efc75457121e175_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3827504d1bb4416a966243425ee8a0f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id80012107add40658f9e2fb319a4e721_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c929c76a9ad4321bf79186a9b2ab1dc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4ad46a8dd94eaa84a356553b207755_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aad9e0f529743d0a71e223bfe29146f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb27a06184e4e31aef700c5aeb48dca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7ef1452afe4c4580b20216f9d426d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35bb901c7d87467e8fac6a7c4651c882_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa9fc66c28764293b5cdc58bd4e86731_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie292ab553fbb4ec4855d3b8096d93cc7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06261a683538461bbd86190f85931bf5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5785a70c9934456af3fe1177ffc0ee5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i303bc5d507cc4c54a23fba781ae5f340_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac73633a71d4e618363eb56e2a3a253_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6594a7d2aa24288ab622eea92cdeba3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb33227ca5de4db4a6b3eb5329ce0367_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886bb35d7ce64dcb868325a77ed5372c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea3fcbfe06448049f8dbed1665c5eac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1548cfd0b12440e2824883003e410515_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820f7b961f97462e883d5674468dcf5b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied7de4ead6ad466a85824c3b11e8d10c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b8461fe0bdb4ab585ffcc851e599cee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc26d6dc7a2499380b2727bb7a926fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb56c4d8b7ae4aaca71bb026b154f0b8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f895582ef4c48da9ac1da31b476fc7f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abcl:AccruedRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92c33e75ce64416b44d79aa0e9d2f2a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abcl:AccruedRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d9776d15fb44e9aa31ce79baa8cec0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abcl:PhaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic267a77a490446c98ef71777d2d5ff57_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001703057</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abcl:PhaseTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtMi0xLTEtNTI3Mg_92991d6a-4576-4aff-9f76-c58a694b9f37 id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtNC0xLTEtNTI3Mg_8f017ef4-53a5-4490-b845-0a1c9b225309 id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItMi0xLTEtNTI3Mg_c3cf669d-13d6-4d81-b4c7-ba4c94b8ed6e id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtMi0xLTEtNTI3Mg_03186103-5cfd-49b5-b43a-ec82449b0862 id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtNC0xLTEtNTI3Mg_48bb8f30-f569-41ba-a070-20906208da85 id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItNC0xLTEtNTI3Mg_24f5017c-e041-4c75-9d3a-f8174654d497" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i25d26736ba6e4b0989ccc984f8a74878_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE1_5b45b7bc-860b-4bcc-97f0-43a3a4460617">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6NjNkNDg2OGQ2ZWRhNGYwMWEwYWI2ZTQyNWI5ZDBkOWEvdGFibGVyYW5nZTo2M2Q0ODY4ZDZlZGE0ZjAxYTBhYjZlNDI1YjlkMGQ5YV8wLTAtMS0xLTYyNQ_1e3383b3-6555-49df-920b-2493c83221b6">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yNDk_718873a8-bb64-4971-867c-60d18c9ca4eb">March 31, 2023</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6M2M4N2JlNWVmNzllNDM3YTkwZThjZDA2YTk0N2E5NzcvdGFibGVyYW5nZTozYzg3YmU1ZWY3OWU0MzdhOTBlOGNkMDZhOTQ3YTk3N18wLTAtMS0xLTYyNQ_9b25f04d-4cbf-4b5e-926d-3f55070b0356">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _________ to _________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE2_38c692a2-10e2-41be-9d19-eaf25b3fb71f">001-39781</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE3_c7c29ff3-2075-4428-9b04-a4d196e136f3">AbCellera Biologics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8wLTAtMS0xLTYyNQ_3e6eb76b-498e-4de3-b677-f1e9daf5b653">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">( State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTAtMS0xLTYyNS90ZXh0cmVnaW9uOmExODQ0ZGE0NTc3NDRlZWU4YjM4NjVlZDFiMjAzMDU5XzQ_ba197f2f-16ba-4af8-83ec-fedd033f221f">2215 Yukon Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTAtMS0xLTYyNS90ZXh0cmVnaW9uOmExODQ0ZGE0NTc3NDRlZWU4YjM4NjVlZDFiMjAzMDU5Xzc_27c22b4d-f530-43b1-ac1d-c53e099c0ded">Vancouver</ix:nonNumeric>, <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTAtMS0xLTYyNS90ZXh0cmVnaW9uOmExODQ0ZGE0NTc3NDRlZWU4YjM4NjVlZDFiMjAzMDU5XzEx_d3a3c69a-640f-4a62-b427-30eff0d84f14">BC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTEtMS0xLTYyNQ_eae27411-50d0-4348-8110-840ab8d2d517">V5Y 0A1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N181OTY_d9c3bfc9-cffc-4ee1-95e9-7154b726f9b9">604</ix:nonNumeric>) <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N182MDA_dd9d44e5-bf67-4224-8bd5-b29edbfa2185">559-9005</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-top:4pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OWEzYzlhYzIyYWZjNGFiMGE0NWVjMWI1NjA3MTFkZGUvdGFibGVyYW5nZTo5YTNjOWFjMjJhZmM0YWIwYTQ1ZWMxYjU2MDcxMWRkZV8xLTAtMS0xLTYyNQ_ab2eaccb-1710-46ba-8702-6bf6c210ecbf">Common shares, no par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OWEzYzlhYzIyYWZjNGFiMGE0NWVjMWI1NjA3MTFkZGUvdGFibGVyYW5nZTo5YTNjOWFjMjJhZmM0YWIwYTQ1ZWMxYjU2MDcxMWRkZV8xLTItMS0xLTYyNQ_4e5eee13-ca07-458f-82b6-894278fb8912">ABCL</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OWEzYzlhYzIyYWZjNGFiMGE0NWVjMWI1NjA3MTFkZGUvdGFibGVyYW5nZTo5YTNjOWFjMjJhZmM0YWIwYTQ1ZWMxYjU2MDcxMWRkZV8xLTQtMS0xLTYyNQ_6dfecf6b-99bd-44bd-a741-e50659c2ad93">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE4_c08931df-369e-4889-8d72-95aad4088170">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE5_0005fa26-89d8-4de2-a6dd-b78b2e71ac65">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OTliZWY2MmE0ZWZjNDQzYjk0YjI0ZWNiOTFkYzQ0NjQvdGFibGVyYW5nZTo5OWJlZjYyYTRlZmM0NDNiOTRiMjRlY2I5MWRjNDQ2NF8wLTAtMS0xLTYyNQ_64fe6f41-0b74-4e20-b964-cb847a34a916">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OTliZWY2MmE0ZWZjNDQzYjk0YjI0ZWNiOTFkYzQ0NjQvdGFibGVyYW5nZTo5OWJlZjYyYTRlZmM0NDNiOTRiMjRlY2I5MWRjNDQ2NF8yLTQtMS0xLTYyNQ_dcc8d324-dc54-4e18-bb90-b5b07b103590">o</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OTliZWY2MmE0ZWZjNDQzYjk0YjI0ZWNiOTFkYzQ0NjQvdGFibGVyYW5nZTo5OWJlZjYyYTRlZmM0NDNiOTRiMjRlY2I5MWRjNDQ2NF80LTEtMS0xLTYyNQ_55e2041c-14ff-49a5-87ab-fd1d71124d16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18zODQ4MjkwNjk5NTA1_870d3e27-57ad-4ef7-9d50-8f9e5875fb5b">x</ix:nonNumeric></span></div><div style="margin-top:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May&#160;1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="ia1073262526243f4a574de999c567cbb_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMTU3_9a781f27-76e5-4ea7-8d2c-8bb35743a5c4">288,728,094</ix:nonFraction> common shares, no par value per share, outstanding.</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:12.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_13">PART I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_25">Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_28">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_76">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_106">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_106">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_109">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_109">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_109">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_112">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_112">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_115">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_115">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_115">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_448">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_448">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_121">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_121">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_124">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_124">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_124">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_127">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_127">69</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i25d26736ba6e4b0989ccc984f8a74878_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25d26736ba6e4b0989ccc984f8a74878_130">70</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of the Material and Other Risks Associated with Our Business </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous material and other risks and uncertainties. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report, including our financial statements and related notes hereto. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. The risks and uncertainties described below may change over time and other risks and uncertainties, including those that we do not currently consider material, may impair our business. These risks include, but are not limited to, the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred losses in certain years since inception and we may not be able to generate sufficient revenue to maintain profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and stock price. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial success depends on the quality of our antibody discovery and development engine and the acceptance by new and existing partners in our industry. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to execute our business strategy could adversely impact our growth and profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot maintain and expand current partnerships and enter new partnerships that generate discovery programs for antibodies, our business could be adversely affected. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Development of a biologic is inherently uncertain, and it is possible that none of the antibody drug candidates discovered using our antibody discovery and development engine that are further developed by our partners will receive marketing approval or become viable commercial products, on a timely basis or at all. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The failure of our partners to meet their contractual obligations to us could adversely affect our business. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to manage our current and future growth effectively, which could make it difficult to execute on our business strategy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have invested, and expect to continue to invest, in research and development efforts that further enhance our antibody discovery and development engine. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs with the antibodies that we have discovered, and the price of our common shares may decline as a result of announcements of unexpected results or developments. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common shares to decline. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The life sciences and biotechnology platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upgrading and integrating our business systems could result in implementation issues and business disruptions.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for our technology, including our discovery and development engine and Celium, our proprietary antibody visualization software, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our data packages may be impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales of a substantial number of our common shares in the public market could cause our share price to fall significantly, even if our business is doing well.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties contained in Part II, Item 1A, Risk Factors, together with all other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other filings with the Securities and Exchange Commission, or the SEC, before investing in our common stock. Any of the risk factors we describe below under Part II, Item 1A, Risk Factors, could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common shares. Additional risks that are currently unknown to us or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See &#8220;Forward-Looking Information&#8221; in this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbCellera Biologics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(All figures in U.S. dollars. Amounts are expressed in thousands except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMy0xLTEtMS02MjU_0e58cdc8-330a-46a7-ba20-e2ee3c9a16f5">386,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMy0zLTEtMS02MjU_12d79a0b-7bab-4a1d-b43b-0b140936c32a">193,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNC0xLTEtMS02MjU_d80ab5ce-0408-4686-8c1c-babb33c3e580">499,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNC0zLTEtMS02MjU_cf018f7f-e8aa-4dfc-b48b-9d526f0b4c22">603,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31.6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="abcl:CashCashEquivalentsAndMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNS0xLTEtMS02MjU_39a91533-fb46-43b2-95b4-88d49ec8aa2d">886,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="abcl:CashCashEquivalentsAndMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNS0zLTEtMS02MjU_ac271066-30c2-45f9-992d-d6d8b68f078e">796,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts and accrued receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="abcl:AccountsAndAccruedReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNi0xLTEtMS02MjU_ab3a7b97-c6c2-45e3-9023-7204a663e8cc">38,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="abcl:AccountsAndAccruedReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNi0zLTEtMS02MjU_a4bc73f7-694e-4688-b370-4b00448540d3">20,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNy0xLTEtMS02MjU_419536ad-a200-4352-9185-6488e1bc9db1">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNy0zLTEtMS02MjU_0da087ef-22c3-42c7-93ee-82cd41524ead">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOC0xLTEtMS02MjU_fa7fa2bf-4fdf-426e-99d7-32c26393d560">75,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOC0zLTEtMS02MjU_fbd6a14c-5198-42dd-b562-f82e911b6ed9">99,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOS0xLTEtMS02MjU_d30a375b-af10-4a60-96dd-3a4e5db7d5c7">1,025,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOS0zLTEtMS02MjU_b43eabbd-12cc-4c51-9a14-e0253ba8ad3c">940,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTEtMS0xLTEtNjI1_b9d384b5-de7b-4a81-9fdf-d4d014afe829">217,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTEtMy0xLTEtNjI1_1778a8a9-2c42-4b1b-9dc6-cda366d8924d">233,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTItMS0xLTEtNjI1_8cb7eff9-b5f4-4fb0-9fae-7e20078f2937">131,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTItMy0xLTEtNjI1_0396c864-5b0a-41be-bce6-03804c66e14b">128,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTMtMS0xLTEtNjI1_84347aff-4ebf-404e-8101-849393567df3">47,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTMtMy0xLTEtNjI1_b102d6ea-2601-4c96-ab01-897ff156125d">47,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in and loans to equity accounted investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTQtMS0xLTEtNjI1_a6c5f204-905f-42c5-85ce-96f5bce7a06b">72,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTQtMy0xLTEtNjI1_48afe048-d9aa-4ef0-a191-8df1fe803c8c">57,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTUtMS0xLTEtNjI1_db21ba93-a88b-4c6a-a784-2b23ddb9dc5a">46,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTUtMy0xLTEtNjI1_6e3a1949-09bd-431c-84a4-89d5c5c4f7ae">89,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTYtMS0xLTEtNjI1_6eea3e16-304f-4df4-a990-3dae7c1657f6">515,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTYtMy0xLTEtNjI1_2b524ce1-38f3-4c78-b1a3-fc407b261925">557,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTctMS0xLTEtNjI1_98919697-e5b4-4d15-ad0b-0670baf1ab71">1,540,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTctMy0xLTEtNjI1_f7d24a67-b034-4133-88fd-88d005a2ad8e">1,497,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjAtMS0xLTEtNjI1_f6844eee-eb19-408b-9560-51c0a78c268c">33,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjAtMy0xLTEtNjI1_115372f9-fe9e-4c18-b8a7-52d544869747">31,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjEtMS0xLTEtNjI1_9dae4a5d-a3f2-4984-9880-32d36f848fec">44,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjEtMy0xLTEtNjI1_ce8d693f-d291-4f5e-bac2-3d3a9e4347f7">42,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjMtMS0xLTEtNjI1_dc09315c-f4c7-48d9-a1b5-92001aaa1f52">19,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjMtMy0xLTEtNjI1_0a67d608-1cce-4dd1-941b-8f086ab2742b">3,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjQtMS0xLTEtNjI1_ed733309-04d8-4e76-8ef5-739d19fe0f6c">21,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjQtMy0xLTEtNjI1_ebacd8e5-1e8e-4ddb-8e9f-8f03758025b1">11,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjUtMS0xLTEtNjI1_28d00cf4-aa68-4993-846d-579775117fbd">118,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjUtMy0xLTEtNjI1_bb6ddbf7-e295-4715-8a9f-4152f7697341">89,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjctMS0xLTEtNjI1_e7c6d6dc-40a1-4686-835e-d99e2d941d0f">76,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjctMy0xLTEtNjI1_92534478-23a9-4ec3-8d46-b987959aa60b">77,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjgtMS0xLTEtNjI1_d967712f-656a-4d72-a188-44bfd509b35a">19,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjgtMy0xLTEtNjI1_9b3d020d-c863-4152-b42d-e84012336c56">25,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="abcl:DeferredGrantsFundingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjktMS0xLTEtNjI1_49cab5ed-b9e4-4e1f-a6a9-9d362cfefbe6">40,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="abcl:DeferredGrantsFundingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjktMy0xLTEtNjI1_b20c8aba-337b-45a8-994e-582f069c91cf">45,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzAtMS0xLTEtNjI1_c2fda527-00a2-42b3-8cde-397d6ff59a49">16,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzAtMy0xLTEtNjI1_5de7e296-10c8-4bcb-9b76-6b152870229c">15,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzEtMS0xLTEtNjI1_2e99db13-2978-48bf-9505-f3cb2bee2873">33,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzEtMy0xLTEtNjI1_58d7c1b2-fe7d-4ecb-9a9f-5e74f5450ee8">33,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzItMS0xLTEtNjI1_9f77d2c7-1877-477a-8ab1-bfa7778bb05f">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzItMy0xLTEtNjI1_6be13418-bf5c-4cf8-9bf6-12c148c164f4">2,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzMtMS0xLTEtNjI1_94480b82-7fee-487b-993c-c87370b01ed1">189,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzMtMy0xLTEtNjI1_4ae6d5b5-26f7-43dc-8ea4-ee020dca22c8">199,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzQtMS0xLTEtNjI1_02559a2d-f448-40f5-ad39-50ab5076cab4">307,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzQtMy0xLTEtNjI1_95faedd3-4170-4c16-98d3-a7fa5eee5e57">289,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzUtMS0xLTEtNDY3Mw_4fc660bb-dacb-4bc3-a9b0-58793f405f9c"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzUtMy0xLTEtNDY3Mw_93ff381f-2943-43e7-af0e-770ac7470da1"></ix:nonFraction></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:19.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares: <ix:nonFraction unitRef="usdPerShare" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MjM0_884a9f86-0396-4948-8c45-2629c662dc38"><ix:nonFraction unitRef="usdPerShare" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="INF" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MjM0_c2d7fd58-55d4-4f9c-9855-1430d7c93975">no</ix:nonFraction></ix:nonFraction> par value, unlimited authorized shares at December&#160;31, 2022 and March&#160;31, 2023: <ix:nonFraction unitRef="shares" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTYz_a4669c9b-bb03-4b2f-b241-d879dcd4d34a"><ix:nonFraction unitRef="shares" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTYz_b10a30c7-9e7e-4ee6-8ac8-0f2a53ab9a81">286,851,595</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTc5_1a371ae5-813d-4b75-9227-a9f9a84eab6f"><ix:nonFraction unitRef="shares" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTc5_1f87a6a4-c2e3-47dd-b753-7c52b82db2cf">288,426,514</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and March&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMS0xLTEtNjI1_bd6e2ad0-7df0-4b2b-8631-88827e0b19e2">734,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMy0xLTEtNjI1_1fdad94b-1233-48a3-82ed-b254e9dcdba9">742,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzgtMS0xLTEtNjI1_60593a9d-9e16-43ea-a1ca-00cb03b553d8">74,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzgtMy0xLTEtNjI1_c3a40283-dc65-45a2-bbc2-585da673d93d">81,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzktMS0xLTEtNjI1_6f6e83f0-0326-40dd-803b-3033d88e24bd">1,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzktMy0xLTEtNjI1_c20ba869-7abc-4396-9cfe-9e88fa62c51c">2,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDAtMS0xLTEtNjI1_15fca4f0-ef8c-4dd8-96cb-3fbe1a4e5019">426,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDAtMy0xLTEtNjI1_9eedcebd-7fe7-49e7-90a0-b0734a268b3b">386,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDEtMS0xLTEtNjI1_46afdf34-f475-476e-8be4-017ca5d95a2d">1,233,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDEtMy0xLTEtNjI1_9ee26a98-16b8-49b9-958f-47dcf5393dae">1,208,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and shareholders' equity</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDItMS0xLTEtNDY2MQ_de5ec490-f127-4ed1-a67f-233434edf517">1,540,907</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDItMy0xLTEtNDY2MQ_50126fff-a672-432e-ac39-c9bfd55bbeee">1,497,919</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbCellera Biologics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.874%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iafcf79187f5d43869ccc9becf7aeccc4_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMy0yLTEtMS01Mjcy_fac34c1e-6792-4ee5-8c73-ab347c7876a5">9,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic5c835c1ffc64e5f833ad6c4e166b620_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMy00LTEtMS01Mjcy_9d298a08-2321-41c1-8cc1-cba6a8897629">10,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i483c9c91d20d4152999b9b47124960fa_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNC0yLTEtMS01Mjcy_0c803a73-d319-4751-84c8-b016f2e94986">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf11690d32474d71aec19ceb33d3618d_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNC00LTEtMS01Mjcy_85f4c81e-01c6-4334-a66b-b24d731849ed">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab73ed844c554fa19226ae861475ca07_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNS0yLTEtMS01Mjcy_580c00e0-2738-4500-8d2e-aefc42647351">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf0bf68b36f4153b40b11c6cbdcbeb0_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNS00LTEtMS01Mjcy_c1529981-9048-4cb8-b0f1-0be74315ebc0">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b1eb70ee5544c889039a3a33f6a3ca1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNi0yLTEtMS01Mjcy_aeb439c2-526e-4044-bfac-3efd249e33f9">307,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic70268a9464e4e829f619d4233df421f_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNi00LTEtMS01Mjcy_7c90228e-27f0-4ff2-b754-a8a2a31d166f">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNy0yLTEtMS01Mjcy_31dd9b27-476a-488c-8b30-29f8be70c58e">316,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNy00LTEtMS01Mjcy_865a47b4-3d5e-4a2f-9224-885558a818f8">12,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfOS0yLTEtMS01Mjcy_580a4899-995b-4cbe-9180-131d7e30725c">44,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfOS00LTEtMS01Mjcy_914d9c64-c2aa-41ca-8597-d81236d63383">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtMi0xLTEtNTI3Mg_92991d6a-4576-4aff-9f76-c58a694b9f37">26,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtNC0xLTEtNTI3Mg_48bb8f30-f569-41ba-a070-20906208da85">52,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtMi0xLTEtNTI3Mg_03186103-5cfd-49b5-b43a-ec82449b0862">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtNC0xLTEtNTI3Mg_8f017ef4-53a5-4490-b845-0a1c9b225309">3,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItMi0xLTEtNTI3Mg_c3cf669d-13d6-4d81-b4c7-ba4c94b8ed6e">14,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItNC0xLTEtNTI3Mg_24f5017c-e041-4c75-9d3a-f8174654d497">15,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTMtMi0xLTEtNTI3Mg_fd98afbe-e5b5-4c56-9469-f232f76bca34">3,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTMtNC0xLTEtNTI3Mg_c1b5dffc-577f-4e3a-ab33-9ddebed239f0">5,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTQtMi0xLTEtNTI3Mg_741da06d-7c78-4b0f-937b-6be104dd2da0">91,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTQtNC0xLTEtNTI3Mg_3f015d6b-50a8-4f8c-b84b-bd92296f9ea9">77,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTUtMi0xLTEtNTI3Mg_335d98f2-f460-4c58-b733-d9745c6046db">224,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTUtNC0xLTEtNTI3Mg_c2648e79-b689-48f0-902f-66ab5ae3715e">64,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctMi0xLTEtNzg1Mw_63a204c8-6df4-48b0-b854-9cdd01098186">665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctNC0xLTEtNzg1Mw_da44feac-0401-4550-9175-9a1bd9610cd9">9,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants and incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:GrantsAndIncentives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctMi0xLTEtNTI3Mg_917abbf7-cbc2-4d11-a3d5-1f3d8674021e">5,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:GrantsAndIncentives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctNC0xLTEtNTI3Mg_bc90a314-8457-473d-a14b-1bf426d4ad45">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTgtMi0xLTEtNTI3Mg_b66f382e-7053-4b27-b17f-2a892a75535d">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTgtNC0xLTEtNTI3Mg_8a14ab24-714e-4264-8fa3-7f89fb937b04">3,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTktMi0xLTEtNTI3Mg_12183add-9808-48de-bbd8-1c1eba3a0dc7">5,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTktNC0xLTEtNTI3Mg_c2954735-6486-452c-8cc0-736df7d5e06a">16,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) before income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjAtMi0xLTEtNTI3Mg_531ad2af-6dc0-4582-a1d5-20c5d1e3821e">230,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjAtNC0xLTEtNTI3Mg_fe0f1eb6-0cc7-419e-bb65-49a749f5cc06">48,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (recovery) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjEtMi0xLTEtNTI3Mg_c5f64262-8d88-4ad0-9d04-780cadc53594">62,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjEtNC0xLTEtNTI3Mg_666e06ce-0a89-4758-8349-dc7a72602340">8,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjItMi0xLTEtNTI3Mg_68c90130-cb7c-4558-966a-df057cf07255">168,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjItNC0xLTEtNTI3Mg_80790802-1b8e-4cac-ab86-e1d999ffb554">40,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjMtMi0xLTEtNTI3Mg_d2adac40-4760-4e85-b366-3d237b7a1e24">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjMtNC0xLTEtNTI3Mg_fdc81f18-eda5-4c29-9dc7-84fd6a11e230">630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjQtMi0xLTEtNTI3Mg_0c82c9c7-480c-49a0-a801-a9f3e62dc9a6">169,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjQtNC0xLTEtNTI3Mg_750eca68-203e-4687-8e7b-80b84b27ae3f">40,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjctMi0xLTEtNTI3Mg_741c8e7b-2aef-4dd9-8069-ace3f33dca84">0.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjctNC0xLTEtNTI3Mg_9d7bfd9e-dd6b-4296-bcae-0d54e3350fe9">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjgtMi0xLTEtNTI3Mg_1083b138-72f2-4143-9701-f826959d786b">0.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjgtNC0xLTEtNTI3Mg_0783ae2e-4a34-41d4-bd46-a286880e7411">0.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzAtMi0xLTEtNTI3Mg_c19ad758-6c4d-4167-92bf-bbe195f7e674">283,895,020</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzAtNC0xLTEtNTI3Mg_39aae419-e13d-4a91-adc3-686f3515b118">287,767,136</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzEtMi0xLTEtNTI3Mg_b77023ed-a45d-49db-a37d-09fecac467d2">311,482,017</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzEtNC0xLTEtNTI3Mg_0b3a069a-8e4a-4a52-ac17-3243269f80fb">287,767,136</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.25pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0" footnoteRole="http://www.xbrl.org/2003/role/footnote">Exclusive of depreciation and amortization</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbCellera Biologics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(All figures in U.S. dollars. Amounts are expressed in thousands except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:33.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.197%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-in <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i248effdeb0124e28aff3eb04055b2003_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtMi0xLTEtNTA5NQ_00015d0f-d349-487d-89f7-b17f9f8f4e6b">286,851,595</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i248effdeb0124e28aff3eb04055b2003_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtNC0xLTEtNTA5NQ_956d748d-c756-4b44-bdfc-e6396cd8ef26">734,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iac2aa801be5c4f8790c550d3f085d3f9_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtNi0xLTEtNTA5NQ_9962425e-d8f7-4b74-8533-02c58d8149f5">74,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2795c9a5ca65468f89a3330586c261c6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtOC0xLTEtNTA5NQ_97eadc34-f9b2-4f6b-9b40-9ab5b89c2769">426,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic8f8fc50fe69495fbd3d33c5d2974485_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtMTAtMS0xLTUwOTU_feb06ef7-06fc-447c-add5-d26c4e642eda">1,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtMTItMS0xLTUwOTU_1d49f7ea-4aa8-43a9-acb2-0565b99817e3">1,233,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares issued and restricted stock units ("RSUs") vested under stock option plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id9aa34c517e046d7ab19dbcb1dd308f2_D20230101-20230331" decimals="INF" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItMi0xLTEtNTA5NQ_95499721-6522-450f-876a-337a7180ac80">1,574,919</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id9aa34c517e046d7ab19dbcb1dd308f2_D20230101-20230331" decimals="-3" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItNC0xLTEtNTA5NQ_b793a583-b87b-42c5-bbe8-1acfcb31f3b0">8,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i780148e6ee1845b8ae18bb190fa364c0_D20230101-20230331" decimals="-3" sign="-" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItNi0xLTEtNTA5NQ_cc04ec0c-aa8e-4545-8ed8-51b6d1168067">7,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItMTItMS0xLTUwOTU_68226ed1-6045-445d-8e18-bd2a7dde9a6a">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i780148e6ee1845b8ae18bb190fa364c0_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjMtNi0xLTEtNTA5NQ_e329166b-4baf-41b4-9a0d-ec7ab780e61b">15,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjMtMTItMS0xLTUwOTU_f10c763e-f066-4831-a82e-2eec1599c73b">15,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iba57c3ec41b7436fa87687bff535045e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjQtMTAtMS0xLTUwOTU_c7a105c1-503c-428f-9d49-cb9e3272e74d">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjQtMTItMS0xLTUwOTU_b7862502-325e-412b-a675-d46ed7448e2e">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i78911cd59bb34e02911e888b48446aaa_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjUtOC0xLTEtNTA5NQ_a4ea3288-b306-4426-ab9f-1b7a564bc1cc">40,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjUtMTItMS0xLTUwOTU_0c246bb7-9ac2-4f97-92d7-8c3046f02296">40,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifb4c8a76d406402399f79719acbd035e_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtMi0xLTEtNTA5NQ_d34aa2da-74a7-4142-8d14-83aaca52ac4d">288,426,514</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifb4c8a76d406402399f79719acbd035e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtNC0xLTEtNTA5NQ_8ce9b8fe-68fa-4d87-a0cd-d9e36b514026">742,816</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d27bab226214438b0d7f573c20ee26e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtNi0xLTEtNTA5NQ_c25760bf-8c75-43a8-82d1-4f65856d83d8">81,630</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idea9ff625cec4672a5d93fbfed8791f3_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtOC0xLTEtNTA5NQ_03c5b956-4f4e-46de-82bd-527dedb044fe">386,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i96ea95c9d57e45c98f3caedf608c417f_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtMTAtMS0xLTUwOTU_ebadc842-1836-496b-8ebf-f3169c09c2f7">2,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtMTItMS0xLTUwOTU_84133b7c-b0e8-4727-8d5c-66eb2e0c96e0">1,208,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:33.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.197%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-in <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated <br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Shareholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0decdf41be2e4a30ae97c1a91fa5b593_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi0yLTEtMS01MTA4_d1ec81e9-7577-4824-8bef-cd30184d2f2a">283,257,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0decdf41be2e4a30ae97c1a91fa5b593_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi00LTEtMS01MTA4_3ad03130-ea9a-412f-a7f4-df557e1176dd">722,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d6682fd53d24996a9444b260c02f16e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi02LTEtMS01MTA4_1bb021cf-6cd0-42ca-959d-c03c5ae63495">35,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i95249fd386d947d39d33c4ef4a83d14e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi04LTEtMS01MTA4_4587e078-2731-490b-8c6e-261ec46b87e5">267,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i861d96426dca41259dd492868210425f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi0xMC0xLTEtNTEwOA_901123e7-72e2-4c64-adf4-72a815bc6856">280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6732b5466cb84d3c9b86f94b68a032d9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi0xMi0xLTEtNTEwOA_bbbd6444-c277-49bd-8ead-2084b5212966">1,025,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares issued and restricted stock units ("RSUs") vested under stock option plan </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7ae52bf585f2406684f9101c92e3ed0d_D20220101-20220331" decimals="INF" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy0yLTEtMS01MTA4_8e11c86b-0457-406f-8805-87d473c51f84">1,264,077</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7ae52bf585f2406684f9101c92e3ed0d_D20220101-20220331" decimals="-3" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy00LTEtMS01MTA4_b493a189-09bf-4058-8b45-52379676a7f7">3,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i82fb29d006754942a2f5913a08541ed7_D20220101-20220331" decimals="-3" sign="-" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy02LTEtMS01MTA4_4ded0605-2a5c-40bb-bc2a-993b901f7024">2,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy0xMi0xLTEtNTEwOA_3050f03d-9ee2-415c-8363-6d1644d15877">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i82fb29d006754942a2f5913a08541ed7_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNC02LTEtMS01MTA4_dcadffff-0754-4c0c-81db-7b78ff0f66b5">12,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNC0xMi0xLTEtNTEwOA_07b36a4c-f021-4b77-9f1f-32d1cf41ffaa">12,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91864d811230449ab2c770081bffde09_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNS0xMC0xLTEtNTEwOA_b140cb8f-b3ef-440a-9ca5-f202a9418671">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNS0xMi0xLTEtNTEwOA_83a6326c-964c-48d1-879c-35d99bb34172">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a2304c602314a149a3829e4bb16839d_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNi04LTEtMS01MTA4_433731b5-6a60-46fa-9820-2272b047190b">168,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNi0xMi0xLTEtNTEwOA_f0a5445b-bcc6-4af7-9239-f719332d3c09">168,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balances as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i63526f8d447e49f5851992c00795cb56_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy0yLTEtMS01MTA4_53cb90d8-7256-4853-ae23-7a2032e4e3b7">284,521,181</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i63526f8d447e49f5851992c00795cb56_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy00LTEtMS01MTA4_d0454f4a-f3a7-4979-987e-a0df4165883b">725,755</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c1534cce0324615ba2ea393852c6c61_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy02LTEtMS01MTA4_79beccd9-83c8-4a08-8e6b-51cde3836814">44,726</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9615a195ad1a4b138c452ec64af6a8b7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy04LTEtMS01MTA4_e4c40fdc-ba9e-4c0e-9249-d73b0eed61eb">436,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7e59f6941600414cacd5ce35743135eb_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy0xMC0xLTEtNTEwOA_8e399c1f-5089-4637-af33-bc5298a2df43">787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy0xMi0xLTEtNTEwOA_c44b100b-1414-486a-8dd0-17485ca39672">1,207,507</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbCellera Biologics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Expressed in thousands of U.S. dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMy0xLTEtMS02MjU_c4e660bd-a726-46a7-91e8-b11a6916b51c">168,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMy0zLTEtMS02MjU_216e7466-f84c-4b1f-bf6f-fb0cc0aaeaa4">40,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNS0xLTEtMS02MjU_3c729061-b185-430e-9d43-3d4e3718bda7">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNS0zLTEtMS02MjU_71f11bcc-0aa7-4d2e-86f3-6d07d823d638">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNi0xLTEtMS02MjU_0951a2ef-fc54-4a4e-a6df-723c0a943a1a">2,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNi0zLTEtMS02MjU_48f36aa5-c4a3-4be9-b493-e1ce64c3a6b5">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNy0xLTEtMS02MjU_d7a44ff8-b475-4222-a55d-c8a7021ba4c2">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNy0zLTEtMS02MjU_bab6f005-62df-45aa-b450-dd2c3f66b1c5">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOC0xLTEtMS02MjU_85e0ee5c-334f-4d62-842c-5137352a54b8">12,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOC0zLTEtMS02MjU_fbefb337-241d-4414-8fdd-7764a98bef93">15,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOS0xLTEtMS02MjU_15b3f7dd-26fb-4de2-a404-d667aa0fa27a">592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOS0zLTEtMS02MjU_49c4b145-b2f5-4fa7-932d-1749b2add5bc">3,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts and accrued research fees receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTEtMS0xLTEtNjI1_e064a210-1179-49d4-a500-487f5ef834f2">8,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTEtMy0xLTEtNjI1_722ab953-eeea-472d-8c45-0e58a651fe2b">7,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:IncreaseDecreaseInAccruedRoyaltiesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTItMS0xLTEtNjI1_27189963-2eb4-4bc2-8d6a-376098e4018a">167,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="abcl:IncreaseDecreaseInAccruedRoyaltiesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTItMy0xLTEtNjI1_c3c8a1d8-bd71-4285-98b9-84055efef09e">9,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTMtMS0xLTEtNjI1_9bfdd45e-59ba-4ff3-99e2-4594620c48f5">69,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTMtMy0xLTEtNjI1_204a3701-cbd9-4d5e-8bc3-bc412b118521">12,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTQtMS0xLTEtNjI1_59e93c70-b9ad-4e3d-99b6-72f1dbce6d8c">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="abcl:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTQtMy0xLTEtNjI1_c3ef8e9e-67da-4dd1-963f-b2b1fc231681">5,778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTUtMS0xLTEtNjI1_db4dcd6d-edc6-48cd-b12f-9218e2dd03aa">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTUtMy0xLTEtNjI1_a49b0e2c-8947-49dc-bd14-3896b150ccf1">3,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTYtMS0xLTEtNjI1_dd256105-fa1e-4d15-8da5-41868f5a5e2f">22,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTYtMy0xLTEtNjI1_35699047-1b97-4d5b-8f00-86c55a46a76b">16,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" sign="-" name="abcl:IncreaseDecreaseInDeferredGrantIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTctMS0xLTEtNjI1_e177446f-2f62-4ad8-a3ba-416b1d4b8a46">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="abcl:IncreaseDecreaseInDeferredGrantIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTctMy0xLTEtNjI1_8f81397e-3991-4bc2-a440-9d658678187e">4,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTgtMS0xLTEtNjI1_3d4f5b9b-5b6f-4885-991b-857b2b505b5e">7,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTgtMy0xLTEtNjI1_dee06f5c-8bf7-450b-a85d-fae88c97e05c">6,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTktMS0xLTEtNjI1_cc414dab-35c6-4533-8aa6-c38bc7201e5c">100,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTktMy0xLTEtNjI1_7ae5921f-9380-4afd-9a0e-e5f61989842e">44,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjEtMS0xLTEtNjI1_25391f64-c261-4d46-ba1c-b70a43c9dcc9">14,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjEtMy0xLTEtNjI1_4e05b55b-1e79-4b2a-a4cc-6d440db08ba3">14,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjMtMS0xLTEtNjI1_d261cccc-af19-41a9-8122-c6cebaad37a3">51,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjMtMy0xLTEtNjI1_c092a485-8d1d-4ac7-98a4-25bca85b116b">360,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjQtMS0xLTEtNjI1_315781dd-dcfa-43d7-a244-c1acb37a70e5">57,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjQtMy0xLTEtNjI1_7b7e02fb-1353-4749-814d-14962815fa80">262,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipt of grant funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:ProceedsFromReceiptOfGrantFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjUtMS0xLTEtNjI1_e80059e0-81ab-4839-adc9-8f0d9b519bbc">2,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:ProceedsFromReceiptOfGrantFunding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjUtMy0xLTEtNjI1_561dfb18-26cc-4625-adde-9b722c9b9b86">2,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term investments and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:PaymentsToAcquireLongTermInvestmentsAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjctMS0xLTEtNjI1_ae859b19-4794-44d6-9236-58625aaf8a2d">11,657</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:PaymentsToAcquireLongTermInvestmentsAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjctMy0xLTEtNjI1_b1b02070-16e3-40b4-ade0-54745bbf2ba8">34,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in and loans to equity accounted investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjgtMS0xLTEtNjI1_eb9ba837-cf72-42e8-9ffe-b54b9b87eaa2">8,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjgtMy0xLTEtNjI1_e4714443-2c2d-4c18-b348-976d3217c36b">4,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjktMS0xLTEtNjI1_4d30e305-2fb4-4aa2-9360-856ba8240abe">26,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjktMy0xLTEtNjI1_382845c1-30fb-46d4-b7e9-79cccc53bc3f">149,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of liability for in-licensing agreement and contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzEtMS0xLTEtNjI1_5e45a1aa-784e-4fba-9517-2332483fdd60">5,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzEtMy0xLTEtNjI1_176b183c-7f3c-47f5-a578-9359883088f3">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from long-term debt and exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:ProceedsFromDebtAndExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzItMS0xLTEtNjI1_72f279c0-3fad-4fed-8f1f-bc494536a697">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:ProceedsFromDebtAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzItMy0xLTEtNjI1_88e06f69-b51e-49db-adfe-ce9ef76bfa79">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzQtMS0xLTEtNjI1_78397500-ad96-451d-b241-acebe410c722">3,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzQtMy0xLTEtNjI1_4911af8c-cd98-423d-bf0f-9b193a66262f">458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzUtMS0xLTEtNjI1_905abf7c-da2f-4129-924c-3c246be3033f">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzUtMy0xLTEtNjI1_ec218818-38ce-4850-9ea5-2e80d739cdc1">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzYtMS0xLTEtNjI1_69ebb4d3-349d-4039-ba80-af74b7bddb8d">70,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzYtMy0xLTEtNjI1_bbd1380f-723a-4c73-8914-423ab40b89bc">194,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6732b5466cb84d3c9b86f94b68a032d9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzctMS0xLTEtNjI1_d2b8b55c-8c0b-4e59-bffb-e5c974271755">501,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzctMy0xLTEtNjI1_c8a88987-691d-426d-be69-c1ebfc541504">414,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzgtMS0xLTEtNjI1_7b682147-d468-40b5-8be8-a3a23ad250cb">571,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzgtMy0xLTEtNjI1_30e18b31-000e-4302-9e7c-bfe5cd696415">220,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzktMS0xLTEtNjI1_4393103d-13f5-48de-a655-675209fbee03">937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzktMy0xLTEtNjI1_b2762747-f5f0-4850-9d4b-426d5e54afed">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash shown on the balance sheet</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDAtMS0xLTEtNjI1_140d6117-e5f7-4c46-9b9a-1b1ee722a216">570,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDAtMy0xLTEtNjI1_feeeaa7e-a034-4cbe-8959-6ec4903b8dd6">218,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDItMS0xLTEtNjI1_1f729a3f-a860-4b8c-a83f-d2effd93b701">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDItMy0xLTEtNjI1_a6a63557-b5ff-4ecd-a40c-c994f98577aa">8,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for operating lease obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="abcl:NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDMtMS0xLTEtNjI1_a12ee269-5f56-4137-b1d4-1eb9197566f3">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="abcl:NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDMtMy0xLTEtNjI1_ed0623eb-c565-4c4c-bfdc-6dfc56c5c149">2,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbCellera Biologics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(All figures in U.S. dollars. Amounts are expressed in thousands except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_37"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zNy9mcmFnOjQ5NTQzMmFjZjg5MTRhNTViOWFmZDg1MmViZjEzNWY3L3RleHRyZWdpb246NDk1NDMyYWNmODkxNGE1NWI5YWZkODUyZWJmMTM1ZjdfNzk3_7de70934-0892-49db-84c8-6d0a64ac55ac" continuedAt="i558388de604b40c9a169b4bb8dc1603e" escape="true">Nature of operations</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i558388de604b40c9a169b4bb8dc1603e" continuedAt="i2db658292b9d4d029b2a9f45e856baa4">AbCellera Biologics Inc.&#8217;s (the &#8220;Company&#8221;) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together</ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2db658292b9d4d029b2a9f45e856baa4">.</ix:continuation> </span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80MC9mcmFnOmFlNzgxNjc0YzExODRhODM4MTk4ZGI3ODVlMDVhYjU3L3RleHRyZWdpb246YWU3ODE2NzRjMTE4NGE4MzgxOThkYjc4NWUwNWFiNTdfMTcwOQ_d318e63d-fcd1-4252-927f-24c7cba36a41" continuedAt="icb5baf34351e40aba240830454fa7496" escape="true"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80MC9mcmFnOmFlNzgxNjc0YzExODRhODM4MTk4ZGI3ODVlMDVhYjU3L3RleHRyZWdpb246YWU3ODE2NzRjMTE4NGE4MzgxOThkYjc4NWUwNWFiNTdfMTcxMA_50da4510-9250-45c5-917d-0cab76d0386a" continuedAt="i92da33f081b94b0dbc41bbadb5e26185" escape="true">Basis of presentation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i92da33f081b94b0dbc41bbadb5e26185"><ix:continuation id="icb5baf34351e40aba240830454fa7496" continuedAt="i7f0a41ff8d58443e959e0e6f6780a0a2"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March&#160;31, 2022 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2022.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f0a41ff8d58443e959e0e6f6780a0a2">All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to &#8220;$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; and &#8220;CAD&#8221; are to Canadian dollars</ix:continuation>.</span></div></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80My9mcmFnOjMwYzBlMTIyMTIxMDRhNDhiOTQ3ZDk4MmJmZjllOWJjL3RleHRyZWdpb246MzBjMGUxMjIxMjEwNGE0OGI5NDdkOTgyYmZmOWU5YmNfMjM5Mg_569d273e-8cf8-4c26-9b6e-67756cfdf112" continuedAt="ib7615c41b7b84f69b41c6ab55b00c038" escape="true">Significant accounting policies </ix:nonNumeric></span></div><ix:continuation id="ib7615c41b7b84f69b41c6ab55b00c038"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80My9mcmFnOjMwYzBlMTIyMTIxMDRhNDhiOTQ3ZDk4MmJmZjllOWJjL3RleHRyZWdpb246MzBjMGUxMjIxMjEwNGE0OGI5NDdkOTgyYmZmOWU5YmNfMjM5Mw_53290967-7aa3-487c-a9f3-4656271d2cbf" escape="true"><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80My9mcmFnOjMwYzBlMTIyMTIxMDRhNDhiOTQ3ZDk4MmJmZjllOWJjL3RleHRyZWdpb246MzBjMGUxMjIxMjEwNGE0OGI5NDdkOTgyYmZmOWU5YmNfMjM5NQ_1ce23d4d-e903-4899-8092-bb183eaf7089" escape="true"><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfODkw_b3357734-0795-43f6-931a-3d23fc3be481" continuedAt="i25a66d1f8b1643649c0ebaac286d6b87" escape="true">Net earnings (loss) per share</ix:nonNumeric></span></div><ix:continuation id="i25a66d1f8b1643649c0ebaac286d6b87"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfODkx_497d52af-673a-4d0b-b161-804558f7dbe6" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) attributable to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMy0yLTEtMS0yMjE5_12b4956f-895d-4d95-a5ff-e91d442d7e29">168,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMy00LTEtMS0yMjE5_7ee4042c-297b-4e82-bda2-ff3800a9c3cd">40,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNC0yLTEtMS0yMjE5_bf04131d-1348-4c75-adf8-095fcbce33c1">283,895,020</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNC00LTEtMS0yMjE5_d5f4d7ae-684b-450c-a442-f9e3178bfc71">287,767,136</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net earnings (loss) per share attributable to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNS0yLTEtMS0yMjE5_20b843fc-a215-4e2c-8cfe-33fffd951b48">0.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNS00LTEtMS0yMjE5_17bd2a71-6063-4134-9a13-26cc8776c903">0.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) attributable to common shareholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOC0yLTEtMS0yMjE5_b31dfe7f-3f0b-4275-990f-afbc125ecbf1">168,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOC00LTEtMS0yMjE5_5078e38f-7e19-44e4-9cc3-33a0c2178731">40,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOS0yLTEtMS0yMjE5_afc359c7-01b7-415c-a6e8-d5c4e4b984f2">283,895,020</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOS00LTEtMS0yMjE5_61eceea3-d49a-4fee-8556-a2f3b9877bbf">287,767,136</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTAtMi0xLTEtMjIxOQ_924df33b-26a7-4791-9735-7775c9e0a4de">27,586,997</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="INF" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTAtNC0xLTEtMjIxOQ_1f6f0bf2-a184-41a1-a076-7c0735081e77">-</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTEtMi0xLTEtMjIxOQ_5cd5e37a-cbc6-4728-944d-aff8acf1063f">311,482,017</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTEtNC0xLTEtMjIxOQ_3bb01e3e-8502-44a8-9114-f00b118f7491">287,767,136</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net earnings (loss) per share attributable to common shareholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTItMi0xLTEtMjIxOQ_8d558a0b-4417-4376-b63f-6d3ad92c42f3">0.54</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTItNC0xLTEtMjIxOQ_3d18a495-604e-4ec1-929d-3e3c323e1c34">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include stock options and restricted share units (&#8220;RSUs&#8221;), have been excluded from the computation of diluted net loss per share for the three months ended March&#160;31, 2023 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March&#160;31, 2023 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded <ix:nonFraction unitRef="shares" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfNjQ4_0943225a-86cc-49ab-8805-b583e01116b5">2,974,052</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfNjU1_7a3b2fda-7a7e-48c5-88c2-12a2b3b7ee91">50,844,425</ix:nonFraction> potential common shares for the three months ended March&#160;31, 2022 and March&#160;31, 2023, respectively, from the computation of diluted net earnings (loss) per share attributable to common shareholders because including them would have had an anti-dilutive effect.</span></div></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfNDEy_e9f16ed1-6d9a-4fa9-8522-e88d7af65225" continuedAt="i16df1b5d854741ce83d93522e123d27f" escape="true">Property and equipment, net</ix:nonNumeric></span></div><ix:continuation id="i16df1b5d854741ce83d93522e123d27f" continuedAt="i0cea1b64e9db4880933871219d1af670"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfNDEz_5c51a121-8c3c-460e-a793-d026f5bdf221" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i42a0bae74c9743ff8ff66ad8ff963146_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMS0yLTEtMS0yNDkw_7cf58152-8025-4ab2-96c4-04df64587e80">8,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6139469318d432e82d6baefdf566dce_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMS00LTEtMS0yNDkw_29d44714-095c-4bc0-aa3d-d7b2c6a919cf">8,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i12e371e7d54148dbba3063693fd8a2d9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMi0yLTEtMS0yNDkw_b85f9669-4d31-4bc2-b279-df2ad0d18c67">53,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e470366e74a442c8d52acc2a9f1b5f5_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMi00LTEtMS0yNDkw_29adf264-b1a2-4dc3-b58d-437817483880">53,405</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iabf93e4e7dd64c7e839faca3ad8410d3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMy0yLTEtMS0yNDkw_3fc5f6a8-e4ea-48dd-a1c7-03c4ea3b5db5">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i406b6a1622cd4dff99832c9462b6e4a7_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMy00LTEtMS0yNDkw_f65d33e3-6d9a-4096-b244-3dc906f3db18">17,493</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4e1c38a1157c413c866c668dd92b9a77_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNC0yLTEtMS0yNDkw_270f5a9a-6319-4d06-9f2c-6297edc048a5">41,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2d27a736c37340be83efab3ba99a8bc0_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNC00LTEtMS0yNDkw_40d74c5e-1f6b-475a-a108-cd12ec9840dc">45,936</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic9c66215525a40069a548e7bd3025c84_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNS0yLTEtMS0yNDkw_1618111e-07d9-461c-a506-5b980d705c07">40,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3a403b1fa38d47ada5644a9f4c1fff58_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNS00LTEtMS0yNDkw_bc4d80cc-d75f-4678-90a4-663446ff8f99">47,800</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i853afd911efa4258a08a6952094096cb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNi0yLTEtMS0yNDkw_00351683-4019-4873-a274-2e0dd07572a3">80,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7d0ae58e07dc4eb983249c3c61c1ad45_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNi00LTEtMS0yNDkw_583792b4-0252-4209-85b2-0ccf880d7a0c">81,356</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNy0yLTEtMS0yNDkw_1a8b98dc-61a3-48c6-a0db-e0e1ce2b4429">235,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNy00LTEtMS0yNDkw_472390c4-2f70-4389-b935-639c887d2180">254,520</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOC0yLTEtMS0yNDkw_d3fd6ca2-c3ea-4b4a-96ab-a9305ec9dac8">18,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOC00LTEtMS0yNDkw_86d1b103-9523-446b-a4de-cfef8e580a1f">21,333</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOS0yLTEtMS0yNDkw_db4e5e1e-1bec-4266-8ecc-1bb237cef6d1">217,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOS00LTEtMS0yNDkw_81e7cd7e-02ce-485f-a250-b9501f533e05">233,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:27pt"><ix:continuation id="i0cea1b64e9db4880933871219d1af670"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and March&#160;31, 2023, leasehold improvements include tenant improvements in progress that have not commenced depreciation in the amount of $<ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMjI4_e18106e8-ed96-4330-b908-58736ec70ad6">25.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMjM1_540e526d-a907-4d71-b77f-c1982f874045">38.9</ix:nonFraction> million, respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Depreciation expense on property and equipment for the three months ended March&#160;31, 2022, and 2023 was $<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMzMx_33176d30-fd79-430d-812c-4e14e859992c">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMTY0OTI2NzQ0MjE3Mw_b823eef4-cff4-4e2b-bbbb-e37d6a6e5610">2.9</ix:nonFraction> million, respectively.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RleHRyZWdpb246YWJhNmY5YTUwNmQ2NDg3Y2FiNGU3NTM1NjM5ZjVlMGRfMTg5_98b86125-521f-4f78-a771-9d6450c51b47" continuedAt="i4f92b2704694433aafa880a6b84a7a42" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="i4f92b2704694433aafa880a6b84a7a42"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RleHRyZWdpb246YWJhNmY5YTUwNmQ2NDg3Y2FiNGU3NTM1NjM5ZjVlMGRfMTkw_b6eae308-301b-4758-b9b0-05ea4b097395" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if039c44ad3504f63aa1ec431499bafec_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMi0xLTEtMS02MjU_385b46a8-b269-468a-b8d5-5b813a28ddaa">37,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if039c44ad3504f63aa1ec431499bafec_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMi0zLTEtMS02MjU_ba9d0fd4-f784-4850-8e9f-8e469becb29f">19,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if039c44ad3504f63aa1ec431499bafec_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMi01LTEtMS02MjU_ed5fabc3-d786-488e-83bc-1c33018ec530">18,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5caae842c49f4155ad44dff34efdb797_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMy0xLTEtMS02MjU_c5b3c8de-2864-4a1e-adf9-a2871433a671">52,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5caae842c49f4155ad44dff34efdb797_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMy0zLTEtMS02MjU_705af3bc-8140-4f3f-a960-3248cc3df519">5,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5caae842c49f4155ad44dff34efdb797_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMy01LTEtMS02MjU_685cd937-7939-40e7-a16d-0523d8e795e6">46,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNC0xLTEtMS02MjU_34e18e74-fb90-4104-8029-188c87597904">64,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNC0zLTEtMS02MjU_4bbd5202-1b40-4502-880f-e3012a84cf7c">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNC01LTEtMS02MjU_7f8354e8-47e6-4f7b-847a-7cac97724cb5">64,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNS0xLTEtMS02MjU_31002a91-8340-464f-9195-559871c5db26">154,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNS0zLTEtMS02MjU_89dfb6cf-96d9-4cb9-a275-46c07eb90077">25,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNS01LTEtMS02MjU_9daf18e7-6373-492f-b33a-328ee23f3484">128,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RleHRyZWdpb246YWJhNmY5YTUwNmQ2NDg3Y2FiNGU3NTM1NjM5ZjVlMGRfMTg4_7120713f-bbb5-4259-a91c-0c3593ee4d32" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfMS0xLTEtMS02MjU_38ee0934-f949-4ac8-87f9-a39df71b1536">10,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfMi0xLTEtMS02MjU_66317600-0d53-4ac9-a7f6-58c32daf0571">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfMy0xLTEtMS02MjU_8c35d384-e5df-4ac7-a14d-d0456cf436c9">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfNC0xLTEtMS02MjU_b2fb21da-14b2-4886-a654-5724fdfaae63">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfNS0xLTEtMS02MjU_3b671b78-8745-4f11-b803-5f8befc7b631">4,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfNi0xLTEtMS02MjU_4eb8e594-a6e3-4bea-b8d3-bed9cd2e3d34">27,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMjUxNg_dc451fa3-28f6-4b0c-8b78-3b22e544bce3" continuedAt="i5a83675ca88c4c798b7f7d5f0181cbbd" escape="true">Investments in and loans to equity accounted investees, and other long-term assets</ix:nonNumeric></span></div><ix:continuation id="i5a83675ca88c4c798b7f7d5f0181cbbd" continuedAt="ie79e5fa9132a496d82e0ce462fa35501"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into <ix:nonFraction unitRef="jointventure" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="INF" name="abcl:NumberOfJointVentures" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTA2OA_5b01c7c1-c448-494b-a56a-f4e27fbf4df6">two</ix:nonFraction> separate <ix:nonFraction unitRef="number" contextRef="ia507651da5b4472a9bda28dcdad3b575_I20230331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMTc_06221a24-77b2-43e5-af76-b80df547adf5"><ix:nonFraction unitRef="number" contextRef="i0148f1e33c6b4510b7104f707a9f1015_I20230331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMTc_5fcce713-38ef-41ec-b2df-ec6bc10810ec">50</ix:nonFraction></ix:nonFraction>% joint ventures, Dayhu JV and Beedie JV, as part of the construction of future office and laboratory headquarters. To date, the Company has recorded immaterial amounts of proportionate income or loss with respect to either venture.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dayhu JV</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). As of March&#160;31, 2023, the equity investment balance was $<ix:nonFraction unitRef="usd" contextRef="i73a7c5f735ad47f2ad483da48085449d_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTY0MDAwNA_1611971b-adc5-466d-8fd6-3e4a65c6b151">41.3</ix:nonFraction>&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March, 2021, the Company made a commitment of up to CAD $<ix:nonFraction unitRef="cad" contextRef="ic7dd7959a16f4e469b26e2d1a0a91144_D20210101-20210331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTA4MQ_4c18dd27-b96d-4039-8fcb-abc0238f3650">82.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ic7dd7959a16f4e469b26e2d1a0a91144_D20210101-20210331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTMwNQ_dc442f69-47c8-4d43-a427-33660ecbfb67">61.2</ix:nonFraction>&#160;million at March&#160;31, 2023) to the Dayhu JV (Dayhu JV Loan) to fund the construction at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of <ix:nonNumeric contextRef="i6bfea07b5a744d6596d3882f182d5906_D20210101-20210331" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMjc_b32b1213-29d5-4b22-b8f3-05131ee57749">thirty months</ix:nonNumeric> from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loan is secured by the underlying land and future assets of the Dayhu JV. At December&#160;31, 2022, and March&#160;31, 2023, the outstanding related party loan balance was $<ix:nonFraction unitRef="usd" contextRef="i1f5e482b7eb34446b5095f10b3fbcd1c_I20221231" decimals="-5" name="abcl:EquityMethodInvestmentOutstandingRelatedPartyLoan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTYzNzg1MA_298ef85d-a91e-45c3-b292-5791f2c0e4c8">38.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i47a8affab5e347a4b46782717c4df146_I20230331" decimals="-5" name="abcl:EquityMethodInvestmentOutstandingRelatedPartyLoan" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM3Ng_dd62d795-a82c-4179-8456-9df0ef70fa5e">nil</ix:nonFraction>, respectively, to the Dayhu JV.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, the Company entered into an agreement of up to CAD $<ix:nonFraction unitRef="cad" contextRef="ifcee6e4ab663465bac83ebdfecfc71e5_D20220701-20220731" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTA5Ng_895e93a0-fd67-49e1-92be-6ce74ca79be8">46.0</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM1Mg_e063125c-14e4-497f-a62f-f400e530fbfe">34.0</ix:nonFraction>&#160;million at March&#160;31, 2023) with Dayhu (New Dayhu Loan) to replace Dayhu&#8217;s portion of the outstanding Dayhu JV Loan balance as at January 1, 2023, at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement. The agreement has a maturity of December 31, 2025, with a call provision, callable by the Company after September 30, 2023, including customary make whole provisions. The loan is secured by the underlying land and existing and future assets of the Dayhu JV. In January 2023, the Company issued CAD $<ix:nonFraction unitRef="cad" contextRef="i9d3ffacd78e54c008bb62a070d409d8e_D20230101-20230131" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTExMQ_49a84486-4d88-419d-8e8e-a2e03d6b9301">46.0</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTY0MDA5Ng_e063125c-14e4-497f-a62f-f400e530fbfe">34.0</ix:nonFraction>&#160;million at March&#160;31, 2023) to Dayhu from the New Dayhu loan, which was used to repay, in part, Dayhu&#8217;s <ix:nonFraction unitRef="number" contextRef="i9d3ffacd78e54c008bb62a070d409d8e_D20230101-20230131" decimals="2" name="abcl:PercentageOfConstructionLoan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMjM_017736a4-4419-440a-844e-a51b1288431b">50</ix:nonFraction>% portion of the Dayhu JV Loan. At March&#160;31, 2023, the loan balance was $<ix:nonFraction unitRef="usd" contextRef="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNTQ5NzU1ODI5OTM5_e063125c-14e4-497f-a62f-f400e530fbfe">34.0</ix:nonFraction>&#160;million and is included in other long-term assets. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beedie JV</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March, 2021, the Company entered into the Beedie joint venture (Beedie JV). As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the equity investment balance was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib925185cbb614e71b24a62dc39dc9707_D20210101-20210331" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM1OQ_ed14f65c-c086-42fa-ab58-18ca3b5c067d">16.3</ix:nonFraction>&#160;million. </span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><ix:continuation id="ie79e5fa9132a496d82e0ce462fa35501"><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, the Company made a commitment to our partner Beedie for a land loan of up to CAD $<ix:nonFraction unitRef="cad" contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTE0MQ_533e954f-abc6-4137-8eb0-98c1c90b5e53">7.5</ix:nonFraction>&#160;million (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM2Ng_3e42710d-209c-493f-b23b-a8ad2298a11d">5.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> at March&#160;31, 2023) plus a construction loan for up to <ix:nonFraction unitRef="number" contextRef="i4bb8630f96284448a0ad62c00db72975_D20220601-20220630" decimals="2" name="abcl:PercentageOfConstructionLoan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMjk_97817886-7682-4e5d-8c0c-c95bd76fafcc">80</ix:nonFraction>% of Beedie&#8217;s share of construction costs. The commitment is at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of <ix:nonNumeric contextRef="i9a27eee6bb20488893688edd304543db_D20220601-20220630" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMzM_e4f951f1-7f98-442d-b9b7-f589fad74ea3">thirty months</ix:nonNumeric> from the date of initial advancement of the construction loan and</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i4bb8630f96284448a0ad62c00db72975_D20220601-20220630" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMzQ_ec280c1d-cf1c-481b-a789-eee3539d5713">five years</ix:nonNumeric> from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the Beedie JV. The loan receivable balance, which was solely related to the land loan to date, was CAD $<ix:nonFraction unitRef="cad" contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTY0MzIyMw_533e954f-abc6-4137-8eb0-98c1c90b5e53">7.5</ix:nonFraction>&#160;million (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331" decimals="-5" name="abcl:EquityMethodInvestmentCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM3Mg_e94fe3f0-ffb6-42ef-bc19-329d9dbfa0c8">5.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and is included in other long-term assets.</span></div></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="abcl:CurrentAssetsAndLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RleHRyZWdpb246NTg5M2Q2ZTU4MzA3NGU0MmJiMDIxNjVkOWMyMTM1ZWJfMTE1_5d1ea021-e2af-4d33-8def-a8a69487e38a" continuedAt="ib7ca9d8f10354ac48a887db0b17085f2" escape="true">Current assets and liabilities</ix:nonNumeric></span></div><ix:continuation id="ib7ca9d8f10354ac48a887db0b17085f2"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RleHRyZWdpb246NTg5M2Q2ZTU4MzA3NGU0MmJiMDIxNjVkOWMyMTM1ZWJfMjM2Mzk0OTk5OTc5MTk_769b0f96-0dbc-487a-bc7a-572f4c64b84f" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax deposits and receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMS0yLTEtMS0xMzE4NA_86d89d19-ba8f-4bc8-9567-f89220179672">64,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMS00LTEtMS0xMzE4NA_49363819-34bb-4dba-af59-de1a1ddbdfdd">79,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="abcl:PrepaidExpenseAndOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMi0yLTEtMS0xMzE4NA_59f56d4d-3e71-4541-baa2-e6925dd52c8b">9,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="abcl:PrepaidExpenseAndOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMi00LTEtMS0xMzE4NA_7009a802-e4af-4135-8f18-d3cccb1b714a">18,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="abcl:MaterialsAndSuppliesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMy0yLTEtMS0xMzE4NA_0b62e365-6fd0-4f20-8662-e33c0efe7501">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="abcl:MaterialsAndSuppliesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMy00LTEtMS0xMzE4NA_649650a3-6c95-4f04-9f29-e34b9dfc5433">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfNC0yLTEtMS0xMzE4NA_db812a49-c224-4b57-a473-4ac8bc921fc2">75,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfNC00LTEtMS0xMzE4NA_9c19b318-07e7-4f4d-bad1-43f5aa7a6e5f">99,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span><br/></span></div><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RleHRyZWdpb246NTg5M2Q2ZTU4MzA3NGU0MmJiMDIxNjVkOWMyMTM1ZWJfMTE2_a5c1db11-fb63-435c-a34d-625c06d0ae6a" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMS0yLTEtMS00MDY5_ef14acf2-3883-41a1-a0d9-dbccf3cc6f7f">14,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMS00LTEtMS00MDY5_155817cf-463e-49f5-b585-60e165f26e1c">17,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMy0yLTEtMS00MDY5_6ef00fd3-0519-414a-a9e3-396f4cbc36d6">5,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMy00LTEtMS00MDY5_5fb641c3-81cd-4c61-a580-7bdb64e77e7a">5,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNC0yLTEtMS00MDY5_7339e0c6-47a0-4fd3-b7eb-b05a397046cd">6,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNC00LTEtMS00MDY5_a8b7a186-bf2c-4b0b-8599-5ca47b000c2d">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of deferred grant funding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="abcl:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNS0yLTEtMS00MDY5_c9126646-a476-42d1-81f8-ecbd72641915">6,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="abcl:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNS00LTEtMS00MDY5_3d2f6e08-684a-4896-adb6-e7da191031dc">6,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNi0yLTEtMS00MDY5_4750047c-91bc-4fbb-b30f-97c3759be0b0">33,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNi00LTEtMS00MDY5_1a35e9fb-089d-4eff-909d-00a3b10aade0">31,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxNw_6704d1c9-c6b2-499b-91dd-fbcad0023861" continuedAt="i9148cfe4a3bb4edea6acff2a47c848b5" escape="true">Shareholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="i9148cfe4a3bb4edea6acff2a47c848b5" continuedAt="i606efe7099a94a0cbf2c06cb8b81b45f"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxMw_67913442-5a45-4901-ad7e-c9866fda889d" continuedAt="ia7f845d578214661bd150cbdf8d18f74" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity under the Pre-IPO Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average&#160;Exercise<br/>Price&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21720092b1fd485a91d701040dc8eaf4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMS0xLTEtMS02MjU_2a02b57d-769b-4fbf-9a54-84791e1e4b04">33,694,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i21720092b1fd485a91d701040dc8eaf4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMS0zLTEtMS02MjU_16f557f7-06a0-4c2a-beb4-f12d84498f4d">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMi0xLTEtMS02MjU_2e9f40ef-f64f-46eb-818e-39f76e41a602">-</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMi0zLTEtMS02MjU_8e0ce59a-e5ac-4daa-b099-2c880ca2ac0c">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMy0xLTEtMS02MjU_a9fd076b-6581-4458-92ae-01adcae9e935">1,087,171</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMy0zLTEtMS02MjU_60af87be-2c34-4bd0-8230-b7ee04ac5340">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNC0xLTEtMS02MjU_4b2efc65-157c-4343-a655-3feff7936527">-</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNC0zLTEtMS02MjU_7c105370-b576-4c5a-935b-7b7c296e3735">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNS0xLTEtMS02MjU_3ee8db9f-6fdd-4a25-8d72-e172398c9ecd">32,606,979</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNS0zLTEtMS02MjU_909f5b3f-5b19-4c04-bcd3-ed5552c1560e">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNi0xLTEtMS02MjU_4d2dabf4-d602-44ac-a790-60726bbfc163">24,079,568</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNi0zLTEtMS02MjU_daf1c1e3-bd28-4097-92fa-3b42bce05b85">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><ix:continuation id="i606efe7099a94a0cbf2c06cb8b81b45f"><ix:continuation id="ia7f845d578214661bd150cbdf8d18f74"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity under the 2020 Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i89a61c2a4c454272afe77744cf55c9ec_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMS0xLTEtMS02MjU_422a49b5-bcbc-4e2d-86a2-a1f75a073802">12,322,933</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i89a61c2a4c454272afe77744cf55c9ec_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMS0zLTEtMS02MjU_287a7f32-c42b-46b1-8825-fd5bc7c02d9a">14.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMi0xLTEtMS02MjU_44bf5d1e-2d07-424d-a6d6-5b7672cc498d">1,617,638</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMi0zLTEtMS02MjU_b7e6f913-5c61-4a29-b5d9-0348c2ffa0b8">10.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMy0xLTEtMS02MjU_a401fa96-023d-4fcd-b3da-59a89a8fffbf">-</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMy0zLTEtMS02MjU_bb1d41d2-33db-479e-8317-552c59926145">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNC0xLTEtMS02MjU_9337c1bb-aa2b-4522-ae26-285cbcd12617">136,180</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNC0zLTEtMS02MjU_667c24de-ca88-4f68-8c6a-dd8f9a2c2e5c">13.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2858e48f05f04827941d142a021d6fad_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNS0xLTEtMS02MjU_9cac7b5b-4fab-4edb-a386-c5756fc319d6">13,804,391</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2858e48f05f04827941d142a021d6fad_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNS0zLTEtMS02MjU_660d76c9-33a4-499d-a6b5-2a1a66e87e7a">14.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2858e48f05f04827941d142a021d6fad_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNi0xLTEtMS02MjU_612388aa-895f-4a18-b433-51c1cd5ce87f">2,881,278</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2858e48f05f04827941d142a021d6fad_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNi0zLTEtMS02MjU_8f9b7e9d-8a9a-408b-b20b-63e86b252345">17.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxNQ_dbd703b2-a885-497f-af89-f4472b1891e1" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSU activity under the 2020 Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic2f5814bf79942159d756fd4d496dc6c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMS0xLTEtMS02MjU_ea7d7a43-e94f-4d86-878b-21c97ebcf141">3,946,985</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2f5814bf79942159d756fd4d496dc6c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMS0zLTEtMS02MjU_772e8158-d009-4cb5-96b1-b925a0b4f8b6">13.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMi0xLTEtMS02MjU_8f962a23-fd7b-4e88-a88b-336276a6ebff">1,065,110</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMi0zLTEtMS02MjU_e19660ec-ffa9-4223-8c46-0ae84353ffd5">10.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and settled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMy0xLTEtMS02MjU_f8b748ae-7d1d-4ba3-ae5a-7154f131c81c">487,748</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMy0zLTEtMS02MjU_944a880f-fd14-45c9-b91a-911cbe8547d8">14.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNC0xLTEtMS02MjU_281c31b7-2ad4-4bef-9678-42fc3ed7cf49">91,292</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNC0zLTEtMS02MjU_25650130-547f-4473-8994-28a4a87c5b6c">13.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6b5c3602feb942b29d99d1347ccefffa_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNS0xLTEtMS02MjU_ecff5f34-616f-475b-8125-a0c2033fc5ae">4,433,055</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b5c3602feb942b29d99d1347ccefffa_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNS0zLTEtMS02MjU_fc3d025d-1837-42ca-97fe-1f3cd3fe5a1f">12.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the number of shares available for issuance under the 2020 Plan was <ix:nonFraction unitRef="shares" contextRef="i2858e48f05f04827941d142a021d6fad_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfNTQ5NzU1ODE1OTk1_e483adf2-f555-43f0-8497-b6b4cf9526df">33,217,073</ix:nonFraction>, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation:</span></div><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxNg_a213500c-eb3a-48d0-8677-d2b8db3530fd" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:71.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib4cf5d989e9741afb07a70513b1e2a5b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMi0xLTEtMS02MjU_ce666e14-a896-47b9-bb03-173a94c58cbc">5,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3c4fd149aa8c46f3800472cd46fa49e2_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMi0zLTEtMS02MjU_fea60933-f517-4520-af12-d0487912c324">7,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7d7c7469d9e04930b97b96e58ef2f063_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMy0xLTEtMS02MjU_8f63eb9e-746f-44ce-a725-f1af19d4f449">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if605d90125084846a2a1044b2692e5de_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMy0zLTEtMS02MjU_55c21d0e-2cc3-4954-b272-214a8b5a4268">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic528446a6c1c4f6d8b57c3c9e62fb472_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNC0xLTEtMS02MjU_10ecd52b-89de-49fc-999f-551d54642b81">5,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3bf8dcc696b24c26bf569ab099f74655_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNC0zLTEtMS02MjU_1c61a6e7-3dd5-4af9-aba2-dff9666c5cbe">6,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNS0xLTEtMS02MjU_9d4d6244-b62e-481b-8473-a54f96a30bd3">12,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNS0zLTEtMS02MjU_79153030-5b34-4c57-af40-6180f9294030">15,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTk3Mw_27077583-11a2-4dde-8c09-f2ad0acdd270" continuedAt="iccbf495890ee4b828c25919401041851" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="iccbf495890ee4b828c25919401041851" continuedAt="i7026242d22ea48f3a8a71276d1d2bce5"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaggregated revenue categories are presented on the face of the condensed consolidated statements of income (loss) and comprehensive income (loss).</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><ix:continuation id="i7026242d22ea48f3a8a71276d1d2bce5"><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTk3NA_aa302abf-08e9-47b1-8a8d-42e50039addc" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue outstanding in each respective period is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6732b5466cb84d3c9b86f94b68a032d9_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS0xLTEtMS02MjU_2fc2c0c1-50bb-45ad-84b2-036a7087d29f">34,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS0zLTEtMS02MjU_bebecae0-e6be-482a-96ac-bd946d8b8112">35,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS01LTEtMS02MjU_8d9d7c63-2ca3-418a-9182-0cd2f4806219">41,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS03LTEtMS02MjU_d886bb01-3e94-4086-a52d-6c8c9640d5e2">37,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTY0OTI2NzQ0Mzc3MA_9ba9ea57-5ef6-40fc-8afb-41863f68ab05">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTY0OTI2NzQ0NDA2OA_7d2c1892-9057-4b49-a2cb-8dbfc55db7a3">4.8</ix:nonFraction> million, respectively, of revenue that had been included in deferred revenue in the previous year.</span></div></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMzUxNQ_ac96d829-5291-4a10-bc94-d96b24c9d740" continuedAt="id0c401f3f929457a9cc4b1da598def8d" escape="true">Financial instruments </ix:nonNumeric></span></div><ix:continuation id="id0c401f3f929457a9cc4b1da598def8d" continuedAt="i5ff5f360799f44b586a4ea890f3a1b87"><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, loans to equity accounted investees, accounts payable and accrued liabilities and royalties payable, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, royalties payable, lo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ans receivable, and loans to equity accounted investees approximate their fair values, and primarily classified as level 2. At March&#160;31, 2023, the Company also held non-marketable securities included in other long term assets of $<ix:nonFraction unitRef="usd" contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMTA5OTUxMTYzOTAwOQ_9da41746-7bc0-4b86-b019-cd5af1e6f390">29.7</ix:nonFraction>&#160;million (December&#160;31, 2022 - $<ix:nonFraction unitRef="usd" contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMTA5OTUxMTYzOTAyMQ_ae1c9c14-7aa9-4130-bddb-78abd37fdb65">18.5</ix:nonFraction>&#160;million). </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition. </span></div><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMzUxNw_fdc4047e-124f-4304-9a6b-fe083572ec06" continuedAt="i00a2eb7624b4436bbeffd4ce3c5e62c4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the liability for contingent consideration:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>beginning of<br/>the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase (decrease) in fair<br/>value of liability for contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>end of the<br/>period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni (i)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib84a76c6a7d040048417a102641bdd98_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMS0yLTEtMS0xMzI0OA_9aa47fec-d1ca-42dd-ac94-2413bd04de1c">22,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i22756f6454b64f73afb36c0c807ea9d5_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMS00LTEtMS0xMzI0OA_becba53c-fc32-474b-aada-2e9b15c90d18">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5df4d4b94b884162a2e0a0a1c655b8a8_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMS02LTEtMS0xMzI0OA_a0fbcf01-75ef-4e80-beff-2f7763486f45">22,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TetraGenetics (ii)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29a81d06f8df44d5835bbc3c04f6a927_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMi0yLTEtMS0xMzI0OA_f29913a7-83a5-48d9-ac35-2eaab7ad9e16">35,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie5b507a22fd14249969fb3270137dd02_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMi00LTEtMS0xMzI0OA_54762e9d-cdc7-4e04-b001-09384838f28f">698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i974a95ee817c4dfaa7fe8e4fd9971189_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMi02LTEtMS0xMzI0OA_53825f8b-114f-4988-b58c-86b27699301f">35,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>beginning of<br/>the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase (decrease) in fair<br/>value of liability for contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>end of the<br/>period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni (i)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i38c6977e90834eb3bd8b3526452e9e35_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMS0xLTEtMS02MjU_f0beccfb-b283-4d04-ade5-d02fa642a06b">23,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1de9aa8ab44841868c7d65c602095235_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMS0zLTEtMS02MjU_52b3e500-dd66-458f-89d5-98cc2d55bb73">2,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i87414b0fe0f34080ae5ec5e948eafda6_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMS01LTEtMS02MjU_ff8fe21f-89c2-4e2b-ad47-b7e00199fb38">20,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TetraGenetics (ii)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia2d15a4aeba64cd299c7371834bb7abf_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMi0xLTEtMS02MjU_f3981558-7385-4d2c-b177-ebf6a3dc2841">36,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i441987f8eb1e43f5b29f11eb02f70403_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMi0zLTEtMS02MjU_8aa380a1-cdd7-4b89-9687-4daec542c557">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9ad3bc7b19842bea7e2bec41c9cce9d_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMi01LTEtMS02MjU_f0ee34ec-e667-4308-9385-25d60cac99c8">37,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.9pt">The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at <ix:nonFraction unitRef="number" contextRef="i2f397da2a35b4cce8dcf8e1c494f9789_I20230331" decimals="0" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMjI5Nw_f67467ec-2cab-4035-a595-5c74fbe6a65e">22</ix:nonFraction>%, the rate that measures the risks inherent in the future cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><ix:continuation id="i5ff5f360799f44b586a4ea890f3a1b87"><div style="padding-left:27pt;text-indent:-27pt"><ix:continuation id="i00a2eb7624b4436bbeffd4ce3c5e62c4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.13pt">The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at <ix:nonFraction unitRef="number" contextRef="i4cae519cf0de46818efc75457121e175_I20230331" decimals="1" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMjcyMw_784c87db-a305-4b65-b788-7c2b855f867b">10.7</ix:nonFraction>%, the rate that measures the risks inherent in the future cash flows.</span></ix:continuation></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company&#8217;s current operations.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.</span></div><ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMzUxOA_e1be9cfa-8339-49de-af17-131060afe422" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at March 31, 2023:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3827504d1bb4416a966243425ee8a0f6_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy0xLTEtMS02MjU_b95853dc-6ba0-4b87-aa81-e072ded9558a">108,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id80012107add40658f9e2fb319a4e721_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy0zLTEtMS02MjU_8a190ac4-78f2-4e84-a29f-c745b76951d4">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6c929c76a9ad4321bf79186a9b2ab1dc_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy01LTEtMS02MjU_5f2d70fb-e7ff-4808-b10e-022fdfa1bae0">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8c4ad46a8dd94eaa84a356553b207755_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy03LTEtMS02MjU_f852feb3-1c1b-4c72-b406-6a9aed154e06">108,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8aad9e0f529743d0a71e223bfe29146f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC0xLTEtMS02MjU_e80c617e-1086-41b9-8998-7c46243624ca">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibfb27a06184e4e31aef700c5aeb48dca_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC0zLTEtMS02MjU_45cbaa3e-e818-44f2-ba74-e5ea2ab7f2ab">260,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ide7ef1452afe4c4580b20216f9d426d3_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC01LTEtMS02MjU_dc0ad9d5-b708-4c02-86d2-710d9af83462">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i35bb901c7d87467e8fac6a7c4651c882_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC03LTEtMS02MjU_073ec3f4-466c-46c1-af3a-3f31483ee9d6">260,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifa9fc66c28764293b5cdc58bd4e86731_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS0xLTEtMS02MjU_f9d82d8f-4c7c-4e5e-9df5-441336aaa408">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie292ab553fbb4ec4855d3b8096d93cc7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS0zLTEtMS02MjU_af245b41-ebae-4389-9227-69a0cb2e1802">68,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06261a683538461bbd86190f85931bf5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS01LTEtMS02MjU_121efd39-d474-47fd-920a-ddb3089c5e30">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie5785a70c9934456af3fe1177ffc0ee5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS03LTEtMS02MjU_cff04a05-78c8-482e-adc0-c5637a28b45c">68,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i303bc5d507cc4c54a23fba781ae5f340_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi0xLTEtMS02MjU_e07b800d-7587-4b8e-b65a-41da8d62b134">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icac73633a71d4e618363eb56e2a3a253_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi0zLTEtMS02MjU_22dafbee-60ec-4364-826d-fe41eed55c9f">144,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if6594a7d2aa24288ab622eea92cdeba3_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi01LTEtMS02MjU_b3d7a30b-11e9-4360-bb9c-3ba59e7940b7">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ieb33227ca5de4db4a6b3eb5329ce0367_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi03LTEtMS02MjU_ba5065d3-bbeb-44a9-9ce3-fa587e2647e4">144,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i886bb35d7ce64dcb868325a77ed5372c_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy0xLTEtMS02MjU_35adef48-240d-4fea-98e6-2aa044be11ec">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifea3fcbfe06448049f8dbed1665c5eac_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy0zLTEtMS02MjU_837e9d4a-96f9-4319-af70-50057da7eef3">21,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1548cfd0b12440e2824883003e410515_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy01LTEtMS02MjU_a6a0427b-8bc4-4ccb-b859-c8a1375270b7">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i820f7b961f97462e883d5674468dcf5b_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy03LTEtMS02MjU_3f55a9f5-6d6b-4056-8110-f14edf88bd46">21,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied7de4ead6ad466a85824c3b11e8d10c_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC0xLTEtMS02MjU_8f52e50a-dcb4-47a3-b602-4282f43d8bcd">108,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9b8461fe0bdb4ab585ffcc851e599cee_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC0zLTEtMS02MjU_b19e11e0-30e4-424b-8233-49c2d803a77d">495,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iabc26d6dc7a2499380b2727bb7a926fc_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC01LTEtMS02MjU_c7e12f50-2335-4e33-ba5d-0f7068b268b6">-</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb56c4d8b7ae4aaca71bb026b154f0b8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC03LTEtMS02MjU_c4f1c0aa-0b52-4fe4-b997-db4ad80947b9">603,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i25d26736ba6e4b0989ccc984f8a74878_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMjM0MQ_e9603aa9-c979-40cf-a4cb-fd147c4d87dd" continuedAt="if899519dc1004b20bcf497a0c2d66670" escape="true">Commitments and contingencies</ix:nonNumeric></span></div><ix:continuation id="if899519dc1004b20bcf497a0c2d66670"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three months ended March&#160;31, 2022 and March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTY0Mzg3Mg_f7c9a73d-92f0-4528-971d-19e936560d05">44.6</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfNDk0NzgwMjMzMjUxNA_16d8c450-b66c-4eab-b0cf-30e2ffa093eb">nil</ix:nonFraction> was expensed related to such obligations, and $<ix:nonFraction unitRef="usd" contextRef="i5f895582ef4c48da9ac1da31b476fc7f_D20220101-20221231" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfNTQ5NzU1ODI5NjE3_6a479c0e-8d3b-45df-8a0f-cd6132430e33">19.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib92c33e75ce64416b44d79aa0e9d2f2a_D20230101-20230331" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTYzNDYyNA_d4554663-010b-4461-ae9e-94ae4143cf79">3.1</ix:nonFraction>&#160;million was included in current liabilities as of December&#160;31, 2022 and March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred expenditures of $<ix:nonFraction unitRef="usd" contextRef="if4d9776d15fb44e9aa31ce79baa8cec0_D20230101-20230331" decimals="-5" name="abcl:StrategicInnovationFundEligibleExpenditure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTYzMDE5NA_e614fceb-25cc-46a5-a76b-991f46712402">46.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic267a77a490446c98ef71777d2d5ff57_D20230101-20230331" decimals="-5" name="abcl:StrategicInnovationFundEligibleExpenditure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTYzMDIwMg_89d07dfa-aa21-4014-b780-60d7f11bab30">38.8</ix:nonFraction>&#160;million under phase 1 and 2, respectively, under the Canadian government&#8217;s Strategic Innovation Fund, or SIF. Spending under phase 1 of the agreement and such amounts are not repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of March&#160;31, 2023, no amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable as of March&#160;31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_79"></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and &#8220;forward-looking information&#8221; within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. Forward-looking statements can often be identified by the use of terminology such as &#8220;subject to&#8221;, &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but are not limited to:</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">our expectations regarding the rate and degree of market acceptance of our antibody discovery and development engine;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">companies and technologies in our industry that compete with our business;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">our ability to manage and grow our business by introducing our antibody discovery and development engine to new partners and expanding our relationships with existing partners;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">our operating results and financial performance;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our partners&#8217; ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties owed to us, in the expected timelines or at all;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to provide our partners with a full solution from target identification to investigational new drug, or IND, submission;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our partners&#8217; ability to develop and commercialize a molecule discovered by us, on a timely basis or at all;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations regarding the completion of our good manufacturing practices, or GMP, facility and our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to establish and maintain intellectual property protection for our technologies and workflows and avoid or defend against claims of patent infringement; </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to attract, hire and retain key personnel and to manage our personnel growth effectively;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to obtain additional financing in future offerings;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the volatility of the trading price of our common shares;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">business disruptions affecting our operations and the development of our antibody discovery and development engine;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the global economic impact of the ongoing conflict between Russia and Ukraine and related sanctions and market volatility;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to avoid material weaknesses or significant deficiencies in our internal control over financial reporting in the future;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations regarding our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Passive Foreign Investment Company, or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> PFIC, status for our taxable year ended December 31, 2023, or any future taxable year;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations regarding our recent business acquisitions and our ability to realize the intended benefits of such acquisitions;</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our expectations regarding the use of our cash resources; </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">our expectations about market trends; and</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to predict and adapt to government regulation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements. We have included important factors in the cautionary statements included in this Quarterly Report, particularly in &#8220;Summary of the Material and Other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risks Associated with Our Business&#8221; above and &#8220;Risk Factors&#8221; below, that we believe could cause actual results or events to differ materially from our forward-looking statements. We operate in a competitive and rapidly changing environment and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, inflation generally affects us by increasing our employee-related costs and certain other expenses. Our financial condition and results of operations may also be impacted by other factors we may not be able to control, such as global supply chain disruptions, uncertain global economic conditions, global trade disputes or political instability as further discussed in the section &#8220;Risk Factors&#8221; in this Quarterly Report.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may differ materially from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All market data used in this Quarterly Report involves assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We express all amounts in this Quarterly Report on Form 10-Q in U.S. dollars, except where otherwise indicated. References to &#8220;$&#8221; and &#8220;US$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; and &#8220;CAD$&#8221; are to Canadian dollars.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to &#8220;AbCellera,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to AbCellera Biologics Inc. and its consolidated subsidiaries.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a team of scientists, engineers, creatives, and business professionals addressing the barriers of conventional antibody drug development. We believe investments in technology will improve the quality, speed, and success of drug development and that long-term value creation begins with building a great company that can create multiple products, repeatedly and successfully.</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus on the development of antibody-based drugs and are committed to improving discovery and development. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to be the best in the world in bringing antibody therapeutics from target to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the start of clinical testing by combining expertise, technologies, and infrastructure to build an integrated engine for antibody drug discovery and development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e think deeply about capital allocation and strive to maximize long-term value while mitigating the risks that are inherent in drug development and in scaling a company. We look for opportunities where we believe low-risk investments in building technology and operational efficiency can create a sustained competitive advantage and drive long-term value by making biologics drug development faster and more efficient. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We structure our agreements in a way that is designed to align our partners&#8217; economic interests with our own. We partner with companies of all sizes and government organizations to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> propel programs to the clinic, together.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We enable discovery against targets that have traditionally been intractable, and we accelerate programs against less difficult targets. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deals emphasize participation in the success and upside of future antibody therapeutic candidates. Our partnership agreements include near-term payments for technology access, research and intellectual property rights, and downstream payments in the form of clinical and commercial milestones, and royalties on net sales. We also participate in alternative investment opportunities including equity in our business partners and various rights for deeper involvement in moving molecules forward. Longer-term we are eligible to receive additional payments upon satisfaction of clinical and commercial milestones, which we refer to as milestone payments, as well as royalties on net sales of approved products derived from antibodies that we discover for our partners. Our discovery partnerships generally include royalty payments on net sales in the single-digit to low-double digit range. </span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus a substantial portion of our resources on research and development efforts towards strengthening our discovery and development engine and we expect to continue to make significant investments in this area for the foreseeable future. We expect to continue to incur significant expenses, and we expect such expenses to increase substantially in connection with our ongoing activities, including as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invest in research and development activities to improve our antibody discovery and development engine including investments in building our new headquarters through our joint ventures and building a new small-scale manufacturing facility; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market and sell our solutions to existing and new partners; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand and enhance operations to deliver programs, including investments in manufacturing; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire businesses or technologies to support the growth of our business; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract, hire and retain qualified personnel; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to establish, protect and defend our intellectual property and patent portfolio, including our ongoing litigation</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have financed our operations primarily from revenue from our antibody discovery partnerships in the form of royalty revenue, government funding from grants, and from the issuance and sale of convertible preferred shares and notes, and common shares.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have grown the number of programs that we have under contract with our partners, as illustrated by the following chart. In the first quarter of 2023, we added three new programs under contract and one molecule was advanced into the clinic. As of March&#160;31, 2023, we had 177 discovery programs that are either completed, in progress or under contract with 41 partners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><img src="abcl-20230331_g1.gif" alt="KBM Image Q1'23.gif" style="height:319px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our key operating results for the quarters ended March&#160;31, 2022 and March&#160;31, 2023. All figures are in U.S. dollars and amounts are expressed in thousands, except share data:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,628</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,419</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,631</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,066</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224,950</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(64,874)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,859)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,726)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) before income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,809</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,148)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Exclusive of depreciation and amortization </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses include stock-based compensation as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Factors Affecting Our Results of Operations and Future Performance</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part II, Item 1A, Risk Factors.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Securing additional programs under contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our potential to grow revenue, in both the near and long term, is dependent on our ability to secure additional programs under contract from new and existing partners. For existing partners, we seek to expand our relationships with them to cover multi-year, multi-target programs. Since our first commercial partnership in 2015, as of March&#160;31, 2023, we had 177 discovery programs that are either completed, in progress or under contract with 41 partners. We are building our business development team across the major biotechnology geographic hubs to bring in new partners and new programs under contract, and we believe that we have a significant opportunity to continue to increase the number of partners who have programs based on our discovery and development engine. Our ability to continue to grow our number of programs under contract is dependent upon our ability to educate the market and support the business through investment in our sales and marketing efforts and through further research and development to enhance our discovery differentiation. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Our partners successfully developing and commercializing the antibodies that we discover.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We estimate that, based on the terms of our existing contracts and estimates of historical rates of success of antibody drug development, the vast majority of the potential value for each program under contract is represented by potential future milestone payments and royalties rather than research fees. As a result, we believe our business and our future results of operations will be highly reliant on the degree to which our partners successfully develop and commercialize the antibodies that we discover based on contracts with our partners. As our partners continue to advance development of the antibodies that we have discovered, we expect to start receiving additional milestone payments and royalties if any partners commence commercial sales of such antibodies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Rate and timing of selecting and initiating discovery projects by our partners. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once programs are secured under contract, partners must select targets and agree on a detailed statement of work before we commence discovery research on any antibodies. The rate and timing of such selection and initiation differs from partner to partner. Research fees that we recognize under our partnerships depend on our delivery of antibodies for development by our partners and delays by our partners in selecting targets and agreeing on statements of work will impact revenue recognition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Investing in enhancements to our discovery and development engine. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to maintain and expand our partnerships is dependent on the advantages our discovery and development engine delivers to our partners. We intend to maintain our leading position through investments in research and development to refine and add capabilities in areas such as computation, protein engineering, immunization technologies, genetically engineered rodents and cell line selection. We have successfully executed and will continue to look for strategic technology acquisitions to improve, broaden and deepen our capabilities and expertise in antibody discovery and development, or those that offer opportunities to expand our partnership business into adjacent therapeutic modalities. We intend to devote substantial resources to continue to improve our discovery differentiation which will impact our financial performance. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Scaling our operations to execute on discovery programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As we secure additional programs under contract and as our partners initiate discovery programs, our operational capacity to execute such research activities may become strained. We are making significant investments in capital and time to increase our ability to address future growth, including building new headquarters through our Dayhu and Beedie joint ventures, building a new small-scale manufacturing facility, investing in research and development, and continuing to hire talented personnel across functions. We have new facilities under development scheduled to take occupancy in 2024 that are intended to materially expand capacity. As we expand our workforce, we expect a significant increase in our operating expenses, including stock-based compensation.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Business Metrics</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative Metrics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change % </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of discovery partners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Programs under contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partnered program starts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecules in the clinic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below outlines the details of molecules in the clinic as of March&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Molecule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Most advanced stage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Therapy areas</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Program type</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bamlanivimab (LY-CoV555)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed, EUA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease &#8211; COVID-19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Pre-partnered Program - Partnered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bebtelovimab (LY-CoV1404)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketed, EUA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease &#8211; COVID-19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Pre-partnered Program - Partnered</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TAK-920/DNL919</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurology - Alzheimer's Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Partner-initiated Discovery</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Partner-initiated Discovery</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni license</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBL-012</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NovaRock Biotherapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology, gastrointestinal, immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni license</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBL-015/FL-301</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NovaRock Biotherapeutics Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni license</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBL-020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND/CTA authorized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NovaRock Biotherapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni license</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IVX-01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical field study</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invetx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Animal health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Partner-initiated Discovery</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Number of discovery partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents the unique number of partners with whom we have executed partnership contracts. We view this metric as an indication of the competitiveness of our engine and our level of market penetration. The metric also relates to our opportunities to secure programs under contract. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Programs under contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represent the number of antibody development programs that are under contract for delivery of discovery research activities. A program under contract is counted when a contract is executed with a partner under which we commit to discover or deliver antibodies against one selected target. A target is any relevant antigen for which a partner seeks our support in developing binding antibodies. We view this metric as an indication of commercial success and technological competitiveness. It further relates to revenue from access fees. The cumulative number of programs under contract with downstream participation is related to our ability to generate future revenue from milestone payments and royalties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered program starts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represent the number of unique programs under contract for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of our operational capacity to execute on programs under contract. It is also an indication of the selection and initiation of discovery projects by our partners and the resulting potential for near-term payments. Cumulatively, partnered program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties in the mid- to long-term. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Molecules in the clinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summary partnership agreements with pharmaceutical and biotechnology companies that include downstream participation from 2016 to March&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"># of Targets&#160;&amp; Duration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Therapeutic Indication or Modality</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Announced</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RQ Biotechnology Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 3 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 22, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 5 targets, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rallybio Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 5 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare metabolic disorder and undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atlas' stealth stage company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 3 targets, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed biotechnology company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 3 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 29, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Empirico Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 additional targets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Everest Medicines Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 10 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology and undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 22, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 6 targets, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA-encoded antibodies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 15, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EQRx, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology and immunology (initially)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 4, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tachyon Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed biotechnology company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 4 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Angios</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ophthalmology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 6, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed biotechnology company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 6, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Empirico Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 targets, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abdera Therapeutics Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 targets, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 14, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invetx, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Animal Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 19, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kodiak Sciences Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ophthalmology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 29, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IGM Biosciences, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology and immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 24, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bispecific</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 3, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 9 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 program and additional indications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 22, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regeneron Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 16, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Invetx, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Animal health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 23, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 25, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 13, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 targets, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurological diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis AG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to 10 targets, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy (CAR-T)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 29, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurological diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 12, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed mid-cap biopharmaceutical company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 25, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membrane protein</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membrane protein</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 5, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed global biotechnology company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multi-target, multi-year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 4, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kodiak Sciences Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Single target</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ophthalmology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 24, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undisclosed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Effective date of agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div id="i25d26736ba6e4b0989ccc984f8a74878_428"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the three months ended March&#160;31, 2022 and March&#160;31, 2023:</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.479%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">307,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(307,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,192&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(304,389)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue decreased by $304.4 million from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. The decrease was driven primarily by the absence of royalty revenue recognized in the period since the FDA announced bebtelovimab is no longer authorized for emergency use in any U.S. region in the fourth quarter of 2022. The increase in milestone payments and research fees of $1.3 million and $1.2 million, respectively, was attributable to the progress of our research and development efforts and an increased number of programs under contract and program starts.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Fees</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,637)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees for the three months ended March 31, 2022 and three months ended March 31, 2023 were $44.6&#160;million and nil, respectively. Royalty fees were attributable to the royalty revenues received by the Company from sales of bamlanivimab and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bebtelovimab</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Eli Lilly and Company ("Lilly") due to AbCellera&#8217;s collaborations in pandemic response. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:25.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $26.3&#160;million, or 100%, from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses reflect the continued growth in program execution, platform development, forward integration, and investment in partnered and pre-partnered programs, all of which contribute to increased capabilities and capacity of AbCellera's engine for antibody discovery and development. Approximately $20.0 million in the first quarter is related to specific one time investments in co-development and pre-partnered programs. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he remaining increase includes a $1.8 million increase in compensation-related expenses consistent with the increase in headcount and a $4.5 million increase in facilities, supplies and services expenditure consistent with the overall growth of the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses increased by $1.4&#160;million, or 59%, from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. The increase was attributable to business development activity, consulting fees, and compensation costs of $1.4 million. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $0.9&#160;million, or 6%, from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. $0.6 million of the increase in general and administrative expense is compensation-related and driven by the increase in headcount. The remaining $0.3 million increase was due to an increase in software, licensing, and facility expenses incurred to support the growth of the Company, partially offset by a decrease in legal and consulting fees. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:27.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 14.5pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or 38%, from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. Depreciation expense increased by $1.5 million due to the depreciation of equipment and facilities related to capital equipment purchases.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest (Income)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,759)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,094)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.1&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or 1368%, from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. The increase was primarily driven by an increase in interest rates on our cash and cash equivalents and marketable securities balances in the quarter ended March&#160;31, 2023, compared to the period ended March&#160;31, 2022.</span></div><div><span><br/></span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants and incentives</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants and incentives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,194)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants and incentives decreased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8&#160;million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the three months ended three months ended March 31, 2022 compared to the three months ended March 31, 2023. This decrease was primarily driven by a decrease in activity relating to research and development expenditures that are eligible for the SIF project for the period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,593)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,593)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.6&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the three months ended March 31, 2022 compared to the three months ended March 31, 2023. The increase included other income of $0.6 million and a $3.5 million gain on fair value adjustments related to held-for-trading marketable securities and contingent consideration, partially offset by a foreign exchange loss of $0.6 million due to fluctuations in the Canadian and U.S. dollar exchange rate.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax (Recovery) Expense</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (recovery) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70,274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense decreased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$70.3&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the three months ended March 31, 2022 to the three months ended March 31, 2023. The decrease is primarily driven by current net earnings in the period and a change in effective income tax rates. </span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had $796.5&#160;million of cash, cash equivalents and marketable securities, comprising $193.0 million in cash and cash equivalents and $603.5 million in marketable securities. The decrease of $90.0&#160;million since December&#160;31, 2022, was primarily from cash flow from operations with an increase in research and development activity and continued investment in the capacity and capabilities of AbCellera&#8217;s discovery and development engine in three months ended March 31, 2023. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated positive operating cash flow cumulatively since our inception in 2012 and in every year from 2018 to 2022. We intend to significantly invest in our business, and as a result may incur operating losses in future periods. We will continue to invest in research and development efforts towards expanding our capabilities and expertise along our discovery and development engine, the building of our business development team and marketing our solutions to new and existing partners, and the expansion of our future office headquarters, and related infrastructure, including execution of long-term office-lease arrangements. Based on our current business plan, we believe that our existing cash, cash equivalents, marketable securities, and anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs and do not anticipate the need of external funding over at least the next 36 months following the date of this report.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate fluctuations on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(194,343)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities decreased from $100.2&#160;million provided by operations in the three months ended March 31, 2022 to $44.1&#160;million used in operations in the three months ended March 31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in cash flows from operations is attributable to no royalty revenue and a reduction in royalty-related payments in the period, in addition to an increase in expenditures that reflect AbCellera&#8217;s investment in research and development activities and growth of the company.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities increased from $26.4&#160;million in the three months ended March 31, 2022 to $149.6&#160;million in the three months ended March 31, 2023. Investing activities during the three months ended March 31, 2022 were primarily attributable to purchases of property and equipment and purchases of long-term investments. For the three months ended March 31, 2023, investing activities included the purchase of property and equipment, long-term investments, and marketable securities.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $3.1&#160;million for the three months ended March 31, 2022 due to the payment of an intangible asset obligation and contingent consideration payment, partly offset by proceeds from long-term debt and the exercise of options for common stock. Net cash used in financing activities was $0.5&#160;million for the three months ended March 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to a contingent consideration payment, par</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tly offset by proceeds from the exercise of options for common stock.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_103"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgements and Estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information about our critical accounting policies and estimates is set forth in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December&#160;31, 2022. There have been no significant changes to these policies during the three months ended March 31, 2023. </span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk is described in Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk of our annual report on Form 10-K for the year ended December&#160;31, 2022. We believe our exposure to market risk has not changed materially since then.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures are designed to ensure that information required to be disclosed is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, to allow timely decisions regarding required disclosure. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2023, the Patent Trial &amp; Appeals Board (&#8220;PTAB&#8221;) issued its Final Written Decision in the Inter Partes Review of U.S. Patent No. 10,087,408 (&#8220;the &#8217;408 Patent&#8221;). See Berkeley Lights, Inc. v. Univ. of British Columbia, IPR2021-01250, US Pat. No. 10,087,408, Paper 38 (PTAB Jan. 19, 2023). In its Final Written Decision, the PTAB found against Defendant Berkeley Lights, Inc. and upheld the validity of all challenged claims of the &#8217;408 Patent. The Company subsequently moved to lift the stay in view of the PTAB&#8217;s decision. Berkeley Lights opposed the motion. A decision on the Company&#8217;s motion to lift the stay is pending before the court.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the pending matter Sabariah Schrader, Executrix of the Estate of John William Schrader et al. v. Carl Lars Genghis Hansen, et al., the Company recently filed a Notice of Application seeking to dismiss certain Company affiliates from the matter. No hearing date has been set. No other activity is occurring with respect to this matter. The Company believes that Plaintiffs&#8217; claim is meritless and frivolous in all respects and intends to defend itself appropriately.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to legal proceedings as set forth in our annual report on Form 10-K for the period ended December&#160;31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_448"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses in certain years since inception and we may not be able to generate sufficient revenue to maintain profitability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue investing in our business. We expect to experience fluctuations in revenue and expenses which makes it difficult to evaluate our business. We may incur losses that are materially larger than what we have previously incurred. We have incurred losses in certain years since our inception and anticipate that we may incur significant losses for the foreseeable future. We expect that our operating expenses will continue to increase significantly, including as we: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">invest in research and development activities to improve our discovery and development engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market our solutions to new and existing partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire businesses or technologies to support our business; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attract, hire and retain qualified personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintain, expand, enforce, protect and defend our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prosecute and defend our ongoing and any future patent litigation; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">build our new GMP manufacturing facility; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">create additional infrastructure to support our operations, including expanding our sales and marketing organization; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">add operational, financial and management information systems and personnel to support our operations as a public company; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">experience any delays or encounter issues with any of the above. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses could increase beyond expectations for a variety of reasons, including our growth strategy and the increase in our operations. Since our inception, we have financed our operations primarily from royalty revenue, revenue from upfront payments generated through our receipt of technology access fees and discovery research fees through the performance of service contracts with our partners, payments from partners upon the satisfaction of clinical milestones, government funding and one-off government grants, the incurrence of indebtedness, and from private placements of our common and convertible preferred shares. Given our strategy and plans to invest in enhancing and scaling our business, we will need to generate significant additional revenue to achieve and sustain future profitability. Even though we have achieved profitability, we cannot be sure that we will remain profitable for any sustained period of time. We may not be able to generate sufficient revenue to sustain profitability and our recent and historical growth should not be considered indicative of our future performance. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue has fluctuated from period to period, and our revenue for any historical period may not be indicative of results that may be expected for any future period. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December 31, 2020, 2021, and 2022, we received payments from our partnership contracts generated upon the satisfaction of clinical milestones, licensing revenue derived from use of the Trianni platform, research fees for research performed for our partners, and royalty payments on sales of bamlanivimab and bebtelovimab. In 2022, we continued to receive royalty payments primarily on sales of bebtelovimab. Upfront technology access fees are generated upon execution of our partnership agreements. Research and discovery fees are generated by research activities that we perform for our partners, the timing and nature of which are dictated by the commencement of antibody discovery campaigns selected by our partners. Clinical milestone payments are generated upon the achievement of development milestones by our partners with respect to the antibodies that we deliver. We are also eligible to receive royalty payments upon net sales of antibodies that we have discovered for our partners. In 2020, 2021, and 2022, these royalty payments related to our partnership with Lilly upon sales of bamlanivimab and bebtelovimab, antibodies designed to treat and prevent COVID-19. Therefore, royalty payments that we have received in recent periods are derived from a compound developed in a single partnership. In November 2022, the FDA announced bebtelovimab was no longer authorized for emergency use in any U.S. region and, as a result, we do not expect to generate significant revenue from royalties associated with Lilly&#8217;s sales of our COVID-19 antibodies. For the three months ended March 31, 2023, we did not generate any royalty revenues. We currently do not generate significant recurring revenue and, until such time as we establish significant recurring revenue, if at all, we will be prone to regular fluctuations in our revenue dependent on the timing of our entry into partnership agreements, our partners initiating discovery programs, and our partners achieving development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">milestones or commercial sales with respect to drug candidates utilizing antibodies discovered using our discovery and development engine. We do not expect to generate significant recurring revenue unless and until such time as we secure additional programs under contract that, in the aggregate, result in regular and continuous execution of new partnership contracts, research discovery activities, achievement of development milestones or commencement of commercial sales. However, we are unable to predict whether and the extent to which the minimum annual payments under our partnership agreements will be exceeded, or the timing of the achievement of any milestones under these agreements, if they are achieved at all. In some cases, the timing and likelihood of payments to us under these agreements is dependent on our partners&#8217; successful utilization of the antibodies discovered using our discovery and development engine, which is outside of our control. Because of these factors, our operating results could vary materially from quarter to quarter from our forecasts.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results have fluctuated in the past and may fluctuate in the future, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of demand for our antibody discovery and development engine and solutions, which may vary significantly; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">royalty payments received from our partnership with Lilly upon sales of bamlanivimab or bebtelovimab, which may vary significantly and are dependent on obtaining emergency use authorization by the FDA; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and cost of, and level of investment in, research, development and commercialization activities relating to our discovery and development engine and technology, which may change from time to time; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the start and completion of programs in which our discovery and development engine is utilized; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the relative reliability and robustness of our discovery and development engine, including the data generation and computational tools within our discovery and development engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the introduction of new technologies, platform features or software, by us or others in our industry; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenditures that we may incur to acquire, develop or commercialize additional technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenditures involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including costs related to our intellectual property litigation with Berkeley Lights, and the outcome of this and any other future patent litigation we may be involved in; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to our civil litigation with the Estate of John Schrader, or Schrader, and the outcome of this and any other future civil litigations we may be involved in;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">natural disasters, outbreaks of disease or public health crises, such as the ongoing COVID-19 pandemic; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and nature of any future acquisitions or strategic partnerships; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">future accounting pronouncements or changes in our accounting policies; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general social, political and economic conditions and other factors, including inflationary pressures and factors unrelated to our operating performance or the operating performance of our competitors. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, 2020 was the first year in which we received payments from a partner beyond upfront fees. The antibody, bamlanivimab developed by Lilly, has undergone clinical testing and has received EUA from the FDA, and we have received associated milestone payments and royalties on net sales in 2020, 2021, and 2022. Lilly progressed into these clinical trials at a greatly accelerated pace as a result of the Coronavirus Treatment Acceleration Program, which is a special emergency program for possible coronavirus therapies created by the FDA in 2020 to expedite the development of potentially safe and effective life-saving treatments to combat the COVID-19 pandemic. With respect to other or future product candidates, there is no assurance that any of our partners or collaborators will be able to advance a product candidate through clinical development on this timeframe again in the future, or at all. We initiated our partnering program in 2015 and have only had three AbCellera discovery programs and three Trianni programs result in milestone or royalty payments to us to date, and we have not yet had a program receive marketing approval. There is no guarantee that we will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to generate the levels of revenue, particularly milestone and royalty revenues, from our partnerships as we have experienced in recent periods. In addition, we have only recently begun to generate licensing revenue from our Trianni humanized rodent platform. There can be no assurance that we will continue to generate or expand our licensing revenue from this product offering in future periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of one of the factors discussed above, or the cumulative effects of a combination of factors discussed above, could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital to fund our existing operations, improve our discovery and development engine or expand our operations. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current business plan, we believe our existing cash and cash equivalents, marketable securities, and anticipated cash flows from operations, will be sufficient to meet our working capital and capital expenditure needs over at least the next 36 months following the date of this report. If our available cash resources together with our anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our antibody discovery and development engine, or the realization of other risks described in this annual report, we may be required to raise additional capital prior to such time through issuances of equity or convertible debt securities, entrance into a credit facility or another form of third party funding or seek other debt financing. Such additional financing may not be available on terms acceptable to us or at all. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any event, we may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. For example, this may include reasons such as to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increase our sales and marketing efforts to drive market recognition of our discovery and development engine and address competitive developments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fund development and marketing efforts of our current and future programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand the capabilities of our discovery and development engine into adjacent therapeutic modalities, including vaccine development and cell therapy; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire, license or invest in technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire or invest in complementary businesses or assets; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">finance capital expenditures and general and administrative expenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future funding requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve revenue growth; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of expanding our operations, including our sales and marketing efforts; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our rate of progress in selling access to our discovery and development engine and marketing activities associated therewith; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our rate of progress in, and cost of research and development activities associated with, antibody discovery; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the effect of competing technological and market developments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the continued impact of the ongoing COVID-19 pandemic on global social, political and economic conditions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the economic and geopolitical impact of the ongoing conflict in the Ukraine;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including costs related to our intellectual property litigation with Berkeley Lights, and the outcome of this and any other future patent litigation we may be involved in; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to our civil litigation with Schrader, and the outcome of this and any other future civil litigations we may be involved in; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to any domestic and international expansion. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders would result. Any preferred equity securities issued also would likely provide for rights, preferences or privileges senior to those of holders of our common shares. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common shares. Debt financing and preferred equity financing, if available, may also involve agreements that include covenants restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures, or declaring dividends. For example, our agreement with the Strategic Innovation Fund, or SIF, requires us to obtain consent in the event that an individual or company (or two or more of them acting in concert) acquires the direct or indirect beneficial ownership of 20% or more of our voting securities. In the event consent is not obtained, the agreement may be terminated and we will be obligated to repay all or a portion of the contribution amounts from SIF. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain adequate financing or financing on terms satisfactory to us, if we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that future deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Moreover, there has been recent instability of the global banking system. Continued disruptions in the banking system, both in the U.S. or abroad, may impact our or our customers&#8217; liquidity and, as a result, negatively impact our business and operating results. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends on the quality of our antibody discovery and development engine and technological capabilities and their acceptance by new and existing partners in our industry. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize our antibody discovery and development engine to identify antibodies for further development and potential commercialization by our partners. As a result, the quality and sophistication of our discovery and development engine is critical to our ability to conduct our research discovery activities and to deliver more promising molecules and to accelerate and lower the costs of discovery as compared to traditional methods for our partnerships. In particular, our business depends, among other things, on: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our discovery and development engine&#8217;s ability to successfully identify therapeutic antibodies on the desired timeframes that can ultimately be used to prevent and treat diseases; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to execute on our strategy to enter into new partnerships with new or existing partners and establish a robust internal pipeline of antibody discovery programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to increase awareness of the capabilities of our technology and solutions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our partners&#8217; and potential partners&#8217; willingness to adopt new technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether our discovery and development engine reliably provides advantages over legacy and other alternative technologies and is perceived by customers to be cost effective; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the rate of adoption of our solutions by pharmaceutical companies, biotechnology companies of all sizes, government organizations and non-profit organizations and others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prices we charge for our data packages and the discoveries that we make; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the relative reliability and robustness of our discovery and development engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to develop new solutions for partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if competitors develop a platform that performs functional testing of cells at a greater throughput than us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and scope of any approval that may be required by the FDA, or any other regulatory body for drugs that are developed based on antibodies discovered by us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of our investments in innovation and commercial growth; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative publicity regarding our or our competitors&#8217; technologies resulting from defects or errors; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to further validate our technology through research and accompanying publications.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will successfully address any of these or other factors that may affect the market acceptance of our discovery and development engine. If we are unsuccessful in achieving and maintaining market acceptance of our discovery and development engine, our business, financial condition, results of operations and prospects could be adversely affected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to execute our business strategy could adversely impact our growth and profitability.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy focuses on the development of antibody-based drugs and improving the way these drugs are discovered and developed. Our strategy assumes a certain degree of capital and capacity growth development. Factors such as insufficient capital, inflation, supply chain interruptions, inadequate forecasting, increases in construction material costs, or labor shortages could interfere with the successful execution of our strategy and our ability to timely build infrastructure to satisfy capacity needs and support business growth. If we are unable to successfully execute on this strategy, this could negatively impact our future results of operations and market capitalization. For additional discussion of our business strategy, please see the section entitled &#8220;Item 1. Business&#8221; included in our Annual Report on Form 10-K for the year ended December 31, 2022. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain and expand current partnerships and agreements and enter new partnerships that generate discovery programs for antibodies, our business could be adversely affected. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is on the discovery of antibodies for targets that are selected by our partners. Our partners then use the data packages provided by us to develop their own drug candidates without our involvement. As a result, our success depends on our ability to expand the number and scope of our partnerships. Many factors may impact the success of these partnerships, including our ability to perform our obligations, our partners&#8217; satisfaction with our data packages, our partners&#8217; ability to successfully develop, secure regulatory approval for and commercialize drug candidates using antibodies discovered using our discovery and development engine, our partners&#8217; internal priorities (including fluctuations in research and developments budgets), our partners&#8217; resource allocation decisions and competitive opportunities, disagreements with partners, the costs required of either party to the partnerships and related financing needs, and operating, legal and other risks in any relevant jurisdiction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our partnership programs, we maintain rights to large unique data sets that connect information at the level of single-cell measurements, DNA sequence and protein function. We use this data to create an accelerating flywheel of learning: data generation from our partnership business provides the basis for AI modules that lead to expanded capabilities and faster data generation which supports our partnership business. As a result, in addition to reducing our revenue or delaying the development of our future solutions, the loss of one or more of these relationships may reduce our exposure to such information, thus hindering our efforts to further our technological differentiation and improve our discovery and development engine. In certain of our partnership programs, we may elect to make additional investments in certain partnership agreements at progressive stages of preclinical development, clinical development, and commercialization in exchange for an increased share of product sales. Because of the inherent uncertainties in drug development described elsewhere in these Risk Factors, there can be no assurance that any additional investments we may elect to make would yield meaningful return, if at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in conversations with companies regarding potential partnerships on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, including due to our inability to discover any usable antibodies for the selected targets or the antibodies that we do discover may not be successfully developed or commercialized by our partners. In such circumstances, we would not generate any substantial revenues from such a collaboration in the form of discovery research fees, milestone payments, royalties or otherwise. Speculation in the biotechnology industry about our existing or potential partnerships can be a catalyst for adverse speculation about us, or our data packages, which can adversely affect our reputation and our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A reduction in demand and research and development activities by current and prospective partners may adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by any significant decrease in drug research and development expenditures by pharmaceutical and biotechnology companies, as well as by government agencies or private foundations. Similarly, economic factors and industry trends that affect our partners in these industries also affect their research and development budgets and, consequentially, our business as well.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners include researchers at pharmaceutical and biotechnology companies. Our ability to continue to grow and win new business is dependent in large part upon the ability and willingness of the pharmaceutical and biotechnology industries to continue to spend on molecules in the non-clinical phases of research and development (and in particular discovery and development assessment) and to outsource the products and services we provide. Furthermore, our partners continue to search for ways to maximize the return on their investments with a focus on lowering research and development costs per drug candidate. Fluctuations in the expenditure amounts in each phase of the research and development budgets of these researchers and their organizations could have a significant effect on the demand for our products and services. Research and development budgets fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities (including available resources of our biotechnology partners, particularly those that are cash-negative, who may be highly focused on rationing their liquid assets in a challenging funding environment), general economic conditions, institutional budgetary policies and the impact of government regulations, including potential drug pricing legislation. Available funding for biotechnology partners in particular may be affected by the capital markets, investment objectives of venture capital investors and priorities of biopharmaceutical industry sponsors. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In recent periods, we have depended on a limited number of partners for our revenue, the loss of any of which could have an adverse impact on our business. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In recent periods, a limited number of partnerships accounted for a significant portion of our revenues. For example, royalty revenue for years ended December 31, 2020, 2021, and 2022, have come exclusively from our partnership with Lilly. Milestone payments and licensing revenue for the years ended December 31, 2020, 2021, and 2022, have come exclusively from our partnership with Lilly and use of the Trianni platform. Because a significant portion of our revenue in 2020, 2021, and 2022 was derived from sales of bamlanivimab and bebtelovimab, the reduction in sales of these compounds that we have experienced in recent periods have reduced or eliminated our royalty revenues attributed to sales of this compound. For example, for the three months ended March 31, 2023, we did not receive any royalty revenues from our partnership with Lilly. If these reductions are not offset by increases in other sources of revenue, our results of operations for future periods may be materially and adversely affected. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing partnerships cover a large number of current programs under contract, and therefore represent a large portion of potential downstream value. In addition, our partnership agreements are typically terminable at will with 90 days&#8217; notice prior to identification of a target, after which point they may only be terminated for cause. As a result, if we fail to maintain our relationships with our partners or if any of our partners discontinue their programs, our future results of operations could be materially and adversely affected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of a biological molecule is inherently uncertain, and it is possible that none of the antibody-drug candidates discovered using our antibody discovery and development engine that are further developed by our partners will receive marketing approval or become viable commercial products, on a timely basis, or at all. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our discovery and development engine to offer antibodies to partners who are engaged in antibody discovery and development. These partners include large cap pharmaceutical companies, biotechnology companies of all sizes and non-profit and government organizations. While we receive upfront payments generated through our receipt of technology access fees and discovery research fees for performing research activities for our partners, we estimate that the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vast majority of the economic value of the contracts that we enter into with our partners is in the downstream payments that are payable if certain milestones are met or approved products are sold. As a result, our future growth is dependent on the ability of our partnerships to successfully develop and commercialize therapies based on antibodies discovered using our discovery and development engine. Due to our reliance on our partners, the risks relating to product development, regulatory clearance, authorization or approval and commercialization apply to us derivatively through the activities of our partners. While we believe our discovery and development engine is capable of identifying high quality antibodies, there can be no assurance that our partnerships will successfully develop, secure marketing approvals for and commercialize any drug candidates based on the antibodies that we discover. As a result, we may not realize the intended benefits of our partnerships. We initiated our partnering program in 2015 and have only had three AbCellera discovery programs and three Trianni programs result in milestone or royalty payments to us to date, and we have not yet had a program receive clinical marketing approval. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, there may not be successful development of any drug candidates with the antibodies that we discover, or we and our partners may choose to discontinue the development of these drug candidates for a variety of reasons, including due to safety, risk versus benefit profile, exclusivity, competitive landscape, commercialization potential, production limitations or prioritization of their resources. It is possible that none of these drug candidates will ever receive regulatory approval and, even if approved, such drug candidates may never be successfully commercialized. For example, under our research agreement with Lilly, we are eligible to receive and have received payments upon the achievement of certain development milestones and are eligible to receive royalties resulting from sales of both COVID-19 and non-COVID-19 products that incorporate antibodies we discovered. While we have received milestone and royalty payments from this collaboration, there can be no assurance that we will receive additional milestone payments or any royalties in the future. For example, in November 2022, the FDA announced bebtelovimab is no longer authorized for emergency use in the U.S., and Lilly and its authorized distributors have paused commercial distribution until further notice by the FDA. Furthermore, there can be no assurance that Lilly will be successful in its further development of bebtelovimab. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if these drug candidates receive regulatory approval in the United States, the drug candidates may never obtain approval or commercialize such drugs outside of the United States, which would limit their full market potential and therefore our ability to realize their potential downstream value. Furthermore, approved drugs may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited. Likewise, we or our partners have to make decisions about which clinical stage and preclinical drug candidates to develop and advance, and we or our partners may not have the resources to invest in all of the drug candidates that contain antibodies discovered using our discovery and development engine, or clinical data and other development considerations may not support the advancement of one or more drug candidates. Decision-making about which drug candidates to prioritize involves inherent uncertainty, and our partners&#8217; development program decision-making and resource prioritization decisions, which are outside of our control, may adversely affect the potential value of those partnerships. Additionally, subject to its contractual obligations to us, if one more of our partners is involved in a business combination, the partner might deemphasize or terminate the development or commercialization of any drug candidate that utilizes an antibody that we have discovered. If one of our strategic partners terminates its agreement with us, we may find it more difficult to attract new partners. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to industry-wide FDA and other regulatory risk. The number of new drug applications, or NDAs, and biologics license applications, or BLAs, approved by the FDA varies significantly over time and if there were to be an extended reduction in the number of NDAs and BLAs approved by the FDA, the biotechnology industry would contract and our business would be materially harmed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to effectively advance, market and sell suitable drug candidates with the antibodies that we discover could have a material adverse effect on our business, financial condition, results of operations and prospects, and cause the market price of our common shares to decline. In addition to the inherent uncertainty in drug development addresses above, our ability to forecast our future revenues may be limited. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of our partners to meet their contractual obligations to us could adversely affect our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on our partners poses a number of additional risks, including the risk that they may not perform their contractual obligations to us to our standards, in compliance with applicable legal or contractual requirements, in a timely manner or at all; they may not maintain the confidentiality of our proprietary information; and disagreements or disputes could arise that could cause delays in, or termination of, the research, development or commercialization of products using our antibodies or result in litigation or arbitration. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our partners are large, multinational organizations that run many programs concurrently, and we are dependent on their ability to accurately track and make milestone payments to us pursuant to the terms of our agreements with them. Any failure by them to inform us when milestones are reached and make related payments to us could adversely affect our results of operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, some of our partners are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, and are often subject to country-specific privacy and data security risk as well as burdensome legal and regulatory requirements. Any of these factors could adversely impact their financial condition and results of operations, which could impair their ability to meet their contractual obligations to us, which may have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to manage our current and future growth effectively, which could make it difficult to execute on our business strategy. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2012, we have experienced rapid growth and anticipate further growth in our business operations. This growth requires managing complexities across all aspects of our business, including complexities associated with increased headcount, integration of acquisitions, expansion of international operations, expansion of facilities, including our new GMP facility, execution on new lines of business and implementations of appropriate systems and controls to grow the business. Our growth has required significant time and attention from our management, and placed strains on our operational systems and processes, financial systems and internal controls and other aspects of our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, engineers, laboratory personnel, client and account services personnel and sales and marketing staff and improve and maintain our technology to properly manage our growth. We may also need to hire, train and manage individuals with expertise that is separate, supplemental or different from expertise that we currently have, and accordingly we may not be successful in hiring, training and managing such individuals. For example, if our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees, or if we are not successful in retaining our existing employees, our business may be harmed. Improving our technology and processes have required us to hire and retain additional scientific, engineering, sales and marketing, software, manufacturing, distribution and quality assurance personnel. As a result, we have experienced rapid headcount growth, resulting in approximately 525 employees as of March&#160;31, 2023. We currently serve partners around the world and plan to continue to expand to new international jurisdictions as part of our growth strategy, which will lead to increased dispersion of our employees. Moreover, we expect that we will need to hire additional accounting, finance and other personnel in connection with our efforts to comply with the requirements of being a public company. As a public company, our management and other personnel need to devote a substantial amount of time towards maintaining compliance with these requirements. A risk associated with maintaining this rate of growth, for example, is that we may face challenges integrating, developing and motivating our rapidly growing and increasingly dispersed employee base. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to maintain the quality, reliability or robustness of our discovery and development engine, or the expected turnaround times of our solutions and support, or to satisfy customer demand as we grow. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. If we are unable to manage our growth properly, we may experience future weaknesses in our internal controls, which we may not successfully remediate on a timely basis or at all. To effectively manage our growth, we must continue to improve our operational and manufacturing systems and processes, our financial systems and internal controls and other aspects of our business and continue to effectively expand, train and manage our personnel. The time and resources required to improve our existing systems and procedures, implement new systems and procedures and to adequately staff such existing and new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could adversely affect our operations and negatively impact our business and financial results. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have invested, and expect to continue to invest, in research and development efforts that further enhance our antibody discovery and development engine. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our discovery and development engine for the discovery of antibodies and, since our inception, we have dedicated a substantial portion of our resources on the development of our engine and the technology that we incorporate to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further enhance our antibody discovery and development engine. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect operating results and that such investments may not generate sufficient technological advantage relative to alternatives in the market which would, in turn, impact revenues to offset liabilities assumed and expenses associated with these new investments. The industry in which we operate changes rapidly as a result of technological and drug developments, which may render our solutions less desirable. We believe that we must continue to invest a significant amount of time and resources in our discovery and development engine to maintain and improve our competitive position. If we do not achieve the benefits anticipated from these investments, if the achievement of these benefits is delayed, or if our discovery and development engine is not able to accelerate the process of antibody discovery as quickly as we anticipate, our revenue and operating results may be adversely affected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs, and the price of our common shares may decline as a result of announcements of unexpected results or developments. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners have significant discretion in determining when and whether to make announcements about the status of our partnerships, including about preclinical and clinical developments and timelines for advancing antibodies discovered using our discovery and development engine. We do not plan to disclose the development status and progress of individual drug candidates of our partners, unless and until those partners do so first. Our partners may wish to report such information more or less frequently than we intend to or may not wish to report such information at all, in which case we would not report that information either. In addition, if partners choose to announce a collaboration with us, there is no guarantee that we will recognize research discovery fees in that quarter or even the following quarter, as such fees are not payable to us until our partner begins discovery activities. The price of our common shares may decline as a result of the public announcement of unexpected results or developments in our partnerships, or as a result of our partners withholding such information. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common shares to decline. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may make public statements regarding the expected timing of certain milestones and key events, as well as regarding developments and milestones under our partnerships, to the extent that our partners have publicly disclosed such information or permit us to make such disclosures. Certain of our partners have also made public statements regarding their expectations for the development of programs under partnership with us and they and other partners may in the future make additional statements about their goals and expectations for partnerships with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future partners&#8217; antibody discovery and development programs, the amount of time, effort, and resources committed by us and our current and future partners, and the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that our partners&#8217; current and future programs will advance or be completed in the time frames we or they expect. If our partners fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected and the price of our common shares could decline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent on the eventual approval and commercialization of products developed by our partners for which we have no control over the clinical development plan, regulatory strategy or commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is dependent on the eventual progression of therapeutic candidates discovered or initially developed utilizing our discovery and development engine into clinical trials and commercialization. This requires us to attract partners and enter into agreements with them that contain obligations for the partners to pay us milestone payments as well as royalties on sales of approved products for the therapeutic candidates they develop that are generated utilizing our discovery and development engine. Given the nature of our relationships with our partners, we do not control the progression, clinical development, regulatory strategy or eventual commercialization, if approved, of these therapeutic candidates. As a result, our future success and the potential to receive milestones and royalties are entirely dependent on our partners&#8217; efforts over which we have no control. Additionally, unless publicly disclosed by our partners, we do not have access to information related to our partners&#8217; preclinical studies or clinical trial results, including serious adverse events, or ongoing communications with the FDA or other regulatory authorities regarding our partners&#8217; development strategy, which limits our visibility into how such programs may be progressing. If our partners determine not to proceed with the future development of a drug candidate discovered or initially developed utilizing our discovery and development engine, or if they implement preclinical, clinical or regulatory strategies that ultimately do not result in the further </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development or approval of the therapeutic candidate, we will not receive the benefits of our partnerships, which may have a material and adverse effect on our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The life sciences and biotechnology platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or sustain profitability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in the life sciences technology market. Our technologies address antibody therapeutic discovery challenges that are addressed by other platform technologies controlled by companies that have a variety of business models, including the development of internal pipelines of therapeutics, technology licensing, and the sale of instruments and devices. Examples of technical competition at different steps of our discovery and development engine include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In the field of single-cell screening, companies that provide access to similar technologies such as Berkeley Lights, HiFiBio Inc., Ligand Pharmaceuticals Inc., and Sphere Fluidics Ltd. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In antibody RepSeq, companies that provide access to similar technologies such as 10X Genomics Inc., Adaptive Biotechnologies Corp., Atreca Inc. and Distributed Bio Inc. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by Charles River</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laboratories in 2021)</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In bispecific antibody engineering, from companies that provide access to similar technologies such as Abbvie Inc., Genmab A/S, Merus N.V. and Zymeworks Inc.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In discovery using genetically engineered rodents, companies that provide access to similar technologies such as Ablexis LLC, Crescendo Biologics Ltd., Harbour Antibodies BV, Kymab Ltd., Ligand Pharmaceuticals Inc., Alloy Therapeutics LLC, and RenBio Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face direct business competition from companies that provide antibody discovery services using technologies such as hybridoma and display. Companies with discovery business models that include downstream payments include Adimab LLC, Distributed Bio Inc. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(acquired </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by Charles River</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laboratories in 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and WuXi Biologics Inc. In addition, we compete with a variety of fee-for-service contract research organizations that provide services, in most cases using legacy technologies, that compete with one or more steps in our discovery and development engine. In addition, our partners may also elect to develop their workflows on legacy systems rather than rely on our discovery and development engine.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors may enjoy a number of competitive advantages over us. For example, these may include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">longer operating histories; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">larger customer bases; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">greater brand recognition and market penetration; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">greater financial resources; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">greater technological and research and development resources; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">better system reliability and robustness; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">greater selling and marketing capabilities; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">better established, larger scale and lower cost manufacturing capabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our competitors and potential competitors may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their platforms or instruments than we can or sell their platforms or instruments, or offer solutions competitive with our discovery and development engine and solutions at prices designed to win significant levels of market share. In addition, we may encounter challenges in marketing our solutions with our pricing model, which is structured to capture the potential downstream revenues associated with drug candidates that were discovered using our discovery and development engine. Our partners and potential partners may prefer one or more pricing models employed by our competitors that involve upfront payments rather than downstream revenues. We may not be able to compete effectively against these organizations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to technology and platform development than we can. If we are unable to compete successfully against current and future competitors, we may be unable to increase market adoption and sales of our discovery and development engine, which could prevent us from increasing our revenue or sustaining profitability. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our antibody discovery and development engine may not meet the expectations of our partners, which means our business, financial condition, results of operations and prospects could suffer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on, among other things, the market&#8217;s confidence that our discovery and development engine is capable of substantially shortening the amount of time necessary to perform certain research activities as compared to the use of legacy and other alternative technologies, and will enable more efficient or improved pharmaceutical and biotechnology product development. For example, while we have in the past been able to identify a potential drug candidate for human testing within 90 days, there is no assurance that we will be able to do so on this timeframe again in the future, or at all. To date, we have only had three AbCellera discovery programs and three Trianni programs result in milestone or royalty payments to us. While our partnership with Lilly has produced bamlanivimab and bebtelovimab, antibodies for which Lilly was granted two EUAs by the FDA, we have not yet had a program receive full marketing approval. We also believe that pharmaceutical and biotechnology companies are likely to be particularly sensitive to defects and errors in the use of our discovery and development engine, including if our engine fails to deliver meaningful acceleration of certain research timelines accompanied by results at least as good as the results generated using legacy or other alternative technologies. There can be no guarantee that our discovery and development engine will meet the expectations of pharmaceutical and biotechnology companies. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to support demand for our antibody discovery and development engine, including ensuring that we have adequate teams and facilities to meet increased demand, or if we are unable to successfully manage our anticipated growth, our business could suffer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant growth in the number of programs under contract in recent periods for which we are conducting research discovery activities. As we secure additional programs under contract and as our partners initiate discovery programs, our operational capacity to execute such research activities may become strained. We are also planning to devote significant resources to vertical integration into our discovery and development engine. As a result, our strategy requires us to successfully scale our teams and facilities to meet future demand for our solutions. Our ability to grow our capacity will depend on our ability to expand our workforce and our facilities and increase efficiency through automation and software solutions. We may also need to purchase additional equipment, some of which can take several months or more to procure and set up. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities or process enhancements will be successfully implemented and in a timely manner. For example, we are currently expanding our facilities in Vancouver and internationally. Such facilities require purpose-built buildings often with rezoning requirements. Such projects are typically long in duration and subject to delays. Failure to manage this growth could result in delays, higher costs, declining quality, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our data packages and could damage our reputation and the prospects for our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our management uses certain key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions and such metrics may not accurately reflect all of the aspects of our business needed to make such evaluations and decisions, in particular as our business continues to grow.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our consolidated financial results, our management regularly reviews a number of operating and financial metrics, including number of programs under contract, the trend of potential downstream revenue terms (milestones and royalties) of the portfolio, the performance of the portfolio in probability of success in achieving clinical milestones as compared to historical averages and the performance of the portfolio in the time taken to achieve clinical milestones, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that these metrics are representative of our current business; however, these metrics may not accurately reflect all aspects of our business and we anticipate that these metrics may change or may be substituted for additional or different metrics as our business grows and as we introduce new solutions. If our management fails to review other relevant information or change or substitute the key business metrics they review as our business grows, their ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sizes of the markets and forecasts of market growth for the demand of our antibody discovery and development engine and other of our key performance indicators are based on a number of complex assumptions and estimates and may be inaccurate. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate annual total addressable markets and forecasts of market growth for our discovery and development engine, data packages and technologies. We have also developed a standard set of key performance indicators in order to enable us to assess the performance of our business in and across multiple markets, and to forecast future revenue. These estimates, forecasts and key performance indicators are based on a number of complex assumptions, internal and third party estimates and other business data, including assumptions and estimates relating to our ability to generate revenue from the development of new workflows. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and indicators. As a result, our estimates of the annual total addressable market and our forecasts of market growth and future revenue from technology access fees, discovery research fees, milestone payments or royalties may prove to be incorrect, and our key business metrics may not reflect our actual performance. For example, if the annual total addressable market or the potential market growth for our discovery and development engine is smaller than we have estimated or if the key business metrics we utilize to forecast revenue are inaccurate, it may impair our sales growth and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must adapt to rapid and significant technological change and respond to introductions of new products and technologies by competitors to remain competitive. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our antibody discovery solution and capabilities in industries that are characterized by significant enhancements and evolving industry standards. As a result, our partners&#8217; needs are rapidly evolving. If we do not appropriately innovate and invest in new technologies, our discovery and development engine may become less desirable in the markets we serve, and our partners could move to new technologies offered by our competitors or engage in antibody discovery themselves. Though we believe partners in our markets display a significant amount of loyalty to their supplier of research or a particular product or service, we also believe that because of the initial time investment required by many of our partners to reach a decision about whether to partner with us, it may be difficult to regain that customer once the customer enters into a partnership or collaboration agreement with a competitor. Without the timely introduction of new solutions and technological enhancements, our offerings will likely become less competitive over time, in which case our competitive position and operating results could suffer. Accordingly, we focus significant efforts and resources on the development and identification of new technologies and markets to further broaden and deepen our capabilities and expertise in antibody discovery and development. For example, to the extent we fail to timely introduce new and innovative technologies or solutions, adequately predict our partners&#8217; needs or fail to obtain desired levels of market acceptance, our business may suffer and our operating results could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our information technology systems, and any failure of these systems could harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting, our discovery and development engine, our advanced automation systems, and advanced application software. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. These implementations were expensive and required a significant effort in terms of both time and effort. In addition to the aforementioned business systems, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including manufacturing operations, laboratory operations, data analysis, quality control, customer service and support, billing, research and development activities, scientific and general administrative activities. A significant risk in implementing these systems, for example, is the integration and communication between separate IT systems. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious software, bugs or viruses, human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Any disruption or loss of information technology or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Upgrading and integrating our business systems could result in implementation issues and business disruptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have been and will continue updating and consolidating systems and automating processes in many parts of our business with a variety of systems, including in connection with the integration of acquired businesses. The expansion and ongoing implementation of operational systems may occur at a future date based on value to the business. In general, the process of planning and preparing for these types of integrated, wide-scale implementations is extremely complex and are required to address a number of challenges, including information security assessment and remediation, data conversion, network and system cutover, user training, and integration with existing processes or systems. Incongruities in any of these areas could cause operational problems during implementation including inconsistent practices, delayed report and/or data shipments, missed sales, billing errors and accounting errors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or protected health information or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store petabytes of sensitive data, including legally protected health information, personally identifiable information, intellectual property and proprietary business information owned or controlled by ourselves or our strategic partners. We manage and maintain our applications and data by utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face four primary risks relative to protecting this critical information: loss of access risk, inappropriate disclosure risk, inappropriate modification risk and the risk of being unable to adequately monitor our controls over the first three risks. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure and that of any third-party provider we may utilize, may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), and regulatory penalties. Although we have implemented security measures and a formal enterprise security program to prevent unauthorized access to sensitive data, there is no guarantee that we can protect our systems from breach. Unauthorized access, loss or dissemination could also disrupt our operations (including our ability to conduct our analyses, pay providers, conduct research and development activities, collect, process and prepare company financial information, provide information about any future products, and manage the administrative aspects of our business) and damage our reputation, any of which could adversely affect our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and its implementing regulations, impose certain requirements relating to the privacy, security, transmission and breach reporting of individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them that involve individually identifiable health information. Mandatory penalties for HIPAA violations can be significant, and criminal and monetary penalties, as well as injunctive relief, may be imposed for HIPAA violations. Although drug manufacturers are not directly subject to HIPAA, prosecutors are increasingly using HIPAA-related theories of liability against drug manufacturers and their agents and we also could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event of a breach as defined by HIPAA, HIPAA regulations impose specific reporting requirements to regulators, individuals impacted by the breach and the media. Issuing such notifications can be costly, time and resource intensive, and can generate significant negative publicity. Breaches of HIPAA may also constitute contractual violations that could lead to contractual damages or terminations. In addition, U.S. states have enacted and are considering enacting laws relating to the protection of patient health and other data, which may be more rigorous than, or impose additional requirements beyond those required by, HIPAA. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which became effective on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations as well as a limited private right of action for data breaches, which may increase the volume of data breach litigation. While limited CCPA exemptions may apply to portions of our business, the recency of the CCPA&#8217;s implementing regulations and the California Attorney General&#8217;s enforcement activity means our obligations under the CCPA could evolve in the future, which may increase our compliance costs and potential liability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a California ballot initiative, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020. The CPRA, which became effective on January 1, 2023, creates additional obligations with respect to processing and storing personal information. Additionally, some observers have noted that the CCPA, as modified by the CPRA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, Virginia, Utah, Colorado, and Connecticut have all enacted comprehensive consumer privacy laws. While these state laws incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also become subject to laws and regulations in non-U.S. countries covering data privacy and the protection of health-related and other personal information. In particular, the European Economic Area (&#8220;EEA&#8221;) has adopted data protection laws and regulations that impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure, processing and security of personal information that identifies or may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations, and have generally become more stringent over time. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EEA including personal health data, is subject to the EU General Data Protection Regulation (&#8220;EU GDPR&#8221;) and similarly, processing of personal data regarding individuals in the UK is subject to the UK General Data Protection Regulation and the UK Data Protection Act 2018 (&#8220;UK GDPR&#8221; and together with the EU GDPR &#8220;GDPR&#8221;). The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA/UK, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million ((&#163;17.5 million under UK GDPR) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers of personal data to countries outside the EEA/UK that are not considered by the European Commission and UK government as providing &#8220;adequate&#8221; protection to personal data (&#8220;third countries&#8221;), including the United States. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR is rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards (for example, the European Commission approved Standard Contractual Clauses (&#8220;SCCs&#8221;)) must be implemented in compliance with European and UK data protection laws. In addition, transfers made pursuant to the SCCs (and other similar appropriate transfer safeguards) need to be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred personal data, to ensure an &#8220;essentially equivalent&#8221; level of protection to that guaranteed in the EEA in the jurisdiction where the data importer is based (&#8220;Transfer Impact Assessment&#8221;). On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA. The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC&#8217;s new standard contractual clauses but has published its own transfer mechanism, the International Data Transfer Agreement and International Data Transfer Addendum (&#8220;IDTA&#8221;), which enable transfers from the UK, and has also implemented a similar Transfer Impact Assessment requirement. We will be required to implement these new safeguards and carry out Transfer Impact Assessments when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost, and may result in us needing to make strategic considerations around where EEA or UK personal data is stored and transferred, and which service providers we can utilize for the processing of EEA/UK personal data.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the UK is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR (&#8220;Adequacy Decision&#8221;) and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. The UK Government has also now introduced a Data Protection and Digital Information Bill (&#8220;UK Bill&#8221;) into the UK legislative process. The aim of the UK Bill is to reform the UK&#8217;s data protection regime following Brexit. If passed, the final version of the UK Bill may have the effect of further altering the similarities between the UK and EEA data protection regime and threaten the UK Adequacy Decision from the EU Commission. This may lead to additional compliance costs and could increase our overall risk. The respective provisions and enforcement of the EU GDPR and UK GDPR may further diverge in the future and create additional regulatory challenges and uncertainties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation and application of consumer, health-related and data protection laws in the United States, the EEA, and elsewhere are often uncertain, contradictory and in flux. Any failure or perceived failure to comply with federal, state or foreign laws or regulations, contractual or other legal obligations related to data privacy or data protection may result in claims, warnings, communications, requests or investigations from individuals, supervisory authorities or other legal or regulatory authorities in relation to our processing of personal data. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition, these privacy regulations vary between states, may differ from country to country, and may vary based on whether testing is performed in the United States or in the local country. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Cyberattacks could include industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, including ransomware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial, or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. If we were to experience an attempted or successful cybersecurity attack of our information systems or data, the costs associated with the investigation, remediation and potential notification of the attack to counterparties, data subjects, regulators or others, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants, could be material. In addition, following any such attack, our remediation efforts may not be successful. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state, federal and international law and may cause a material adverse impact to our reputation, affect our ability to conduct new studies, and potentially disrupt our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketing department is expanding, and if we are unable to continue this growth and effectively execute on our marketing strategy, our business may be adversely affected. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expand our commercial organization in order to effectively market our solutions to existing and new partners. Competition for employees capable of negotiating and entering into partnerships with pharmaceutical and biotechnology companies is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our discovery and development engine and limit our revenue growth and potential profitability. In addition, the time and cost of establishing a specialized sales, marketing and service force for a particular service may be difficult to justify in light of the revenue generated or projected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To perform sales, marketing, and partner support successfully, we will face a number of risks, including that our sales, marketing force may be unable to initiate and execute successful commercialization activities with respect to new products or markets we may seek to enter. If our sales and marketing efforts are not successful, our new technologies and products may not gain market acceptance, which could materially impact our business operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to successfully sell our programs and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of any member of our senior management team or our ability to attract and retain talent across the Company, including senior management, could adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management and other members of our management team as well as our senior scientists, software engineers and salespeople. Our success depends on the skills, experience and performance of key members of our senior management team, scientists, software engineers, salespeople and our other employees. The individual and collective efforts of our employees will be important as we continue to develop our discovery and development engine, and as we expand our commercial activities. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. While certain of our executive officers are party to employment contracts with us, we cannot guarantee their retention for any period of time beyond the applicable notice period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and engineers. We may not be able to attract or retain qualified scientists and engineers in the future due to the competition for qualified personnel among life science businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific and engineering personnel. We may have difficulties locating, recruiting or retaining qualified salespeople and other employees. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. A key risk in this area, for example, is that certain of our employees are at-will, which means that either we or the employee may terminate their employment at any time </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have made technology acquisitions and expect to acquire businesses or assets or make investments in other companies or technologies that could negatively affect our operating results, dilute our shareholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made technology acquisitions and expect to pursue acquisitions of businesses and assets in the future. We also may pursue strategic alliances and joint ventures that leverage our technologies and industry experience to expand our offerings or distribution. Although we have acquired other businesses or assets in the past, we may not be able to find suitable partners or acquisition or asset purchase candidates in the future, and we may not be able to complete such transactions on favorable terms, if at all. The competition for partners or acquisition candidates may be intense, and the negotiation process will be time-consuming and complex. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, these acquisitions may not strengthen our competitive position, the transactions may be viewed negatively by partners or investors, we may be unable to retain key employees of any acquired business, relationships with key suppliers, manufacturers or partners of any acquired business may be impaired due to changes in management and ownership, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. We cannot guarantee that we will be able to fully recover the costs of any acquisition. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture. We also may experience losses related to investments in other companies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Acquisitions may also expose us to a variety of international and business related risks, including intellectual property, regulatory laws, local laws, tax and accounting. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or asset purchase, we may choose to issue securities as consideration, which would dilute the ownership of our shareholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common shares is low or volatile, we may not be able to acquire companies or assets using our securities as consideration.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could become subject to government regulation and the regulatory approval and maintenance process may be expensive, time-consuming and uncertain both in timing and in outcome.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data packages are currently not subject to approval by the FDA. However, our business could in the future become subject to regulation by the FDA, or comparable international agencies. For example, in May 2020, we announced that we received a commitment from the Government of Canada under Innovation, Science and Economic Development&#8217;s, or ISED, Strategic Innovation Fund, or SIF, of up to CAD $175.6</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million ($129.9&#160;million as of March&#160;31, 2023)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the proceeds of which are being used to build a GMP facility in Vancouver, British Columbia, which will house our manufacturing and manufacturing support infrastructure. This facility, once completed, will become subject to various regulations, which could include regular inspections, certifications and audits. Such regulatory approval processes or clearances may be expensive, time-consuming and uncertain, and our failure to obtain or comply with such approvals and clearances could have an adverse effect on our business, financial condition and operating results. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, including regulation of our data packages, could arise at any time, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our data packages or future products, if required.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our billing and collections processing activities are time-consuming, and any delay in transmitting invoices or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for our data packages can be time-consuming, as many of our partners are large pharmaceutical or biotechnology companies and engage various models for their accounts payable matters, including outsourcing to third parties. We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, which could require to write-off significant accounts receivable and recognize bad debt expenses, which could adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our operating facilities become damaged or inoperable or we are required to vacate a facility, our ability to conduct and pursue our research and development efforts may be jeopardized. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive the majority of our revenue based upon scientific and engineering research and development and testing conducted in Vancouver, British Columbia. Our facilities and equipment could be harmed or rendered </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inoperable or inaccessible by natural or man-made disasters or other circumstances beyond our control, including fire, earthquake, power loss, communications failure, war or terrorism, or another catastrophic event, such as a pandemic or similar outbreak or public health crisis, which may render it difficult or impossible for us to support our partners and develop updates, upgrades and other improvements to our discovery and development engine, advanced automation systems, and advanced application and workflow software for some period of time. The inability to address system issues could develop if our facilities are inoperable or suffers a loss of utilization for even a short period of time, may result in the loss of partners or harm to our reputation, and we may be unable to regain those partners or repair our reputation in the future. Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify new facilities or license or transfer our proprietary technology to a third-party. Even in the event we are able to find a third-party to assist in research and development efforts, we may be unable to negotiate commercially reasonable terms to engage with the third &#8211; party.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter and our policies have limits and significant deductibles. Some of the policies we currently maintain include general liability, property, umbrella and directors&#8217; and officers&#8217; insurance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. A successful liability claim, or series of claims, in which judgments exceed our insurance coverage could adversely affect our business, financial condition, results of operations and prospects, including preventing or limiting the use of our discovery and development engine to discover antibodies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating as a public company makes it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage, seek alternative insurance options or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we generate and store sensitive data, including research data, intellectual property and proprietary business information owned or controlled by ourselves or our employees, partners and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, accidental exposure, unauthorized access, inappropriate modification and the risk of our being unable to adequately monitor and audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf. Further, to the extent our employees are working remotely, additional risks may arise as a result of depending on the networking and security put into place by the employees. The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use or disclosure, no security measures can be perfect and our information technology and infrastructure may be vulnerable to attacks by hackers or infections by viruses or other malware or breached due to employee erroneous actions or inactions by our employees or contractors, malfeasance or other malicious or inadvertent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, any of which could adversely affect our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of Canada and the United States. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have operations in Canada, the United States, Australia and the United Kingdom and our business strategy incorporates future international expansion. Doing business internationally involves a number of risks including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, tariffs, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure by us or our distributors to obtain approvals to conduct our business in various countries; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">differing intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complexities and difficulties in obtaining intellectual property protection, enforcing our intellectual property and defending against third party intellectual property claims; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulties in staffing and managing foreign operations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">logistics and regulations associated with shipping systems and parts and components for systems, consumables and reagent kits, as well as transportation delays; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">travel restrictions that limit the ability of marketing, presales, sales, services and support teams to service partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our data packages, and exposure to foreign currency exchange rate fluctuations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">international trade disputes that could result in tariffs and other protective measures;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the Canadian Corruption of Foreign Public Officials Act, or CFPOA, or U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our business, financial condition, results of operations and prospects. In addition, certain international markets are subject to significant political and economic uncertainty, including for example the effect of the withdrawal of the United Kingdom from the European Union. Significant political and economic developments in international markets for which we intend to operate, or the perception that any of them could occur, creates further challenges for operating in these markets in addition to creating instability in global economic conditions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to risks relating to foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have operations in Canada, the United States, Australia and the United Kingdom and our business strategy incorporates future international expansion. Substantially all of our revenue is paid in US dollars. We expect that our US dollar earned revenue will continue to account for a significant percentage of our total revenue for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in foreign currency exchange rates, could materially adversely impact our results. Foreign currencies in which we record expenses could be subject to unfavorable exchange rates with the U.S. dollar, resulting in a reduction in the amount of cash flow (and an increase in the amount of expenses) that we recognize and causing fluctuations in reported financial results. We also carry foreign currency exposure associated with differences between where we conduct business, including receipt of government funding denominated in foreign currencies. For example, certain contracts are denominated in currencies other than the currency in which we incur expenses related to those contracts. Where expenses </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are incurred in currencies other than those in which contracts are priced, fluctuations in the relative value of those currencies could have a material adverse effect on our results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to currency exchange rate fluctuations results from the currency translation exposure associated with the preparation of our consolidated financial statements, as well as from the exposure associated with transactions of our subsidiaries that are denominated in a currency other than the respective subsidiary&#8217;s functional currency. While our financial results are reported in U.S. Dollars, the financial statements of certain of our equity method investments are prepared using the local currency as the functional currency. During consolidation, these results are translated into U.S. Dollars by applying appropriate exchange rates. As a result, fluctuations in the exchange rate of the U.S. Dollar relative to the local currencies in which our equity method investments report could cause significant fluctuations in our reported results. Moreover, as exchange rates vary, our operating results may differ materially from our expectations. Adjustments resulting from financial statement translations are included as a separate component of shareholders&#8217; equity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities are subject to the FCPA and other anti-bribery and anti-corruption laws of the United States and other countries in which we operate, as well as U.S. and certain foreign export controls and trade sanctions. Violations of such legal requirements could subject us to liability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the FCPA, which among other things prohibits companies and their third-party intermediaries from offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Companies in the biotechnology and biopharmaceutical field are highly regulated and therefore involve interactions with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. We are also subject to the Canadian equivalent to the FCPA, the CFPOA. These laws are complex and far-reaching in nature, and, as a result, there is no certainty that all of our employees, agents or contractors will comply with such laws and regulations. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, financial condition, results of operations and prospects. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our data packages may be subject to U.S. and foreign export controls and trade sanctions. Compliance with applicable regulatory requirements regarding the export of our data packages may create delays in us providing our data packages in international markets or, in some cases, prevent the export thereof to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our data packages by, or in our decreased ability to export our data packages to, existing or potential customers with international operations. Any decreased use of our data packages or limitation on our ability to export or sell our data packages would likely adversely affect our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of suppliers for laboratory equipment and materials and may not be able to find replacements or immediately transition to alternative suppliers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a limited number of suppliers to provide certain consumables and equipment that we use in our operations, as well as reagents and other laboratory materials involved in the development of our technology. Fluctuations in the availability and price of materials and equipment could have an adverse effect on our ability to meet our development goals with our partners and thus our results from operations as well as future partnership opportunities. An interruption in the availability of raw materials or our laboratory operations could occur if we encounter delays, quality issues or other difficulties in securing these consumables, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In addition, while we believe suitable additional or alternative suppliers are available to accommodate our operations, if needed, any transition to new or additional suppliers may cause delays in our processing of samples or development and commercialization of our technology. Any such interruption could significantly affect our business, financial condition, results of operations and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must continue to secure and maintain sufficient and stable supplies of raw materials. Any shortage of raw materials or materials necessary for our operations may adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unexpected shortages in raw materials or other materials and other unanticipated events could adversely affect our business, prospects, financial condition and results of operation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we grow, our existing suppliers may not be able to meet our increasing demand, and we may need to find additional suppliers. There is no assurance that we will always be able to secure suppliers who provide raw materials at the specification, quantity and quality levels that we demand (or at all) or be able to negotiate acceptable fees and terms of services with any such suppliers. Identifying a suitable supplier is an involved process that requires us to become satisfied with their quality control, responsiveness and service, financial stability and labor and other ethical practices. Even if we are able to expand existing sources, we may encounter delays and added costs as a result of the time it takes to train suppliers in our methods and quality control standards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We historically have not entered into agreements with our suppliers but secure our raw materials and component parts we use in our equipment on a purchase order basis. Our suppliers may reduce or cease their supply of raw materials, component parts and outsourced services and products to us at any time in the future. If the supply of raw materials, component parts and the outsourced services and products is interrupted due to shortages or other reasons, our operations may be delayed. If any such event occurs, our operation and financial position may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with materials, including chemicals, biological agents and compounds that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, provincial, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. We are subject to periodic inspections by Canadian provincial and federal authorities to ensure compliance with applicable laws. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which could cause an interruption of our commercialization efforts, research and development programs and business operations, as well as environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations. In the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our discovery and development engine utilizes various species of animals that could contract disease or die and could otherwise subject us to controversy and adverse publicity, which may interrupt our business operations or harm our reputation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery and development engine utilizes animals to discover and produce antibodies. We cannot completely eliminate the risks of animals contracting disease, or a natural or man-made disaster that could cause death to valuable production animals, or those of the CRO that maintain our mouse colonies. We cannot make any assurance that we or our CROs will be able to contain or reverse any such instance of disease. Although we maintain backup colonies of our animals, disease or death on a broad scale could materially interrupt business operations as animals are a key part of our antibody discovery and development programs, which could have a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, genetic engineering and testing of animals has been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals in the United States, the EU and other jurisdictions have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities and the ability for us and our partners to use our discovery and development engine could be interrupted or delayed, our costs could increase and our reputation could be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Once completed, our manufacturing operations will be dependent upon third party suppliers, including single source suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building a GMP facility in Vancouver, British Columbia, to house our manufacturing and manufacturing support infrastructure. We anticipate that some of the suppliers of critical components or materials for our processes may be single or sole source suppliers and the replacement of these suppliers or the identification and qualification of suitable second sources may require significant time, effort and expense, and could result in delays in production, which could negatively impact our business operations and revenue. There can be no assurance that our supply of components necessary for the operation of this facility will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In addition, loss of any critical component provided by a single source supplier could require us to change the design of our manufacturing process based on the functions, limitations, features and specifications of the replacement components. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, several other non-critical components and materials that comprise our systems are currently manufactured by a single supplier or a limited number of suppliers. In many of these cases, we have not yet qualified alternate suppliers and rely upon purchase orders, rather than long-term supply agreements. A supply interruption or an increase in demand beyond our current suppliers&#8217; capabilities could harm our ability to manufacture our systems unless and until new sources of supply are identified and qualified. Our reliance on these suppliers subjects us to a number of risks that could harm our business, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a lack of long-term supply arrangements for key components with our suppliers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a modification or change in a manufacturing process or part that unknowingly or unintentionally negatively impacts the operation of our systems; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay in delivery due to our suppliers prioritizing other customer orders over ours; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">damage to our brand reputation caused by defective components produced by our suppliers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increased cost of our warranty program due to product repair or replacement based upon defects in components produced by our suppliers; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other partners. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interruption in the supply of components or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our partners, which would have an adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we expect our recent business acquisitions will result in synergies and other benefits to us, we may not realize those benefits because of difficulties related to integration and uncertainties related to certain assets acquired as a result of the acquisitions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we consummated the Trianni acquisition. In September 2021, we consummated the TetraGenetics acquisition. We expect that the integration process will require significant time and resources, and we may not be able to manage the process successfully. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential difficulties we may encounter as part of the integration process include (i) the challenge of integrating complex systems, operating procedures, regulatory compliance programs, technology, networks and other assets of the acquisitions in a seamless manner that minimizes any adverse impact on our employees, patients, suppliers and other business partners; and (ii) potential unknown liabilities, liabilities that are significantly larger than we currently anticipate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and unforeseen increased expenses or delays associated with the acquisitions, including costs to integrate the businesses that may exceed the costs that we currently anticipate. As part of our ongoing research and development we may make changes in our planned use of in process research and development which could result in a future impairment of the corresponding intangible asset.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in connection with the acquisition, we acquired a suite of transgenic humanized rodent lines currently being validated and available for discovery projects in the near future. There can be no assurance that these rodent lines will ever be validated or available for use by us or our partners. Further, it is possible that we will experience disruption of either company&#8217;s or both companies&#8217; ongoing businesses, including as we continue to service Trianni&#8217;s existing contracts for the foreseeable future. In addition, we have only recently begun to generate licensing revenue from our Trianni humanized rodent platform. There can be no assurance that we will continue to generate or expand our licensing revenue from this product offering in future periods. Accordingly, the contemplated benefits of the Trianni acquisition may not be realized fully, or at all, or may take longer to realize than expected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our technology, including our discovery and development engine and Celium, our proprietary antibody visualization software, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our data packages may be impaired. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict the use of our intellectual property. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors&#8217; products and services, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States, Canada and in other countries with respect to our discovery and development engine, our software and our technologies, without infringing the intellectual property rights of others. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our discovery and development engine and related technologies and uses thereof, as we deem appropriate. Our patents and patent applications in the United States, Canada and certain foreign jurisdictions relate to our technology. However, obtaining and enforcing patents in our industry is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that issues as a patent), will exclude others from making, using or selling our technology or technology that is substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we owned or exclusively licensed over 80 issued or allowed patents and over 80 pending patent applications worldwide. We own registered trademarks and trademark applications for AbCellera, AbCellera Australia Pty. Ltd. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(formerly Channel Bio)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Celium, Trianni, the Trianni Mouse, and AbCellera Boston (formerly TetraGenetics Inc.) in the U.S., Canada, Australia and Europe. It is possible that none of our pending patent applications </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our technology. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that in the future some of our patents, licensed patents and patent applications may be challenged at the United States Patent and Trademark Office, or USPTO, or in proceedings before the patent offices of other jurisdictions. We may not be successful in defending any such challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in loss of exclusivity or freedom to operate, patent claims being narrowed, the unenforceability or invalidity of such patents, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, limit the duration of the patent protection of our technology, and increased competition to our business. We may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes we make to our technology, including changes that may be required for commercialization or that cause them to have what we view as more advantageous properties may not be covered by our existing patent portfolio, and we may be required to file new applications and/or seek other forms of protection for any such alterations to our technology. There can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to our technology. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technology. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary platforms, methods and technologies that are patentable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 16, 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third-party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our technology or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presented in a district court action. Accordingly, a third - party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third - party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our and our licensors&#8217; ability to obtain new patents or to enforce existing patents and may facilitate third-party challenges to any owned or licensed patents. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our discovery and development engine could be found invalid or unenforceable if challenged. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review or interference. Any successful third party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that they no longer cover our discovery and development engine, which may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our discovery and development engine. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be aware of all third party intellectual property rights potentially relating to our discovery and development engine. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions covered by each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on in-licenses from third parties. If we lose these rights, our business may be materially adversely affected, our ability to develop improvements to our discovery and development engine may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a royalty-bearing license agreement with the University of British Columbia that grants us exclusive rights to exploit certain patent rights that are related to our systems. Through our acquisition of Lineage, we obtained an exclusive license from Stanford University to patents and patent applications directed toward immune repertoire sequencing. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. Some of our license agreements impose, and we expect that any future exclusive in-license </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements will impose, various development, diligence, commercialization and other obligations on us. We may enter into engagements in the future, with other licensors under which we obtain certain intellectual property rights relating to our discovery and development engine. These engagements take the form of exclusive license or of actual ownership of intellectual property rights or technology from third parties. Our rights to use the technology we license are subject to the continuation of and compliance with the terms of those agreements. In some cases, we may not control the prosecution, maintenance or filing of the patents to which we hold licenses, or the enforcement of those patents against third parties. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise with respect to our licensing or other upstream agreements, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of rights granted under the agreements and other interpretation-related issues; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which our systems and consumables, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the sublicensing of patent and other rights under our collaborative development relationships; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our diligence obligations under the license agreements and what activities satisfy those diligence obligations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the priority of invention of patented technology. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our efforts to comply with our obligations under our in-license agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such in-license is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. In addition, absent the rights granted to us under such license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our development and commercialization activities which are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which may not be ultimately successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our rights to certain components of our discovery and development engine are licensed to us on a non-exclusive basis. The owners of these non-exclusively licensed technologies are therefore free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the counterparty, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot acquire or license rights to use technologies on reasonable terms or if we fail to comply with our obligations under such agreements, we may not be able to commercialize new technologies or services in the future and our business could be harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may identify third party intellectual property and technology we may need to license in order to engage in our business, including to develop or commercialize new technologies or services, and the growth of our business may depend in part on our ability to acquire, in-license or use this technology. However, such licenses may not be available to us on acceptable terms or at all. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if such licenses are available, we may be required to pay the licensor in return for the use of such licensor&#8217;s technology, lump-sum payments, payments based on certain milestones such as sales volumes, or royalties based on sales of our discovery and development engine. In addition, such licenses may be non-exclusive, which could give our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors access to the same intellectual property licensed to us. We may also need to acquire or negotiate licenses to patents or patent applications before or after introducing a new service. The acquisition and licensing of third-party patent rights is a competitive area, and other companies may also be pursuing strategies to acquire or license third party patent rights that we may consider attractive. We may not be able to acquire or obtain necessary licenses to patents or patent applications. Even if we are able to obtain a license to patent rights of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize technology covered by these license agreements. If these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Additionally, termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more technologies that rely on such agreements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to further commercialize our technology may be materially harmed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. If other third parties have ownership rights to patents or patent applications we in-license, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other rights are found to be invalid or unenforceable. Moreover, we could encounter delays in the introduction of services while we attempt to develop alternatives. Defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing products, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our discovery and development engine, software, systems, workflows and processes in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States and Canada can be less extensive than those in the United States and Canada. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States and Canada, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. Further, we may encounter </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States and Canada, or from selling or importing products made using our inventions in and into the United States, Canada or other jurisdictions. </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, as a result of the Russia sanctions and the potential retaliatory acts from Russia, we may be unable to obtain patent rights to our Trianni and microfluidic platforms as well as bamlanivimab which are protected in other jurisdictions around the world. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own platform or technologies and may also sell their products or services to territories where we have patent protection, but enforcement is not as strong as that in the United States and Canada. These platforms and technologies may compete with ours. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may result in patent protection that does not adequately cover our technologies in those countries.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, or that are initiated against us, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and Canada and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we, or our current or future collaborators, might not have been the first to make the inventions covered by the issued patents and pending patent applications that we license or may own in the future; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we, or our current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we cannot ensure that we will be able to further commercialize our technology on a substantial scale, if approved, before the relevant patents that we own or license expire; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our technology; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not develop additional proprietary technologies that are patentable; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents or intellectual property rights of others may harm our business; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our discovery and development engine, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States and Canada may be less willing, or unwilling, to protect trade secrets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employed and expect to employ individuals who were previously employed at universities or other companies. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, advisors, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">face increased competition to our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential technologies and solutions, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such rights, we may not be able to use these trademarks to develop brand recognition of our discovery and development engine. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered AbCellera in the United States and Canada as well as certain of our trademarks outside of the United States and Canada. If we apply to register these trademarks in other countries, and/or other trademarks in the United States, Canada and other countries, our applications may not be allowed for registration in a timely fashion or at all; and further, our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may in the future be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In addition, third parties may file first for our trademarks in certain countries. If they succeed in registering such trademarks, and if we are not successful in challenging such third party rights, we may not be able to use these trademarks to market our technologies in those countries. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, which could harm our business, financial condition, results of operations and prospects. And, over the long-term, if we are unable to establish name recognition based on our trademarks, then our marketing abilities may be materially adversely impacted. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, partners or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems, including our software, workflows, consumables and reagent kits. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and in the future may be involved in litigation and other proceedings related to intellectual property, which could be time-intensive and costly and may adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, there has been significant litigation in the United States and other jurisdictions involving intellectual property rights. We are and may in the future be involved with litigation or actions at the USPTO or the patent offices of other jurisdictions with various third parties that claim we or our partners using our solutions have misappropriated, misused or infringed other parties&#8217; intellectual property rights. We expect that the number of such claims may increase as our business and the level of competition in our industry segments grow. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of the business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses) or royalty payments, or result in potential or existing partners delaying purchases of our data packages or entering into engagements with us pending resolution of the dispute. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we move into new markets and applications for our discovery and development engine, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success may depend in part upon our ability to develop, manufacture, market and sell any products and services that we may develop and use without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties, or the invalidity of such patents or proprietary rights. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and commercialization activities may in the future be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation and other patent challenges, both within and outside the United States and Canada, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings before the USPTO, and corresponding foreign patent offices. Third parties may initiate legal proceedings against us or our licensor, and we or our licensor may initiate legal proceedings against third parties. The outcome of such proceedings would be uncertain and could have a material adverse effect on the success of our business. Numerous U.S., Canadian and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our discovery and development engine. As the biotechnology industry expands and more patents are issued, the risk increases that our technologies may be subject to claims of infringement of the patent rights of third parties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the risks of being involved in such litigation and proceedings may increase if our technology nears commercialization. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and one or more third parties may assert that our technologies infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. An unfavorable outcome in any such proceeding could require us to cease using the related technology or developing or commercializing our technology, or to attempt to license rights to it from the prevailing party, which may not be available on commercially reasonable terms, or at all. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. We are also aware of issued U.S. patents and patent applications with subject matter related to our discovery and development engine, systems, workflows and processes, and there may be other related third party patents or patent applications of which we are not aware. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we are or may become aware of patents or pending patent applications that we think do not relate to our technology or that we believe are invalid or unenforceable, but that may nevertheless be interpreted to encompass our technology and to be valid and enforceable. Thus, we do not know with certainty that our technology, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may receive in the future, correspondence from third parties referring to the relevance of such third parties&#8217; intellectual property to our technology, our workflows or our advanced automated systems, and we are currently engaged in litigation with such third parties (i.e., Berkeley Lights and Schrader). Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future programs or technologies may infringe. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our discovery and development engine, or the systems, workflows, consumables and reagent kits that comprise our discovery and development engine, infringes these patents. As to pending third party applications, we cannot predict with any certainty which claims will issue, if any, or the scope of such issued claims. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our discovery and development engine, including our systems, workflows, consumables and reagent kits. Under the applicable law of certain jurisdictions, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our technologies. We may incorrectly determine that our technologies are not covered by a third party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our technologies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will prevail in any suit initiated against us by third parties, successfully settle or otherwise resolve patent infringement claims. A court of competent jurisdiction could hold that third party patents are valid, enforceable and infringed, which could materially and adversely affect our ability and the ability of our licensor to commercialize any technology we may develop and any other technologies covered by the asserted third-party patents. Third parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell data packages, and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors and other third parties gaining access to the same intellectual property. In addition, we could encounter delays and incur significant costs in service introductions while we attempt to develop alternative processes, technologies or services, or redesign our technologies or services, to avoid infringing third party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses or to develop a workaround could prevent us from commercializing products or services, and the prohibition of sale or the threat of the prohibition of sale of any of our data packages could materially affect our business and our ability to gain market acceptance for our technologies. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our agreements with some of our partners, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any uncertainties resulting from the initiation and continuation of any litigation or administrative proceeding could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcome of our litigation with Berkeley Lights may adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a complaint against Berkeley Lights, in the United States District Court for the District of Delaware, alleging that Berkeley Lights infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by the Company, including U.S. Patent Nos. 10,107,812; 10,274,494; 10,466,241; 10,578,618; 10,697,962; 10,087,408; 10,421,936 and 10,704,018, by making, using, offering for sale, selling and/or importing Berkeley Lights&#8217; Beacon Optofluidic System. In August 2020, we filed an additional related complaint against Berkeley Lights in the United States District Court for the District of Delaware, alleging that Berkeley Lights infringed and continues to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe, directly and indirectly, U.S. Patent Nos. 10,718,768; 10,738,270; 10,746,737 and 10,753,933. In September 2020, we filed another complaint against Berkeley Lights in the United States District Court for the District of Delaware, alleging that Berkeley Lights infringed and continues to infringe, directly and indirectly, U.S. Patent Nos. 10,775,376; 10,775,377 and 10,775,378. On December 3, 2020, the judge assigned to these three lawsuits ordered that they be transferred to the U.S. District Court for the Northern District of California. In these lawsuits, we are seeking, among other things, a judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney&#8217;s fees and treble damages for willful infringement). In February 2021, these lawsuits were consolidated and assigned to the Honorable Judge Lucy Koh. In February 2021, Berkeley Lights filed a motion seeking leave to amend its counterclaims to add the allegations of unfair competition (as plead in the case described below) against AbCellera only. In July 2021, the Court allowed Berkeley to amend its counterclaims to add the unfair competition claims subject to our right to seek dismissal with prejudice should the counterclaims not overcome objections previously presented by us to the court. The Company is continuing to oppose the unfounded counterclaim and we intend to seek dismissal with prejudice. In March 2021, the court set this matter down for a jury trial with a December 12, 2022 start date. In July 2021, Berkeley Lights filed a Petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of U.S. Patent No. 10,087,408 that we exclusively license from the University of British Columbia. In July 2021, Berkeley Lights filed a second Petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of U.S. Patent No. 10,421,936 that we exclusively license from the University of British Columbia. In August 2021, Berkeley Lights filed a third Petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of U.S. Patent No. 10,738,270 that we exclusively license from the University of British Columbia. In August 2021, the court stayed the patent litigation against Berkeley Lights in view of the Petitions for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review filed by Berkeley Lights. In January 2022, the PTAB denied one petition and instituted one petition. In February 2022, the PTAB denied the final petition. Trial on the instituted petition occurred in November 2022. In January 2023, the PTAB issued its Final Written Decision with respect to our U.S. Patent No. 10,087,408 rejecting all of Berkeley Lights&#8217; grounds of unpatentability and determining that none of the challenged claims are unpatentable. Because the three aforementioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review matters have been resolved, we have sought relief from the Court to lift the pending stay and resume our patent infringement action against Berkeley Lights. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Berkeley Lights filed a complaint in the Northern District of California against us and our wholly-owned subsidiary Lineage Inc. The complaint includes two counts of unfair competition and one count of non-infringement of a U.S. patent: Patent No. 10,058,839 (the &#8220;&#8217;839 patent&#8221;). Berkeley Lights is seeking, among other things, damages and a declaratory judgment of non-infringement of the &#8217;839 patent. We filed a motion to dismiss the action for lack of jurisdiction and failure to state a claim upon which relief can be granted pursuant to Federal Rules of Civil Procedure 12(b) 1, 2, and 6. In January 2021, the Court determined that there was no jurisdiction over AbCellera or Lineage and dismissed the unfair competition claims but ordered jurisdictional discovery on a limited basis with respect to AbCellera only regarding Berkeley Lights&#8217; request for declaratory judgment on the &#8217;839 patent. In July 2021, Berkeley Lights voluntarily dismissed this lawsuit. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that Berkeley Lights were to prevail in the litigation against us, as a result of which Berkeley Lights could continue to sell its products, it could reduce our competitive advantage and differentiation in the market place, impairing our ability to bring in new business. Furthermore, Berkeley Lights may seek to invalidate the asserted patents during the litigation. If Berkeley Lights succeeds in invalidating the asserted patents, the strength of our intellectual property portfolio could be adversely affected and our ability to protect our technology, business and reputation or to generate licensing revenue from our intellectual property would be adversely impacted.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcome of our civil litigation with Schrader may adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recently became aware of a civil lawsuit filed by the Estate of John Schrader and another corporate entity naming as co-defendants the Company, some of its affiliates and Dr. Carl Hansen, the Company's CEO. The lawsuit was filed in October 2022, in the Supreme Court of British Columbia (Vancouver). The complaint alleges breach of an implied partnership or joint venture between Dr. John Schrader and Dr. Hansen and further alleges patent infringement of an issued Canadian patent (No. 2,655,511). The complaint seeks financial damages as well as other declarations. The Company believes that the claims are meritless and frivolous in all respects and intends to defend itself appropriately.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, even if resolved in our favor, may cause us to incur substantial costs and divert the attention of our management and technical personnel from their normal responsibilities in defending against any of these claims. Parties making claims against us may be able to sustain the costs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of complex patent litigation more effectively than we can because they have substantially greater resources. Such litigation or proceedings could substantially increase our operating costs and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property proceedings could harm our ability to compete in the marketplace. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have a material adverse effect on the success of our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors, could be infringing, misappropriating or otherwise violating our intellectual property rights. Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors&#8217; products and services, and may in the future seek to enforce our rights against potential infringement, misappropriation or violation of our intellectual property. However, the steps we have taken to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our data packages. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary for us to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. We are currently engaged in a lawsuit with Berkeley Lights based upon our allegations of its infringement of our intellectual property rights and we may become involved in additional lawsuits in the future. We are also engaged in a civil lawsuit with Schrader based upon allegations of, among other things, infringement of their intellectual property. If we do not prevail in such legal proceedings, we may be required to pay damages, we may lose significant intellectual property protection for our technologies, such that competitors could copy our technologies and we could be forced to cease selling certain of our data packages. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, financial condition, results of operations and prospects. In any lawsuit we bring to enforce our intellectual property rights, a court may refuse to stop the other party from using the technology at issue on grounds that our intellectual property rights do not cover the technology in question. Further, in such proceedings, the defendant could counterclaim that our intellectual property is invalid or unenforceable and the court may agree, in which case we could lose valuable intellectual property rights. The outcome in any such lawsuits are unpredictable. Even if we do prevail in any future litigation related to intellectual property rights, the cost and time requirements of the litigation could negatively impact our financial results. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on issued United States and most foreign patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications in order to maintain such patents and patent applications. We have systems in place to remind us to pay these fees, and we engage an outside service and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, if we or our licensors fail to maintain the patents and patent applications covering our products and technology our competitors may be able to enter the market with similar or identical products or technology without infringing our patents and this circumstance would have a material adverse effect on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our technology for an adequate amount of time. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our discovery and development engine or technology are obtained, once the patent life has expired, we may be open to competition from others. If our discovery and development engine or technologies require extended development and/or regulatory review, patents protecting our discovery and development engine or technologies might expire before or shortly after we are able to successfully commercialize them. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing processes or technologies similar or identical to ours. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of open source software could compromise our ability to offer our data packages and subject us to possible litigation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use open source software in connection with our technology and computational engine of our platform, Celium. Companies that incorporate open source software into their technologies and services have, from time to time, faced claims challenging their use of open source software and compliance with open source license terms. As a result, we could be subject to lawsuits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to the licensee&#8217;s software that incorporates, links or uses such open source software, and make available to third parties for no cost, any derivative works of the open source code created by the licensee, which could include the licensee&#8217;s own valuable proprietary code. While we monitor our use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, or could be claimed to have occurred, in part because open source license terms are often ambiguous. There is little legal precedent in this area and any actual or claimed requirement to disclose our proprietary source code or pay damages for breach of contract could harm our business and could help third parties, including our competitors, develop technologies that are similar to or better than ours. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our intellectual property rights may have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our technology pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. To date, only our work in helping develop bamlanivimab may be subject to government funding or &#8220;march-in&#8221; rights. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Shares </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have effective internal financial and accounting controls and procedures in place so that we can produce financial statements that are, in all material respects, in conformity with accounting principles generally accepted in the United States of America, on a timely basis is a costly and time-consuming effort that needs to be re-evaluated annually. We are also subject to the reporting and compliance requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, which require annual management assessment of the effectiveness of our internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In our efforts to maintain proper and effective internal control over financial reporting, we may discover significant deficiencies or material weaknesses in our internal control over financial reporting, which we may not successfully remediate on a timely basis or at all. Any failure to remediate any significant deficiencies or material weaknesses identified by us or to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we identify one or more material weaknesses in the future, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements, which may harm the market price of our shares. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common shares or rights to purchase common shares, including pursuant to our Employee Share Option and Incentive Plan, or EIP, could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations, including expanded research and development activities, and costs associated with operating as a public company. To raise capital, we may sell common shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common shares, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing shareholders, and new investors could gain rights, preferences, and privileges senior to the holders of our common shares, including common shares sold in our IPO. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our incentive plan, that we adopted in connection with our IPO, our management is authorized to grant equity incentive awards to our employees, directors and consultants. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, the aggregate number of our common shares that may be issued pursuant to share awards under the EIP was 21,280,000 shares. The number of common shares reserved for issuance under the EIP shall be cumulatively increased on January 1, 2022 and each January 1 thereafter by 5% of the total number of common shares outstanding on December 31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our shareholders may experience additional dilution, which could cause our share price to fall. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses on terms unfavorable to us. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common shares, so any returns will be limited to the value of our common shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation, expansion and continued investment into our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, we may enter into agreements that prohibit us from paying cash dividends without prior written consent from our contracting parties, or which other terms prohibiting or limiting the amount of dividends that may be declared or paid on our common shares. Any return to shareholders will therefore be limited to the appreciation of their common shares, which may never occur. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal shareholders and management own a significant percentage of our shares and will be able to exert significant influence over matters subject to shareholder approval. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors, and 5% shareholders beneficially currently own over twenty percent of our common shares in the aggregate, based on ownership information filed by such holders. Therefore, these shareholders have the ability to influence us through this ownership position. These shareholders may be able to determine all matters requiring shareholder approval. For example, these shareholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common shares that you may feel are in your best interest as one of our shareholders. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of our common shares in the public market could cause our share price to fall significantly, even if our business is doing well. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of our common shares in the public market could occur at any time. If our shareholders sell, or the market perceived that our shareholders intend to sell, substantial amounts of our common shares in the public market, the market price of our common shares could decline significantly. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed registration statements on Form S-3 and on Form S-8 to register our common shares that are issuable pursuant to our equity incentive plans. Shares registered under Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain holders of our common shares have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other shareholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common shares could decline. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are governed by the corporate laws of Canada which in some cases have a different effect on shareholders than the corporate laws of the United States. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by the Business Corporations Act (British Columbia), or BCBCA, and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction, and may, together with our charter documents, have the effect of delaying, deferring or discouraging another party from acquiring control of our company by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance. The material differences between the BCBCA and Delaware General Corporation Law, or DGCL, that may have the greatest such effect include, but are not limited to, the following: (i) for certain corporate transactions (such as mergers and amalgamations or amendments to our articles) the BCBCA generally requires the voting threshold to be a special resolution approved by 66 2/3% of shareholders, or as set out in the articles, as applicable, whereas DGCL generally only requires a majority vote; and (ii) under the BCBCA a holder of 5% or more of our common shares can requisition a special meeting of shareholders, whereas such right does not exist under the DGCL. We cannot predict whether investors will find our company and our common shares less attractive because we are governed by foreign laws. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our articles and certain Canadian legislation contain provisions that may have the effect of delaying, preventing or making undesirable an acquisition of all or a significant portion of our shares or assets or preventing a change in control. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our articles and certain provisions under the BCBCA, together or separately, could discourage, delay or prevent a merger, acquisition or other change in control of us that shareholders may consider favorable, including transactions in which they might otherwise receive a premium for their common shares. These provisions include the establishment of a staggered board of directors, which divides the board into three groups, with directors in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or remove incumbent members of our board of directors. As such, these provisions could also limit the price that investors might be willing to pay in the future for our common shares, thereby depressing the market price of our common shares. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it more difficult for shareholders to replace members of our board of directors. Among other things, these provisions include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">shareholders cannot amend our articles unless such amendment is approved by shareholders holding at least 66 2/3% of the shares entitled to vote on such approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our board of directors may, without shareholder approval, issue preferred shares in one or more series having any terms, conditions, rights, preferences and privileges as the board of directors may determine; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">shareholders must give advance notice to nominate directors or to submit proposals for consideration at shareholders&#8217; meetings. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-Canadian must file an application for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a &#8220;Canadian business&#8221; within the meaning of the Investment Canada Act, where prescribed financial thresholds are exceeded. A reviewable acquisition may not proceed unless the Minister is satisfied that the investment is likely to be of net benefit to Canada. If the applicable financial thresholds were exceeded such that a net benefit to Canada review would be required, this could prevent or delay a change of control and may eliminate or limit strategic opportunities for shareholders to sell their common shares. Furthermore, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation has a pre-merger notification regime and mandatory waiting period that applies to certain types of transactions that meet specified financial thresholds, and permits the Commissioner of Competition to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our articles designate specific courts in Canada and the United States as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our articles, unless we consent in writing to the selection of an alternative forum, the courts of the Province of British Columbia and the appellate courts therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought on our behalf; (b) any action or proceeding asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of ours to us; (c) any action or proceeding asserting a claim arising out of any provision of the BCBCA or our articles (as either may be amended from time to time); or (d) any action or proceeding asserting a claim or otherwise related to our affairs, or the Canadian Forum Provision. The Canadian Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. In addition, our articles further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving any complaint filed in the United States asserting a cause of action arising under the Securities Act, or the U.S. Federal Forum Provision. In addition, our articles provide that any person or entity purchasing or otherwise acquiring any interest in our common shares is deemed to have notice of and consented to the Canadian Forum Provision and the U.S. Federal Forum Provision; provided, however, that shareholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Canadian Forum Provision and the U.S. Federal Forum Provision in our articles may impose additional litigation costs on shareholders in pursuing any such claims. Additionally, the forum selection clauses in our amended articles may limit our shareholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and employees, even though an action, if successful, might benefit our shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts, including courts in Canada and other courts within the U.S., will enforce our U.S. Federal Forum Provision. If the U.S. Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The U.S. Federal Forum Provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The courts of the Province of British Columbia and the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a shareholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are a Canadian company, it may be difficult to serve legal process or enforce judgments against us. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated and maintain operations in Canada. In addition, while certain of our directors and officers reside in the United States, many of them reside outside of the United States. Accordingly, service of process upon us may be difficult to obtain within the United States. Furthermore, because substantially all of our assets are located outside the United States, any judgment obtained in the United States against us, including one predicated on the civil liability provisions of the U.S. federal securities laws, may not be collectible within the United States. Therefore, it may not be possible to enforce those actions against us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, it may be difficult to assert U.S. securities law claims in original actions instituted in Canada. Canadian courts may refuse to hear a claim based on an alleged violation of U.S. securities laws against us or these persons on the grounds that Canada is not the most appropriate forum in which to bring such a claim. Even if a Canadian court agrees to hear a claim, it may determine that Canadian law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Canadian law. Furthermore, it may not be possible to subject foreign persons or entities to the jurisdiction of the courts in Canada. Similarly, to the extent that our assets are located in Canada, investors may have difficulty collecting from us any judgments obtained in the U.S. courts and predicated on the civil liability provisions of U.S. securities provisions. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, as provided in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates.&#8221; The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common shares. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on our reputation, business, financial position, and profit. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our non-U.S. subsidiary is a CFC there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our common shares. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a controlled foreign corporation, or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income,&#8221; global intangible low taxed income, and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such Ten Percent Shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly, indirectly, or constructively, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Code) who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. In addition, recent changes to the attribution rules relating to the determination of CFC status may make it difficult to determine our CFC status for any taxable year. In addition, those changes to the attribution rules may result in ownership of the stock of our non-U.S. subsidiaries being attributed to our U.S. subsidiaries, which could result in our non-U.S. subsidiaries being treated as CFCs and certain U.S. Holders of our common shares being treated as Ten Percent Shareholders of such non-U.S. subsidiary CFCs. In addition, it is possible that a shareholder treated as a U.S. person for U.S. federal income tax purposes will acquire, directly or indirectly, enough of our common shares to be treated as a Ten Percent Shareholder. We believe that we and our non-U.S. subsidiaries will not be treated as CFCs in the 2022 taxable year solely by virtue of direct or indirect ownership by Ten Percent Shareholders. However, we believe that our non-U.S. subsidiaries may be treated as CFCs in the 2022 taxable year due to attribution rules that deem constructive ownership by our U.S. subsidiaries. It is unclear whether we would be treated as a CFC in a subsequent taxable year. We cannot provide any assurances that we will assist holders of our common shares in determining whether we or any of our non-U.S. subsidiaries are treated as a CFC or whether any holder of the common shares is treated as a Ten Percent Shareholder with respect to any such CFC or furnish to any Ten Percent Shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Holders should consult their tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC, including the possibility and consequences of becoming a Ten Percent Shareholder in our non-U.S. subsidiaries that may be treated as CFCs due to the changes to the attribution rules. If we are classified as both a CFC and a PFIC (as defined below), we generally will not be treated as a PFIC with respect to those U.S. Holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC (referred to as the &#8220;CFC/PFIC overlap rule&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of our common shares and is (i) an individual who is a citizen or resident of the United States, (ii) a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income taxation regardless of its source or (iv) a trust if (1) a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2) the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations. Recent proposed changes to PFIC regulations, if adopted, would expand the definition of &#8220;U.S. Holder&#8221; for purposes of the CFC/PFIC overlap rule and other PFIC rules, elections, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reporting requirements discussed below. The proposed regulations would require domestic partnerships and S-corporations to be treated as an aggregate of their partners or shareholders rather than as entities, which may result in such partners and shareholders to now be subject to the PFIC rules where they previously were not. It is unclear whether these proposed regulations may be adopted or if they will undergo further modifications before they are finalized. If adopted, it is also unclear when will be the effective date of the final regulations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our U.S. shareholders may suffer adverse tax consequences if we are characterized as a PFIC. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules governing passive foreign investment companies, or PFICs, can have adverse effects on U.S. Holders for U.S. federal income tax purposes. Generally, if, for any taxable year, at least 75% of our gross income is passive income (such as interest income), or at least 50% of the gross value of our assets (determined on the basis of a weighted quarterly average) is attributable to assets that produce passive income or are held for the production of passive income (including cash), we would be characterized as a PFIC for U.S. federal income tax purposes. The determination of whether we are a PFIC, which must be made annually after the close of each taxable year, depends on the particular facts and circumstances and may also be affected by the application of the PFIC rules, which are subject to differing interpretations. Our status as a PFIC will depend on the composition of our income and the composition and value of our assets (including goodwill and other intangible assets), which will be affected by how, and how quickly, we utilize any cash that was raised in any of our financing transactions. If we were a publicly traded CFC or not a CFC for any part of such year, the value of our assets generally may be determined by reference to the fair market value of our common shares, which may be volatile. Moreover, our ability to earn specific types of income that will be treated as non-passive for purposes of the PFIC rules is uncertain with respect to future years. We believe we were not classified as a PFIC during the taxable year ended December 31, 2022. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Accordingly, we cannot provide any assurances regarding our PFIC status for any current or future taxable years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are classified as a PFIC, a U.S. Holder would be subject to adverse U.S. federal income tax consequences, such as ineligibility for certain preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements under U.S. federal income tax laws and regulations. A U.S. Holder may in certain circumstances mitigate adverse tax consequences of the PFIC rules by filing an election to treat the PFIC as a qualified electing fund, or QEF, or, if shares of the PFIC are &#8220;marketable stock&#8221; for purposes of the PFIC rules, by making a mark-to-market election with respect to the shares of the PFIC. U.S. Holders are urged to consult their own tax advisors regarding the potential consequences if we were or were to become classified as a PFIC, including the availability, and advisability, of, and procedure for, making QEF or mark-to-market elections. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state, and local and non-U.S. taxation are constantly under review by persons involved in the legislative process, the Internal Revenue Service, the U.S. Treasury Department and other taxing authorities. Changes to tax laws or tax rulings, or changes in interpretations of existing laws (which changes may have retroactive application), could adversely affect us or holders of our common stock. These changes could subject us to additional income-based taxes and non-income taxes (such as payroll, sales, use, value-added, digital tax, net worth, property, and goods and services taxes), which in turn could materially affect our financial position and results of operations. Additionally, new, changed, modified, or newly interpreted or applied tax laws could increase our customers&#8217; and our compliance, operating and other costs, as well as the costs of our products. In recent years, many such changes </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been made, and changes are likely to continue to occur in the future. As we expand the scale of our business activities, any changes in the U.S. and non-U.S. taxation of such activities may increase our effective tax rate and harm our business, financial condition, and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business has been and may continue to be adversely affected by the ongoing COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2019, a novel strain of coronavirus, SARS-CoV-2, which resulted in the evolving COVID-19 pandemic, surfaced in Wuhan, China. Since then, COVID-19 has spread across the globe and to multiple regions within the United States and Canada, including British Columbia, where our primary office and laboratory space is located. The COVID-19 pandemic to date has led to the implementation of various responses, including government imposed shelter-in-place orders, quarantines, travel restrictions and other public health safety measures, as well as reported adverse impacts on healthcare resources, facilities and providers, in Canada, across the United States and in other countries. In the event that government authorities were to further modify current restrictions, our employees conducting research and development or manufacturing activities may not be able to access our laboratory and manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the ongoing COVID-19 pandemic, or similar pandemics and outbreaks, we have experienced and may continue to experience severe delays and disruptions, including, for example: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interruption of or delays in receiving products and supplies from third parties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on our business operations by local, state, provincial and/or federal governments that could impact our ability to sell our data packages; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in negotiations with partners and potential partners; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increases in facilities costs to comply with physical distancing guidance; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working from home, travel limitations, cyber-security and data accessibility, or communication or mass transit disruptions; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on employee resources that would otherwise be focused on the conduct of our activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could severely impact our research and development activities, business operations and sales, or delay necessary interactions with local regulators, manufacturing sites and other important contractors and partners. These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19, could continue to spread to additional countries, or could return to countries where the pandemic has been partially contained, and could further adversely impact our ability to conduct our business generally and have a material adverse impact on our operations and financial condition and results. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may negatively impact our operations and results of operations or those of our stakeholders will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing military action between Russia and Ukraine and related sanctions could adversely affect our business, financial condition, and patent administration.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February of 2022, Russian military forces invaded Ukraine, and sustained conflict and disruption in the region is likely. Although the length, impact and outcome of the ongoing military conflict in Ukraine is highly unpredictable, this conflict could lead to significant market disruptions, including significant volatility in commodity prices and supply of energy resources, instability in financial markets, higher inflation, supply chain interruptions, political and social instability, cyber attacks and cybersecurity threats, and could also aggravate the other risk factors that we identify herein. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the impact of sanctions against Russia and the potential retaliatory acts from Russia, could have a material adverse effect on our business and intellectual property rights. </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we may be unable to obtain patent rights to our Trianni and microfluidic platforms as well as bamlanivimab which are protected in other jurisdictions around the world.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.</span><span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price pertaining to our acquisitions in recent years have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. Refer to Note 20 of our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2022 for additional information. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, and insider trading. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the applicable laws and regulations in the United States, Canada and abroad, report financial information or data accurately or disclose unauthorized activities to us. These laws and regulations may restrict or prohibit a wide range of pricing, discounting and other business arrangements. Such misconduct could result in legal or regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and any other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common shares may be volatile, and you could lose all or part of your investment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common shares is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. These factors include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the introduction of new technologies or enhancements to existing technology by us or others in our industry; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to establish additional collaborations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">departures of key scientific or management personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">publication of research reports about us or our industry, or antibody discovery in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the market valuations of similar companies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">overall performance of the equity markets; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our common shares by us or our shareholders in the future; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">trading volume of our common shares; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant lawsuits, including patent or shareholder litigation; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the ongoing COVID-19 pandemic on our business; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general political and economic conditions, including those resulting from the conflict between Russia and Ukraine and the attendant sanctions; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other events or factors, many of which are beyond our control. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Global Select Market and technology and life sciences companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common shares, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements associated with being a public company will increase our costs significantly, as well as divert significant company resources and management attention. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of this report, we are subject to the reporting requirements of the Exchange Act or the other rules and regulations of the SEC and any securities exchange relating to public companies. Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market LLC, or Nasdaq, to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8216;&#8216;say on pay&#8217;&#8217; voting requirements that apply to us since we ceased to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business. In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#8217; and officers&#8217; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common shares will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our cash and cash equivalents are maintained in high credit quality and liquid held for trading marketable securities, bank accounts and term deposits at Canadian banking institutions. Cash and cash equivalent held in depository accounts may exceed the C$100,000 Canadian Deposit Insurance Corporation insurance limits. Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the first quarter of 2023, a number of financial institutions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. were placed into receivership by the Federal Deposit Insurance Corporation. Any material loss that we may experience in the future could have a material adverse effect on our financial condition and could materially impact our ability to pay our operational expenses or make other payments. Although we were not a depositor with any such financial institution placed into receivership, if the banking institutions that hold our deposits were to fail, we could lose all or a portion of those amounts held in excess of applicable insurance limitations. In such an event, our access to our cash in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we were to borrow money in the future and if any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, if any of our customers, suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay or perform their obligations to us or to enter into new commercial arrangements requiring additional payments to us or additional funding could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect our company, the financial institutions with which the Company has credit agreements or arrangements directly, or the financial services industry or economy in general.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These could include, but may not be limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential or actual breach of statutory, regulatory or contractual obligations, including obligations that require the Company to maintain letters of credit or other credit support arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i25d26736ba6e4b0989ccc984f8a74878_124"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed with this Quarterly Report on Form 10-Q:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1703057/000156459021016713/abcl-ex31_425.htm">Articles of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 30, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001703057/000119312520299507/d29983dex41.htm">Amended and Restated Investors Rights Agreement among the Registrant and certain of its shareholders, dated March 23, 2020 (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-250838) filed on November 20, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1703057/000119312520311091/d29983dex42.htm">Form of Specimen Common Share Certificate (incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-250838) filed on December 7, 2020).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="abcl-20230331xexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="abcl-20230331xexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="abcl-20230331xexx321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="abcl-20230331xexx322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><div id="i25d26736ba6e4b0989ccc984f8a74878_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbCellera Biologics Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Carl L.G. Hansen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carl L.G. Hansen, Ph.D.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Andrew Booth</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Booth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>abcl-20230331xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i689a89c036be439992bc3b551a91949d_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Carl L. G. Hansen certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report of AbCellera Biologics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Carl L. G. Hansen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carl L. G. Hansen, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer and Director</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>abcl-20230331xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibc2600381b14452fbe8ab13ac9fe90ca_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew Booth, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report of AbCellera Biologics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew Booth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Booth</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>abcl-20230331xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1dc69d2c6a1645d6a7a45a453f7a21a8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of AbCellera Biologics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Carl L. G. Hansen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carl L. G. Hansen</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer and Director</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>abcl-20230331xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i52e8b3b3d2264be092799069683bf12c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of AbCellera Biologics Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew Booth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Booth</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>abcl-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:650343a1-ca86-4cd1-b410-9b387e72615d,g:7bff7bb1-4386-4395-9d16-110d609544b1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abcl="http://www.abcellera.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abcellera.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abcl-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abcl-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abcl-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abcl-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.abcellera.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofoperations" roleURI="http://www.abcellera.com/role/Natureofoperations">
        <link:definition>0000007 - Disclosure - Nature of operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentation" roleURI="http://www.abcellera.com/role/Basisofpresentation">
        <link:definition>0000008 - Disclosure - Basis of presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantaccountingpolicies" roleURI="http://www.abcellera.com/role/Significantaccountingpolicies">
        <link:definition>0000009 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netearningslosspershare" roleURI="http://www.abcellera.com/role/Netearningslosspershare">
        <link:definition>0000010 - Disclosure - Net earnings (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyandequipmentnet" roleURI="http://www.abcellera.com/role/Propertyandequipmentnet">
        <link:definition>0000011 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://www.abcellera.com/role/Intangibleassets">
        <link:definition>0000012 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets" roleURI="http://www.abcellera.com/role/Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets">
        <link:definition>0000013 - Disclosure - Investments in and loans to equity accounted investees, and other long-term assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Currentassetsandliabilities" roleURI="http://www.abcellera.com/role/Currentassetsandliabilities">
        <link:definition>0000014 - Disclosure - Current assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareholdersequity" roleURI="http://www.abcellera.com/role/Shareholdersequity">
        <link:definition>0000015 - Disclosure - Shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.abcellera.com/role/Revenue">
        <link:definition>0000016 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialinstruments" roleURI="http://www.abcellera.com/role/Financialinstruments">
        <link:definition>0000017 - Disclosure - Financial instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://www.abcellera.com/role/Commitmentsandcontingencies">
        <link:definition>0000018 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesPolicies" roleURI="http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies">
        <link:definition>0000019 - Disclosure - Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetearningslosspershareTables" roleURI="http://www.abcellera.com/role/NetearningslosspershareTables">
        <link:definition>0000020 - Disclosure - Net earnings (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentnetTables" roleURI="http://www.abcellera.com/role/PropertyandequipmentnetTables">
        <link:definition>0000021 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://www.abcellera.com/role/IntangibleassetsTables">
        <link:definition>0000022 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CurrentassetsandliabilitiesTables" roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesTables">
        <link:definition>0000023 - Disclosure - Current assets and liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityTables" roleURI="http://www.abcellera.com/role/ShareholdersequityTables">
        <link:definition>0000024 - Disclosure - Shareholders&#8217; equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.abcellera.com/role/RevenueTables">
        <link:definition>0000025 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsTables" roleURI="http://www.abcellera.com/role/FinancialinstrumentsTables">
        <link:definition>0000026 - Disclosure - Financial instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails" roleURI="http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails">
        <link:definition>0000027 - Disclosure - Net earnings (loss) per share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetearningslosspershareAdditionalInformationDetails" roleURI="http://www.abcellera.com/role/NetearningslosspershareAdditionalInformationDetails">
        <link:definition>0000028 - Disclosure - Net earnings (loss) per share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails">
        <link:definition>0000029 - Disclosure - Property and equipment, net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentnetAdditionalInformationDetails" roleURI="http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails">
        <link:definition>0000030 - Disclosure - Property and equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofIntangibleAssetsDetails" roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails">
        <link:definition>0000031 - Disclosure - Intangible assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails" roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails">
        <link:definition>0000032 - Disclosure - Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails" roleURI="http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails">
        <link:definition>0000033 - Disclosure - Investments in and loans to equity accounted investees, and other long-term assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CurrentassetsandliabilitiesOtherCurrentAssetsDetails" roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails">
        <link:definition>0000034 - Disclosure - Current assets and liabilities - Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails">
        <link:definition>0000035 - Disclosure - Current assets and liabilities - Schedule of Accounts Payable and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequitySummaryofStockOptionActivityDetails" roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails">
        <link:definition>0000036 - Disclosure - Shareholders&#8217; equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails" roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails">
        <link:definition>0000037 - Disclosure - Shareholders&#8217; equity - Summary of Restricted Share Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityAdditionalInformationDetails" roleURI="http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails">
        <link:definition>0000038 - Disclosure - Shareholders&#8217; equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequitySummaryofStockBasedCompensationExpenseDetails" roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails">
        <link:definition>0000039 - Disclosure - Shareholders' equity - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueSummaryofDeferredRevenueOutstandingDetails" roleURI="http://www.abcellera.com/role/RevenueSummaryofDeferredRevenueOutstandingDetails">
        <link:definition>0000040 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetails" roleURI="http://www.abcellera.com/role/RevenueAdditionalInformationDetails">
        <link:definition>0000041 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsAdditionalInformationDetails" roleURI="http://www.abcellera.com/role/FinancialinstrumentsAdditionalInformationDetails">
        <link:definition>0000042 - Disclosure - Financial instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails" roleURI="http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails">
        <link:definition>0000043 - Disclosure - Financial instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000044 - Disclosure - Financial instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandcontingenciesDetails" roleURI="http://www.abcellera.com/role/CommitmentsandcontingenciesDetails">
        <link:definition>0000045 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abcl_OperatingLeaseRightOfUseAssetsMember" abstract="true" name="OperatingLeaseRightOfUseAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_CommitmentsContingenciesAndOtherLineItems" abstract="true" name="CommitmentsContingenciesAndOtherLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abcl_DayhuJointVentureMember" abstract="true" name="DayhuJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_PreInitialPublicOfferingPlanMember" abstract="true" name="PreInitialPublicOfferingPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_TrianniMember" abstract="true" name="TrianniMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" abstract="false" name="NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_NewDayluLoanMember" abstract="true" name="NewDayluLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_ResearchFeesMember" abstract="true" name="ResearchFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" abstract="false" name="NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_DayluJVLoanMember" abstract="true" name="DayluJVLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_LicenseBasedIntangibleAssetsMember" abstract="true" name="LicenseBasedIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_PhaseTwoMember" abstract="true" name="PhaseTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" abstract="false" name="RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_MaterialsAndSuppliesCurrent" abstract="false" name="MaterialsAndSuppliesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_AccruedRoyaltiesPayableMember" abstract="true" name="AccruedRoyaltiesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" abstract="false" name="IncreaseDecreaseInAccruedRoyaltiesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_CashCashEquivalentsAndMarketableSecurities" abstract="false" name="CashCashEquivalentsAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_NumberOfJointVentures" abstract="false" name="NumberOfJointVentures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abcl_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_PhaseOneMember" abstract="true" name="PhaseOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_EquityMethodInvestmentCommitmentAmount" abstract="false" name="EquityMethodInvestmentCommitmentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_CommitmentsContingenciesAndOtherTable" abstract="true" name="CommitmentsContingenciesAndOtherTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abcl_StrategicInnovationFundEligibleExpenditure" abstract="false" name="StrategicInnovationFundEligibleExpenditure" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_AccountsAndAccruedReceivableCurrent" abstract="false" name="AccountsAndAccruedReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_GrantsAndIncentives" abstract="false" name="GrantsAndIncentives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" abstract="false" name="IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" abstract="true" name="TwoThousandTwentyShareOptionAndIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" abstract="false" name="StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abcl_IncreaseDecreaseInDeferredGrantIncome" abstract="false" name="IncreaseDecreaseInDeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_ProceedsFromReceiptOfGrantFunding" abstract="false" name="ProceedsFromReceiptOfGrantFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_TetraGeneticMember" abstract="true" name="TetraGeneticMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" abstract="false" name="PaymentsToAcquireLongTermInvestmentsAndOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_PercentageOfConstructionLoan" abstract="false" name="PercentageOfConstructionLoan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" abstract="false" name="EquityMethodInvestmentOutstandingRelatedPartyLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_MilestonePaymentsMember" abstract="true" name="MilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_ProceedsFromDebtAndExerciseOfStockOptions" abstract="false" name="ProceedsFromDebtAndExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_BeedieJointVentureMember" abstract="true" name="BeedieJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abcl_PrepaidExpenseAndOtherCurrent" abstract="false" name="PrepaidExpenseAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" abstract="false" name="StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abcl_CurrentAssetsAndLiabilitiesTextBlock" abstract="false" name="CurrentAssetsAndLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abcl_DeferredGrantsFundingNoncurrent" abstract="false" name="DeferredGrantsFundingNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>abcl-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:650343a1-ca86-4cd1-b410-9b387e72615d,g:7bff7bb1-4386-4395-9d16-110d609544b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CashCashEquivalentsAndMarketableSecurities_23ad01f2-c2c8-46c9-8ea6-51f86a56e67d" xlink:href="abcl-20230331.xsd#abcl_CashCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e6cd940-2676-45b0-9fb9-8fd5a3428bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abcl_CashCashEquivalentsAndMarketableSecurities_23ad01f2-c2c8-46c9-8ea6-51f86a56e67d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e6cd940-2676-45b0-9fb9-8fd5a3428bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a85fe647-30fb-4794-9deb-3781e3ed2da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abcl_CashCashEquivalentsAndMarketableSecurities_23ad01f2-c2c8-46c9-8ea6-51f86a56e67d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a85fe647-30fb-4794-9deb-3781e3ed2da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_971e0fb0-a2be-4c4d-b000-ba8722b9069d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_49a6baf1-135f-4ed5-bcbb-d11c23b9cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_971e0fb0-a2be-4c4d-b000-ba8722b9069d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_49a6baf1-135f-4ed5-bcbb-d11c23b9cb77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_213a72c7-eecd-433d-8324-ec705f5a6bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_971e0fb0-a2be-4c4d-b000-ba8722b9069d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_213a72c7-eecd-433d-8324-ec705f5a6bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_77c722ef-5e95-4424-9cae-ec459610afda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_971e0fb0-a2be-4c4d-b000-ba8722b9069d" xlink:to="loc_us-gaap_Goodwill_77c722ef-5e95-4424-9cae-ec459610afda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3671a14d-7162-4ba7-bd32-48652ff4cfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_971e0fb0-a2be-4c4d-b000-ba8722b9069d" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_3671a14d-7162-4ba7-bd32-48652ff4cfc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d0141d20-f891-4be4-9aa9-65fd8e2bf810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_971e0fb0-a2be-4c4d-b000-ba8722b9069d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d0141d20-f891-4be4-9aa9-65fd8e2bf810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cd09da50-1d66-4cfb-8d6d-7fa335348e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CashCashEquivalentsAndMarketableSecurities_26628f2f-617c-4096-bf27-0acad381dce9" xlink:href="abcl-20230331.xsd#abcl_CashCashEquivalentsAndMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cd09da50-1d66-4cfb-8d6d-7fa335348e09" xlink:to="loc_abcl_CashCashEquivalentsAndMarketableSecurities_26628f2f-617c-4096-bf27-0acad381dce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_AccountsAndAccruedReceivableCurrent_d40cd57c-487c-4158-b38d-97ee5c0719e8" xlink:href="abcl-20230331.xsd#abcl_AccountsAndAccruedReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cd09da50-1d66-4cfb-8d6d-7fa335348e09" xlink:to="loc_abcl_AccountsAndAccruedReceivableCurrent_d40cd57c-487c-4158-b38d-97ee5c0719e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f375dce1-7847-46d4-bb02-dfc38ff6a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cd09da50-1d66-4cfb-8d6d-7fa335348e09" xlink:to="loc_us-gaap_RestrictedCash_f375dce1-7847-46d4-bb02-dfc38ff6a08e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a853de19-b7ae-4966-8d38-dd14313779bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cd09da50-1d66-4cfb-8d6d-7fa335348e09" xlink:to="loc_us-gaap_OtherAssetsCurrent_a853de19-b7ae-4966-8d38-dd14313779bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_87008ade-3e33-4f4b-8709-5eafd9804b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5176286d-2e0b-40ba-9503-db48c3c3c6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87008ade-3e33-4f4b-8709-5eafd9804b1a" xlink:to="loc_us-gaap_Liabilities_5176286d-2e0b-40ba-9503-db48c3c3c6d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_84f806d8-88f6-41d4-b331-b89edb588bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87008ade-3e33-4f4b-8709-5eafd9804b1a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_84f806d8-88f6-41d4-b331-b89edb588bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_deb2230d-98b8-48cd-934e-37bb5be0bff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87008ade-3e33-4f4b-8709-5eafd9804b1a" xlink:to="loc_us-gaap_StockholdersEquity_deb2230d-98b8-48cd-934e-37bb5be0bff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_879b6854-f20d-4431-97a1-7964d858a585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0a832c48-4f2d-467c-9df5-09bd51863380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_879b6854-f20d-4431-97a1-7964d858a585" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0a832c48-4f2d-467c-9df5-09bd51863380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fd2578ca-eaaa-4f37-9f3d-7d2b2a4ed26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_879b6854-f20d-4431-97a1-7964d858a585" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fd2578ca-eaaa-4f37-9f3d-7d2b2a4ed26c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_621d140b-63d6-48d4-9d9a-e3b51e63fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_879b6854-f20d-4431-97a1-7964d858a585" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_621d140b-63d6-48d4-9d9a-e3b51e63fed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_202e97dd-f330-47d8-8e86-472512d69e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_879b6854-f20d-4431-97a1-7964d858a585" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_202e97dd-f330-47d8-8e86-472512d69e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_140662d1-377b-41f9-927d-d3ce558bd781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3b9bc500-234b-4ab4-bf8a-248eb2d2a408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_140662d1-377b-41f9-927d-d3ce558bd781" xlink:to="loc_us-gaap_AssetsCurrent_3b9bc500-234b-4ab4-bf8a-248eb2d2a408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_13da5ed9-6c86-45dc-b0ac-ba6411f75706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_140662d1-377b-41f9-927d-d3ce558bd781" xlink:to="loc_us-gaap_AssetsNoncurrent_13da5ed9-6c86-45dc-b0ac-ba6411f75706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_80789d0a-c58b-4762-9759-fb9ef7eeb1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f945931-a477-4f83-baf1-522813413e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_80789d0a-c58b-4762-9759-fb9ef7eeb1e1" xlink:to="loc_us-gaap_LiabilitiesCurrent_6f945931-a477-4f83-baf1-522813413e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4e8821cb-5a5f-4a71-86f9-ccf47748c782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_80789d0a-c58b-4762-9759-fb9ef7eeb1e1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4e8821cb-5a5f-4a71-86f9-ccf47748c782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_55c4d0c9-867f-4701-ac8c-492577ec3c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_55c4d0c9-867f-4701-ac8c-492577ec3c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6888b461-fd49-4604-bf01-c4ae06f7982b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6888b461-fd49-4604-bf01-c4ae06f7982b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ba224dcc-8c42-4b19-8715-40fc5b6ce9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ba224dcc-8c42-4b19-8715-40fc5b6ce9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_611f59c0-e746-4129-9a08-b43faf23abda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_611f59c0-e746-4129-9a08-b43faf23abda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_faa1844f-e9d5-426f-8bf7-f72bab9b727e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_faa1844f-e9d5-426f-8bf7-f72bab9b727e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DeferredGrantsFundingNoncurrent_7c1c145f-d142-40b3-9d84-bfc4e2a3dd15" xlink:href="abcl-20230331.xsd#abcl_DeferredGrantsFundingNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_97475cae-cc59-4196-95d0-5cc9cc1b6a94" xlink:to="loc_abcl_DeferredGrantsFundingNoncurrent_7c1c145f-d142-40b3-9d84-bfc4e2a3dd15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_031aa384-25a5-4cf3-8675-7df903448fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6ea9c4db-7380-47c5-a192-8d72e907eb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_031aa384-25a5-4cf3-8675-7df903448fb3" xlink:to="loc_us-gaap_CommonStockValue_6ea9c4db-7380-47c5-a192-8d72e907eb35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e0f02cd-5888-447d-95b0-36a9c9a761b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_031aa384-25a5-4cf3-8675-7df903448fb3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3e0f02cd-5888-447d-95b0-36a9c9a761b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea979799-ebe8-48fb-90d4-7e60d79030d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_031aa384-25a5-4cf3-8675-7df903448fb3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea979799-ebe8-48fb-90d4-7e60d79030d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b51733d0-4d9e-49e5-a8c8-3c6e82dca9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_031aa384-25a5-4cf3-8675-7df903448fb3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b51733d0-4d9e-49e5-a8c8-3c6e82dca9ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccbdddd5-f976-4e70-a9fe-68111adeabac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5dce8342-01c7-4007-990f-4b4a4dc6fae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccbdddd5-f976-4e70-a9fe-68111adeabac" xlink:to="loc_us-gaap_NetIncomeLoss_5dce8342-01c7-4007-990f-4b4a4dc6fae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_335d258a-a97a-4638-8c26-900fa698eed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ccbdddd5-f976-4e70-a9fe-68111adeabac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_335d258a-a97a-4638-8c26-900fa698eed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5f9f1564-2825-49d0-bf5e-33110a7c733e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_79fbf45a-e725-4c34-942b-389c7ed1a6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5f9f1564-2825-49d0-bf5e-33110a7c733e" xlink:to="loc_us-gaap_RoyaltyExpense_79fbf45a-e725-4c34-942b-389c7ed1a6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_363ba966-0184-446c-9f4e-b7695355d84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5f9f1564-2825-49d0-bf5e-33110a7c733e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_363ba966-0184-446c-9f4e-b7695355d84b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_61fba3a0-e158-43e6-88a9-bfa75689fcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5f9f1564-2825-49d0-bf5e-33110a7c733e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_61fba3a0-e158-43e6-88a9-bfa75689fcbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d56b9c3d-94cb-41d9-a330-308579f67bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5f9f1564-2825-49d0-bf5e-33110a7c733e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d56b9c3d-94cb-41d9-a330-308579f67bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_09b2ccbd-c582-4f75-b8af-39e72c20b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5f9f1564-2825-49d0-bf5e-33110a7c733e" xlink:to="loc_us-gaap_DepreciationAndAmortization_09b2ccbd-c582-4f75-b8af-39e72c20b23b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c0a43c08-c3a8-43f5-8825-018b5d6cdc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de633472-7599-4ec6-830b-8a943b37dc08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c0a43c08-c3a8-43f5-8825-018b5d6cdc2e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de633472-7599-4ec6-830b-8a943b37dc08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7425dfd9-5836-4c7d-b54d-f72d15b7c6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c0a43c08-c3a8-43f5-8825-018b5d6cdc2e" xlink:to="loc_us-gaap_OperatingExpenses_7425dfd9-5836-4c7d-b54d-f72d15b7c6f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_921e8870-c1ab-4ff3-8912-058c7da4c74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_687f4d71-26a5-441f-ab27-2c1b5f94b4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_921e8870-c1ab-4ff3-8912-058c7da4c74f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_687f4d71-26a5-441f-ab27-2c1b5f94b4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5de269d3-e441-4417-b2b9-c89f27e3507c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_921e8870-c1ab-4ff3-8912-058c7da4c74f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5de269d3-e441-4417-b2b9-c89f27e3507c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ff5aab22-3d7d-4448-93db-c257861f2a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_75d3f245-d26e-4987-bb05-03f6510a0b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ff5aab22-3d7d-4448-93db-c257861f2a0d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_75d3f245-d26e-4987-bb05-03f6510a0b48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_GrantsAndIncentives_404b982c-3431-4fd9-84f3-2bc590627d84" xlink:href="abcl-20230331.xsd#abcl_GrantsAndIncentives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ff5aab22-3d7d-4448-93db-c257861f2a0d" xlink:to="loc_abcl_GrantsAndIncentives_404b982c-3431-4fd9-84f3-2bc590627d84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a06a8d2d-dcb9-4f4e-b3e4-d03a873f2987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ff5aab22-3d7d-4448-93db-c257861f2a0d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a06a8d2d-dcb9-4f4e-b3e4-d03a873f2987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b87ce87c-0199-486a-a187-e16d7731fc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6f84e5dd-7df6-4afb-81cb-2fb489ca9b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b87ce87c-0199-486a-a187-e16d7731fc5a" xlink:to="loc_us-gaap_OperatingIncomeLoss_6f84e5dd-7df6-4afb-81cb-2fb489ca9b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_877b699f-99be-471f-8f51-fe9d4d52359a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b87ce87c-0199-486a-a187-e16d7731fc5a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_877b699f-99be-471f-8f51-fe9d4d52359a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f94d2c2-57b6-4a26-a315-3eda51110464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_a6ba7ef6-173b-4508-9d40-467cb961333a" xlink:href="abcl-20230331.xsd#abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f94d2c2-57b6-4a26-a315-3eda51110464" xlink:to="loc_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_a6ba7ef6-173b-4508-9d40-467cb961333a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ProceedsFromDebtAndExerciseOfStockOptions_ae2c858c-323e-4469-95b9-774a6e947aef" xlink:href="abcl-20230331.xsd#abcl_ProceedsFromDebtAndExerciseOfStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f94d2c2-57b6-4a26-a315-3eda51110464" xlink:to="loc_abcl_ProceedsFromDebtAndExerciseOfStockOptions_ae2c858c-323e-4469-95b9-774a6e947aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0e534ca2-d434-4322-9de9-d5655d35a275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_589d4c30-e1f6-4480-b42d-43eb4fea6582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0e534ca2-d434-4322-9de9-d5655d35a275" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_589d4c30-e1f6-4480-b42d-43eb4fea6582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9cba558a-ec5c-4d9c-9167-5887b1e95492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0e534ca2-d434-4322-9de9-d5655d35a275" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9cba558a-ec5c-4d9c-9167-5887b1e95492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc40d6bf-11ad-4173-94b0-1cd45c7fbc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93ba45f9-b755-45a6-b275-4d54d6809f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc40d6bf-11ad-4173-94b0-1cd45c7fbc07" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_93ba45f9-b755-45a6-b275-4d54d6809f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8cb5c886-ae28-463a-afe8-1c665d68b93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc40d6bf-11ad-4173-94b0-1cd45c7fbc07" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8cb5c886-ae28-463a-afe8-1c665d68b93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eeda35d8-df81-4a07-a8b5-0611b4ecf593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc40d6bf-11ad-4173-94b0-1cd45c7fbc07" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eeda35d8-df81-4a07-a8b5-0611b4ecf593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bbd73698-0a38-4fbd-97cd-845ab43dede4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bc40d6bf-11ad-4173-94b0-1cd45c7fbc07" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bbd73698-0a38-4fbd-97cd-845ab43dede4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e684b595-d3e0-4441-8c0a-bc1458bc4bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e684b595-d3e0-4441-8c0a-bc1458bc4bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_84a506e3-ba42-4b80-90ec-884e2c0a56d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_84a506e3-ba42-4b80-90ec-884e2c0a56d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_595b03c6-c9ee-4b8f-8a3a-54c412c672f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_595b03c6-c9ee-4b8f-8a3a-54c412c672f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ProceedsFromReceiptOfGrantFunding_52c708a5-2a6f-488f-b529-fb75a48c7505" xlink:href="abcl-20230331.xsd#abcl_ProceedsFromReceiptOfGrantFunding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:to="loc_abcl_ProceedsFromReceiptOfGrantFunding_52c708a5-2a6f-488f-b529-fb75a48c7505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_de1582bd-dfc8-4185-b3d4-4a15579b96f5" xlink:href="abcl-20230331.xsd#abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:to="loc_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_de1582bd-dfc8-4185-b3d4-4a15579b96f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8b9fc5c8-3ce7-4446-99ed-e86bf2920083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697b7c9-ede9-4799-9589-11d0fbb16868" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_8b9fc5c8-3ce7-4446-99ed-e86bf2920083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c42f124-da2f-4bf5-993b-991a37a869a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_ProfitLoss_1c42f124-da2f-4bf5-993b-991a37a869a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4dbf214e-f840-4af2-a076-cb7bec426462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_Depreciation_4dbf214e-f840-4af2-a076-cb7bec426462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_38db0a20-32e9-4523-b8e4-eabc07f04762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_38db0a20-32e9-4523-b8e4-eabc07f04762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d9b02e93-fd87-4e6c-9cf4-3c5cdc722f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d9b02e93-fd87-4e6c-9cf4-3c5cdc722f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3b0b6c7-7754-44eb-a07f-2253e831aaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_ShareBasedCompensation_d3b0b6c7-7754-44eb-a07f-2253e831aaaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2b390331-35d8-4f7d-b065-1cb3f38324f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2b390331-35d8-4f7d-b065-1cb3f38324f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_85223efd-c576-42b6-b731-d99c94a7d2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_85223efd-c576-42b6-b731-d99c94a7d2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_c95efe32-d78e-4449-bd34-c76994426755" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_c95efe32-d78e-4449-bd34-c76994426755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_59623dd1-55ce-4971-a9c2-b9480dd75ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_59623dd1-55ce-4971-a9c2-b9480dd75ce2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_6a208112-6259-496c-b471-51f2a579fbfe" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_6a208112-6259-496c-b471-51f2a579fbfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_ebd47b98-9413-42de-acbd-fdb65dd3f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_ebd47b98-9413-42de-acbd-fdb65dd3f3e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_fb532f79-f7e1-4a00-a405-f5ff5302f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_fb532f79-f7e1-4a00-a405-f5ff5302f8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInDeferredGrantIncome_1da5c498-f75e-41f2-ab47-8b86b092bbe4" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInDeferredGrantIncome"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_abcl_IncreaseDecreaseInDeferredGrantIncome_1da5c498-f75e-41f2-ab47-8b86b092bbe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aeb0a87c-ab72-4077-a644-eeef4e01b2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8ad5ec77-c5dc-4aff-b537-c076186907d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aeb0a87c-ab72-4077-a644-eeef4e01b2c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce272367-54d0-4c51-a224-42782001c4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f82c56e-4aef-45bc-9e3b-9efcf9411ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce272367-54d0-4c51-a224-42782001c4c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9f82c56e-4aef-45bc-9e3b-9efcf9411ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cc148449-d0ed-4103-aabc-b7aef461baa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ce272367-54d0-4c51-a224-42782001c4c7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cc148449-d0ed-4103-aabc-b7aef461baa8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaf6e32-f575-47b4-9d53-308b12e614e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_efebcca5-2789-435d-8246-1837de06ebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaf6e32-f575-47b4-9d53-308b12e614e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_efebcca5-2789-435d-8246-1837de06ebcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9858f5e3-be30-410b-abf9-c762272bb2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaf6e32-f575-47b4-9d53-308b12e614e6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9858f5e3-be30-410b-abf9-c762272bb2ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#IntangibleassetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88b83510-c45b-4e8c-9347-fcceb805d809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4b43bb9e-cbd2-410f-9895-29aecfad8e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88b83510-c45b-4e8c-9347-fcceb805d809" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4b43bb9e-cbd2-410f-9895-29aecfad8e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_be50a502-8e9f-46cb-98e9-9170e3c680ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88b83510-c45b-4e8c-9347-fcceb805d809" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_be50a502-8e9f-46cb-98e9-9170e3c680ba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7eaa275c-1867-43bf-96c3-a016d74e79af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8a251510-9890-405c-bc2f-0db07cafe13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7eaa275c-1867-43bf-96c3-a016d74e79af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8a251510-9890-405c-bc2f-0db07cafe13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3473aaa8-eaec-4125-a596-535b5509fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7eaa275c-1867-43bf-96c3-a016d74e79af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3473aaa8-eaec-4125-a596-535b5509fc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fcb878bb-e5a4-41a8-bf6c-38856e0a8304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7eaa275c-1867-43bf-96c3-a016d74e79af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fcb878bb-e5a4-41a8-bf6c-38856e0a8304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16c24f4f-4833-4016-93e8-d1d9c6f3d8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7eaa275c-1867-43bf-96c3-a016d74e79af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_16c24f4f-4833-4016-93e8-d1d9c6f3d8a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fe006e50-a1c5-4224-bb8d-16b73d7bb9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7eaa275c-1867-43bf-96c3-a016d74e79af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fe006e50-a1c5-4224-bb8d-16b73d7bb9ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#CurrentassetsandliabilitiesOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f8b4b865-a0e5-448c-808d-d2df4102d5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_f0dc7645-2632-4c2a-a15b-a03a12f83a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f8b4b865-a0e5-448c-808d-d2df4102d5be" xlink:to="loc_us-gaap_IncomeTaxesReceivable_f0dc7645-2632-4c2a-a15b-a03a12f83a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PrepaidExpenseAndOtherCurrent_b6b1badd-bdf8-45a4-88fe-5f000ec8d08a" xlink:href="abcl-20230331.xsd#abcl_PrepaidExpenseAndOtherCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f8b4b865-a0e5-448c-808d-d2df4102d5be" xlink:to="loc_abcl_PrepaidExpenseAndOtherCurrent_b6b1badd-bdf8-45a4-88fe-5f000ec8d08a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MaterialsAndSuppliesCurrent_c6cd4dc6-87f9-4d97-a493-8c7d371ce325" xlink:href="abcl-20230331.xsd#abcl_MaterialsAndSuppliesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_f8b4b865-a0e5-448c-808d-d2df4102d5be" xlink:to="loc_abcl_MaterialsAndSuppliesCurrent_c6cd4dc6-87f9-4d97-a493-8c7d371ce325" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2133e6c2-d9a8-4872-bbe9-d6456c870920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7457409e-9123-40d4-b098-ea3f2d840747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2133e6c2-d9a8-4872-bbe9-d6456c870920" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7457409e-9123-40d4-b098-ea3f2d840747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_78bba7a5-c55b-406f-834b-0ac6993e2c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2133e6c2-d9a8-4872-bbe9-d6456c870920" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_78bba7a5-c55b-406f-834b-0ac6993e2c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DeferredGrantFundingCurrent_a6dcaaf5-0b77-4578-a677-866c1c5b620b" xlink:href="abcl-20230331.xsd#abcl_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2133e6c2-d9a8-4872-bbe9-d6456c870920" xlink:to="loc_abcl_DeferredGrantFundingCurrent_a6dcaaf5-0b77-4578-a677-866c1c5b620b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_df9ff14d-9248-4c67-9f06-aed748d4680c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2133e6c2-d9a8-4872-bbe9-d6456c870920" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_df9ff14d-9248-4c67-9f06-aed748d4680c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>abcl-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:650343a1-ca86-4cd1-b410-9b387e72615d,g:7bff7bb1-4386-4395-9d16-110d609544b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="extended" id="i84828c908fb145fcaba2fdf163a5d147_CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f25f83a-96ae-43a7-9c89-5111439725c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_RevenuesAbstract_3f25f83a-96ae-43a7-9c89-5111439725c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4324f53f-c9cd-4387-926b-18ff9efb2737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_3f25f83a-96ae-43a7-9c89-5111439725c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4324f53f-c9cd-4387-926b-18ff9efb2737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_390ed966-16d5-4888-86c0-2c594e5adfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_RoyaltyExpense_390ed966-16d5-4888-86c0-2c594e5adfb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fc4d50d7-5150-47ad-9540-580924a5c016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fc4d50d7-5150-47ad-9540-580924a5c016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_73e060a8-f685-472f-af55-2e4ef705f209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_SellingAndMarketingExpense_73e060a8-f685-472f-af55-2e4ef705f209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4ba0dc2c-7dd1-49c4-8ca8-56f065ff4cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4ba0dc2c-7dd1-49c4-8ca8-56f065ff4cf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d026796-0028-4aec-aa0f-7cb6e63f13d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d026796-0028-4aec-aa0f-7cb6e63f13d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9202aa5b-bd56-4c11-ad97-551a6c640e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_OperatingExpenses_9202aa5b-bd56-4c11-ad97-551a6c640e78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af9526c4-3284-4cb9-bedd-153fd08f853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_OperatingIncomeLoss_af9526c4-3284-4cb9-bedd-153fd08f853a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_72ff03d7-a1a9-4b9f-8bd1-10a3c32ec9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_72ff03d7-a1a9-4b9f-8bd1-10a3c32ec9ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_GrantsAndIncentives_0c1a6cec-7112-417b-9e52-c27c3f1b990e" xlink:href="abcl-20230331.xsd#abcl_GrantsAndIncentives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_abcl_GrantsAndIncentives_0c1a6cec-7112-417b-9e52-c27c3f1b990e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c6f228c9-b0ea-424b-93b6-eb1d9a498164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c6f228c9-b0ea-424b-93b6-eb1d9a498164" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25dd280b-92c6-4ead-81e8-71131b3ddd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25dd280b-92c6-4ead-81e8-71131b3ddd21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_91f83d85-447c-4d81-84f6-70ee30313642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_91f83d85-447c-4d81-84f6-70ee30313642" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6574ea35-da70-4b48-b79d-2ef4feeaba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6574ea35-da70-4b48-b79d-2ef4feeaba6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b00950b-4fd8-42d6-be9c-7df2d0f391ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_NetIncomeLoss_4b00950b-4fd8-42d6-be9c-7df2d0f391ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c5e2f0dc-adce-4fca-9661-04c5901a5e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c5e2f0dc-adce-4fca-9661-04c5901a5e6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a8201c7-afc4-4967-b35c-eba560d9ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a8201c7-afc4-4967-b35c-eba560d9ad7b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e27d681a-e8d6-4358-9c5f-e2406ac300c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:to="loc_us-gaap_EarningsPerShareBasic_e27d681a-e8d6-4358-9c5f-e2406ac300c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_76418a3d-7960-4790-9708-789ec00e1789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:to="loc_us-gaap_EarningsPerShareDiluted_76418a3d-7960-4790-9708-789ec00e1789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88660318-5602-4af6-aa89-34f489747dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88660318-5602-4af6-aa89-34f489747dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef084024-157c-4fdd-a115-00fdedb8ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef084024-157c-4fdd-a115-00fdedb8ab64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:to="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67b4d717-46b0-4746-b371-e23267bb8af4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:to="loc_srt_ProductsAndServicesDomain_67b4d717-46b0-4746-b371-e23267bb8af4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:to="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ResearchFeesMember_8f34aa39-6677-4f15-acd7-84889d2bd893" xlink:href="abcl-20230331.xsd#abcl_ResearchFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_abcl_ResearchFeesMember_8f34aa39-6677-4f15-acd7-84889d2bd893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cc734d87-f5f5-4e98-b22e-80926f076627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_us-gaap_LicenseMember_cc734d87-f5f5-4e98-b22e-80926f076627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MilestonePaymentsMember_c735962a-e1c2-4ef3-a9d4-f243262c100e" xlink:href="abcl-20230331.xsd#abcl_MilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_abcl_MilestonePaymentsMember_c735962a-e1c2-4ef3-a9d4-f243262c100e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b32cc8ce-958d-4e96-b3d2-64b20498883a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_us-gaap_RoyaltyMember_b32cc8ce-958d-4e96-b3d2-64b20498883a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2b03e0cd5faa438c893e11e0255038d0_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b2d2fcb-ffd9-46f0-b8d0-cd17a5b55640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1b2d2fcb-ffd9-46f0-b8d0-cd17a5b55640" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6054bd31-a8ce-4bdf-b780-f131cf72a34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_SharesOutstanding_6054bd31-a8ce-4bdf-b780-f131cf72a34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77fc7b5e-f0de-4fd4-8e83-f02d3e806924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_StockholdersEquity_77fc7b5e-f0de-4fd4-8e83-f02d3e806924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_bf0a2978-6177-4b60-8c50-0f5dbc636170" xlink:href="abcl-20230331.xsd#abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_bf0a2978-6177-4b60-8c50-0f5dbc636170" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_b7ba3aed-3904-4f4c-bcce-bef91db830fc" xlink:href="abcl-20230331.xsd#abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_b7ba3aed-3904-4f4c-bcce-bef91db830fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34640e58-186e-4738-8751-29b5ea8af815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34640e58-186e-4738-8751-29b5ea8af815" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0184064d-8203-4faa-b18c-e48181bca12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0184064d-8203-4faa-b18c-e48181bca12e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70887e57-47c6-4e0a-89d0-a94c85759e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_NetIncomeLoss_70887e57-47c6-4e0a-89d0-a94c85759e53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7cd2ccd7-5eb5-4312-97ec-ab748e351b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b087a32-0630-4663-a48b-93c9953924be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1b2d2fcb-ffd9-46f0-b8d0-cd17a5b55640" xlink:to="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:to="loc_us-gaap_EquityComponentDomain_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:to="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_91e29c51-6355-405e-b37f-f47afcb0815a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_CommonStockMember_91e29c51-6355-405e-b37f-f47afcb0815a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a9008da0-3361-4c7b-90c9-0457118b2770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a9008da0-3361-4c7b-90c9-0457118b2770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_65366a70-e39c-4c35-b5bd-b0ee1bbc4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_RetainedEarningsMember_65366a70-e39c-4c35-b5bd-b0ee1bbc4fcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2689c044-1ddc-474e-b485-8b27b824bb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2689c044-1ddc-474e-b485-8b27b824bb75" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="i98fc4a71002b43e4b951e2b396521256_PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3761f8ad-30c0-49f2-b8b6-27de8293bd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3761f8ad-30c0-49f2-b8b6-27de8293bd1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa7bca2b-1bfb-4c35-bbab-150ecba1cc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa7bca2b-1bfb-4c35-bbab-150ecba1cc4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c82d8ea-7b0d-4355-bde8-caff26ba95b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c82d8ea-7b0d-4355-bde8-caff26ba95b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87b12036-c0e3-438b-8bee-9c457cc1484a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87b12036-c0e3-438b-8bee-9c457cc1484a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_a5c08f3e-560e-4e2c-bc1d-7eae36c1144b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_ComputerEquipmentMember_a5c08f3e-560e-4e2c-bc1d-7eae36c1144b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_7587c24d-7bdc-4054-b7b9-e8b958cbe0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_LandMember_7587c24d-7bdc-4054-b7b9-e8b958cbe0fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_28595fa9-5e44-487e-8be2-77e7e4409924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_BuildingMember_28595fa9-5e44-487e-8be2-77e7e4409924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_LaboratoryEquipmentMember_fe248b7c-82e9-44ed-8cc3-a8fd45e526b0" xlink:href="abcl-20230331.xsd#abcl_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_abcl_LaboratoryEquipmentMember_fe248b7c-82e9-44ed-8cc3-a8fd45e526b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f205f44d-8784-49e4-9160-181b27df6279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f205f44d-8784-49e4-9160-181b27df6279" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_OperatingLeaseRightOfUseAssetsMember_7220e02e-5153-4209-9050-773d97f34780" xlink:href="abcl-20230331.xsd#abcl_OperatingLeaseRightOfUseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_abcl_OperatingLeaseRightOfUseAssetsMember_7220e02e-5153-4209-9050-773d97f34780" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#IntangibleassetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i4aff7e6e95144952b15c52593a28aed9_IntangibleassetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62ea47c0-3a08-4296-a1aa-5e39d7689656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62ea47c0-3a08-4296-a1aa-5e39d7689656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc1241ea-e04c-49da-935d-0f5fb7c066a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc1241ea-e04c-49da-935d-0f5fb7c066a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f0248c7-3d95-4085-819b-a2611717734d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f0248c7-3d95-4085-819b-a2611717734d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54201260-a254-4d82-ab63-f7178e612b96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54201260-a254-4d82-ab63-f7178e612b96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_LicenseBasedIntangibleAssetsMember_3c961c5c-ced7-40ad-8bb1-736822a98306" xlink:href="abcl-20230331.xsd#abcl_LicenseBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:to="loc_abcl_LicenseBasedIntangibleAssetsMember_3c961c5c-ced7-40ad-8bb1-736822a98306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d060c586-c7be-46b7-8517-017c839570bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d060c586-c7be-46b7-8517-017c839570bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a9b8e451-d526-421c-be5b-4e643cf26431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a9b8e451-d526-421c-be5b-4e643cf26431" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails" xlink:type="extended" id="i75b8d072012d488d98489285ad468a67_InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NumberOfJointVentures_e6d07b8e-a454-4026-81f4-a48ac21e397a" xlink:href="abcl-20230331.xsd#abcl_NumberOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_NumberOfJointVentures_e6d07b8e-a454-4026-81f4-a48ac21e397a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ff5af26c-afdf-4256-86a1-66a943ef40c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ff5af26c-afdf-4256-86a1-66a943ef40c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_25d07030-db52-4110-9fc8-f5b814374eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_25d07030-db52-4110-9fc8-f5b814374eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_EquityMethodInvestmentCommitmentAmount_7a8bf9cc-1bbd-43d5-be30-5b4371d58ed9" xlink:href="abcl-20230331.xsd#abcl_EquityMethodInvestmentCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_EquityMethodInvestmentCommitmentAmount_7a8bf9cc-1bbd-43d5-be30-5b4371d58ed9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_6de42129-afa6-4614-80ea-fba50434179a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_DebtInstrumentTerm_6de42129-afa6-4614-80ea-fba50434179a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_38c1b5e3-20b4-4ccc-b41c-9b6a8ef9ff13" xlink:href="abcl-20230331.xsd#abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_38c1b5e3-20b4-4ccc-b41c-9b6a8ef9ff13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PercentageOfConstructionLoan_72816bdf-163f-4470-a420-07c3e9052d4c" xlink:href="abcl-20230331.xsd#abcl_PercentageOfConstructionLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_PercentageOfConstructionLoan_72816bdf-163f-4470-a420-07c3e9052d4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_baa26997-d999-48cf-b496-90d6b4a5794d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_baa26997-d999-48cf-b496-90d6b4a5794d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DayhuJointVentureMember_ac2b3948-40fd-4f45-89c7-1bbee2ab7a98" xlink:href="abcl-20230331.xsd#abcl_DayhuJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:to="loc_abcl_DayhuJointVentureMember_ac2b3948-40fd-4f45-89c7-1bbee2ab7a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_BeedieJointVentureMember_02dc36df-dd39-4303-8738-9a87b5e7e320" xlink:href="abcl-20230331.xsd#abcl_BeedieJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:to="loc_abcl_BeedieJointVentureMember_02dc36df-dd39-4303-8738-9a87b5e7e320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78f4ad62-1161-463b-bac5-fc204cf4cb5d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:to="loc_srt_RangeMember_78f4ad62-1161-463b-bac5-fc204cf4cb5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:to="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_517d68fd-c35d-48a6-8f42-5822f606595e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:to="loc_srt_MaximumMember_517d68fd-c35d-48a6-8f42-5822f606595e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_618fa045-5f5e-43c5-a742-5996922bb8df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:to="loc_srt_MinimumMember_618fa045-5f5e-43c5-a742-5996922bb8df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d8201d6-5a6c-417e-abec-d0af6236baa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d8201d6-5a6c-417e-abec-d0af6236baa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DayluJVLoanMember_b1944a87-7fbb-4f50-a10d-e8c4372ae7a0" xlink:href="abcl-20230331.xsd#abcl_DayluJVLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:to="loc_abcl_DayluJVLoanMember_b1944a87-7fbb-4f50-a10d-e8c4372ae7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NewDayluLoanMember_2c94757f-9f92-4e7f-b520-f6facf87c508" xlink:href="abcl-20230331.xsd#abcl_NewDayluLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:to="loc_abcl_NewDayluLoanMember_2c94757f-9f92-4e7f-b520-f6facf87c508" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequitySummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails" xlink:type="extended" id="i3845987e72f748ae8ea1593bedea51f0_ShareholdersequitySummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e8a751a-1abd-4370-85b0-63b66d715f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e8a751a-1abd-4370-85b0-63b66d715f7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0c84c42-f2f8-4038-9a93-861115388cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0c84c42-f2f8-4038-9a93-861115388cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233edac9-6d6e-4def-bdd1-194c82446924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233edac9-6d6e-4def-bdd1-194c82446924" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7fa342c8-2579-43b8-9d84-8a57f68ea1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7fa342c8-2579-43b8-9d84-8a57f68ea1ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d1ef659-ea8d-4648-803c-110b03b31bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b3eac473-6988-49ab-af8f-3b9416a9e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b3eac473-6988-49ab-af8f-3b9416a9e3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b226ebb9-ae2f-4b2f-9209-69305fcd6a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b226ebb9-ae2f-4b2f-9209-69305fcd6a53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e7475c2-05cf-420b-a46d-a3fbeb7c8d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e7475c2-05cf-420b-a46d-a3fbeb7c8d5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_22bb0cec-cff8-4a17-ab27-b4f68960f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_22bb0cec-cff8-4a17-ab27-b4f68960f1af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3df8aeec-9657-4acc-949d-d88f8784cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3df8aeec-9657-4acc-949d-d88f8784cde5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37e9740e-b546-4807-a7c5-e91ba5aa821e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69614f-f28c-4aaf-9a1f-7c7abbabdac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69614f-f28c-4aaf-9a1f-7c7abbabdac0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:to="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_24d810fd-e7a3-4a71-a1b5-10843d5dc539_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:to="loc_us-gaap_PlanNameDomain_24d810fd-e7a3-4a71-a1b5-10843d5dc539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:to="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PreInitialPublicOfferingPlanMember_a278ec01-d166-4aa3-8647-a3a65dae0a60" xlink:href="abcl-20230331.xsd#abcl_PreInitialPublicOfferingPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:to="loc_abcl_PreInitialPublicOfferingPlanMember_a278ec01-d166-4aa3-8647-a3a65dae0a60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_fb6640bb-e82b-4b7b-9226-fa09d502607e" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:to="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_fb6640bb-e82b-4b7b-9226-fa09d502607e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails" xlink:type="extended" id="i8a2402d9bd2241e18803bdeb5e05c4fb_ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83420862-d5c1-41b9-a263-b516888895d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83420862-d5c1-41b9-a263-b516888895d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55872ffe-f3b2-4bdb-a39f-bb36b4f05f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55872ffe-f3b2-4bdb-a39f-bb36b4f05f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8b50e0-68b3-4777-9138-d66d0f1dd470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8b50e0-68b3-4777-9138-d66d0f1dd470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a67c8f35-55cd-4b80-8668-09741ac76986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a67c8f35-55cd-4b80-8668-09741ac76986" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff3f4e33-9681-4931-bcb0-962a75d33a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74d27a90-a038-41e5-a382-71849b93ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74d27a90-a038-41e5-a382-71849b93ca07" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38ca9bb6-46c8-4213-b387-ac675f5159db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38ca9bb6-46c8-4213-b387-ac675f5159db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4f9e5045-e9ce-4f96-a930-82f361bdd96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4f9e5045-e9ce-4f96-a930-82f361bdd96a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a51b0b03-27cf-46a7-b9b1-29b407c4ba68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a51b0b03-27cf-46a7-b9b1-29b407c4ba68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_625f3cc8-f6cc-47f2-80aa-2a3d2bf9aefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:to="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b124fcf1-b906-4eb2-9ad5-561ad01edd90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:to="loc_us-gaap_PlanNameDomain_b124fcf1-b906-4eb2-9ad5-561ad01edd90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d8a678c-b590-4805-a198-fa3c1205db45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:to="loc_us-gaap_PlanNameDomain_6d8a678c-b590-4805-a198-fa3c1205db45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_eed94e1a-b3fc-463b-9aae-7600300a006c" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d8a678c-b590-4805-a198-fa3c1205db45" xlink:to="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_eed94e1a-b3fc-463b-9aae-7600300a006c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:to="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e36ccdf-0320-45cc-91e3-21c5c13d74cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2e36ccdf-0320-45cc-91e3-21c5c13d74cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_625697c2-7b6c-4577-9703-698953109582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_625697c2-7b6c-4577-9703-698953109582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8fd4f0cc-604e-4faa-8e9b-7ab8d9a2f763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_625697c2-7b6c-4577-9703-698953109582" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8fd4f0cc-604e-4faa-8e9b-7ab8d9a2f763" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails" xlink:type="extended" id="i8e0275713ae64453bc4e476846f90d0b_ShareholdersequityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fbb90f0-65f6-43b7-a7ea-7f4562a6e174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5631119-f4c0-49ed-b790-845e48a512ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fbb90f0-65f6-43b7-a7ea-7f4562a6e174" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5631119-f4c0-49ed-b790-845e48a512ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fbb90f0-65f6-43b7-a7ea-7f4562a6e174" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:to="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e5d18513-80f6-4c10-9e55-766d6f55d1a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:to="loc_us-gaap_PlanNameDomain_e5d18513-80f6-4c10-9e55-766d6f55d1a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_204928d6-2768-4853-be3a-404679e0312b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:to="loc_us-gaap_PlanNameDomain_204928d6-2768-4853-be3a-404679e0312b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_567bb914-e32d-46f2-a5e9-a179d9bfb3f6" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_204928d6-2768-4853-be3a-404679e0312b" xlink:to="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_567bb914-e32d-46f2-a5e9-a179d9bfb3f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails" xlink:type="extended" id="i367de90e05cf4e30ae9bf437b42f071a_ShareholdersequitySummaryofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e5fbac-d4bd-41a4-a77a-ffd539ead94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2efbb769-3b0a-495c-999a-5ba1ca04b447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e5fbac-d4bd-41a4-a77a-ffd539ead94a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2efbb769-3b0a-495c-999a-5ba1ca04b447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e5fbac-d4bd-41a4-a77a-ffd539ead94a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d1acd30-3c0b-4f49-84e2-aedb706000ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d1acd30-3c0b-4f49-84e2-aedb706000ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47215e66-dd29-4025-9146-dbb311aaed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47215e66-dd29-4025-9146-dbb311aaed0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_b257b523-bac7-41fe-993c-d1a1879dee54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_b257b523-bac7-41fe-993c-d1a1879dee54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e2fddc-d8ed-4abd-bb2f-3b6a9bfb0cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e2fddc-d8ed-4abd-bb2f-3b6a9bfb0cd0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails" xlink:type="extended" id="i0eb40bf7f9de4a1b9a10cc112e158af2_FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_49d78411-afc2-42a9-b60b-f738c0cf7e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_49d78411-afc2-42a9-b60b-f738c0cf7e00" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_606b7a88-be90-4980-aabb-4c43b88a1882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_606b7a88-be90-4980-aabb-4c43b88a1882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f8ad10bd-8d69-46e3-bd95-9c53945f3557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f8ad10bd-8d69-46e3-bd95-9c53945f3557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a4f40e3-0c77-4380-9195-d9542609f1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_80b63eb3-968d-485e-a60f-74bf2ea5dcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_80b63eb3-968d-485e-a60f-74bf2ea5dcea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_49d78411-afc2-42a9-b60b-f738c0cf7e00" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1a105774-5744-4036-9475-9afb1e5bc848_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1a105774-5744-4036-9475-9afb1e5bc848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d6b76a1-10aa-4a44-b56f-989b18fbfbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d6b76a1-10aa-4a44-b56f-989b18fbfbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ContingentConsiderationMember_5b123a43-2389-402b-858a-a093efd4732b" xlink:href="abcl-20230331.xsd#abcl_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d6b76a1-10aa-4a44-b56f-989b18fbfbb5" xlink:to="loc_abcl_ContingentConsiderationMember_5b123a43-2389-402b-858a-a093efd4732b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_858e9fa1-9468-4357-95dd-7a51d15735e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_858e9fa1-9468-4357-95dd-7a51d15735e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e79f34b3-c68e-4960-add2-c5f2c91a2fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e79f34b3-c68e-4960-add2-c5f2c91a2fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ac545ed1-637e-488f-9727-a35f5135861c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e79f34b3-c68e-4960-add2-c5f2c91a2fd1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ac545ed1-637e-488f-9727-a35f5135861c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25694661-0aab-4b5f-ab74-668ca48f636b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25694661-0aab-4b5f-ab74-668ca48f636b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TrianniMember_d33776b7-48ce-4fef-9a62-865b382a3771" xlink:href="abcl-20230331.xsd#abcl_TrianniMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:to="loc_abcl_TrianniMember_d33776b7-48ce-4fef-9a62-865b382a3771" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TetraGeneticMember_95b02603-2431-4cf9-ac8e-ed5a265a8cdc" xlink:href="abcl-20230331.xsd#abcl_TetraGeneticMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:to="loc_abcl_TetraGeneticMember_95b02603-2431-4cf9-ac8e-ed5a265a8cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_15ca8ee4-7054-401f-9ac1-c711ea1d30ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_15ca8ee4-7054-401f-9ac1-c711ea1d30ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_456d38d3-5884-4b2a-9214-19e52db00f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_456d38d3-5884-4b2a-9214-19e52db00f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cf1b4cf0-94a9-460a-8585-9c59789ba905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_456d38d3-5884-4b2a-9214-19e52db00f21" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cf1b4cf0-94a9-460a-8585-9c59789ba905" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="ibacfeda2889f43fc9db8ca270d1812b7_FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb1d71a9-acdd-41dd-8df6-01e9b3196a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bf93b34b-ff10-4aa9-871c-fe0f685fc44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb1d71a9-acdd-41dd-8df6-01e9b3196a32" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bf93b34b-ff10-4aa9-871c-fe0f685fc44c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb1d71a9-acdd-41dd-8df6-01e9b3196a32" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c561ab97-c12d-4c3b-b86b-fbbb185e7650_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c561ab97-c12d-4c3b-b86b-fbbb185e7650_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_52a1be21-8c12-4be4-972c-1ca830e267af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_52a1be21-8c12-4be4-972c-1ca830e267af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_be8ba88c-ed25-435a-8707-c51493b6fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_52a1be21-8c12-4be4-972c-1ca830e267af" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_be8ba88c-ed25-435a-8707-c51493b6fcb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_026978ff-019e-406d-94fc-e3631026fb2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_026978ff-019e-406d-94fc-e3631026fb2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef58fd19-4d94-4d31-ab9e-6338e9a21224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef58fd19-4d94-4d31-ab9e-6338e9a21224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4747ae9b-9443-4b38-aca3-ad9e3743ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4747ae9b-9443-4b38-aca3-ad9e3743ee79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3042257f-9643-4ab2-8084-58618eea6d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3042257f-9643-4ab2-8084-58618eea6d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c5eb8c19-11a9-492e-89b2-ea523dc8c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c5eb8c19-11a9-492e-89b2-ea523dc8c69e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_139a2ec5-9363-45f4-9690-88b2fac30ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_139a2ec5-9363-45f4-9690-88b2fac30ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f68dd06d-0394-40f4-9019-00115aa4bb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_CommercialPaperMember_f68dd06d-0394-40f4-9019-00115aa4bb61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4291daae-b137-412b-8c9f-b40610842ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4291daae-b137-412b-8c9f-b40610842ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5007ad25-d44f-4d28-a110-0924b593d09b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5007ad25-d44f-4d28-a110-0924b593d09b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09700313-6f0d-478f-98bb-e4ccc4f7d010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09700313-6f0d-478f-98bb-e4ccc4f7d010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1580c566-48f3-4595-a420-7d7b1eda904d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_09700313-6f0d-478f-98bb-e4ccc4f7d010" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1580c566-48f3-4595-a420-7d7b1eda904d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8930fcc-930a-4e33-8401-6c691e81a10a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8930fcc-930a-4e33-8401-6c691e81a10a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33b81d15-d4c4-449f-be9f-fc79292d77ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33b81d15-d4c4-449f-be9f-fc79292d77ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MarketableSecuritiesMember_f0f1daf3-413f-46a3-87f2-c22af8ffff95" xlink:href="abcl-20230331.xsd#abcl_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33b81d15-d4c4-449f-be9f-fc79292d77ca" xlink:to="loc_abcl_MarketableSecuritiesMember_f0f1daf3-413f-46a3-87f2-c22af8ffff95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CommitmentsandcontingenciesDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#CommitmentsandcontingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.abcellera.com/role/CommitmentsandcontingenciesDetails" xlink:type="extended" id="iffa73fad920d40b080d73a42b1b3737b_CommitmentsandcontingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:href="abcl-20230331.xsd#abcl_CommitmentsContingenciesAndOtherLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_aa342832-7066-4322-beeb-c66e44ec5180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:to="loc_us-gaap_RoyaltyExpense_aa342832-7066-4322-beeb-c66e44ec5180" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StrategicInnovationFundEligibleExpenditure_48217565-1ac6-449e-b5d9-580a28082353" xlink:href="abcl-20230331.xsd#abcl_StrategicInnovationFundEligibleExpenditure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:to="loc_abcl_StrategicInnovationFundEligibleExpenditure_48217565-1ac6-449e-b5d9-580a28082353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:href="abcl-20230331.xsd#abcl_CommitmentsContingenciesAndOtherTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:to="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_59dc60d1-5525-46dd-b1b9-725055fb41f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_59dc60d1-5525-46dd-b1b9-725055fb41f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c6d619ad-cc25-4e0f-b0cd-8595e0a20c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c6d619ad-cc25-4e0f-b0cd-8595e0a20c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_AccruedRoyaltiesPayableMember_4a2e447f-30a3-4595-a0ee-c53e3fe28b55" xlink:href="abcl-20230331.xsd#abcl_AccruedRoyaltiesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c6d619ad-cc25-4e0f-b0cd-8595e0a20c34" xlink:to="loc_abcl_AccruedRoyaltiesPayableMember_4a2e447f-30a3-4595-a0ee-c53e3fe28b55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5ec3db53-93be-4d6c-8450-f4ff9fc464ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5ec3db53-93be-4d6c-8450-f4ff9fc464ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PhaseOneMember_49d48d50-e204-4b42-829b-c5811df5d560" xlink:href="abcl-20230331.xsd#abcl_PhaseOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:to="loc_abcl_PhaseOneMember_49d48d50-e204-4b42-829b-c5811df5d560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PhaseTwoMember_c5d9a617-3a2b-4ad2-8d18-5f043d42fc14" xlink:href="abcl-20230331.xsd#abcl_PhaseTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:to="loc_abcl_PhaseTwoMember_c5d9a617-3a2b-4ad2-8d18-5f043d42fc14" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abcl-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:650343a1-ca86-4cd1-b410-9b387e72615d,g:7bff7bb1-4386-4395-9d16-110d609544b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_37e6e3a6-e981-42d0-8caa-1964c722da86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9d758cbd-8d7e-4c33-a0a5-3539b4886b97_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_dfd10d8b-7123-4a5c-9d6c-8519a839946e_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_603c0277-5080-4746-b173-73e405e5a107_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1273883d-920d-4500-83ec-2479f5851bb5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a518e1d8-1985-4a4e-afa6-7cbe4a65f09f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a4412703-2921-4cbe-bb7a-c4751a5c54bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_71830691-282e-4ec3-a765-a97778a471c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (recovery) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5e526899-8ad1-4907-8959-59d1746f80b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9e080c6b-b67f-486f-9ebc-fd44c065037b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5ef8c59d-3a67-4758-9428-1d0479697e84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_166b8d74-37e4-4874-9f30-dc488c21c25a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f52bffae-69d8-4102-a740-1d15aefe94dc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c90ea31e-5605-4982-a7d4-410b0667564a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ae21f6eb-59e0-4ac9-9f02-3566fe158c70_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_NewDayluLoanMember_e2292b87-4515-4887-8d10-816c1f4deac9_terseLabel_en-US" xlink:label="lab_abcl_NewDayluLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Daylu Loan</link:label>
    <link:label id="lab_abcl_NewDayluLoanMember_label_en-US" xlink:label="lab_abcl_NewDayluLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Daylu Loan [Member]</link:label>
    <link:label id="lab_abcl_NewDayluLoanMember_documentation_en-US" xlink:label="lab_abcl_NewDayluLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Daylu Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NewDayluLoanMember" xlink:href="abcl-20230331.xsd#abcl_NewDayluLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_NewDayluLoanMember" xlink:to="lab_abcl_NewDayluLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_42e7e5f7-61b0-4d92-8981-7e5bd44e47fe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_b6b1dda1-e2ad-44bc-abbb-065ff3215333_terseLabel_en-US" xlink:label="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and restricted stock units ("RSUs") vested under stock option plan</link:label>
    <link:label id="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued and Restricted Stock Units vested during period value stock options exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" xlink:href="abcl-20230331.xsd#abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" xlink:to="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_6500dafb-dc23-443f-823b-1daa1324f93d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_72b4b223-d76f-4161-8135-c6f83b7c012d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a4dab9e9-4974-4cf1-905d-ff1082d84960_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_75aa724e-24ad-4803-b8f5-31fe8d2fc281_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions_26111ada-1442-4b49-bcc0-ba884024793e_terseLabel_en-US" xlink:label="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt and exercise of stock options</link:label>
    <link:label id="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions_label_en-US" xlink:label="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Debt And Exercise Of Stock Options</link:label>
    <link:label id="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions_documentation_en-US" xlink:label="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt and exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ProceedsFromDebtAndExerciseOfStockOptions" xlink:href="abcl-20230331.xsd#abcl_ProceedsFromDebtAndExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_ProceedsFromDebtAndExerciseOfStockOptions" xlink:to="lab_abcl_ProceedsFromDebtAndExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_PrepaidExpenseAndOtherCurrent_ba901752-83e1-41e0-9330-2bd297b3348e_terseLabel_en-US" xlink:label="lab_abcl_PrepaidExpenseAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_abcl_PrepaidExpenseAndOtherCurrent_label_en-US" xlink:label="lab_abcl_PrepaidExpenseAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense And Other Current</link:label>
    <link:label id="lab_abcl_PrepaidExpenseAndOtherCurrent_documentation_en-US" xlink:label="lab_abcl_PrepaidExpenseAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense And Other Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PrepaidExpenseAndOtherCurrent" xlink:href="abcl-20230331.xsd#abcl_PrepaidExpenseAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_PrepaidExpenseAndOtherCurrent" xlink:to="lab_abcl_PrepaidExpenseAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ab31cc91-12dc-4092-9431-f956b5028581_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities_96ea537e-e149-4164-a063-f7675967c85c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_fcd8e8a0-e30c-4d00-b73f-2291450740cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4e2012b9-c9d0-45bb-bcc4-6969db5a7d7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_148f6bc7-a0ac-4bf5-9457-0581b1981a4f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares: no par value, unlimited authorized shares at December&#160;31, 2022 and March&#160;31, 2023: 286,851,595 and 288,426,514 shares issued and outstanding at December&#160;31, 2022 and March&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_AccountsAndAccruedReceivableCurrent_48c14008-4bbc-4ed3-b71d-1f0d77ecf6c2_terseLabel_en-US" xlink:label="lab_abcl_AccountsAndAccruedReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and accrued receivable</link:label>
    <link:label id="lab_abcl_AccountsAndAccruedReceivableCurrent_label_en-US" xlink:label="lab_abcl_AccountsAndAccruedReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts And Accrued Receivable Current</link:label>
    <link:label id="lab_abcl_AccountsAndAccruedReceivableCurrent_documentation_en-US" xlink:label="lab_abcl_AccountsAndAccruedReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and accrued receivable, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_AccountsAndAccruedReceivableCurrent" xlink:href="abcl-20230331.xsd#abcl_AccountsAndAccruedReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_AccountsAndAccruedReceivableCurrent" xlink:to="lab_abcl_AccountsAndAccruedReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_c70e09c2-a4b4-4d31-be98-80793370b0d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a731bfd1-413e-42b1-b636-429c7d10ffd6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_03b01f69-02eb-45d8-adcd-fae379c25236_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_30d381d3-6d27-42d0-9d4b-f4769d478736_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_96f69af4-85e3-4b85-b2f2-4f6fceae7893_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_a26b656c-b9de-4c92-8c6d-a942ca5317ef_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense on property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf4f22ab-4307-42b8-91f8-015b07ff1d72_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_f645cb50-200f-48e5-a50d-aebc0e2b0767_terseLabel_en-US" xlink:label="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares)</link:label>
    <link:label id="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Restricted Stock Units Vested During Period Shares Stock Options Exercised</link:label>
    <link:label id="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_documentation_en-US" xlink:label="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued and Restricted Stock Units vested during period shares stock options exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" xlink:href="abcl-20230331.xsd#abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_26539811-46ca-4427-b08c-7faa239dd654_terseLabel_en-US" xlink:label="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Option and Incentive Plan</link:label>
    <link:label id="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_label_en-US" xlink:label="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Share Option And Incentive Plan [Member]</link:label>
    <link:label id="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_documentation_en-US" xlink:label="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share option and incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" xlink:to="lab_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable_fdaed4a9-5951-479c-9919-694987933ecc_terseLabel_en-US" xlink:label="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment in accounts payable</link:label>
    <link:label id="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable_label_en-US" xlink:label="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable</link:label>
    <link:label id="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable_documentation_en-US" xlink:label="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash or part non cash acquisition property and equipment purchases in accounts payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" xlink:href="abcl-20230331.xsd#abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" xlink:to="lab_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf8cd1a0-ca2e-4505-b0c4-895dcbbeae19_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af958087-207a-4540-809a-5560b6a7189c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8f7261b9-16bd-4dd9-abce-837a1a06f589_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_IncreaseDecreaseInDeferredGrantIncome_2fa8bc01-041d-4e48-8651-de37463e87a3_negatedLabel_en-US" xlink:label="lab_abcl_IncreaseDecreaseInDeferredGrantIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant revenue</link:label>
    <link:label id="lab_abcl_IncreaseDecreaseInDeferredGrantIncome_label_en-US" xlink:label="lab_abcl_IncreaseDecreaseInDeferredGrantIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Deferred Grant Income</link:label>
    <link:label id="lab_abcl_IncreaseDecreaseInDeferredGrantIncome_documentation_en-US" xlink:label="lab_abcl_IncreaseDecreaseInDeferredGrantIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in deferred grant income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInDeferredGrantIncome" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInDeferredGrantIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="lab_abcl_IncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6b7563ee-d9e9-4015-92d2-0f29c6f19c3d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65ef1cf0-a4d5-44fe-a55f-2c059923606a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown on the balance sheet</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_ce50c55d-ebf0-41d8-951e-b7006caeb2e3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f627fecb-af74-453a-b2aa-6db7f4a35ebf_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ffc9f419-f85d-4953-98d9-d5826414750c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6f8094c7-82ba-4d5d-8484-435495139295_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) attributable to common shareholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_4207e47d-87bc-4705-a78a-6f4724843bc4_negatedLabel_en-US" xlink:label="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties receivable</link:label>
    <link:label id="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_label_en-US" xlink:label="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accrued Royalties Receivable</link:label>
    <link:label id="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_documentation_en-US" xlink:label="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accrued royalties receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" xlink:to="lab_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c167068a-4f83-48e7-bb85-43cf070fe408_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_09bd4c27-ae52-408b-9cec-fe3ff3335c1a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_93c06b70-3140-4f27-9713-7d24f836d0c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c72e98fe-5425-4632-9fff-02418eab5ae0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e16ebc98-2612-4cdc-b73b-3664d3da703e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3ee314c-f96e-4244-9a77-4a2302c8ccfc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential common shares excluded</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_b4352f73-b4f7-486b-ba30-81265752eafc_terseLabel_en-US" xlink:label="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_label_en-US" xlink:label="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable</link:label>
    <link:label id="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_documentation_en-US" xlink:label="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" xlink:to="lab_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b6ef19f1-e572-4f66-b7b7-dcf3cc1b9305_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_91ddd260-dea7-40ac-b7b6-31635faaa55d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4a917dbc-0002-47f0-990a-27b6be120ba6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8cd32e2-ca53-47ab-abad-1757cbe65c5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_TrianniMember_cd1f744a-6e23-4e8f-9196-08ed8a93fe2e_terseLabel_en-US" xlink:label="lab_abcl_TrianniMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trianni</link:label>
    <link:label id="lab_abcl_TrianniMember_label_en-US" xlink:label="lab_abcl_TrianniMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trianni [Member]</link:label>
    <link:label id="lab_abcl_TrianniMember_documentation_en-US" xlink:label="lab_abcl_TrianniMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trianni.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TrianniMember" xlink:href="abcl-20230331.xsd#abcl_TrianniMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_TrianniMember" xlink:to="lab_abcl_TrianniMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_63eac401-1cd0-457e-89ac-378398933c87_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_bee3a85c-6aba-426a-89c3-1b8cb1f2ccf4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_0eb8b061-82ba-4413-99dd-5e2f6afaedbd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a7c20113-87c7-4202-bda2-a2257c528e9c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_69264919-1130-4158-9137-dedb2c72b202_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f6d8ca5f-f24e-4d23-92b9-4a8af4c939c6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1c15ce28-971b-456d-8fde-e2121702ebe1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6c76c10-2155-4954-a7ff-8e3f688d1b85_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e1bc8b92-b3f5-477d-b76b-183854758d0b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66593b03-2a3a-43e3-a406-70181575e3bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_621d9cd7-d1c6-4bb0-86f8-63dd4ae7f013_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options exercisable as of March 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8b45e6ee-94fa-4e69-8a86-fbddc78cdb80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5e143e22-9593-4a4e-a9b8-d82730dc6d4a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_4340d916-cb2a-4b2c-b029-674a630d82b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_aa5d6c19-7e2b-4268-a2ac-796e73379f90_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_93564261-26ed-4c29-ae82-360bb9a68d91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6863884e-0bdd-4b70-9a37-d15993e4fb44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d346e43b-e0f0-4c40-a3cb-126d3aa31b2e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e6a2c39a-a379-4079-8e2d-b500592e846d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_5a31e966-63bd-4ab5-8fd6-758bd3412dba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4923e08a-15b6-4869-a9e7-16255bb87aca_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bcabd6d2-6951-43ed-98c9-bea0a496cb80_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a1db8fab-5702-4397-937a-a24f31cf375a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_880764b1-137f-40b3-ad41-957a18ff588e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_91edf3b8-f514-45a2-b751-17d0d7755378_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccb7776a-17ab-4957-96d2-3f15dd01f626_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4f3e4cbd-a719-4f53-8720-f6c44df0bba3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_49e99bb1-fd0b-4870-a1ef-031eab375972_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_14a24afd-5925-4d2f-8690-bf9789de077f_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_CommitmentsContingenciesAndOtherTable_5b396d6a-b50b-4fbf-ab03-64ead96cf235_terseLabel_en-US" xlink:label="lab_abcl_CommitmentsContingenciesAndOtherTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Contingencies And Other [Table]</link:label>
    <link:label id="lab_abcl_CommitmentsContingenciesAndOtherTable_label_en-US" xlink:label="lab_abcl_CommitmentsContingenciesAndOtherTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Contingencies And Other [Table]</link:label>
    <link:label id="lab_abcl_CommitmentsContingenciesAndOtherTable_documentation_en-US" xlink:label="lab_abcl_CommitmentsContingenciesAndOtherTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Contingencies And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CommitmentsContingenciesAndOtherTable" xlink:href="abcl-20230331.xsd#abcl_CommitmentsContingenciesAndOtherTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherTable" xlink:to="lab_abcl_CommitmentsContingenciesAndOtherTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_6e9f3681-7c4d-4284-8938-fc4b946d5e01_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0dbeecf2-ab67-4e23-83b6-fa4acfb2bd82_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_4cafa724-8b90-447d-9b2b-5907deefe935_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_71c0f8f6-0665-45cb-acef-cbfb11acc6b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b14d9c94-9cd3-471a-8497-4d691b8d1544_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9f29c261-9563-4903-b0d2-ec6aed33a0e1_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f35d30af-e22b-4b21-9d4f-536d67e456d9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_4e27a7d4-705e-487c-adc3-cb7ec3b03920_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_1f6e87cd-757e-4d3d-b1fe-8176b8ff57f1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_80ab6bfb-b9cd-4f06-a094-25e29b8224e4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_ffe0346d-5907-42ce-99b6-14f001e40d63_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dec1fd37-f5d0-49c6-a965-ed1a312c6396_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f62f307d-cc1f-435f-a37b-b7b4cb8ab54f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b00458db-4f92-4e12-acfb-452130e1a376_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2a53c068-a9ba-40af-96d9-893c91815892_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8e1581c5-e2fb-48a7-9f1d-f134adc221a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_MaterialsAndSuppliesCurrent_46c25642-761d-4f92-bf3b-20aab3e9a5f2_terseLabel_en-US" xlink:label="lab_abcl_MaterialsAndSuppliesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials and supplies</link:label>
    <link:label id="lab_abcl_MaterialsAndSuppliesCurrent_label_en-US" xlink:label="lab_abcl_MaterialsAndSuppliesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials And Supplies Current</link:label>
    <link:label id="lab_abcl_MaterialsAndSuppliesCurrent_documentation_en-US" xlink:label="lab_abcl_MaterialsAndSuppliesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Materials And Supplies Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MaterialsAndSuppliesCurrent" xlink:href="abcl-20230331.xsd#abcl_MaterialsAndSuppliesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_MaterialsAndSuppliesCurrent" xlink:to="lab_abcl_MaterialsAndSuppliesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_08d8a32a-90be-44dd-bf91-51d8395b15db_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_24fc8185-3e50-4f65-a3a2-1ec43ad72740_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71df7148-edee-4e9b-b150-f8c2f7ddbdab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1cd08827-294d-4c44-83c1-d86731754732_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_116f4bcd-1af5-4c06-9eca-acee4f472276_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_98a5b958-fb42-4e86-b51f-a78f3b3245c0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c996e9d0-f3e3-4e33-a1a0-462ef9fd7796_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_MarketableSecuritiesMember_956d75d2-f4ad-4c31-9291-5a6da28c535b_terseLabel_en-US" xlink:label="lab_abcl_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_abcl_MarketableSecuritiesMember_label_en-US" xlink:label="lab_abcl_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_abcl_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_abcl_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MarketableSecuritiesMember" xlink:href="abcl-20230331.xsd#abcl_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_MarketableSecuritiesMember" xlink:to="lab_abcl_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_06905190-fc27-47ad-abd7-90145aed811f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c37e26f1-4580-4ff2-9ed1-7e30b4757065_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ff51e93f-0af3-4646-af61-362384cba86b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2eb81de9-b95a-43a4-8183-3a5fb3ae6158_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f5a7d231-8fd6-40bc-8919-a3fe463a92a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balances (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_aa9aa11c-a4a9-44fa-9985-61e07681fdc7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balances (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3eabf4b3-9f78-45a6-b8ac-b281b6c0e273_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_8c0d1c1f-3061-402e-85d2-654b69e7c166_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_565c2954-a36a-4430-b31d-663c1cc9890d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_02fd2e64-d4ea-49cb-9d96-bb5e165ffa11_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_72fa1f3d-7107-4544-b845-5e768d796da6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_a41f3ece-f867-4a9e-b773-8bc2f9f48c97_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c25fec49-f1e2-4497-883d-ba0eb8332499_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bfecd1af-be9b-495d-8682-b8c932c47195_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2fe3cec7-12e4-45d6-a003-d298ace70176_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2bf248d4-d1b5-4839-97d7-3747bd1e050b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ee4d2dc1-8bd0-445c-bb6e-e8678a3207f3_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d7e13ae1-1537-4283-9b9e-bda2d87c11ee_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a181e364-23f6-4342-9ac7-058c05f45e25_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_BeedieJointVentureMember_c35f4f4c-9dbd-4021-8d4b-8ba14e2a6f4c_terseLabel_en-US" xlink:label="lab_abcl_BeedieJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beedie JV</link:label>
    <link:label id="lab_abcl_BeedieJointVentureMember_label_en-US" xlink:label="lab_abcl_BeedieJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beedie Joint Venture [Member]</link:label>
    <link:label id="lab_abcl_BeedieJointVentureMember_documentation_en-US" xlink:label="lab_abcl_BeedieJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beedie joint venture.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_BeedieJointVentureMember" xlink:href="abcl-20230331.xsd#abcl_BeedieJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_BeedieJointVentureMember" xlink:to="lab_abcl_BeedieJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_e3a1804b-67fa-4d03-a04d-bea76306433a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_ContingentConsiderationMember_67bbfcd3-fe55-401c-bde0-99e72f3a6a6f_terseLabel_en-US" xlink:label="lab_abcl_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_abcl_ContingentConsiderationMember_label_en-US" xlink:label="lab_abcl_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_abcl_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_abcl_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ContingentConsiderationMember" xlink:href="abcl-20230331.xsd#abcl_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_ContingentConsiderationMember" xlink:to="lab_abcl_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_24a1a1b6-0741-4710-80d6-c20ca2d8df38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1cd0af47-95e9-4f02-b8e9-c8ec0e81785d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6ba0634b-9ca0-4df4-ae46-4a1959cc0c60_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_369b726e-f68c-49ef-bcb6-6d19b3a66f44_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Revenue Outstanding</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock_8b572590-4337-4f91-9158-5286a23b37d1_terseLabel_en-US" xlink:label="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets and liabilities</link:label>
    <link:label id="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock_label_en-US" xlink:label="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets And Liabilities [Text Block]</link:label>
    <link:label id="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CurrentAssetsAndLiabilitiesTextBlock" xlink:href="abcl-20230331.xsd#abcl_CurrentAssetsAndLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_CurrentAssetsAndLiabilitiesTextBlock" xlink:to="lab_abcl_CurrentAssetsAndLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_72dc1785-18a5-4a07-a082-222a8f1341ad_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_LicenseBasedIntangibleAssetsMember_71ec00d6-eeac-4f3a-a645-bb15096e5b54_terseLabel_en-US" xlink:label="lab_abcl_LicenseBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_abcl_LicenseBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_abcl_LicenseBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Based Intangible Assets [Member]</link:label>
    <link:label id="lab_abcl_LicenseBasedIntangibleAssetsMember_documentation_en-US" xlink:label="lab_abcl_LicenseBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License based intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_LicenseBasedIntangibleAssetsMember" xlink:href="abcl-20230331.xsd#abcl_LicenseBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_LicenseBasedIntangibleAssetsMember" xlink:to="lab_abcl_LicenseBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_DeferredGrantFundingCurrent_da478354-145c-484f-91b7-de542373436c_terseLabel_en-US" xlink:label="lab_abcl_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred grant funding</link:label>
    <link:label id="lab_abcl_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_abcl_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding Current</link:label>
    <link:label id="lab_abcl_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_abcl_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DeferredGrantFundingCurrent" xlink:href="abcl-20230331.xsd#abcl_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_DeferredGrantFundingCurrent" xlink:to="lab_abcl_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_05c38900-2c2c-4034-bd1a-1c10dd3b660e_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_fb996421-8497-4954-9931-ead2c34d8976_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_571c642c-b0a3-46e5-99e5-ee138038bec1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_GrantsAndIncentives_9fd5caa8-3a97-4248-9cf4-9c256e437491_negatedLabel_en-US" xlink:label="lab_abcl_GrantsAndIncentives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants and incentives</link:label>
    <link:label id="lab_abcl_GrantsAndIncentives_label_en-US" xlink:label="lab_abcl_GrantsAndIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants And Incentives</link:label>
    <link:label id="lab_abcl_GrantsAndIncentives_documentation_en-US" xlink:label="lab_abcl_GrantsAndIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants and Incentives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_GrantsAndIncentives" xlink:href="abcl-20230331.xsd#abcl_GrantsAndIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_GrantsAndIncentives" xlink:to="lab_abcl_GrantsAndIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_610a3986-143e-4421-8399-a650ace0f159_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fe65dcd8-3237-43a5-96f2-e2e5edc94ed0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_EquityMethodInvestmentCommitmentAmount_4bad903f-9090-4a3c-a345-3a0b95fe0aaa_terseLabel_en-US" xlink:label="lab_abcl_EquityMethodInvestmentCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, commitment amount</link:label>
    <link:label id="lab_abcl_EquityMethodInvestmentCommitmentAmount_label_en-US" xlink:label="lab_abcl_EquityMethodInvestmentCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment Commitment Amount</link:label>
    <link:label id="lab_abcl_EquityMethodInvestmentCommitmentAmount_documentation_en-US" xlink:label="lab_abcl_EquityMethodInvestmentCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_EquityMethodInvestmentCommitmentAmount" xlink:href="abcl-20230331.xsd#abcl_EquityMethodInvestmentCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_EquityMethodInvestmentCommitmentAmount" xlink:to="lab_abcl_EquityMethodInvestmentCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_57236bf0-8392-4f73-99df-99d1821e642f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_35d2e391-6949-40d2-8098-688b8102032a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bb465da6-5828-4d37-8aaa-fa339c7600c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9742b9c6-8712-47ef-8e84-230bd03eefe6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ac5e544e-3c37-45c8-82eb-4434a7829721_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b18b850b-07ec-46f7-9cc1-0ba5b28a5323_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e09412dd-7b51-4ee6-bb02-77b2494ef1fd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_23b70ebc-9ac9-4e31-ae5d-95a8a7ae5bf4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0ff06db3-91df-4288-a498-23474d618162_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9ef320fd-1b49-4ca0-863b-b8340ec6f752_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll liabilities</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_550844f0-ea10-4839-8d0b-c3679237849f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Backed Securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_50e661be-d32d-4149-ba67-e92eeb5a4d55_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f2038720-5b31-4fa1-8d3b-52ce2c1e2c28_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bec33d7e-ceab-43ba-aaf0-9b13df8a8aae_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7b071880-2769-4b4c-82fc-19e82558983c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_NumberOfJointVentures_f1f63f8a-f4ef-4f57-8fd9-3c87df31f050_terseLabel_en-US" xlink:label="lab_abcl_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of joint ventures</link:label>
    <link:label id="lab_abcl_NumberOfJointVentures_label_en-US" xlink:label="lab_abcl_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Joint Ventures</link:label>
    <link:label id="lab_abcl_NumberOfJointVentures_documentation_en-US" xlink:label="lab_abcl_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of joint ventures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NumberOfJointVentures" xlink:href="abcl-20230331.xsd#abcl_NumberOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_NumberOfJointVentures" xlink:to="lab_abcl_NumberOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation_609f2eb6-1e6d-4016-9080-93df0771351e_terseLabel_en-US" xlink:label="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease obligation</link:label>
    <link:label id="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation_label_en-US" xlink:label="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation</link:label>
    <link:label id="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation_documentation_en-US" xlink:label="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" xlink:href="abcl-20230331.xsd#abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" xlink:to="lab_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_e4b92986-5784-43ac-b248-803d37d2b937_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_424ce0ba-38a5-46a9-ac34-f939706fc5a1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9cb62a59-a4da-4a3f-b309-faf2a34879a8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31aaa1d2-2e0b-417b-be83-c63b77862bfe_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44149a72-131a-4418-b954-3ced3fec8d68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_OperatingLeaseRightOfUseAssetsMember_07fbadb6-0c8a-4187-a28a-73225536bd31_terseLabel_en-US" xlink:label="lab_abcl_OperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_abcl_OperatingLeaseRightOfUseAssetsMember_label_en-US" xlink:label="lab_abcl_OperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Assets [Member]</link:label>
    <link:label id="lab_abcl_OperatingLeaseRightOfUseAssetsMember_documentation_en-US" xlink:label="lab_abcl_OperatingLeaseRightOfUseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_OperatingLeaseRightOfUseAssetsMember" xlink:href="abcl-20230331.xsd#abcl_OperatingLeaseRightOfUseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_OperatingLeaseRightOfUseAssetsMember" xlink:to="lab_abcl_OperatingLeaseRightOfUseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3b3c44a1-c8ec-4495-9eca-bd00af06212e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_TetraGeneticMember_87b65493-1961-412f-885c-ac136110e1ee_terseLabel_en-US" xlink:label="lab_abcl_TetraGeneticMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TetraGenetics</link:label>
    <link:label id="lab_abcl_TetraGeneticMember_label_en-US" xlink:label="lab_abcl_TetraGeneticMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tetra Genetic [Member]</link:label>
    <link:label id="lab_abcl_TetraGeneticMember_documentation_en-US" xlink:label="lab_abcl_TetraGeneticMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TetraGenetics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TetraGeneticMember" xlink:href="abcl-20230331.xsd#abcl_TetraGeneticMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_TetraGeneticMember" xlink:to="lab_abcl_TetraGeneticMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_f536c748-9380-4ec1-a3be-54caeb81b4da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax deposits and receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_b21ed8fa-3ac0-403a-ab80-83f4c116999a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_337d8524-b83a-46e1-94ce-da3f0d289d73_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, ownership percent</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cd4de426-8ad4-43c7-8013-4eaa4677decc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b570a50f-1515-4cde-bb3a-8a9176879d37_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_553b3b7b-df39-4a8c-8361-6fdeaea0195d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e3dc576e-faf3-41c8-9d13-93150490f6df_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d9ab8fe6-f570-42bb-939b-e7d393a46e2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a900b7c1-8f3d-4183-bf36-510e90a2038c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_e8ac6d5d-3329-481e-a4ff-788ec6b06a6f_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_LaboratoryEquipmentMember_61770d3d-84fd-46d5-afdc-23c1aa6c1363_terseLabel_en-US" xlink:label="lab_abcl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_abcl_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_abcl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_abcl_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_abcl_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_LaboratoryEquipmentMember" xlink:href="abcl-20230331.xsd#abcl_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_LaboratoryEquipmentMember" xlink:to="lab_abcl_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_CashCashEquivalentsAndMarketableSecurities_835458bb-0a7e-4be0-83dc-780c72c04e90_totalLabel_en-US" xlink:label="lab_abcl_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_abcl_CashCashEquivalentsAndMarketableSecurities_label_en-US" xlink:label="lab_abcl_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Marketable Securities</link:label>
    <link:label id="lab_abcl_CashCashEquivalentsAndMarketableSecurities_documentation_en-US" xlink:label="lab_abcl_CashCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash Equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CashCashEquivalentsAndMarketableSecurities" xlink:href="abcl-20230331.xsd#abcl_CashCashEquivalentsAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_CashCashEquivalentsAndMarketableSecurities" xlink:to="lab_abcl_CashCashEquivalentsAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6424e4dd-2d93-469f-b1b3-47657c4b4773_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f57a0fe9-7db3-48d7-b5e0-ca465c0ebdfc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_658f283b-3c6d-4a07-bdb9-5c6a57dd4d4c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_a1d53bac-8612-41eb-b57a-ac88b0fa5ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_ce845e33-f3ba-4cb1-9c12-a6d6b9f62936_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_05fb9175-66e5-4a63-a611-30e7fd1d48b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_StrategicInnovationFundEligibleExpenditure_f6c07baf-3f8c-4a47-ac40-fed71b0070e6_terseLabel_en-US" xlink:label="lab_abcl_StrategicInnovationFundEligibleExpenditure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic innovation fund eligible expenditure</link:label>
    <link:label id="lab_abcl_StrategicInnovationFundEligibleExpenditure_label_en-US" xlink:label="lab_abcl_StrategicInnovationFundEligibleExpenditure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Innovation Fund Eligible Expenditure</link:label>
    <link:label id="lab_abcl_StrategicInnovationFundEligibleExpenditure_documentation_en-US" xlink:label="lab_abcl_StrategicInnovationFundEligibleExpenditure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic innovation fund eligible expenditure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StrategicInnovationFundEligibleExpenditure" xlink:href="abcl-20230331.xsd#abcl_StrategicInnovationFundEligibleExpenditure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_StrategicInnovationFundEligibleExpenditure" xlink:to="lab_abcl_StrategicInnovationFundEligibleExpenditure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0ff2effd-ddfa-4cca-97ca-95d8dc5ebd3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_a65c2b5a-87fe-4ad2-b9b6-c26d405b668a_negatedLabel_en-US" xlink:label="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments and other assets</link:label>
    <link:label id="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_label_en-US" xlink:label="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Long Term Investments And Other Assets</link:label>
    <link:label id="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_documentation_en-US" xlink:label="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire long-term investments and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" xlink:href="abcl-20230331.xsd#abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" xlink:to="lab_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8b20667a-cb2d-4ae0-9a91-c114f640406f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3825a332-b646-4a46-b125-b5bd50a1388d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_9fbd4a3a-5304-48aa-a242-92b2cab52ec8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_465d6c3e-4cef-4f63-bfb2-e2fba4351217_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_120f663b-8520-467c-bfbf-84929a42b4cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_286724f3-eaee-44d0-8073-78326fdaa2ab_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_fb5d4d75-3fbc-4af6-be63-b70329ce2866_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7548e6db-17e5-4ee2-88ea-7cc46384a6d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_0ecade8b-2d81-45a8-9b04-0f0c4dd37aaa_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_be316079-db46-4ea0-9150-2d54b22404aa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_65f92188-defc-470c-9fb5-98a901e4060d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_579d6902-9951-44bc-b837-d11b18ca5e23_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7b8e1e64-a031-4ad8-ada2-b740a5853802_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_6d694371-acd7-466a-bd6b-dc7d0d382784_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_be2fa646-26bf-499a-96f7-746acac5c9c1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_23f292fe-d0d7-456b-8142-bc169023b420_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty fees</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_PhaseOneMember_2446753a-d4ca-4d1e-b4c4-b3f511f7bbf0_terseLabel_en-US" xlink:label="lab_abcl_PhaseOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1</link:label>
    <link:label id="lab_abcl_PhaseOneMember_label_en-US" xlink:label="lab_abcl_PhaseOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase One [Member]</link:label>
    <link:label id="lab_abcl_PhaseOneMember_documentation_en-US" xlink:label="lab_abcl_PhaseOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PhaseOneMember" xlink:href="abcl-20230331.xsd#abcl_PhaseOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_PhaseOneMember" xlink:to="lab_abcl_PhaseOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_25183c89-c228-49cd-8ed8-410e3a1543b7_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e2442850-23b2-4f01-990a-f62dcab62c88_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8a880465-cbd4-45e8-b322-0f9d66c8fc9c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1c1da365-ee48-4e17-8eae-8af7779fe306_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_PercentageOfConstructionLoan_99188065-7ebb-4e3f-97d6-eb1933c22e65_terseLabel_en-US" xlink:label="lab_abcl_PercentageOfConstructionLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of construction loan</link:label>
    <link:label id="lab_abcl_PercentageOfConstructionLoan_label_en-US" xlink:label="lab_abcl_PercentageOfConstructionLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Construction Loan</link:label>
    <link:label id="lab_abcl_PercentageOfConstructionLoan_documentation_en-US" xlink:label="lab_abcl_PercentageOfConstructionLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of construction loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PercentageOfConstructionLoan" xlink:href="abcl-20230331.xsd#abcl_PercentageOfConstructionLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_PercentageOfConstructionLoan" xlink:to="lab_abcl_PercentageOfConstructionLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_12296391-45b4-4a00-84a4-fff702df5338_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_45cb46bc-61cc-4f2e-8c47-bd3c2f55b383_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_426d249d-13ab-4a21-9f9a-98c251984e4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Royalties Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a476023e-ed3e-42ae-819a-82d941ac40b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f36bd464-c058-43db-8eaf-a3f57a734506_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_37117696-f640-4cd5-a298-aa8518cf4398_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3ded91fc-1801-4ad7-98a2-bb40f271f0c9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0c3fe004-5948-4add-80b0-61dc1404eac2_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_51eabc02-7388-46fd-b48a-d699b162f11b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_dd76490f-b749-43e6-b31f-d8db0dd6cf1c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and accrued research fees receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4f89d48d-fe21-4604-8536-3ecbfb87ce45_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_912a0281-351d-481e-93a1-f15af3aacedb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements include tenant improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_90e31878-9e20-4947-b3d0-8e058daf3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7010fde-45d4-488d-bbe2-ad8926e77bfc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_CommitmentsContingenciesAndOtherLineItems_d3a77eb1-178e-482e-b401-97d68b2d05cc_terseLabel_en-US" xlink:label="lab_abcl_CommitmentsContingenciesAndOtherLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Contingencies And Other [Line Items]</link:label>
    <link:label id="lab_abcl_CommitmentsContingenciesAndOtherLineItems_label_en-US" xlink:label="lab_abcl_CommitmentsContingenciesAndOtherLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Contingencies And Other [Line Items]</link:label>
    <link:label id="lab_abcl_CommitmentsContingenciesAndOtherLineItems_documentation_en-US" xlink:label="lab_abcl_CommitmentsContingenciesAndOtherLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Contingencies And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CommitmentsContingenciesAndOtherLineItems" xlink:href="abcl-20230331.xsd#abcl_CommitmentsContingenciesAndOtherLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherLineItems" xlink:to="lab_abcl_CommitmentsContingenciesAndOtherLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4c2578b0-5d1f-4b16-bece-137a7dfa42f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1ac2d5d0-1976-49c2-af91-697a585a5684_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_46262149-46a8-4ce5-94b4-eddd8a8580d3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_704740ce-8bac-4d2a-af63-7ae7fb1d1f11_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7f823582-ed67-4cc1-9f12-277f421652ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fe37f461-5168-431c-a41f-7de39ae3eddd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) attributable to common shareholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e8f749d6-39c0-417f-b11f-1ac3de4c897c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4094cf5d-1389-457c-bac9-efc13ee00730_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ea990646-0e38-4e97-873e-d276eb168bec_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a956d84f-5662-489a-8823-c9d5407a9b25_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net book value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_50b76f87-a0b0-4617-86ac-34584a4b8fae_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f5501833-1ff0-4128-ad0c-7489e58c2c84_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_05d6d841-7a28-4f2c-852a-8d4751846c00_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8533fe4a-2445-46e4-87c7-001e2c94bcb9_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8cc2542a-68a6-4571-8cbe-c00ee251d143_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability at end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_81271185-1555-463b-85d7-d018368a00d1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_bae15efd-aec7-4878-b594-46f4f0d047d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a1e92b5a-cd82-45d4-933c-6fdddcd0f293_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_DayhuJointVentureMember_a2ff7792-cb6f-4630-81d4-c4915f842af1_terseLabel_en-US" xlink:label="lab_abcl_DayhuJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dayhu JV</link:label>
    <link:label id="lab_abcl_DayhuJointVentureMember_label_en-US" xlink:label="lab_abcl_DayhuJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dayhu Joint Venture [Member]</link:label>
    <link:label id="lab_abcl_DayhuJointVentureMember_documentation_en-US" xlink:label="lab_abcl_DayhuJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dayhu joint venture.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DayhuJointVentureMember" xlink:href="abcl-20230331.xsd#abcl_DayhuJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_DayhuJointVentureMember" xlink:to="lab_abcl_DayhuJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4f7fdc51-762b-44b2-ab2a-a7efbfe6a165_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Share Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f354718a-1629-4308-873f-7f7cfa95cb00_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1e39120c-fad6-460d-936d-9b059ff51b61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e60af8e1-f7f6-4fa7-ab58-a21a508dfb98_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_491a4860-6121-4b88-bb1e-7ddb97bdbaf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_44ae7217-9bcf-47de-8e55-0872aec79985_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_MilestonePaymentsMember_c0e04a8d-4eb1-4d5f-98ea-d7ed5b44ecd8_terseLabel_en-US" xlink:label="lab_abcl_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_abcl_MilestonePaymentsMember_label_en-US" xlink:label="lab_abcl_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments [Member]</link:label>
    <link:label id="lab_abcl_MilestonePaymentsMember_documentation_en-US" xlink:label="lab_abcl_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MilestonePaymentsMember" xlink:href="abcl-20230331.xsd#abcl_MilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_MilestonePaymentsMember" xlink:to="lab_abcl_MilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_68dd1c3e-d5e4-408b-b84e-bee2827c4f69_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_68d832b6-47d4-47a5-824d-eb039ba3f55f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_184911e1-daa2-4b6c-a2e1-430beb7774ec_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0228a29f-4c60-4d43-9c59-2ee837341b8d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d48009e5-01bd-4293-9bd9-71ac5828b8ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_35e85d1d-05ed-4aa9-82e0-7ec6c46d9df4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_84fc2d94-7dbf-415b-b76b-98f027396ccc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_69d02305-ca71-480a-9eae-cc90a000a14c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a2afb1a4-61c3-469b-9e1e-8fc50ef2bec1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f63bd4d7-a552-4d5b-93de-929a8f5741ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a082a1f6-0084-4f66-8cda-8303e839d9f7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0c336964-7a85-445a-b62d-3b34ae3b826a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ccbcb5ff-1354-43d6-87ca-502763416f03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_5758bd39-b72e-43c7-bc32-4b21963f763a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_015c76b0-c40a-451e-b19e-8ddbafa7d9eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c6111637-6d74-4ebe-8309-ad9431179f2c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_205a1bdd-25c5-43a2-8e6c-087120906440_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value of Liability for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_PreInitialPublicOfferingPlanMember_ad99bc9e-f772-434e-93ea-c2bf31b6ba8e_terseLabel_en-US" xlink:label="lab_abcl_PreInitialPublicOfferingPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-IPO Plan</link:label>
    <link:label id="lab_abcl_PreInitialPublicOfferingPlanMember_label_en-US" xlink:label="lab_abcl_PreInitialPublicOfferingPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Initial Public Offering Plan [Member]</link:label>
    <link:label id="lab_abcl_PreInitialPublicOfferingPlanMember_documentation_en-US" xlink:label="lab_abcl_PreInitialPublicOfferingPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-initial public offering plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PreInitialPublicOfferingPlanMember" xlink:href="abcl-20230331.xsd#abcl_PreInitialPublicOfferingPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_PreInitialPublicOfferingPlanMember" xlink:to="lab_abcl_PreInitialPublicOfferingPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_406991f4-75c4-4546-b86b-68651a6da016_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7068db2c-56e6-4192-b3f9-383d68bd34b9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_38b79a77-5126-4e20-83e9-81c009e4f346_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30cac9cb-218d-4273-855e-f6341990dfb5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares, Vested and settled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b9701597-07a6-4303-a5de-0fefbbdf2bff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a406d1e8-6b73-44e3-8b44-8e3c77d7db55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_81fad7b7-b1bd-4d90-a639-192c3f90a084_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_623a750f-e4af-4d64-8d9d-a7a4727c07ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value, Vested and settled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_e848c138-1ea7-4d3c-8016-d899c9eb22cd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_426a3d0a-4d72-462a-8ad2-645a338d98b8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_261116b8-a43d-4cec-9c84-3c41bdaa3d96_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_85b1fcef-8a9e-4650-bcbb-ba111b357837_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_ef848a5e-2c9c-4c79-be42-ef8ec022e994_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, no par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_AccruedRoyaltiesPayableMember_a2555b22-2b8d-4af6-bd8f-7d83d35158eb_terseLabel_en-US" xlink:label="lab_abcl_AccruedRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties Payable</link:label>
    <link:label id="lab_abcl_AccruedRoyaltiesPayableMember_label_en-US" xlink:label="lab_abcl_AccruedRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties Payable [Member]</link:label>
    <link:label id="lab_abcl_AccruedRoyaltiesPayableMember_documentation_en-US" xlink:label="lab_abcl_AccruedRoyaltiesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_AccruedRoyaltiesPayableMember" xlink:href="abcl-20230331.xsd#abcl_AccruedRoyaltiesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_AccruedRoyaltiesPayableMember" xlink:to="lab_abcl_AccruedRoyaltiesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_67f188a3-c17b-4901-9579-9eacf6d8a67f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4c6b32a8-ac6b-4964-861b-d71f5ef1fcb9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_01b2584e-b8e3-410c-8cab-7a271ba347b0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_663c1947-a656-4b12-bfdf-4b9c0913bb84_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_PhaseTwoMember_6ab7f748-203f-4b91-9a28-75ea81ce9554_terseLabel_en-US" xlink:label="lab_abcl_PhaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2</link:label>
    <link:label id="lab_abcl_PhaseTwoMember_label_en-US" xlink:label="lab_abcl_PhaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Two [Member]</link:label>
    <link:label id="lab_abcl_PhaseTwoMember_documentation_en-US" xlink:label="lab_abcl_PhaseTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PhaseTwoMember" xlink:href="abcl-20230331.xsd#abcl_PhaseTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_PhaseTwoMember" xlink:to="lab_abcl_PhaseTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_972f172c-c1a2-4008-940d-d96eb7b915c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in fair value of liability for contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ff7fad8-080f-43a4-a650-8892b36d8103_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_e485d250-76a7-4e13-96da-fa603d148b47_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_cd020614-a2eb-4bbf-b6aa-a69f813370f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b7ef1754-96e7-4e21-822c-b0c0efb9659d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_9929828a-9449-4b8a-b0d4-a33bcb8fccc0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3235c597-af32-42e3-9bc9-a6b9a19c04f6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e6821ac2-c08b-445b-aa84-1ed61ea5e6ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_86114780-7f96-4991-b780-b01433e471fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b67e066e-67c6-4edc-ab78-d585730b7cd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_32fd1c52-e849-4890-95aa-8a857227538b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2efcdc69-533d-4718-8254-8e03f4d23a2f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1e8e5641-6cd6-4b2b-87a0-064c8af0c60d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options exercisable as of March 31, 2023 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_046f066a-2d30-4feb-bf3e-9b8e800b29ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_cb238c9c-aec0-48f0-b306-5240d09352c9_terseLabel_en-US" xlink:label="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, outstanding related party loan</link:label>
    <link:label id="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_label_en-US" xlink:label="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment Outstanding Related Party Loan</link:label>
    <link:label id="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_documentation_en-US" xlink:label="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, outstanding related party loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" xlink:href="abcl-20230331.xsd#abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" xlink:to="lab_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_28b8f47f-5f94-44a0-a1b1-a49ebead4f0e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f0b6c80a-0d99-4756-8201-37d78f3b55b7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_e6eeafce-9031-4696-b70e-b6999c3aba75_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Amortization Expense on Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_81f09fbc-90bc-41ee-8b6b-1b91112e3ae7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d03bf7c6-5fab-46e9-8a75-2bcbaa912185_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_83718919-7e31-4280-bab1-52bfeee22ad0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6c60ab4c-00d6-40a9-9cd8-8df27a49962f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9379e594-5a2e-405c-a11a-5399aa3e9826_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_19a5bcb9-b7ca-4b2c-80a2-1682c131afc8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b006d252-efb8-4301-894f-de951d242954_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29de7ed0-afd4-4fd9-9275-a7302ca09c7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9e906170-6a02-4f47-977e-bc706871824c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_fc35e6c2-aca7-4997-9873-13899c81d8ee_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (income)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1a9ffced-99cb-4392-9a76-864676858088_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2a56936e-eda9-40df-aa89-1b73e34b78a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_DayluJVLoanMember_7384dcfe-0648-4f5e-99f4-1fddf4c876f8_terseLabel_en-US" xlink:label="lab_abcl_DayluJVLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daylu JV Loan</link:label>
    <link:label id="lab_abcl_DayluJVLoanMember_label_en-US" xlink:label="lab_abcl_DayluJVLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daylu JV Loan [Member]</link:label>
    <link:label id="lab_abcl_DayluJVLoanMember_documentation_en-US" xlink:label="lab_abcl_DayluJVLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daylu JV Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DayluJVLoanMember" xlink:href="abcl-20230331.xsd#abcl_DayluJVLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_DayluJVLoanMember" xlink:to="lab_abcl_DayluJVLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7b931b57-823d-4bbb-9b4d-00bee4987b16_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9071690e-ebc8-4d0e-8400-6ba5508aa528_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_1ef011a4-3ff3-43d4-a56c-2863d5f62eab_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eef29860-b8a1-4f11-a19f-3a8a0e90161f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_01a98a34-18fc-45f5-be46-3a3d47b6565d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_21435238-95e7-4381-b4d8-143fae663422_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8425189a-d0c9-4752-9714-0d813c61c1e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8685bb30-db09-40f1-85f2-9cfae710a31c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in and loans to equity accounted investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_52bff268-4fb0-405a-acf4-e8fb2458349d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_be316f52-9440-498e-add7-51613bdb4044_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and loans to equity accounted investees, and other long-term assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ddab6dbc-5fc6-46b5-9abd-a8cbb648caa5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b48f2381-4675-4b5d-a812-01f58b5b2414_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33e8b929-c002-4e4c-a806-4142b43fc584_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_DeferredGrantsFundingNoncurrent_318b94fd-4614-44b9-8be7-69bbaff805f7_terseLabel_en-US" xlink:label="lab_abcl_DeferredGrantsFundingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding</link:label>
    <link:label id="lab_abcl_DeferredGrantsFundingNoncurrent_label_en-US" xlink:label="lab_abcl_DeferredGrantsFundingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grants Funding Noncurrent</link:label>
    <link:label id="lab_abcl_DeferredGrantsFundingNoncurrent_documentation_en-US" xlink:label="lab_abcl_DeferredGrantsFundingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grants Funding Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DeferredGrantsFundingNoncurrent" xlink:href="abcl-20230331.xsd#abcl_DeferredGrantsFundingNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_DeferredGrantsFundingNoncurrent" xlink:to="lab_abcl_DeferredGrantsFundingNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_52e0fbb6-7648-4314-9937-91e24bb358d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_52832100-d15e-454d-a8c5-2635254f7ee1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9e9c2e90-0c7a-47d9-9f4b-826930d478cf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9bce98a5-e4ba-4f6b-b828-c3abcb7037d8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c1614031-820c-4519-b44f-9559b0e6d34d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_949ba995-6818-4077-931b-ba70de5af5e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_cd0d05e4-f4f5-4a3e-8dd1-d93d35a3b2fa_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-marketable securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_ResearchFeesMember_a9d3b17e-ce31-4d17-b321-91849a80520b_terseLabel_en-US" xlink:label="lab_abcl_ResearchFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research fees</link:label>
    <link:label id="lab_abcl_ResearchFeesMember_label_en-US" xlink:label="lab_abcl_ResearchFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Fees [Member]</link:label>
    <link:label id="lab_abcl_ResearchFeesMember_documentation_en-US" xlink:label="lab_abcl_ResearchFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ResearchFeesMember" xlink:href="abcl-20230331.xsd#abcl_ResearchFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_ResearchFeesMember" xlink:to="lab_abcl_ResearchFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_e30e5640-d521-4db9-86be-741c998ce39b_negatedLabel_en-US" xlink:label="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of liability for in-licensing agreement and contingent consideration</link:label>
    <link:label id="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_label_en-US" xlink:label="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Liability For In Licensing Agreement And Contingent Consideration</link:label>
    <link:label id="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_documentation_en-US" xlink:label="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt and contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" xlink:href="abcl-20230331.xsd#abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" xlink:to="lab_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_abcl_ProceedsFromReceiptOfGrantFunding_62ccd9d8-2483-4a32-bbd8-2f0c7db034b9_terseLabel_en-US" xlink:label="lab_abcl_ProceedsFromReceiptOfGrantFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of grant funding</link:label>
    <link:label id="lab_abcl_ProceedsFromReceiptOfGrantFunding_label_en-US" xlink:label="lab_abcl_ProceedsFromReceiptOfGrantFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Receipt Of Grant Funding</link:label>
    <link:label id="lab_abcl_ProceedsFromReceiptOfGrantFunding_documentation_en-US" xlink:label="lab_abcl_ProceedsFromReceiptOfGrantFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from receipt of grant funding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ProceedsFromReceiptOfGrantFunding" xlink:href="abcl-20230331.xsd#abcl_ProceedsFromReceiptOfGrantFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abcl_ProceedsFromReceiptOfGrantFunding" xlink:to="lab_abcl_ProceedsFromReceiptOfGrantFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_61a9e64a-a07b-456e-9097-5f4f15fdb729_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_457e1ca4-9eb0-4383-89a0-0f9fb3ec83a0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment balance, contributions made in joint venture</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_36db59e1-ac67-4172-afb3-4afa2bccaf12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_aebc1dcc-8de3-45a7-9b40-6ef8a64aaab8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and loans to equity accounted investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_cb823c51-0c27-49a6-8a9a-451eea7717f6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abcl-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:650343a1-ca86-4cd1-b410-9b387e72615d,g:7bff7bb1-4386-4395-9d16-110d609544b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abcellera.com/role/Cover" xlink:type="simple" xlink:href="abcl-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9a6d792b-9b32-4bfb-9bb1-d9d49f797f50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_DocumentType_9a6d792b-9b32-4bfb-9bb1-d9d49f797f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e7bae7d5-262f-4c3b-86a6-15782456a8e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_DocumentQuarterlyReport_e7bae7d5-262f-4c3b-86a6-15782456a8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bf411eb7-3a7a-4b64-865b-9cca11d71099" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_DocumentPeriodEndDate_bf411eb7-3a7a-4b64-865b-9cca11d71099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_011b3ad6-c9ee-4210-9952-3c7a7ebcac0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_DocumentTransitionReport_011b3ad6-c9ee-4210-9952-3c7a7ebcac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_01533de4-5e9a-4f28-a804-9a1df8650803" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityFileNumber_01533de4-5e9a-4f28-a804-9a1df8650803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fd41af35-8d14-4999-8502-118315cb97e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityRegistrantName_fd41af35-8d14-4999-8502-118315cb97e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_78da94b3-0bd7-4887-a7c5-91c10d80467d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityIncorporationStateCountryCode_78da94b3-0bd7-4887-a7c5-91c10d80467d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f92b6d7b-6711-4360-9761-6a0d9ab076e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityAddressAddressLine1_f92b6d7b-6711-4360-9761-6a0d9ab076e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_61b87abc-5a8a-4a63-a0f7-ae3af0c3c11e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityAddressCityOrTown_61b87abc-5a8a-4a63-a0f7-ae3af0c3c11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_16421f9e-07d2-4ed2-b401-3a9fec468d1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityAddressStateOrProvince_16421f9e-07d2-4ed2-b401-3a9fec468d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_457b3afe-699f-45ec-9329-5adce3334aa6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityAddressPostalZipCode_457b3afe-699f-45ec-9329-5adce3334aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ae73c182-90ec-45a2-8543-e77b45f5db7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_CityAreaCode_ae73c182-90ec-45a2-8543-e77b45f5db7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ac96742c-cddc-4b54-8b4d-03124ae57e2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_LocalPhoneNumber_ac96742c-cddc-4b54-8b4d-03124ae57e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_497301ff-2f0d-4a16-b34c-5d2cc5875f16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_Security12bTitle_497301ff-2f0d-4a16-b34c-5d2cc5875f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d5b69134-e38f-4d5b-9efe-ca958e24643b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_TradingSymbol_d5b69134-e38f-4d5b-9efe-ca958e24643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_629d5c67-e1fa-42fc-a307-a1a992c0039c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_SecurityExchangeName_629d5c67-e1fa-42fc-a307-a1a992c0039c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ef729ae7-0453-4e55-8fb5-4b661c125b3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityCurrentReportingStatus_ef729ae7-0453-4e55-8fb5-4b661c125b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_42a42506-0de5-477e-a4c6-ae63eff03a1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityInteractiveDataCurrent_42a42506-0de5-477e-a4c6-ae63eff03a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ac1bb29a-9ad7-4339-88ba-7bdeed5922bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityFilerCategory_ac1bb29a-9ad7-4339-88ba-7bdeed5922bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dfe512aa-34f6-412f-83d3-b91df7ca2d42" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntitySmallBusiness_dfe512aa-34f6-412f-83d3-b91df7ca2d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_679ccda0-1de4-4d84-af29-9c90c723501e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityEmergingGrowthCompany_679ccda0-1de4-4d84-af29-9c90c723501e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b54efaab-d8fc-4b6b-bcbe-a6277cb3a3be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityShellCompany_b54efaab-d8fc-4b6b-bcbe-a6277cb3a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a9e6f380-7e00-44d7-b5c3-b3a2390dbf6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a9e6f380-7e00-44d7-b5c3-b3a2390dbf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_920f5e5f-532a-4a51-8b3b-effcd0fcb988" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_EntityCentralIndexKey_920f5e5f-532a-4a51-8b3b-effcd0fcb988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c6141835-17e1-4e2c-8734-e56f4288256e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_CurrentFiscalYearEndDate_c6141835-17e1-4e2c-8734-e56f4288256e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_93721877-6569-4407-b5f6-aad546028546" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_DocumentFiscalPeriodFocus_93721877-6569-4407-b5f6-aad546028546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_322508ee-9ea8-4eb3-b30e-6922a1bf2f3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_DocumentFiscalYearFocus_322508ee-9ea8-4eb3-b30e-6922a1bf2f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_961b318b-8d98-4d22-accc-85a7f350db8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_665ac2ef-54dd-450b-8eb2-e513e8303639" xlink:to="loc_dei_AmendmentFlag_961b318b-8d98-4d22-accc-85a7f350db8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7b387471-3bdc-434f-bfaa-ee332a579539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c4562088-aa3d-4f4c-9298-3ac72089d5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7b387471-3bdc-434f-bfaa-ee332a579539" xlink:to="loc_us-gaap_AssetsAbstract_c4562088-aa3d-4f4c-9298-3ac72089d5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4562088-aa3d-4f4c-9298-3ac72089d5e5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7786887-5ba0-4821-ad54-a86021ff6443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7786887-5ba0-4821-ad54-a86021ff6443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b243c4c-7ec8-479d-a92c-568f4d4ae37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b243c4c-7ec8-479d-a92c-568f4d4ae37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CashCashEquivalentsAndMarketableSecurities_55429a95-3bf9-4dcb-9ae3-c6bd5b9b431d" xlink:href="abcl-20230331.xsd#abcl_CashCashEquivalentsAndMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_abcl_CashCashEquivalentsAndMarketableSecurities_55429a95-3bf9-4dcb-9ae3-c6bd5b9b431d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_AccountsAndAccruedReceivableCurrent_afe24584-d114-431d-b1ae-7180785cba57" xlink:href="abcl-20230331.xsd#abcl_AccountsAndAccruedReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_abcl_AccountsAndAccruedReceivableCurrent_afe24584-d114-431d-b1ae-7180785cba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1d30a7d7-ebe9-417e-8129-fc2e99deef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_us-gaap_RestrictedCash_1d30a7d7-ebe9-417e-8129-fc2e99deef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7e76717b-dba9-4cfb-9cb8-12ff2e477c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_us-gaap_OtherAssetsCurrent_7e76717b-dba9-4cfb-9cb8-12ff2e477c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eb362948-e01a-4fc0-bdae-80e8070250cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d9e3c29-34ea-4237-833c-5e6b4c1f29cc" xlink:to="loc_us-gaap_AssetsCurrent_eb362948-e01a-4fc0-bdae-80e8070250cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4562088-aa3d-4f4c-9298-3ac72089d5e5" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aff8ac35-c5cc-4706-b75b-2fef95d45f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_aff8ac35-c5cc-4706-b75b-2fef95d45f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_17331d94-b6de-442d-9df4-46211ce3a6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_17331d94-b6de-442d-9df4-46211ce3a6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e0f271ef-e467-44a5-aa19-41333858ff01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:to="loc_us-gaap_Goodwill_e0f271ef-e467-44a5-aa19-41333858ff01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e438de05-de82-4727-a9be-b2bea2b11a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e438de05-de82-4727-a9be-b2bea2b11a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_617bbb2a-855a-4d4c-9d7b-10879d36f534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_617bbb2a-855a-4d4c-9d7b-10879d36f534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_082c618f-47b3-44a8-aa0e-82368ea18204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7905411a-6e0e-4b8f-8008-47452f616c04" xlink:to="loc_us-gaap_AssetsNoncurrent_082c618f-47b3-44a8-aa0e-82368ea18204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_16e1cd2d-9706-4d12-81e0-6a8abf4fed2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c4562088-aa3d-4f4c-9298-3ac72089d5e5" xlink:to="loc_us-gaap_Assets_16e1cd2d-9706-4d12-81e0-6a8abf4fed2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7b387471-3bdc-434f-bfaa-ee332a579539" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_946c881f-7233-4fd1-bdee-8d7a5d03b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilities_946c881f-7233-4fd1-bdee-8d7a5d03b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_55e4b70a-8f2c-4e77-957e-3d356ac304f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_55e4b70a-8f2c-4e77-957e-3d356ac304f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_9337e787-f835-486f-a0f4-9ff5f15fe5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_9337e787-f835-486f-a0f4-9ff5f15fe5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fcde2cf4-0924-4c5b-aa18-60416f053250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fcde2cf4-0924-4c5b-aa18-60416f053250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c83449fa-9fbe-41cd-ac33-6e5231cbb5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15ca7a79-f29f-4163-b201-29274ad334e0" xlink:to="loc_us-gaap_LiabilitiesCurrent_c83449fa-9fbe-41cd-ac33-6e5231cbb5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95b905d6-0c14-489f-897f-7f4399970082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95b905d6-0c14-489f-897f-7f4399970082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ef6a4bd3-ef4e-4b65-a57e-5c21e6a09505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ef6a4bd3-ef4e-4b65-a57e-5c21e6a09505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DeferredGrantsFundingNoncurrent_7d2fe943-8f5d-43e5-97c3-8f6366567f2e" xlink:href="abcl-20230331.xsd#abcl_DeferredGrantsFundingNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_abcl_DeferredGrantsFundingNoncurrent_7d2fe943-8f5d-43e5-97c3-8f6366567f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f447bb3b-1cb3-40a6-8f9d-4da78841d7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f447bb3b-1cb3-40a6-8f9d-4da78841d7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_86fd33ea-88b9-4f15-89b6-a67acf04abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_86fd33ea-88b9-4f15-89b6-a67acf04abd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e31bc8e9-4d5e-4374-a01c-33045e5cb219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e31bc8e9-4d5e-4374-a01c-33045e5cb219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_01444152-d7cb-4773-acd8-6ebdea332511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e62e5605-5dd4-401f-aefd-aaea9660fdf1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_01444152-d7cb-4773-acd8-6ebdea332511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d618eba9-45d1-47ca-af06-c014eef16a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_Liabilities_d618eba9-45d1-47ca-af06-c014eef16a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9bb47018-2c75-40fc-b2be-e72d48f82723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9bb47018-2c75-40fc-b2be-e72d48f82723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_7a5fb200-9bef-4df1-86bb-6bb6a246d930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_CommonStockNoParValue_7a5fb200-9bef-4df1-86bb-6bb6a246d930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3c44858e-1e50-497e-a68f-6bfd203e2d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:to="loc_us-gaap_CommonStockValue_3c44858e-1e50-497e-a68f-6bfd203e2d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0b1937c3-706c-419a-8051-cb9184c9ad1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0b1937c3-706c-419a-8051-cb9184c9ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3f19668-34be-4df0-ad80-9e871cdaca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3f19668-34be-4df0-ad80-9e871cdaca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99db3480-037e-43ec-bd10-8bb95cd77f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99db3480-037e-43ec-bd10-8bb95cd77f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f3fabe6d-cb18-4ebd-bf39-e33cbd85c316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8eb5b188-c7f6-4996-8b97-877284268c9e" xlink:to="loc_us-gaap_StockholdersEquity_f3fabe6d-cb18-4ebd-bf39-e33cbd85c316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25eb9802-9a38-4ab1-9c12-694c774e241e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a786742-2563-4179-89c7-0abb91fc0420" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25eb9802-9a38-4ab1-9c12-694c774e241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9f4001ee-3615-43e0-aa18-604973316844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4752a997-9e7a-4fc5-a25f-6a70e2794dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9f4001ee-3615-43e0-aa18-604973316844" xlink:to="loc_us-gaap_CommonStockSharesIssued_4752a997-9e7a-4fc5-a25f-6a70e2794dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bdfc88d8-2ada-491b-9b05-2b42a32aaf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9f4001ee-3615-43e0-aa18-604973316844" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bdfc88d8-2ada-491b-9b05-2b42a32aaf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c95842b1-21c6-42e6-b6d9-0afb325aec3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c95842b1-21c6-42e6-b6d9-0afb325aec3d" xlink:to="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:to="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_67b4d717-46b0-4746-b371-e23267bb8af4" xlink:to="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ResearchFeesMember_8f34aa39-6677-4f15-acd7-84889d2bd893" xlink:href="abcl-20230331.xsd#abcl_ResearchFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_abcl_ResearchFeesMember_8f34aa39-6677-4f15-acd7-84889d2bd893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cc734d87-f5f5-4e98-b22e-80926f076627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_us-gaap_LicenseMember_cc734d87-f5f5-4e98-b22e-80926f076627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MilestonePaymentsMember_c735962a-e1c2-4ef3-a9d4-f243262c100e" xlink:href="abcl-20230331.xsd#abcl_MilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_abcl_MilestonePaymentsMember_c735962a-e1c2-4ef3-a9d4-f243262c100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b32cc8ce-958d-4e96-b3d2-64b20498883a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb748f16-3077-4d0c-b1aa-bf98a9cb190c" xlink:to="loc_us-gaap_RoyaltyMember_b32cc8ce-958d-4e96-b3d2-64b20498883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0649a888-93cd-4135-bd52-1a79726eac22" xlink:to="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_3f25f83a-96ae-43a7-9c89-5111439725c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_RevenuesAbstract_3f25f83a-96ae-43a7-9c89-5111439725c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4324f53f-c9cd-4387-926b-18ff9efb2737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3f25f83a-96ae-43a7-9c89-5111439725c2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4324f53f-c9cd-4387-926b-18ff9efb2737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_390ed966-16d5-4888-86c0-2c594e5adfb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_RoyaltyExpense_390ed966-16d5-4888-86c0-2c594e5adfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fc4d50d7-5150-47ad-9540-580924a5c016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fc4d50d7-5150-47ad-9540-580924a5c016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_73e060a8-f685-472f-af55-2e4ef705f209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_SellingAndMarketingExpense_73e060a8-f685-472f-af55-2e4ef705f209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4ba0dc2c-7dd1-49c4-8ca8-56f065ff4cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4ba0dc2c-7dd1-49c4-8ca8-56f065ff4cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9d026796-0028-4aec-aa0f-7cb6e63f13d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_DepreciationAndAmortization_9d026796-0028-4aec-aa0f-7cb6e63f13d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9202aa5b-bd56-4c11-ad97-551a6c640e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d399e8f4-0947-4208-85b1-57d9c632ffec" xlink:to="loc_us-gaap_OperatingExpenses_9202aa5b-bd56-4c11-ad97-551a6c640e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_af9526c4-3284-4cb9-bedd-153fd08f853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_OperatingIncomeLoss_af9526c4-3284-4cb9-bedd-153fd08f853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_72ff03d7-a1a9-4b9f-8bd1-10a3c32ec9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_72ff03d7-a1a9-4b9f-8bd1-10a3c32ec9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_GrantsAndIncentives_0c1a6cec-7112-417b-9e52-c27c3f1b990e" xlink:href="abcl-20230331.xsd#abcl_GrantsAndIncentives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_abcl_GrantsAndIncentives_0c1a6cec-7112-417b-9e52-c27c3f1b990e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c6f228c9-b0ea-424b-93b6-eb1d9a498164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c6f228c9-b0ea-424b-93b6-eb1d9a498164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25dd280b-92c6-4ead-81e8-71131b3ddd21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4a5890ac-a99c-49fc-b646-a271a21fe0f3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25dd280b-92c6-4ead-81e8-71131b3ddd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_91f83d85-447c-4d81-84f6-70ee30313642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_91f83d85-447c-4d81-84f6-70ee30313642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6574ea35-da70-4b48-b79d-2ef4feeaba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6574ea35-da70-4b48-b79d-2ef4feeaba6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b00950b-4fd8-42d6-be9c-7df2d0f391ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_NetIncomeLoss_4b00950b-4fd8-42d6-be9c-7df2d0f391ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c5e2f0dc-adce-4fca-9661-04c5901a5e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c5e2f0dc-adce-4fca-9661-04c5901a5e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a8201c7-afc4-4967-b35c-eba560d9ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8a8201c7-afc4-4967-b35c-eba560d9ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e27d681a-e8d6-4358-9c5f-e2406ac300c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:to="loc_us-gaap_EarningsPerShareBasic_e27d681a-e8d6-4358-9c5f-e2406ac300c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_76418a3d-7960-4790-9708-789ec00e1789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f0aa52c-bdc0-417b-bbb1-1ace0d46c993" xlink:to="loc_us-gaap_EarningsPerShareDiluted_76418a3d-7960-4790-9708-789ec00e1789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec3b9413-8124-4a3b-8b15-b48b4af0304a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88660318-5602-4af6-aa89-34f489747dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88660318-5602-4af6-aa89-34f489747dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef084024-157c-4fdd-a115-00fdedb8ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4da4b38e-da80-4332-8adc-ff094608ced2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ef084024-157c-4fdd-a115-00fdedb8ab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1a128ea3-a85d-40d5-b227-6c94910c6b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1a128ea3-a85d-40d5-b227-6c94910c6b2b" xlink:to="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d8dadd9-7f4e-4c24-b1fd-55c1e7b92664" xlink:to="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_91e29c51-6355-405e-b37f-f47afcb0815a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_CommonStockMember_91e29c51-6355-405e-b37f-f47afcb0815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a9008da0-3361-4c7b-90c9-0457118b2770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a9008da0-3361-4c7b-90c9-0457118b2770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_65366a70-e39c-4c35-b5bd-b0ee1bbc4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_RetainedEarningsMember_65366a70-e39c-4c35-b5bd-b0ee1bbc4fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2689c044-1ddc-474e-b485-8b27b824bb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8cefadb2-0666-472b-b4e4-18ec0f074ee9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2689c044-1ddc-474e-b485-8b27b824bb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1b2d2fcb-ffd9-46f0-b8d0-cd17a5b55640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_195570cb-fa6b-4fc8-b41a-7528e0bc37fe" xlink:to="loc_us-gaap_StatementLineItems_1b2d2fcb-ffd9-46f0-b8d0-cd17a5b55640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1b2d2fcb-ffd9-46f0-b8d0-cd17a5b55640" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6054bd31-a8ce-4bdf-b780-f131cf72a34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_SharesOutstanding_6054bd31-a8ce-4bdf-b780-f131cf72a34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77fc7b5e-f0de-4fd4-8e83-f02d3e806924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_StockholdersEquity_77fc7b5e-f0de-4fd4-8e83-f02d3e806924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_bf0a2978-6177-4b60-8c50-0f5dbc636170" xlink:href="abcl-20230331.xsd#abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised_bf0a2978-6177-4b60-8c50-0f5dbc636170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_b7ba3aed-3904-4f4c-bcce-bef91db830fc" xlink:href="abcl-20230331.xsd#abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised_b7ba3aed-3904-4f4c-bcce-bef91db830fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34640e58-186e-4738-8751-29b5ea8af815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34640e58-186e-4738-8751-29b5ea8af815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0184064d-8203-4faa-b18c-e48181bca12e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0184064d-8203-4faa-b18c-e48181bca12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70887e57-47c6-4e0a-89d0-a94c85759e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_NetIncomeLoss_70887e57-47c6-4e0a-89d0-a94c85759e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7cd2ccd7-5eb5-4312-97ec-ab748e351b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_SharesOutstanding_7cd2ccd7-5eb5-4312-97ec-ab748e351b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b087a32-0630-4663-a48b-93c9953924be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9a7687ab-36ec-4565-ab4f-ac1eb1d47fba" xlink:to="loc_us-gaap_StockholdersEquity_0b087a32-0630-4663-a48b-93c9953924be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="abcl-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c5bfa58-66d2-43c2-a12e-8c2b852c8414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c5bfa58-66d2-43c2-a12e-8c2b852c8414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0dd05baa-3573-4c22-90eb-5e6f399893ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c5bfa58-66d2-43c2-a12e-8c2b852c8414" xlink:to="loc_us-gaap_ProfitLoss_0dd05baa-3573-4c22-90eb-5e6f399893ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c5bfa58-66d2-43c2-a12e-8c2b852c8414" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_de079c6b-a89a-48ec-8560-d2752e5014c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:to="loc_us-gaap_Depreciation_de079c6b-a89a-48ec-8560-d2752e5014c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_151a7f77-9f48-4812-ba57-0e42499b3824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_151a7f77-9f48-4812-ba57-0e42499b3824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_413f4188-e1a2-4a9b-b2df-8ebf40711cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_413f4188-e1a2-4a9b-b2df-8ebf40711cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_877123fb-e228-411d-83d0-43aa3ee46a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:to="loc_us-gaap_ShareBasedCompensation_877123fb-e228-411d-83d0-43aa3ee46a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f24ca9c9-bdc6-4216-acff-d9028863bae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_49b6f62f-4d28-4837-9051-e4151567e80a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f24ca9c9-bdc6-4216-acff-d9028863bae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c5bfa58-66d2-43c2-a12e-8c2b852c8414" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_e8debc43-5dce-4611-84e3-c91311646396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_e8debc43-5dce-4611-84e3-c91311646396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_6eee0b88-98c4-4632-824a-91cb11cf0b7f" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable_6eee0b88-98c4-4632-824a-91cb11cf0b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0a5e1a0e-f1d5-4dcf-913c-5c3e8a0d469b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_0a5e1a0e-f1d5-4dcf-913c-5c3e8a0d469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_0da49a5e-5177-42d6-99d8-dd9723b5a082" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable_0da49a5e-5177-42d6-99d8-dd9723b5a082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6b0382df-3520-4e71-9a52-dde12eab6270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6b0382df-3520-4e71-9a52-dde12eab6270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_6c52fe22-96c6-4fbe-8455-87ca3c1685a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_6c52fe22-96c6-4fbe-8455-87ca3c1685a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_IncreaseDecreaseInDeferredGrantIncome_2d0e9628-f779-4df3-ba49-e8d043518506" xlink:href="abcl-20230331.xsd#abcl_IncreaseDecreaseInDeferredGrantIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_abcl_IncreaseDecreaseInDeferredGrantIncome_2d0e9628-f779-4df3-ba49-e8d043518506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_98b9087d-b9a8-4f41-b668-eed8d0055c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ee8ed10-eda3-4359-8b1a-b97c50f423e8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_98b9087d-b9a8-4f41-b668-eed8d0055c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9da7a3bb-e481-4531-9979-03e2d4c2e6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c5bfa58-66d2-43c2-a12e-8c2b852c8414" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9da7a3bb-e481-4531-9979-03e2d4c2e6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17b973f6-a0be-4efd-af2d-9b95e77e0188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17b973f6-a0be-4efd-af2d-9b95e77e0188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e21c4ccf-cdf3-45df-adb3-15f4779dc52c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e21c4ccf-cdf3-45df-adb3-15f4779dc52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_592b9045-00c9-489a-8fe2-94789b5e05b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_592b9045-00c9-489a-8fe2-94789b5e05b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ProceedsFromReceiptOfGrantFunding_3ba39949-835c-46bd-a2b5-3529175ab2a8" xlink:href="abcl-20230331.xsd#abcl_ProceedsFromReceiptOfGrantFunding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_abcl_ProceedsFromReceiptOfGrantFunding_3ba39949-835c-46bd-a2b5-3529175ab2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_cdcaabc2-0467-44ec-89a8-b60f45106aa0" xlink:href="abcl-20230331.xsd#abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets_cdcaabc2-0467-44ec-89a8-b60f45106aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b504b81e-bc64-4451-92df-d8aeb27d1ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_b504b81e-bc64-4451-92df-d8aeb27d1ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c63f92f-d1a1-44c3-8fda-a1808b7b56b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f43a3def-c65e-4640-9640-b608a23071c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c63f92f-d1a1-44c3-8fda-a1808b7b56b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66578083-3585-4f1d-9bcc-f44128492fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66578083-3585-4f1d-9bcc-f44128492fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_74a677c9-df45-42a7-9ff0-846448afe7f4" xlink:href="abcl-20230331.xsd#abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66578083-3585-4f1d-9bcc-f44128492fac" xlink:to="loc_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration_74a677c9-df45-42a7-9ff0-846448afe7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ProceedsFromDebtAndExerciseOfStockOptions_4692f0b5-18b8-4e8e-8f3e-da2a4728094a" xlink:href="abcl-20230331.xsd#abcl_ProceedsFromDebtAndExerciseOfStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66578083-3585-4f1d-9bcc-f44128492fac" xlink:to="loc_abcl_ProceedsFromDebtAndExerciseOfStockOptions_4692f0b5-18b8-4e8e-8f3e-da2a4728094a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38035993-0e79-4b8e-ac03-b3a13a3bb6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66578083-3585-4f1d-9bcc-f44128492fac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38035993-0e79-4b8e-ac03-b3a13a3bb6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41bdb812-6b0d-4f4b-9ca3-4d29e5c7a069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41bdb812-6b0d-4f4b-9ca3-4d29e5c7a069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39a03e9c-f3f4-41df-8522-09c293462c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39a03e9c-f3f4-41df-8522-09c293462c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f18b893b-25a7-4794-a0dc-c0edcf3aa78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f18b893b-25a7-4794-a0dc-c0edcf3aa78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_53b89190-4225-4924-9a69-99fc77d87a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_53b89190-4225-4924-9a69-99fc77d87a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_036ef09b-fac4-4807-bb76-60152f26dde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_036ef09b-fac4-4807-bb76-60152f26dde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5252cf84-32a7-4388-aaa6-fda2439229bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5252cf84-32a7-4388-aaa6-fda2439229bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_06eb6b24-e602-4003-b37f-b113ca950660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_434e24ac-8520-4e47-8581-380847dcf718" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_06eb6b24-e602-4003-b37f-b113ca950660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable_478ec1af-4872-49d8-9eb9-25b295385b40" xlink:href="abcl-20230331.xsd#abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_06eb6b24-e602-4003-b37f-b113ca950660" xlink:to="loc_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable_478ec1af-4872-49d8-9eb9-25b295385b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation_3bcef7f0-d57e-48ce-9ba6-2c2402a93d9f" xlink:href="abcl-20230331.xsd#abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_06eb6b24-e602-4003-b37f-b113ca950660" xlink:to="loc_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation_3bcef7f0-d57e-48ce-9ba6-2c2402a93d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Natureofoperations" xlink:type="simple" xlink:href="abcl-20230331.xsd#Natureofoperations"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Natureofoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0fb229f6-a44d-4d0a-811b-f613290bc81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_78e52848-9e46-4387-9553-8bbe4e9efbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0fb229f6-a44d-4d0a-811b-f613290bc81b" xlink:to="loc_us-gaap_NatureOfOperations_78e52848-9e46-4387-9553-8bbe4e9efbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Basisofpresentation" xlink:type="simple" xlink:href="abcl-20230331.xsd#Basisofpresentation"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Basisofpresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be4866ec-aed8-4036-9e8e-98c10dc2af24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_68e8603a-787f-4bd1-ab12-05c99f657ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be4866ec-aed8-4036-9e8e-98c10dc2af24" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_68e8603a-787f-4bd1-ab12-05c99f657ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Significantaccountingpolicies" xlink:type="simple" xlink:href="abcl-20230331.xsd#Significantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Significantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_decbd2b3-f76b-4dbd-99f3-c938fb9266a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8fb22989-4454-4697-9eb0-c7f872118ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_decbd2b3-f76b-4dbd-99f3-c938fb9266a6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8fb22989-4454-4697-9eb0-c7f872118ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Netearningslosspershare" xlink:type="simple" xlink:href="abcl-20230331.xsd#Netearningslosspershare"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Netearningslosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_49052002-ec01-401c-840c-d248371c38da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0d56d706-f4f6-461d-8314-3a6af848404f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_49052002-ec01-401c-840c-d248371c38da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0d56d706-f4f6-461d-8314-3a6af848404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Propertyandequipmentnet" xlink:type="simple" xlink:href="abcl-20230331.xsd#Propertyandequipmentnet"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Propertyandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e8a3275c-8fc0-4670-be4e-1657ca69f0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_698abb84-75f2-4309-9c14-4d2a7d939084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e8a3275c-8fc0-4670-be4e-1657ca69f0eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_698abb84-75f2-4309-9c14-4d2a7d939084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Intangibleassets" xlink:type="simple" xlink:href="abcl-20230331.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_247f8f33-9472-41cd-8577-12ec1831bd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_368d5125-e50c-4d8e-909e-4fb11694f313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_247f8f33-9472-41cd-8577-12ec1831bd4a" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_368d5125-e50c-4d8e-909e-4fb11694f313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets" xlink:type="simple" xlink:href="abcl-20230331.xsd#Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_80d37b6c-e9dd-4f9e-a52d-b250bf1184aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_c2905249-d08b-4be8-ada0-2cac093d0a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_80d37b6c-e9dd-4f9e-a52d-b250bf1184aa" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_c2905249-d08b-4be8-ada0-2cac093d0a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Currentassetsandliabilities" xlink:type="simple" xlink:href="abcl-20230331.xsd#Currentassetsandliabilities"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Currentassetsandliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2de31aeb-4cd5-45ef-b0a0-098a938bfc56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CurrentAssetsAndLiabilitiesTextBlock_22b19333-e24a-4b57-8c78-df83af3d110d" xlink:href="abcl-20230331.xsd#abcl_CurrentAssetsAndLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2de31aeb-4cd5-45ef-b0a0-098a938bfc56" xlink:to="loc_abcl_CurrentAssetsAndLiabilitiesTextBlock_22b19333-e24a-4b57-8c78-df83af3d110d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Shareholdersequity" xlink:type="simple" xlink:href="abcl-20230331.xsd#Shareholdersequity"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Shareholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c9b1dc6-0efa-4fed-aa8c-2c73ae5103ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_eea1f977-8105-4e9f-95c8-a0bf8f2bd145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c9b1dc6-0efa-4fed-aa8c-2c73ae5103ea" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_eea1f977-8105-4e9f-95c8-a0bf8f2bd145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Revenue" xlink:type="simple" xlink:href="abcl-20230331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2c611e51-a6a6-4ad5-ad45-e80a74924278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b8623120-d673-45be-b2e3-1c597399b3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2c611e51-a6a6-4ad5-ad45-e80a74924278" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b8623120-d673-45be-b2e3-1c597399b3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Financialinstruments" xlink:type="simple" xlink:href="abcl-20230331.xsd#Financialinstruments"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Financialinstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4bd4cfcc-d64e-45b6-b5b0-dd2a470506f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_cc4cb63e-ef0e-470a-9981-612b9a43dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4bd4cfcc-d64e-45b6-b5b0-dd2a470506f9" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_cc4cb63e-ef0e-470a-9981-612b9a43dbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="abcl-20230331.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65c83f74-4b57-45d4-b772-d473a0b43b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b9ed99f5-9a90-4039-b7c7-98517c1df043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65c83f74-4b57-45d4-b772-d473a0b43b75" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b9ed99f5-9a90-4039-b7c7-98517c1df043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="abcl-20230331.xsd#SignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6443fa24-386a-4217-b98d-8dbd0713d04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2583d29c-7dfd-4238-a390-2a965f2a7810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6443fa24-386a-4217-b98d-8dbd0713d04a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2583d29c-7dfd-4238-a390-2a965f2a7810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dd49b32c-f303-4fee-af28-113396b802fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6443fa24-386a-4217-b98d-8dbd0713d04a" xlink:to="loc_us-gaap_UseOfEstimates_dd49b32c-f303-4fee-af28-113396b802fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cbfe3e2b-bcb1-419b-95c3-1f8dc284154e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6443fa24-386a-4217-b98d-8dbd0713d04a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cbfe3e2b-bcb1-419b-95c3-1f8dc284154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/NetearningslosspershareTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#NetearningslosspershareTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/NetearningslosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_096c4be0-b676-4913-8029-9e9a822e2978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_05e0571e-a912-4c41-abf4-6771e5f5610a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_096c4be0-b676-4913-8029-9e9a822e2978" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_05e0571e-a912-4c41-abf4-6771e5f5610a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/PropertyandequipmentnetTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#PropertyandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/PropertyandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34fb20fa-11f5-439d-aaab-28d2ba6b82e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4f6000ad-b839-4d9e-b981-a7ef389ace68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34fb20fa-11f5-439d-aaab-28d2ba6b82e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4f6000ad-b839-4d9e-b981-a7ef389ace68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e65bb7a-2aa4-4fd0-8bdc-ada39ed8ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0253fd9d-5a00-4fe5-9c75-2611a96e92c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e65bb7a-2aa4-4fd0-8bdc-ada39ed8ddc8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0253fd9d-5a00-4fe5-9c75-2611a96e92c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_eed39157-e419-4fd0-8dad-06159021fd87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8e65bb7a-2aa4-4fd0-8bdc-ada39ed8ddc8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_eed39157-e419-4fd0-8dad-06159021fd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#CurrentassetsandliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CurrentassetsandliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9ea93f85-2132-465a-a05a-aa6e81b0bb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_54eb2759-ba2a-4373-900b-6aa426264935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9ea93f85-2132-465a-a05a-aa6e81b0bb08" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_54eb2759-ba2a-4373-900b-6aa426264935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ea1836e5-be1f-4305-8a05-7603a7db3159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9ea93f85-2132-465a-a05a-aa6e81b0bb08" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ea1836e5-be1f-4305-8a05-7603a7db3159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequityTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/ShareholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c6c01f1-7762-44fb-a956-3d36309e36b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d32c308f-9faa-46df-afe5-cd250c5f5c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c6c01f1-7762-44fb-a956-3d36309e36b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d32c308f-9faa-46df-afe5-cd250c5f5c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6b47061f-e8ab-4b57-8ee0-5d945f0506fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c6c01f1-7762-44fb-a956-3d36309e36b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6b47061f-e8ab-4b57-8ee0-5d945f0506fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1cc6cae9-4217-4049-8c22-f1f228e4bada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c6c01f1-7762-44fb-a956-3d36309e36b9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1cc6cae9-4217-4049-8c22-f1f228e4bada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/RevenueTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50bba312-1610-422b-abc8-9cd639116e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_33eb6006-2836-4324-bc85-7f2e95584c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50bba312-1610-422b-abc8-9cd639116e40" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_33eb6006-2836-4324-bc85-7f2e95584c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/FinancialinstrumentsTables" xlink:type="simple" xlink:href="abcl-20230331.xsd#FinancialinstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/FinancialinstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3e83267b-b3fa-432a-b504-baa57105e90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_502bc729-192f-4376-83ce-92b0f8bc3653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3e83267b-b3fa-432a-b504-baa57105e90c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_502bc729-192f-4376-83ce-92b0f8bc3653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e14f63f1-d705-4f5d-91d4-48c15f663861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3e83267b-b3fa-432a-b504-baa57105e90c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_e14f63f1-d705-4f5d-91d4-48c15f663861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_649e0fd7-4f9d-4b17-baa1-9fbc5d3b3b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_83bda955-c141-4797-9f55-fe345492077a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_649e0fd7-4f9d-4b17-baa1-9fbc5d3b3b05" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_83bda955-c141-4797-9f55-fe345492077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_05bc5e2b-24b1-474c-9cd6-427e97543ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_83bda955-c141-4797-9f55-fe345492077a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_05bc5e2b-24b1-474c-9cd6-427e97543ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5223bb8-e919-4f1b-be94-dcc8f3badd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_83bda955-c141-4797-9f55-fe345492077a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5223bb8-e919-4f1b-be94-dcc8f3badd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0ce71844-eede-4fe1-bdf3-e25cb5311853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_83bda955-c141-4797-9f55-fe345492077a" xlink:to="loc_us-gaap_EarningsPerShareBasic_0ce71844-eede-4fe1-bdf3-e25cb5311853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_08d949fd-29e4-483d-8e16-d4200b33be13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_649e0fd7-4f9d-4b17-baa1-9fbc5d3b3b05" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_08d949fd-29e4-483d-8e16-d4200b33be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1945c64f-1878-4dbd-b949-ea8f30d451f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_08d949fd-29e4-483d-8e16-d4200b33be13" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1945c64f-1878-4dbd-b949-ea8f30d451f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ec081d1-8080-40e5-a73b-1aad3e87aa96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_08d949fd-29e4-483d-8e16-d4200b33be13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ec081d1-8080-40e5-a73b-1aad3e87aa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_96ccff2e-a290-488f-b1fd-d9a1ac08b4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_08d949fd-29e4-483d-8e16-d4200b33be13" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_96ccff2e-a290-488f-b1fd-d9a1ac08b4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_345d6cde-4f89-42b7-b4d7-54d350a9d45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_08d949fd-29e4-483d-8e16-d4200b33be13" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_345d6cde-4f89-42b7-b4d7-54d350a9d45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_651d5001-b11f-4fc2-a886-dd4a500ddf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_649e0fd7-4f9d-4b17-baa1-9fbc5d3b3b05" xlink:to="loc_us-gaap_EarningsPerShareDiluted_651d5001-b11f-4fc2-a886-dd4a500ddf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/NetearningslosspershareAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#NetearningslosspershareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/NetearningslosspershareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8bc1eb03-e1f1-4309-bb77-e0cc99fb79f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ddc8c1eb-69c8-4fea-80aa-7dc87bbdfb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8bc1eb03-e1f1-4309-bb77-e0cc99fb79f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ddc8c1eb-69c8-4fea-80aa-7dc87bbdfb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9f78a27e-5fe8-4934-bb96-27793a5e72eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9f78a27e-5fe8-4934-bb96-27793a5e72eb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_87b12036-c0e3-438b-8bee-9c457cc1484a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_a5c08f3e-560e-4e2c-bc1d-7eae36c1144b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_ComputerEquipmentMember_a5c08f3e-560e-4e2c-bc1d-7eae36c1144b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_7587c24d-7bdc-4054-b7b9-e8b958cbe0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_LandMember_7587c24d-7bdc-4054-b7b9-e8b958cbe0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_28595fa9-5e44-487e-8be2-77e7e4409924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_BuildingMember_28595fa9-5e44-487e-8be2-77e7e4409924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_LaboratoryEquipmentMember_fe248b7c-82e9-44ed-8cc3-a8fd45e526b0" xlink:href="abcl-20230331.xsd#abcl_LaboratoryEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_abcl_LaboratoryEquipmentMember_fe248b7c-82e9-44ed-8cc3-a8fd45e526b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f205f44d-8784-49e4-9160-181b27df6279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f205f44d-8784-49e4-9160-181b27df6279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_OperatingLeaseRightOfUseAssetsMember_7220e02e-5153-4209-9050-773d97f34780" xlink:href="abcl-20230331.xsd#abcl_OperatingLeaseRightOfUseAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1d721f32-2c6d-450e-b20d-05a3b36a3093" xlink:to="loc_abcl_OperatingLeaseRightOfUseAssetsMember_7220e02e-5153-4209-9050-773d97f34780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_82d876b6-138d-492d-a363-6182a6e4194c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3761f8ad-30c0-49f2-b8b6-27de8293bd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3761f8ad-30c0-49f2-b8b6-27de8293bd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa7bca2b-1bfb-4c35-bbab-150ecba1cc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_aa7bca2b-1bfb-4c35-bbab-150ecba1cc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c82d8ea-7b0d-4355-bde8-caff26ba95b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3420a32-fbf9-412f-b073-09d0f7f934f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c82d8ea-7b0d-4355-bde8-caff26ba95b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#PropertyandequipmentnetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8e90974e-2772-4fbf-8cf2-6deb027b54aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_aab2b5dd-2031-42f8-9521-0979a256f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8e90974e-2772-4fbf-8cf2-6deb027b54aa" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_aab2b5dd-2031-42f8-9521-0979a256f7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6302ea80-ec12-43ee-a1e5-0e70aa0bcc60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8e90974e-2772-4fbf-8cf2-6deb027b54aa" xlink:to="loc_us-gaap_Depreciation_6302ea80-ec12-43ee-a1e5-0e70aa0bcc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#IntangibleassetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d9ea85c8-d05e-4e11-8cf6-24fb61d23c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d9ea85c8-d05e-4e11-8cf6-24fb61d23c4d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54201260-a254-4d82-ab63-f7178e612b96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_LicenseBasedIntangibleAssetsMember_3c961c5c-ced7-40ad-8bb1-736822a98306" xlink:href="abcl-20230331.xsd#abcl_LicenseBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:to="loc_abcl_LicenseBasedIntangibleAssetsMember_3c961c5c-ced7-40ad-8bb1-736822a98306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d060c586-c7be-46b7-8517-017c839570bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_d060c586-c7be-46b7-8517-017c839570bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a9b8e451-d526-421c-be5b-4e643cf26431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ac59d37-089d-4ca4-b8a1-56416afc6560" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a9b8e451-d526-421c-be5b-4e643cf26431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_abfc8450-4a13-4f43-8c35-10502e629bd3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62ea47c0-3a08-4296-a1aa-5e39d7689656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62ea47c0-3a08-4296-a1aa-5e39d7689656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc1241ea-e04c-49da-935d-0f5fb7c066a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc1241ea-e04c-49da-935d-0f5fb7c066a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f0248c7-3d95-4085-819b-a2611717734d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44a51052-bf6d-4d63-b01f-1ddd85eda06f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6f0248c7-3d95-4085-819b-a2611717734d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d78e87a3-aaf0-4e96-904f-25c438bdf5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d78e87a3-aaf0-4e96-904f-25c438bdf5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6fdc56ca-0ee1-435d-ada2-238d468b31af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6fdc56ca-0ee1-435d-ada2-238d468b31af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4136c03e-0434-49be-8c71-4da01930756c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4136c03e-0434-49be-8c71-4da01930756c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1e3af69e-b0b4-449c-9445-50e75490196d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1e3af69e-b0b4-449c-9445-50e75490196d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_67d54402-1f6d-4699-b8ca-2680b57fe072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_67d54402-1f6d-4699-b8ca-2680b57fe072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_209b9ac8-b4f5-4688-9b19-5fb2fa768888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f5d3206-d897-4158-831d-c992fd27de15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_209b9ac8-b4f5-4688-9b19-5fb2fa768888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9fad0489-78e1-4c58-a61d-656125fd55ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9fad0489-78e1-4c58-a61d-656125fd55ae" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_baa26997-d999-48cf-b496-90d6b4a5794d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DayhuJointVentureMember_ac2b3948-40fd-4f45-89c7-1bbee2ab7a98" xlink:href="abcl-20230331.xsd#abcl_DayhuJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:to="loc_abcl_DayhuJointVentureMember_ac2b3948-40fd-4f45-89c7-1bbee2ab7a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_BeedieJointVentureMember_02dc36df-dd39-4303-8738-9a87b5e7e320" xlink:href="abcl-20230331.xsd#abcl_BeedieJointVentureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1ce432c1-00b0-4b34-86d6-8357b6562e1a" xlink:to="loc_abcl_BeedieJointVentureMember_02dc36df-dd39-4303-8738-9a87b5e7e320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_78f4ad62-1161-463b-bac5-fc204cf4cb5d" xlink:to="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_517d68fd-c35d-48a6-8f42-5822f606595e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:to="loc_srt_MaximumMember_517d68fd-c35d-48a6-8f42-5822f606595e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_618fa045-5f5e-43c5-a742-5996922bb8df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f21c6b2f-e5e5-4f20-bd8e-d37acf101944" xlink:to="loc_srt_MinimumMember_618fa045-5f5e-43c5-a742-5996922bb8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0d8201d6-5a6c-417e-abec-d0af6236baa2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DayluJVLoanMember_b1944a87-7fbb-4f50-a10d-e8c4372ae7a0" xlink:href="abcl-20230331.xsd#abcl_DayluJVLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:to="loc_abcl_DayluJVLoanMember_b1944a87-7fbb-4f50-a10d-e8c4372ae7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NewDayluLoanMember_2c94757f-9f92-4e7f-b520-f6facf87c508" xlink:href="abcl-20230331.xsd#abcl_NewDayluLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_677cffe1-ad71-40b0-b164-8bdd03eed947" xlink:to="loc_abcl_NewDayluLoanMember_2c94757f-9f92-4e7f-b520-f6facf87c508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_9a67a668-5ca5-46d7-838d-20481bef2c4c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_NumberOfJointVentures_e6d07b8e-a454-4026-81f4-a48ac21e397a" xlink:href="abcl-20230331.xsd#abcl_NumberOfJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_NumberOfJointVentures_e6d07b8e-a454-4026-81f4-a48ac21e397a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ff5af26c-afdf-4256-86a1-66a943ef40c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ff5af26c-afdf-4256-86a1-66a943ef40c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_25d07030-db52-4110-9fc8-f5b814374eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_25d07030-db52-4110-9fc8-f5b814374eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_EquityMethodInvestmentCommitmentAmount_7a8bf9cc-1bbd-43d5-be30-5b4371d58ed9" xlink:href="abcl-20230331.xsd#abcl_EquityMethodInvestmentCommitmentAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_EquityMethodInvestmentCommitmentAmount_7a8bf9cc-1bbd-43d5-be30-5b4371d58ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_6de42129-afa6-4614-80ea-fba50434179a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_us-gaap_DebtInstrumentTerm_6de42129-afa6-4614-80ea-fba50434179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_38c1b5e3-20b4-4ccc-b41c-9b6a8ef9ff13" xlink:href="abcl-20230331.xsd#abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan_38c1b5e3-20b4-4ccc-b41c-9b6a8ef9ff13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PercentageOfConstructionLoan_72816bdf-163f-4470-a420-07c3e9052d4c" xlink:href="abcl-20230331.xsd#abcl_PercentageOfConstructionLoan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_177f9ae5-87d6-4146-873c-e2726d6344bd" xlink:to="loc_abcl_PercentageOfConstructionLoan_72816bdf-163f-4470-a420-07c3e9052d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#CurrentassetsandliabilitiesOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7e75b989-2f9e-4472-b3fb-d384ed381174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_1ab24084-a2e3-47ba-9804-95c778ed9287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e75b989-2f9e-4472-b3fb-d384ed381174" xlink:to="loc_us-gaap_IncomeTaxesReceivable_1ab24084-a2e3-47ba-9804-95c778ed9287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PrepaidExpenseAndOtherCurrent_8ca15db4-8460-44f5-ae43-62eefc1612bc" xlink:href="abcl-20230331.xsd#abcl_PrepaidExpenseAndOtherCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e75b989-2f9e-4472-b3fb-d384ed381174" xlink:to="loc_abcl_PrepaidExpenseAndOtherCurrent_8ca15db4-8460-44f5-ae43-62eefc1612bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MaterialsAndSuppliesCurrent_07cbef72-ea07-4e2c-8213-2ea6ef2f1171" xlink:href="abcl-20230331.xsd#abcl_MaterialsAndSuppliesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e75b989-2f9e-4472-b3fb-d384ed381174" xlink:to="loc_abcl_MaterialsAndSuppliesCurrent_07cbef72-ea07-4e2c-8213-2ea6ef2f1171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_041b853a-b766-4f86-8e37-c0b0e1a4c982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7e75b989-2f9e-4472-b3fb-d384ed381174" xlink:to="loc_us-gaap_OtherAssetsCurrent_041b853a-b766-4f86-8e37-c0b0e1a4c982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9401589a-ac16-44b8-8d6a-2142113e5cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d82e1ce-919c-4186-a46c-d7b3ce68d2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9401589a-ac16-44b8-8d6a-2142113e5cf4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4d82e1ce-919c-4186-a46c-d7b3ce68d2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_86da557e-9745-4b3b-aec8-2054c80ab13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9401589a-ac16-44b8-8d6a-2142113e5cf4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_86da557e-9745-4b3b-aec8-2054c80ab13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_96a7de10-f408-4e47-b4cc-992fe249e978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9401589a-ac16-44b8-8d6a-2142113e5cf4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_96a7de10-f408-4e47-b4cc-992fe249e978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_DeferredGrantFundingCurrent_97207abd-75e0-4bfd-a309-5a07eb39d063" xlink:href="abcl-20230331.xsd#abcl_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9401589a-ac16-44b8-8d6a-2142113e5cf4" xlink:to="loc_abcl_DeferredGrantFundingCurrent_97207abd-75e0-4bfd-a309-5a07eb39d063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ce4f87c9-bb37-4ca5-b0a9-0225260299ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9401589a-ac16-44b8-8d6a-2142113e5cf4" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ce4f87c9-bb37-4ca5-b0a9-0225260299ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequitySummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_105f8aaa-0fd8-4f58-b419-b363a9008df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_105f8aaa-0fd8-4f58-b419-b363a9008df2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:to="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_24d810fd-e7a3-4a71-a1b5-10843d5dc539" xlink:to="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PreInitialPublicOfferingPlanMember_a278ec01-d166-4aa3-8647-a3a65dae0a60" xlink:href="abcl-20230331.xsd#abcl_PreInitialPublicOfferingPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:to="loc_abcl_PreInitialPublicOfferingPlanMember_a278ec01-d166-4aa3-8647-a3a65dae0a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_fb6640bb-e82b-4b7b-9226-fa09d502607e" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dc92b05a-b565-409d-a930-d03c10e49386" xlink:to="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_fb6640bb-e82b-4b7b-9226-fa09d502607e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_872b61f2-7273-4859-a007-67b22cbe3200" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e8a751a-1abd-4370-85b0-63b66d715f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e8a751a-1abd-4370-85b0-63b66d715f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0c84c42-f2f8-4038-9a93-861115388cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d0c84c42-f2f8-4038-9a93-861115388cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233edac9-6d6e-4def-bdd1-194c82446924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233edac9-6d6e-4def-bdd1-194c82446924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7fa342c8-2579-43b8-9d84-8a57f68ea1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7fa342c8-2579-43b8-9d84-8a57f68ea1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d1ef659-ea8d-4648-803c-110b03b31bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8dcf26cc-cee6-4564-90de-c892b623049c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d1ef659-ea8d-4648-803c-110b03b31bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b3eac473-6988-49ab-af8f-3b9416a9e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b3eac473-6988-49ab-af8f-3b9416a9e3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b226ebb9-ae2f-4b2f-9209-69305fcd6a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b226ebb9-ae2f-4b2f-9209-69305fcd6a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e7475c2-05cf-420b-a46d-a3fbeb7c8d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e7475c2-05cf-420b-a46d-a3fbeb7c8d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_22bb0cec-cff8-4a17-ab27-b4f68960f1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_22bb0cec-cff8-4a17-ab27-b4f68960f1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3df8aeec-9657-4acc-949d-d88f8784cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3df8aeec-9657-4acc-949d-d88f8784cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37e9740e-b546-4807-a7c5-e91ba5aa821e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37e9740e-b546-4807-a7c5-e91ba5aa821e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69614f-f28c-4aaf-9a1f-7c7abbabdac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7eb8a92f-2764-40df-8948-fdd8b12dd571" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69614f-f28c-4aaf-9a1f-7c7abbabdac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86459a54-0234-442b-aa69-5bfb544943f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86459a54-0234-442b-aa69-5bfb544943f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:to="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d8a678c-b590-4805-a198-fa3c1205db45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b124fcf1-b906-4eb2-9ad5-561ad01edd90" xlink:to="loc_us-gaap_PlanNameDomain_6d8a678c-b590-4805-a198-fa3c1205db45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_eed94e1a-b3fc-463b-9aae-7600300a006c" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d8a678c-b590-4805-a198-fa3c1205db45" xlink:to="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_eed94e1a-b3fc-463b-9aae-7600300a006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:to="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_625697c2-7b6c-4577-9703-698953109582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2e36ccdf-0320-45cc-91e3-21c5c13d74cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_625697c2-7b6c-4577-9703-698953109582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8fd4f0cc-604e-4faa-8e9b-7ab8d9a2f763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_625697c2-7b6c-4577-9703-698953109582" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8fd4f0cc-604e-4faa-8e9b-7ab8d9a2f763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ce5462d-187a-4806-a057-7ad9b52013d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83420862-d5c1-41b9-a263-b516888895d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83420862-d5c1-41b9-a263-b516888895d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55872ffe-f3b2-4bdb-a39f-bb36b4f05f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55872ffe-f3b2-4bdb-a39f-bb36b4f05f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8b50e0-68b3-4777-9138-d66d0f1dd470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8e8b50e0-68b3-4777-9138-d66d0f1dd470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a67c8f35-55cd-4b80-8668-09741ac76986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a67c8f35-55cd-4b80-8668-09741ac76986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff3f4e33-9681-4931-bcb0-962a75d33a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff3f4e33-9681-4931-bcb0-962a75d33a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74d27a90-a038-41e5-a382-71849b93ca07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74d27a90-a038-41e5-a382-71849b93ca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38ca9bb6-46c8-4213-b387-ac675f5159db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_38ca9bb6-46c8-4213-b387-ac675f5159db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4f9e5045-e9ce-4f96-a930-82f361bdd96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4f9e5045-e9ce-4f96-a930-82f361bdd96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a51b0b03-27cf-46a7-b9b1-29b407c4ba68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a51b0b03-27cf-46a7-b9b1-29b407c4ba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_625f3cc8-f6cc-47f2-80aa-2a3d2bf9aefa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f75db74a-1de3-4c08-8cdb-1b40c2972686" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_625f3cc8-f6cc-47f2-80aa-2a3d2bf9aefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a76f724-031e-485d-b590-8af5a13e47e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a76f724-031e-485d-b590-8af5a13e47e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:to="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_204928d6-2768-4853-be3a-404679e0312b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e5d18513-80f6-4c10-9e55-766d6f55d1a7" xlink:to="loc_us-gaap_PlanNameDomain_204928d6-2768-4853-be3a-404679e0312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_567bb914-e32d-46f2-a5e9-a179d9bfb3f6" xlink:href="abcl-20230331.xsd#abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_204928d6-2768-4853-be3a-404679e0312b" xlink:to="loc_abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember_567bb914-e32d-46f2-a5e9-a179d9bfb3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fbb90f0-65f6-43b7-a7ea-7f4562a6e174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee3b1531-1b34-42ef-9646-cc55481cdf53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fbb90f0-65f6-43b7-a7ea-7f4562a6e174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5631119-f4c0-49ed-b790-845e48a512ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fbb90f0-65f6-43b7-a7ea-7f4562a6e174" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b5631119-f4c0-49ed-b790-845e48a512ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b136118-cd95-4fea-aebb-00fe9618a9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b136118-cd95-4fea-aebb-00fe9618a9c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d1acd30-3c0b-4f49-84e2-aedb706000ee" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47215e66-dd29-4025-9146-dbb311aaed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_47215e66-dd29-4025-9146-dbb311aaed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_b257b523-bac7-41fe-993c-d1a1879dee54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_b257b523-bac7-41fe-993c-d1a1879dee54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e2fddc-d8ed-4abd-bb2f-3b6a9bfb0cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c90224b1-e5bc-4c32-aaf4-17ffe2cbeadc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a6e2fddc-d8ed-4abd-bb2f-3b6a9bfb0cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e5fbac-d4bd-41a4-a77a-ffd539ead94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5b8b78b6-d560-44dc-b047-1700f18c375c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e5fbac-d4bd-41a4-a77a-ffd539ead94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2efbb769-3b0a-495c-999a-5ba1ca04b447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e5fbac-d4bd-41a4-a77a-ffd539ead94a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2efbb769-3b0a-495c-999a-5ba1ca04b447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/RevenueSummaryofDeferredRevenueOutstandingDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#RevenueSummaryofDeferredRevenueOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/RevenueSummaryofDeferredRevenueOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aeafa9be-33d2-4198-884d-d6fdd4e6e525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_90177292-bb68-4049-8160-ea17f04cd647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_aeafa9be-33d2-4198-884d-d6fdd4e6e525" xlink:to="loc_us-gaap_ContractWithCustomerLiability_90177292-bb68-4049-8160-ea17f04cd647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/RevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#RevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/RevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_40b7655d-b022-4e86-a116-8d66e26467b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_02c28f1e-eed8-412b-b0f5-d85f9ae2120a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_40b7655d-b022-4e86-a116-8d66e26467b7" xlink:to="loc_us-gaap_ContractWithCustomerLiability_02c28f1e-eed8-412b-b0f5-d85f9ae2120a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a694e978-43e4-4055-b2e5-72a23d41fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_40b7655d-b022-4e86-a116-8d66e26467b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_a694e978-43e4-4055-b2e5-72a23d41fb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/FinancialinstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#FinancialinstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/FinancialinstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2139e6a1-aa25-491c-95cf-9449866c6568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5cfa51d7-4d49-4bba-8f21-d4785f21faf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2139e6a1-aa25-491c-95cf-9449866c6568" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5cfa51d7-4d49-4bba-8f21-d4785f21faf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_c27e0f15-6fa1-4e94-87f0-3a8731e5b214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_c27e0f15-6fa1-4e94-87f0-3a8731e5b214" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d6b76a1-10aa-4a44-b56f-989b18fbfbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1a105774-5744-4036-9475-9afb1e5bc848" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d6b76a1-10aa-4a44-b56f-989b18fbfbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_ContingentConsiderationMember_5b123a43-2389-402b-858a-a093efd4732b" xlink:href="abcl-20230331.xsd#abcl_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5d6b76a1-10aa-4a44-b56f-989b18fbfbb5" xlink:to="loc_abcl_ContingentConsiderationMember_5b123a43-2389-402b-858a-a093efd4732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e79f34b3-c68e-4960-add2-c5f2c91a2fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_858e9fa1-9468-4357-95dd-7a51d15735e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e79f34b3-c68e-4960-add2-c5f2c91a2fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ac545ed1-637e-488f-9727-a35f5135861c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e79f34b3-c68e-4960-add2-c5f2c91a2fd1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ac545ed1-637e-488f-9727-a35f5135861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25694661-0aab-4b5f-ab74-668ca48f636b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TrianniMember_d33776b7-48ce-4fef-9a62-865b382a3771" xlink:href="abcl-20230331.xsd#abcl_TrianniMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:to="loc_abcl_TrianniMember_d33776b7-48ce-4fef-9a62-865b382a3771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_TetraGeneticMember_95b02603-2431-4cf9-ac8e-ed5a265a8cdc" xlink:href="abcl-20230331.xsd#abcl_TetraGeneticMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0a1ce62-baf0-4d9b-a9e0-19553587cf32" xlink:to="loc_abcl_TetraGeneticMember_95b02603-2431-4cf9-ac8e-ed5a265a8cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_456d38d3-5884-4b2a-9214-19e52db00f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_15ca8ee4-7054-401f-9ac1-c711ea1d30ca" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_456d38d3-5884-4b2a-9214-19e52db00f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cf1b4cf0-94a9-460a-8585-9c59789ba905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_456d38d3-5884-4b2a-9214-19e52db00f21" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cf1b4cf0-94a9-460a-8585-9c59789ba905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_49d78411-afc2-42a9-b60b-f738c0cf7e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_f63de7f5-cc2b-4be7-ab43-184215818f3b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_49d78411-afc2-42a9-b60b-f738c0cf7e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_49d78411-afc2-42a9-b60b-f738c0cf7e00" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_606b7a88-be90-4980-aabb-4c43b88a1882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_606b7a88-be90-4980-aabb-4c43b88a1882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f8ad10bd-8d69-46e3-bd95-9c53945f3557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_f8ad10bd-8d69-46e3-bd95-9c53945f3557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a4f40e3-0c77-4380-9195-d9542609f1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a4f40e3-0c77-4380-9195-d9542609f1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_80b63eb3-968d-485e-a60f-74bf2ea5dcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_40c7cb65-0293-41cf-82be-9652d8249cd2" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_80b63eb3-968d-485e-a60f-74bf2ea5dcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9b210691-65a2-4ae8-abb6-3cd6ad772dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9b210691-65a2-4ae8-abb6-3cd6ad772dd3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_52a1be21-8c12-4be4-972c-1ca830e267af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c561ab97-c12d-4c3b-b86b-fbbb185e7650" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_52a1be21-8c12-4be4-972c-1ca830e267af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_be8ba88c-ed25-435a-8707-c51493b6fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_52a1be21-8c12-4be4-972c-1ca830e267af" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_be8ba88c-ed25-435a-8707-c51493b6fcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_026978ff-019e-406d-94fc-e3631026fb2e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ef58fd19-4d94-4d31-ab9e-6338e9a21224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ef58fd19-4d94-4d31-ab9e-6338e9a21224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4747ae9b-9443-4b38-aca3-ad9e3743ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4747ae9b-9443-4b38-aca3-ad9e3743ee79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3042257f-9643-4ab2-8084-58618eea6d87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0389cd3-637d-4de6-89ea-e5cb8b8b73d3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3042257f-9643-4ab2-8084-58618eea6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8b64ddf6-d1fc-4776-a71c-e3242cd13e3d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c5eb8c19-11a9-492e-89b2-ea523dc8c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c5eb8c19-11a9-492e-89b2-ea523dc8c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_139a2ec5-9363-45f4-9690-88b2fac30ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_139a2ec5-9363-45f4-9690-88b2fac30ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f68dd06d-0394-40f4-9019-00115aa4bb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_CommercialPaperMember_f68dd06d-0394-40f4-9019-00115aa4bb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4291daae-b137-412b-8c9f-b40610842ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_721565ab-1545-40cd-809b-f7fe477458fc" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4291daae-b137-412b-8c9f-b40610842ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09700313-6f0d-478f-98bb-e4ccc4f7d010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5007ad25-d44f-4d28-a110-0924b593d09b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09700313-6f0d-478f-98bb-e4ccc4f7d010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1580c566-48f3-4595-a420-7d7b1eda904d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_09700313-6f0d-478f-98bb-e4ccc4f7d010" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1580c566-48f3-4595-a420-7d7b1eda904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33b81d15-d4c4-449f-be9f-fc79292d77ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a8930fcc-930a-4e33-8401-6c691e81a10a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33b81d15-d4c4-449f-be9f-fc79292d77ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_MarketableSecuritiesMember_f0f1daf3-413f-46a3-87f2-c22af8ffff95" xlink:href="abcl-20230331.xsd#abcl_MarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33b81d15-d4c4-449f-be9f-fc79292d77ca" xlink:to="loc_abcl_MarketableSecuritiesMember_f0f1daf3-413f-46a3-87f2-c22af8ffff95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb1d71a9-acdd-41dd-8df6-01e9b3196a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_535246f7-e4b8-40c1-8487-a979f992a962" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb1d71a9-acdd-41dd-8df6-01e9b3196a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bf93b34b-ff10-4aa9-871c-fe0f685fc44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_bb1d71a9-acdd-41dd-8df6-01e9b3196a32" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bf93b34b-ff10-4aa9-871c-fe0f685fc44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.abcellera.com/role/CommitmentsandcontingenciesDetails" xlink:type="simple" xlink:href="abcl-20230331.xsd#CommitmentsandcontingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.abcellera.com/role/CommitmentsandcontingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d1d0e34-6476-452f-b237-4b44f74b3e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:href="abcl-20230331.xsd#abcl_CommitmentsContingenciesAndOtherTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d1d0e34-6476-452f-b237-4b44f74b3e95" xlink:to="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c6d619ad-cc25-4e0f-b0cd-8595e0a20c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_59dc60d1-5525-46dd-b1b9-725055fb41f2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c6d619ad-cc25-4e0f-b0cd-8595e0a20c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_AccruedRoyaltiesPayableMember_4a2e447f-30a3-4595-a0ee-c53e3fe28b55" xlink:href="abcl-20230331.xsd#abcl_AccruedRoyaltiesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c6d619ad-cc25-4e0f-b0cd-8595e0a20c34" xlink:to="loc_abcl_AccruedRoyaltiesPayableMember_4a2e447f-30a3-4595-a0ee-c53e3fe28b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5ec3db53-93be-4d6c-8450-f4ff9fc464ff" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PhaseOneMember_49d48d50-e204-4b42-829b-c5811df5d560" xlink:href="abcl-20230331.xsd#abcl_PhaseOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:to="loc_abcl_PhaseOneMember_49d48d50-e204-4b42-829b-c5811df5d560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_PhaseTwoMember_c5d9a617-3a2b-4ad2-8d18-5f043d42fc14" xlink:href="abcl-20230331.xsd#abcl_PhaseTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c2cb7b98-060b-49eb-9c92-1cf9c3445acb" xlink:to="loc_abcl_PhaseTwoMember_c5d9a617-3a2b-4ad2-8d18-5f043d42fc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:href="abcl-20230331.xsd#abcl_CommitmentsContingenciesAndOtherLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherTable_4f1fcef4-2648-4536-af8c-34776cfcc9cd" xlink:to="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_aa342832-7066-4322-beeb-c66e44ec5180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:to="loc_us-gaap_RoyaltyExpense_aa342832-7066-4322-beeb-c66e44ec5180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abcl_StrategicInnovationFundEligibleExpenditure_48217565-1ac6-449e-b5d9-580a28082353" xlink:href="abcl-20230331.xsd#abcl_StrategicInnovationFundEligibleExpenditure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abcl_CommitmentsContingenciesAndOtherLineItems_cd398709-71e1-417a-9b34-63c79141a8d7" xlink:to="loc_abcl_StrategicInnovationFundEligibleExpenditure_48217565-1ac6-449e-b5d9-580a28082353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>abcl-20230331_g1.gif
<TEXT>
begin 644 abcl-20230331_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M>FPER B)+.1-%:.;\M!$%VW1)#=P2B]"R\B\)K]PF7R#2;P:K)"U,6 ;5:1
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MA!A!TBE6=2JL@F5B2B-6$_4^R\B&G:X@6&MB0?:J4$(I<R >52T:?CRE<^*
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MU I?A$HP!?%!"S)M&R+$PS\RN$%*-RF$S%@AU+420G1ND#,-G>!$#*9"IND
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M%9(<A;0%-XP#\Y8TX9## ;G!?!ETX@S]9A;CV-'? 7%8BH*#!I2OTA:Y-%"
MHI,2:SE<&$)(I1E2Y)1,.M.G+I]L6O(0TX1K&9\IL6*>DF>%N 0'$ZH5;+]Z
M:+Z@&M,\:8Q6@., B]R V M236 R'4TNLVC9A6ETBD!] U'?@-3L>7:SO=,;
MA"3FR#'"0;(Q4AB$6&34!9GTE1$RANJD>T'_[.Z2KA\];^U(]R^)=DB^F:SO
MJQAE*<%6SY*9?( Q;XHLM)9S2O"];X;G.R'^9H@8 +XM923G.:0Y3 RRW!0A
M1QL];S!S#(9X(FW'*KQY\3&_%1,#3^/$+/J.#"BLLV\]SXGF(JS2P:^2\.P0
MPW!@YK5 ;E[R[2AE(\^)4>%N,/*,R!KA!2$&D)]2<+]$G<29Z1+1Z;UUM]B8
M+D6IR)6+/3[(S-K*UP9/NADRFT\52-TQ0/M4;A#VY'2[?+5&S-FYI8RU'^;B
ML7$(TP>B28LX(-+848JJ9=!R$QU Q<@ZO%0VK6[9:#03.YG[52 C[K^\'3)S
M\GSDQ>/VR,3=.J H)7:);P#OE(0^Z.Q91F2,XG=OZT3PI#])03[Q=JA49_>R
MEP'WN(3_7*X7_SKRWHO/B:.3R,3 \'I.NH'6 W*'9.A3L);U#3@O%>4?G?D;
M<?[*DVX8Z6^K0-[.OM]C QDF50;&'C\/2(19$3^CR,N\DL&.!9,8S6=_^P79
MM.I+C-:P#@%$##93/_@S$>RKB/_;CLMS"*Q+"0.\"A7ID<H#O+Q[/^7 " 9D
MB"VQNABANKX(0<GPDM ROA2LCON3"U!0O[_#N+IC.?68A$WKCT^!M@"4N;=P
M08O+P.<X#,-@O&FY/!]\BC%X@TE(PAO1,^:K/]Z /M&K#N!(C#=@D9,+%J^;
M"_1+.L$;"&+0P/%SP+V(0JT[D3)4P [)P9;8P?"HP;P;08) _\,4H8@7A(H?
MB0\D&9^G0#$D:8D20;T!?#V\"$39RP$OP4(55,2Y,$.,<+_(N \  1!BL!#Y
M #PIW NR*(WK<[KD&,.:&#^6LY!1I$1-L,3BP$1>"<7%H!",^)"DLPB%2T U
MC#7(>$(3T<)=03Z]T, P5*^"2(,83#_3LXOQTS\X,48OH3(#_$3LT,2(:XID
M/!$P1#H= 04QB*8\T[P.[$3%$#?WDXTX3+[8$$<4R<5%1$>.&T1"3#_(2+BB
M>(YF[ X]- POM!1Z5 B>\P@7#,-WS$!Y-)%EJ,'"&<(]F8GB*,B!*,(;3(F%
MC(P.>3C-N\4.24578<&XX$+^2T@TC"21 R#&NK!#FS/"7YP4>CP >]R'D"2Y
M[)NZH7"[Q/"T',0*3:G_R'1,0;:J#FJ<O6O+A/ZK")3T#OKPP7*L%(WP0;BK
MD=A RJ'HR28TCB\!0W4#RCMI2K.3M/*9.(QP2)QK#_2SPA5I1%8)RY_(2(L3
M/JTT._0CP.J8O;%\C[9,PT991@DD";BTLU#$ 5);!M=#+5C3LV30%+>T27H3
M3)E 0[0+12^,CS$XO\/1D$S(RK@X$B'$"/2;RJ; $O[PD<AL"F)X@Q>#,LB\
MB\F<P93P3-!\3,YLBCS\-C%H$(%P.S[,C\.4/,M\"]),2)FH06P<,GWT"!$3
M R3!$"I1B>^[-;>X$)$K-?EH3(W;$-5T"RQIS2(AB ]!3=_$C3 D2H*H!]K
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M1C<]5-162/X%=_X=N1[C7]32AV=$]:3T:::4@><(D$C_7+ST,RZD.D/&@7J
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MAC*C1#U8.1H34:>^*4&I-.?'0PE6=.HD,5J8A&U1Q'-\'7@0ETS)4EW 3NW
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MU8.FD5XT>OM$CB19TN1)E"G_2VZ$MJ^>/HP@HUT4"5)DO9OZ]G7<IU/COI!
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M)V;!QS>\K5FCO. I9%AC"$*NB-A2#"S_99[_T<6WG->'Y"* 23[98#%U\EB
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M2@^S:@,_\*D.O-K-''%-X\U2$Y*XD2[4DI=&@\J1XS1P72\AZM%ZD[K;K$E
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M1BIJ)+W%\)A#?N^UC3+#L6RS9\/EYZO+I&(5!A2GFZ)9H&ZJ(PR%>]M^U3:
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M?.<:@TGJ-,CED@P??RESXH^?'E*%RO%"&&@'+5*JG$R?J ],R@>ZEHHA1\Z
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MVEIO8R,YIV0J0J>7)4_OH7ZU,2#!EH .V![X>:$I+$CIAHVG%6NWEDT#$D.
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M<4-(ELP<3GJ4@ZCE@MXG,RL?__(__U91B.AL\)AXS0H/0,8"+ !AZA,H.Z!
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M<*,8N(&DH$=B4\9[Q,=\5#]H.#>TH*W>^C]"\C^!3 M#ZHG_)5F>KH%"OP#
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MGF*ZB:+,S?]B0LGAX2X NI4I!:>-<SPI33+8H3"3DLHFQ2V9##!1LB^/2Y.
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MAD8$^9EB %"IR*2&$%8S\EBN0@OY((M&P$7'E-:IT"10S0R#QJN\SJOUI6-
MWE]XB8W;E)^#L(T_MF/@!*A_ )EJ4!))H.=\GLVWQ5L[CE\[)NR![&MX($W!
MYHV T"O&9JS&!J ^5,F"F5-_10F#,1@^/9A_@4G$C?\8@?W.^OE7B'J)A#Y8
M!2)@F%0<F8A&B1S,21A0 XT4F@E7EZ:BH/[9^GS,)-#I6-JITMXITRZMTHKE
MECKJJ<19PSS=[<75%<6%^W!1SSIG-!##6,9 )EPK)#J,)-X #MS AG*0)MS
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M5;#%:%Y48^8WZ<<P6UY6[K:#?G!*D+)B>G!G#&4T%#3M?5H3U6H\5I(OD:S
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ME>+2[@T'F@#@KTA#VL5-XGQB QW_Z8B!+&$R:,;W7-"S0'L#,>Q(A;;:7D&
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M"G._[)*1OJ("/!4L%F,_!=.DML4RG&WZ'.2:P.2/D .O_+"!]-$S)NT.!R5
M]D'O/I."]H$2%[$_BN,Q4)/'^B@A'-'%L-1I=,-8- &5?F50DBP&H&8_B$%S
M,L%I>(5N)-([TB"T\$8[&*2:+"4@10==]V$20 SQ*D0PO93+AO$TH^, /@-F
M^J><4NV$(@9(9J@FE7%0',,D'1)=?\]*M 8]7#%._\#3KGYIE2P#,[Q'P0[,
M4FQ/SW94%)%DLOJ*CR!E2N+$,UF#4HCT?GZ'/A,D1BP+J%[&FDX(1XAJX.8#
M02'%84/25G'L;QPD-5 '8M\*?THHL5;CLAXEZ83OU;X,&T.R4U+%+K81)?FP
M]%XFV,13JZ94@7J,LFBTV$!TKX*G/OQ$AN P9!4M)D=GEL(Q>&IR>NK6K-8L
M02PN6^ #!\ST)@@'662"/'0BF0"64A$W<16WB:;R*Z/R(10&)!"&!.EHN<P(
MN1CBBX:0)\#L.D1(AA8"X;X2ME;PX8A+7O((WU!7=>4(3]U*IFI%,A9W=FFW
M=FT7**(A*PRSY$#)Y$CIO__> B<28E398PWM@C!'SBP@B7?)\#!K+I3.JT*X
M]33&M%KH3X (*U9Z=E<EKT*_(R6[9QACZ1O;L2"DK-P\(ZST03N916X695S)
M8TX$11&G0_;4",'F0W1VU5[;I@_W 2C+(SX/Y=<4]CMT2)PL9,".Q38DJD4:
MJ^6>!6G053OX5\ED(DM0,Y;L[$]^5"!7\L$JRX$1*,Z8;A^%$1VU9O>XRB1C
MR6@C]E5.Q5-VA&[!@WH)J/@"\--@R:TBTESQ)S9*>+%\UD?$Y#MA6)8>I3LB
M$+'H@X!U[T59^"XN4H;3[&)CN%O+1B4V!#UD2F>WBI9^6%&>%B(M:T],M#E@
MEO6XF&]X)@S_N+@]5H/R0$BP1!*D;H_;1H=5/.4SGZT9'255#!![+&[Y5I26
MWK@VJ ^/']6%KQ9K!OBPV*];0"L#;6)]3?$QH$4GWF"8;K>3/?F3G:(IRS((
M(2((7Q %JW*YIM)T"V8V<8*[DF]"Z@)0!Y5<3KD%(R[A#.8$06)1L^-R!*[
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M(8V_TTX[ARE&6*/O$()*$+@#*31XZ]Y_#W[XXH]/?OGFBV]HH("62<&@:FI
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MAYHO1E8SA%PL(W)U-:=KB8,B-$+20C99 TE$YDZS1!D/)G>]-'69Q#0N\E2
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M'KS95?IEQJ!ET.XIUR*Y5^;A"K\0FK QQKW@FJ?]Q%94!6&ET+%8H";F6U\
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MX,T@_9%=.68J-@9SX$9R,F)CC,=ZF*9.7&.T-:.\@5J _F* XN'KE!?%J!7
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M-)SE7+JM2:4ITGDXF\A'_[*-&7+$$5MQ6;)41;D)B(,M&!9!JA<C!H;_,9A
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M95!3D=KS:1&Z6Q"JBJJ+7U"Q#6.6 ]N6NA2+0ZM/(BNR#IJ"/_JD7_J^$]S
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M:EH2YX4CXB7%3:"/-3X.3"CH"_:%>G5E78#<51!<S3B #Y22>'$<7O2;#_@
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M9!J &(@IQL(I<O^NHMAT) QDQP?$ "(.$"*.HLM8HO#TJ"UF!OM<<1G734*
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M1L8B )RPE,%@P!M_CDI 2@/=MD8H$PTQ1&DLEF26D815FK=D\J(ZGPR;D(5
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M3T*#:!1R9"AXXT-H54]C5#8I-PH;0Q62V*@1;$UAPM!M5#@@?% &@<R# V\
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M&$Q^ G6_8;58A-$ !5OC_MWN 8<:?187W8<06&25EH$I! 1MK]X[@(=-M'$
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M0 1<N;PBNB040HUD1!.<K&/#>K22PRP&@6!L(@(A5B%]=$6;>9';5$"PA+V
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MN(N;<QMH"(C@+AQT<VYHPPM:MG("L;R3G7(+*M!BQ4#T2AF#CAO<#4J;F66
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M/DRUY)-.GXPU\FVU+46<978*'DLYHKM='=VN&TVZ5"C75%2%W:NN%&['CV>
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MA2ZO8\ELBJ"8,E2L67HJ_+"TIQ+*4,=>1^GMTKV6MTKJS5C?KD$Y7*(DK6F
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M\9PP.S)C2<QJ_T(R[H+&;V'P^=(7TS)3W@S&'F/$P%O.U\Z_ZJQ=+2<Z/_6
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M*H]V)GVUE,XK34UVZXFYTIWFY*>T^J=;^]WG=(8CV?MH;-)#2]'Z[F>5+S5
M[ 6S5GP)Z+)/IYR\26^%S.HN31@0US_1A_LK$@TWI14H8FC3+0>^?_[WW_\8
M[*L3:JP!?)5C$Y54X8,4 JQ7015-<:$[6CA(XIAEL3@ADJR):PD=^C0)\8L
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M?>54=BJ>7[I5EY'_26\P7QJ5(7]HJXCU:FC[\QX-P?4L;MGLANVZXUN4HI]
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M'B$2)B'E0,-]&%0^5=.-Z&"!-$C5T4<OR:"!,90, F'&Y5R+D4;]Y50%845
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M81=9XUI=TJ,>D9O@EF:-"B>!:E7Y6%)]3&+DVP7=1%QEUW_"HJT4']5R5%]
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M?H]V- Q(DRV#>P3A:).4*?_X:R:1@_TY4I4*>3*1L7WX\RWB%4,:TQ;JUR-
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M3P&+4TBG.M%I92I52=U*F8)2T4W%/+:QBV?\@Y_=A8\N .1,>2XDO=U],#,
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MKM ]J,"]J)BIYK$V"KFVT."K\$.@S/ I\I.@\:N+@IR>1<,+Z'"C%2O_K&7
MONN#C^6;$ W\/[K E9&8Q7!3QZM9(4UH"+)J1Y=\29B,2?O9R QL-$3CC/#C
M'H8$$-YY-O&H!P7\-,S(24EK-(/TR8O@D \QNY:Y$6.+(+Q(M@R\C;C*J[^
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M3Y;_F3>OS)DCNJY5"DZ7Y9"NVI^3S*J&4+-9@1WF$,<8^%L.35S%75SOB J
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MMPK:+N5(G.]7_&\Z%Y1!&]1!B44?F,C8O%%"W[/2:H]@KC&$;(_3("A1\+%
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M9)]JF<) B7HZ9Q(X6\_W.*UQ@(__G,\#VZ$"\<8N%\V*5>ZF9LCT=)O")YI
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M7&+)G5R&1<BRMHJR@"N.(;B]1![JHU[J424^?[C:)NW1[DJ&!SC\Z&KKS]R
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MY232OU!5A44>$8G#B-B^)*(H5D0<R;_:="R$5(I/IDJ1PR BI(2$YRHI])A
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M5N?G5H!41Z-6$,J0"0T4 W^2*<3P=.1V79(0:RT9<F^E#\3P!BG9 #$@!FA
M# /'*2DQ#)B2!JP6D+<$'9DP0#&  ']R5$WY)T\Y)SII;+;U2!Y8DM!QDRGY
M)&*0"5JR+#M#*&YE7"NA0I*U,8UB2>06_VX;V9 3QVS[$HF'-%R^U28] QTD
M:#@CDT"MQ6KY)F^N]%Q!)#X>:#GJ(FQ&)S,O5T'Q8S([TEL=Z5="HUSY!X6@
M-$(+YT&(]3!RU2.98Q+F8C+/83&5&$_KE8E91U)41''GI7$647/.)E:5]4E=
M D<0*4B0V3#)%5S?\YDSY":@\B[Y<D,M=W1/\46("5P?1XF/>%X2(4\*,U;Q
MQB6>9G5_6(.FY#%R15YC=45\A!$0Z#%ILIOK6)[F*8K1T(LNUG=9\W>K:';N
M>8M^ES7RJ35VX!?&U(N)<6.@P >6<4QF-W=5,V-8HW=8$QKYE#R#]WO8L6>:
M9X^)YDV2,XWX1&(:BM9YRM@6S;%(V+@4I[-.DM=0C%.ALG>0['2-V^)=776>
M+-JB+OJB2:,/32:-0,8ZR=A2)")\>;$=[/1[- IZS<AFWZ&C@]60$"@25H12
M=,8:-;I[[H@[!GD:1/":=>AGF_\S'RFB1((U<6T26V5Y+2C8;QZS1:%B+&L5
M:P=P7-Q92$F)*8:"*3&0!C2A%=$P"0X0 T>%IE 9 YH@0]! #&D0:^ES T[2
ME4_X1:"@E+]V1J>R,P5!#.F#?GDZJ80ZJ&) 7^J2A&>H#&D E;&6IY,@A0EQ
M "H)E4ZBDH;"IR]16*XV/E[*21PG<E]G1X?D%??W)<+6</$R(?RR1:TV,S72
M*RYG+0 I;[>E,A?)<T!#<=@9+E$!5#>C1X"U)D1S0OR7@W4H/C&2J1)(/A0D
M@A!CA5B'2P=F/087F8S$7MYS?U\I,-8:F L8JT?7:I:W%9B6/3N$$S/X14+4
M2=OC)B3_Q"J=M&Z>:3UE5#+?XIF) C_*.J>#%#).Y#$[4[ " RU)L5-R^2F0
MLJ),=$CBLW0<*AX<=(-2HPR:, R:,)-K@9*GZFO3 Z,P&[,,4:!D,W>GR)[*
MA#5:\QDW^YZ-D34JYK,"VG>\N+,\%I]B<QFO2(O+^(SO2")OUE"BQQ^"TQ<*
MLHTB\E'>N&9[@Z&Q5V1M\9H\18XYPJ3Y6**:-[43:AH+L9?RY$<R&[=R.[=T
MZQ;WN*1-MJ1(EH\%J1T8!7R+1J$%Z62"BWALH4))2C@6$@T$*:* HY!\0Z(2
MZB%UJ"+EP4+S09BLF2PI6HCR0X79N2AKE9BXDD*_>EU->6US__DBT* ,%]AK
M> J[F*)67:(/G5JI<)J[B (1F> D>3HGDYH)5%<AO#9 @9(J^7*%,M&[D9J[
MJ>N4<"H#/M")! ,K"=-63T*I3BD&LA62;]J\?Z*R6HI'#T@O\69K<^0^&.1%
M/;=NN)2(WV*K-1)J4R:LE3NZ16.P#3B87^1G.;2$]U<O7YI=/[-6&:,N[C<S
MPVHS6Z(N%QNP&"M4Y#D]+%1)WII7W<:Z&N.J6=2E;]AJJ21SK$I=TRE8M4E4
M"T=Q=])P77IILF1SAMA$#EFN6-4C^G,3+#AU#8,NY*>:1Z$K2H6)G\*$.#-@
MK>:VO<,I^9*K(!D\35A^$L<]I&DJD/\H0]TS/_Z2L+?Y-,K@IHB2%O.7/CA
MJ)E2MV:<COO9=YYQ8YE1&32FM,RD8\@TH#D;=Q4F8SP;8_I)-5YC33K[BJ#@
M->K9-6ISML5A>%V[CX!+>7P!?(B6MOOH-K*''>]4CG*H7Q?!4A4E'/M49;.7
M3H[[9'H9'3.5A6=\RJB<RN@H&DKF-_^1M13E&]T$.41J%P2)R&8+R:$\N))K
M46M!)@QI+PX!@:^W>>K$>TVZMJ]3!&I94BSRLI&FO]HF/Q3)1S%2E>OE@0IQ
M)_Q%6*)E*G#*K,57*A>(*6*@"9] #)K0J6&" YJP,9/PJ?*<IP]D.'+R)#?0
ME7.*DGDZ##3_J0FQ1I2JA&EP FG8JSYF42-O\">!<A:2)<48P6MA(@-HH DG
MJPG6A@/<2\7[ +N"JKL!,ZRLLIFT BL46)M-Q<.EM87#F=)?\IB5>\+ZDEFI
M,D.)J+#&E5F.:C*G573/"D,'A#"3F5U'4S.$R& @=R[8NDF/]+$-=G$E]W$6
M))P!PRX7S(3]0YT*G":-Z%BDA75YQ#V?9'[X]:VQ K&AAIL8;"H<*BRO*8=/
MK828-CZ@DB:,Y2,C#3&39JLER86"Y,V_J<*K^UPWC#],*(BVN56_^K\A1S2'
M.M4C"['41:SP99%/4\Y/TM!H(=$W, :9  J 2E6J/-IC!W<ZJ[-P_Y?:IPV@
MU;3:?A>T-189A0%C>?S&OPACI9 9T+1WE/$8?^&@RF=H3H9GBN87B*9/W"BU
M@9MGU3$XO>E' 7NW"BF/5QNE0*8\&C"V4P9*I-W=WOW=%*8/Q[@ZM2-Z. JX
MR;B,BJS+;A:.RAT;;-$[[9<BC99\C@O+"KK>X-C>D;,!2.H[*=(B1[%_A9C!
M+Z?"SN)?WYQ>O+4FG[):Z->)+(2 F((#_APM,S'&,K"3624OMRL##^30)Y&
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M=&[_K.2 0Y1)>VN9_WA">SL[HPU(89M7'@[C:?GPCIIB'N8X^JEMCV5*E@V
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MWGBTB?XE8B)!)DV4LY8./\3&' 6*&S=)R9;023B%R9I]]I9F-G*T*42Q[TC
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MX7G5?;,SGX3BRM5O;>E960+AB@R+UDI=:DH/=!>I@+BME[Y'B.MB4C:56+^
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M]BAD-6P.)VD%(ST2B%@+1V9O1"8Z\F;KHB0C^"D;EBEDLG'-HBT6%%6%=46
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M]Y([FA)&RT94!S<0OY)^9#0J\3-H_L,M,T0HO0)\/RAPX98@K@-(*K5&[1-
MW@AJ0?4[HS<E960P<B8PEW&-F6%3[S-ON\>0^J%4-5A:^3%<>O1JT'*1975
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M8Y&9>K+-:Y_ F+77JQ2Q2)+/.Y+K*[(5V8_*Z1^V6* "&1!;S$=]W$=^[$?
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M4*P55S:IA-+0,)=LM5?[0](&1 0-7^F/58*J0/\TT"Q!U2E-__AK%+0.F"8
M0M"!_Y,2 #= P @]BCGEX9H!#YBD#/(/@BCTU07]1R9\A4M?#_G>#&E80QO>
M$(<YU.$.<[@,"#[+3;=*8?YR9:4VM0E_ 402"W?5)E2]*G\:[))^\"+"^$2$
M:_10A@E7%2U5L?"$4%Q4D] TIB(8JSU?(8@:L^>3N*WN+F-)#MDH4J#4-<58
M5//:0)+6G*\E!2SVBDZ\&(8P;:E-=Z,S3 AEDIV>'*Q/[GD;VS;B'J"T[#UQ
MPXG&>-8[N=@N+B4CFTA@QIN],(R-9A%;6\C3EM2Q;F>F+(O)H@,=HT2'-TQ3
MERK7MB=Y@65V3 -)*]'R+;/ "Y5;>?_93-;CQGU1K"S1B>-B:+F7AB7'+E I
MUTC<:!5X>?,I@@0,61JCD(&8Y)PHZR1ANBF6>G7'*Y(*SC;WT1G ,:YNJM&,
M;1ZCA!#(AC:/$UP_\\8:T$Q&,R98'.'P"1E_[HTVD<E;"&@ST25$=#22.0UM
M6LF8DEW'(8SI5^[V];NJY&QI\V0E[3:)+906Y)HBPR,=D8(<\91$(CV;V-%>
M0JUR?:Y:9('+, /C2-_\DG7=(T:!_',#IQKH!C@@1GZ4(08#,:]X4^7A5KG:
M5:^*ZD?JHY\=3-$^%YGB?"5"T5@_@58=^6BM+Z(1BX04HB*Z2H$E-&(1O=BD
M+<T)5LKZ(:__*,@E!WH01'WE(@7U"J5D"5%:$L(BH![RIXHLHXN*2A6=9*5$
M9TD)G?#2B6490JFOGA:UJ57M:EG;6JYJ%E&<?6P0'9BH5&V ""&B1P O>*<,
MWK970SP2L/ #$BR&3#AP88@R+'BD"<IV559Z;@6GA)AF8L2ZVML9PQ*FNNC,
MD1[C.HOK#JE+K>1%F16!VAJCHDU,@FYWR!3*(H^INHV1K6T/<20=T_:>GQGR
M6H6T"'CR)<]M+2TND@3.SJ@SRVQF!">4,ICHT)BNJ22&E2H1R^K@>9+^.L5/
M9*EBR-I#.H=4)YN_68I%TG)3F;1D/'#,W7B9.=.+W5(I#>,->EF'_Q%1>G,\
M.UL=+0]"WN]@>(Z*:0M1(0R?>H'G7&-!"GWD\S6RR"U?]<!;W4Y0T846+C66
MB2AG+!KFA@[NS)&)C=]>$[C7&+2AFIGH9W0W8YS6%%Q5HW$N0Z<P;$[,D"5^
MRB4?DA=8DDV]W?+E-NG5S=DI1&V?5)G%N.NG3M9W96PY5B)AMTB><$\3:4"#
M#' @ S2, 7L1T@0:BH<#Z;D6UK&6M0[I)SX8S144]IN1CLX7)+B.CT>[EE&/
M>J1;*:(P5[WE+76AV*5"$?=#]1"3J[YTV,VJ,(B'RFV(?-O<)F9;@)_-TK8C
MQ)8XLE,@^DB@"0?;Q%L),%F!=:Z1*@E#SD+U9M;YUO>^^=UO?^,0&H6R-A%G
M"T15/=97220XG@8^1E9UMMF.5:R7]&,L8KE$C6[DDQ+KY$0T_9#:S)[5Q9.S
M%HO_E6I=,0G:7U3F-FP5Z,]'UN.?;%+3K41%/)N$J>ENZFB2!D8K%5$D2-79
M2IC4N.:%[F11JKQ*TDEEFP?YW;Z:DQYDAC+(CR+9? 6YW/%43'1?BZ?82C;,
M>269/DJ1W(I7\K/?$2LN<GO;B#<6L_DV&BWQPNF)E9R=2&YL/:J3V]+V!&)K
MM<?/Z6;P+3T*GR3W-_"?W!=/]<Y*0>(EG3633E Y5W.I <HZ5FM:+F_ST,P$
MU,R@$>AM7).W+ZLFHJ7I<N,,-^>!VLWVHCD]FO-6F%..!Y8RG;3DJP-4B4 S
M\^>I"Q__&$-Z"09C?$P..7/)<TK/]\;;L3 PA9X8EJ^$_VLUYD[*8?IO\Y\?
M_17"]?S0Q_X2N3](ZQ]V_-L_?_B[7T0N(K;ZVC=6\9'U_VX$?7[-1U0DK59D
M338KY#*KW89(4$;DMJ +Y.8-KY!-N$)$VL1M60XNVVR+@>Y$3R#")$804@(E
M KV- 5=EN@QK3D:KDEB'+DPK_6:0!FO0!F\PUFSEKC HML8HB'[0X+X$VCH$
M&H@$33Y.2J+K!"U0N-*$W.Y#C93K9J[%6#R" ^FDL03KKE2PA&JFM*1&0$H%
MT32FO:0">$Y)'P[@0(:%,6SJ+#JM88XF\+2"T=0.SU)G.'0J#Q^IDW;I)BA,
MCT:P6'JF+CZ,*7P);9CLG RMY?_>(YT<R;1@1CLL3&NL@^FHKBS0<,=FKI1
MAN6^Q?,*B?F>PQ!!C\ "+-T$C';<IJ?T#KUZXNB4QM+,\&(HIY'B9J>Z G98
M#,7@QB7JXL<V25ML4<B*:A9Q,=(N"ZF0+"0 IONP1>Q&[PUS9_'BRS1HKS)
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M_W0PD-A7^H-$/J1N+70#L;5BF"F)':) T"6^,UR&=KJ9&7)9=(0]L"8&N8(
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M*8[:IEKC%K!I0T=)08"Y-GDBIV#K*(Q5)JLQF!%TP6XYESUZSWCJ1V3E#+D
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M6"UCMGDCX]W[-G#'Q:;J(C;L&?+GMIWGUKVK]Z];4)B;:MB@H?7K"J]=;Z
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M4Q.YY]!.;?+4$1H.-H@##D99Y%-)8NS)8(3#Y+2/&#%,>,,P.[VG3!HW,'C
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M64<HSH5)ROY-G9 =P#;^&LG<43K%GRLIQ*<!S-V!RE:FRXA]!.Q=2I.A9%&
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M[.D"F)O \0@A(C!D48K6B-H";&\,"]<..,,45V??R2 [ O5.HB5"[$O2(/2
M]H6WP23YM/50B@Q3 ,7*Z+7'@')99:5<GJ\EV144<,PD%TF'/TGXI _)9F4I
MCVSZHF_X;OB'K_*4*DE45,66-/!=PHG3W*\Q.XV7@LDVR=($9Q-DK0__)!;-
M2#9G((I9U#).]"JS$$+_/&HYD18OAQ9>UL4GY#BS;@N& 3F0!7F0"3EF4*TW
M-;.AGB6@S.]KY 6D2@W]D$F<9A/8NJR-84VB,JXK3VZJ= T%C18%VZ\$B>DL
MP28;61 =_V/S/=DS1R$UZ#AB[H PM=+&<VL-1%0JPR1H2&102?*M"GVB+2TQ
M$S=X>:C'$I<HO_!1K0P,X.[.@8VK[U3*08=D[Z0M1/60;YN7#%'9;N!-CL1M
M.N2'-]XB-S2NOOI6;P8R(!6ON*KT@>=-O\(M@GF9[Y"H,=KQ*PBH1^ZMIC#O
M/#G$4KUQ; ]O[UH921E,!Q/FB'1+@M#P2H).XSIN;9F7%,L#BOZ"0?5-1A!Q
M<%-H&D'(/2XD?<TK0U+H[=9C?S\H0,QWZ[XT2]DN/W)Q%W5Q/R8$Z2H+=+1(
M27(W>5ED\Y[92+#MG,4-A#MTC'P:P_B&H#-QL+IP;*(N/XUY;?\"6C+&B)T$
M6%-U1*C8,S7A*7MHXB&WI(7"I(\*.9!CB?AFF(>/U2DA98>'3,AT+XK?VH@1
M*<8RQ5@Z!55&19)BS%4T)2J73(DK)5MYA5Y_S%U5LI+\^H@UB;#Q1 -)F?V<
M]@$OQFN\S_YRR9\4N6!#;0.1I<N(5J <$)$I%C&?Q4U*LS0MXGJ[*&C2.)&Y
M;-4LF]=T!M_J M+*]JQYN[=]^[>!.YCO$FRAEELBMK+I4FF->XRUII1=MHP=
MTTO<ZJH!<PJ_0\OL<FCU,I1?-KLW !+3R),#R9H5%WD N#1:@H!%M>FT$'B!
M:G@1N*(-C&ZN1[ET,&V12JEH,D&#.E3_2<2E$@^,^@U)"X_=PE.HHRC?KDAM
MY_9N1Y%'X"@@KZ3;.C<'1<2O]@'T4&.G1'B+E(N!\K%YT:JQ$$SQ9/>_XWMY
M#->+,GIW7W1\*B\RNDB6C3!S*4JBN[="-U0Y %R=:7"+>%D[7J0+E6? D@NY
MLF1UN2D](\S1S$A/$5P1-2[K[E>]NNNEU0,*V$[K]M>D2]JEP=RD;RBEK[R\
MN+2E0V!MK&W9$"=&M%#'7X2V&'?! UJ! [(SEEF")>-TZZ:!%-AC<FJSWK!#
MSI.V/K4TV&V+CO=ZP1-"@SF$X^F RB1,*$.LMT1]@KMG.6F(@87Y]-K%EN_%
M@F^P\;I8)@74_U<EE7H868[5*HTLL9DR**N5^G(,LN_$^)8O)2_)BK7U4D#%
MU+.5D=SUUX>%4LK% M5X8$D0V;$FF,:2MN.%,+NXC._,^A19V5TV_#HJS])2
M3,C-.R#'.[(6CP_6LN<2. /FU>1E;0*-0/\XT^$]WN5]W@D0U;C= 8_[N3US
M W)S5KRIG,[]-X=;8)G[E)D&V:[[ SG/:ERVC;66N4EY7X1M%A&>A&&FR5FD
M\X"N"D&&(V)$#(<$".4+;>+0&Z4->DWBOJAH;I2$J.)M[BZ8<1GZB#2QX%8*
MIPT.#_-+#T<#G%44>Q_#NIDD@OI74"<Z%/L&O])6L_Z91XF'?7#@ /]VPGP:
M:,35BD5L)#V5%'.C!%(S=:GWW+T +S8:^&Y>UZ$#7'!9^>](/&_(4!33B9WY
MU$A/1$D6&JCSAD<%[ZN2Y49]^N8FT7BM8MT<UXR"GG<KPA9C^KFJ'(2ZG+NJ
M"Z3#_#U8&DL97WVQ;D*V=/%Q\4X1.IIK/IJ5''+RCB>&Y*9(?'E>:A:G3>N5
MYT3664INRL31RO0-^@JK/DMD=^XD=Z(Y;QWW,"NLK4.NR)U&+$W$)'L\K$M>
M]0WHW35C:95T$BCAVO6 N%T7R=;M!)(,J=<S:5!"R?>D'_NI?Y$>A91>)=9+
MY1.8;]3U9/TA)?@@:?FF,OV#+_ZUOTYFUK/_0_;9 4+#!@T""Q8<6+#"08,#
M-^Q["#&BQ(D4]S5D2/#B0H0*#1KLJ!'D1@T*&U8\B7+?0HP4+B)\N; EP9(9
M1XY$2##E0VC1]"WSJ:]GSY_+5,)<B=,E08P7:1Y5*E F0J'[H-6+5@]:U:W*
M='K]"C:LV+%DRYH]BS:MVK5LV[I]"S>NW+ETZ]HM&ZTFQKT@*=B$.E D8+\F
MU];;*#-F0\)ZE09N/'-EXL(4K4:CMX_H/GH]KV(FNG?#Y)JB<8I<>!HUY(-
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M*1;94Y'9Q+5:T&C$U-JK*;[T7T179&M[<G;%>6;0\%QYZ$<[A;9&4!=E56O
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MMRG\>>Q]N#$7+[@=N/BIOX//1RX_YW+<K#&+_U>>OAZT[>"3#JCB +0..IX
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M-)_D\$<?YXP!!VI;G(^U:<&3G$@<W:S0//YVW-%'V[ ,CTQD81L=5JJ<S?S
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M:O\PK+)X!NLGE)Y6>>R Q@FV5D8@-0?-,M'^*FV3;D[[:*=[;M!0<]A.A2N
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M6?27^.S%T*?RT;$B&EJ/*).E4H.??1&84@T,6CPU6PR]6)2:^)^OPT!5J.N
MOP"6+]V8Q5([B=_RU0EB@6G)Q%9S8XAU_#$C6M^X-KU0M4N-8K6"-F&=QWZI
M:[QUHNH?(/8)'+AO6<%]T?9!4XB07C2'^C1HV"!Q(@6*%"=JS$CQHD2,'S>&
MY#@RY$:'!Z'56Z@RH3*",&/*G$FSILV;.'/2)'8#1R:=0(,*'4JTJ-&C2),J
M7<JTJ=.G4*/&C.8Q9 63(C66U)HU8]>*("DR_4A!:]BO9[UN\*C6)$FS$\>V
M_>IV*TBS9>^NO2MR \UE^AY&TU=/L,/_P_M>*FM+\2K:JGJMTN5+<D.1@OH
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MWN\%7\STWK@D"Z3(06B"J&-+C0ITC*3YB?KC&U]ES,M$F8$MU_.]3/55&K3
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M_2&&4B6$$TM+)XHQ'NE)%>_)).T.92346.\V;_>V;UN0TX$M'/_7=J7LB6Z
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M#\+-,92]<: ;SY0/\I8'*IT95R-<V: E#Y_K6V*Z(FZ5*=!\IKMA)I@+?BL
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MPK-3UHYC?X$=U#NHV"5XJ@WT('KY@75"Q?BC&_/J;9.F+C]7F'B+PYK O#?
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MW,5=6KU-!L(EVKCE2<\=W,]M6LIEVKA5*'_%VKH=W;KMT<?UUZDU7+=-6IE
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M?"P#,HD!242#,KR![,F3>OA*S]E2CF#1&\I .]XCE<D>_(@!#1J:*29?##0
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MVSP8[E6$8W)GH+]?+D_S@<.HO!*\CTN$&9(KQ+\\ZC8$*3'_C)1@Y8FC>41
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MR)LT=,7J#QOP1KM6";^3/<_3/9T)P3/-&5F9GIZ%%#@A$ #[D#[!*YKHM1Q
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M9N=XI\0'Y7+(&N.-L:<BGVIJ\\SSO3M\T6R<,?,95YW[]MQW[_WWX(<O?D7
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MFRCY$3G1/\L EH%AF:_&2: #C9F3G@(ZH 0::7TDFN956K+U*$<"&;(U.-$
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M5*4\!B:R=,=<TX;)*9<&K;+!CLA/:J9PD>/(O!S-TIRC"NI1LRK%M<5X-AA
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M]CQ.)-T40FS-0QO!9TSK#VCMC-_VQ/;>Y*T "#1GP@6=U>%>3^AD#!_M0NO
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*B4^,XA2#)B  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118410352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AbCellera Biologics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2215 Yukon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V5Y 0A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">559-9005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, no par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABCL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,728,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001703057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741116545120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 193,017<span></span>
</td>
<td class="nump">$ 386,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">603,478<span></span>
</td>
<td class="nump">499,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_CashCashEquivalentsAndMarketableSecurities', window );">Total cash, cash equivalents, and marketable securities</a></td>
<td class="nump">796,495<span></span>
</td>
<td class="nump">886,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_AccountsAndAccruedReceivableCurrent', window );">Accounts and accrued receivable</a></td>
<td class="nump">20,003<span></span>
</td>
<td class="nump">38,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">99,155<span></span>
</td>
<td class="nump">75,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">940,653<span></span>
</td>
<td class="nump">1,025,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">233,187<span></span>
</td>
<td class="nump">217,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">128,845<span></span>
</td>
<td class="nump">131,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">47,806<span></span>
</td>
<td class="nump">47,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and loans to equity accounted investees</a></td>
<td class="nump">57,583<span></span>
</td>
<td class="nump">72,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">89,845<span></span>
</td>
<td class="nump">46,331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">557,266<span></span>
</td>
<td class="nump">515,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,497,919<span></span>
</td>
<td class="nump">1,540,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">31,814<span></span>
</td>
<td class="nump">33,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration payable</a></td>
<td class="nump">42,876<span></span>
</td>
<td class="nump">44,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties payable</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="nump">19,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">11,807<span></span>
</td>
<td class="nump">21,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">89,591<span></span>
</td>
<td class="nump">118,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">77,265<span></span>
</td>
<td class="nump">76,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">25,416<span></span>
</td>
<td class="nump">19,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_DeferredGrantsFundingNoncurrent', window );">Deferred grant funding</a></td>
<td class="nump">45,026<span></span>
</td>
<td class="nump">40,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">15,733<span></span>
</td>
<td class="nump">16,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">33,426<span></span>
</td>
<td class="nump">33,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,962<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">199,828<span></span>
</td>
<td class="nump">189,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">289,419<span></span>
</td>
<td class="nump">307,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value (USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares: no par value, unlimited authorized shares at December&#160;31, 2022 and March&#160;31, 2023: 286,851,595 and 288,426,514 shares issued and outstanding at December&#160;31, 2022 and March&#160;31, 2023, respectively</a></td>
<td class="nump">$ 742,816<span></span>
</td>
<td class="nump">$ 734,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">81,630<span></span>
</td>
<td class="nump">74,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss)</a></td>
<td class="num">(2,021)<span></span>
</td>
<td class="num">(1,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated earnings</a></td>
<td class="nump">386,075<span></span>
</td>
<td class="nump">426,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">1,208,500<span></span>
</td>
<td class="nump">1,233,277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 1,497,919<span></span>
</td>
<td class="nump">$ 1,540,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_AccountsAndAccruedReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts and accrued receivable, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_AccountsAndAccruedReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash cash Equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_DeferredGrantsFundingNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grants Funding Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_DeferredGrantsFundingNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118304880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">286,851,595<span></span>
</td>
<td class="nump">288,426,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">286,851,595<span></span>
</td>
<td class="nump">288,426,514<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741116868160">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,192<span></span>
</td>
<td class="nump">$ 316,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,647<span></span>
</td>
<td class="nump">26,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,134<span></span>
</td>
<td class="nump">14,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,514<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,066<span></span>
</td>
<td class="nump">91,631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(64,874)<span></span>
</td>
<td class="nump">224,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,759)<span></span>
</td>
<td class="num">(665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_GrantsAndIncentives', window );">Grants and incentives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(5,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,593)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,726)<span></span>
</td>
<td class="num">(5,859)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net earnings (loss) before income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48,148)<span></span>
</td>
<td class="nump">230,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (recovery) expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,038)<span></span>
</td>
<td class="nump">62,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,110)<span></span>
</td>
<td class="nump">168,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(630)<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (40,740)<span></span>
</td>
<td class="nump">$ 169,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287,767,136<span></span>
</td>
<td class="nump">283,895,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">287,767,136<span></span>
</td>
<td class="nump">311,482,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abcl_ResearchFeesMember', window );">Research fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,570<span></span>
</td>
<td class="nump">$ 9,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">372<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abcl_MilestonePaymentsMember', window );">Milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 307,017<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Exclusive of depreciation and amortization</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_GrantsAndIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants and Incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_GrantsAndIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abcl_ResearchFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abcl_ResearchFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abcl_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abcl_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741113819024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,257,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balances at Dec. 31, 2021</a></td>
<td class="nump">$ 1,025,733<span></span>
</td>
<td class="nump">$ 722,430<span></span>
</td>
<td class="nump">$ 35,357<span></span>
</td>
<td class="nump">$ 267,666<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised', window );">Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised', window );">Shares issued and restricted stock units ("RSUs") vested under stock option plan</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">$ 3,325<span></span>
</td>
<td class="num">(2,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">12,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings (loss)</a></td>
<td class="nump">168,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balances (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,521,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balances at Mar. 31, 2022</a></td>
<td class="nump">1,207,507<span></span>
</td>
<td class="nump">$ 725,755<span></span>
</td>
<td class="nump">44,726<span></span>
</td>
<td class="nump">436,239<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,851,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balances at Dec. 31, 2022</a></td>
<td class="nump">1,233,277<span></span>
</td>
<td class="nump">$ 734,365<span></span>
</td>
<td class="nump">74,118<span></span>
</td>
<td class="nump">426,185<span></span>
</td>
<td class="num">(1,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised', window );">Shares issued and restricted stock units ("RSUs") vested under stock option plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,574,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised', window );">Shares issued and restricted stock units ("RSUs") vested under stock option plan</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">$ 8,451<span></span>
</td>
<td class="num">(7,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">15,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings (loss)</a></td>
<td class="num">(40,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balances (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,426,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balances at Mar. 31, 2023</a></td>
<td class="nump">$ 1,208,500<span></span>
</td>
<td class="nump">$ 742,816<span></span>
</td>
<td class="nump">$ 81,630<span></span>
</td>
<td class="nump">$ 386,075<span></span>
</td>
<td class="num">$ (2,021)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued and Restricted Stock Units vested during period shares stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued and Restricted Stock Units vested during period value stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741113798944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings (loss)</a></td>
<td class="num">$ (40,110)<span></span>
</td>
<td class="nump">$ 168,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">2,656<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,474<span></span>
</td>
<td class="nump">12,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(3,634)<span></span>
</td>
<td class="num">(592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts and accrued research fees receivable</a></td>
<td class="nump">7,915<span></span>
</td>
<td class="num">(8,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable', window );">Accrued royalties receivable</a></td>
<td class="nump">9,260<span></span>
</td>
<td class="num">(167,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(12,614)<span></span>
</td>
<td class="nump">69,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(5,778)<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(3,905)<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Accrued royalties payable</a></td>
<td class="num">(16,253)<span></span>
</td>
<td class="nump">22,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_IncreaseDecreaseInDeferredGrantIncome', window );">Deferred grant revenue</a></td>
<td class="nump">4,525<span></span>
</td>
<td class="nump">4,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(6,063)<span></span>
</td>
<td class="num">(7,557)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(44,063)<span></span>
</td>
<td class="nump">100,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14,984)<span></span>
</td>
<td class="num">(14,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(360,752)<span></span>
</td>
<td class="num">(51,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from marketable securities</a></td>
<td class="nump">262,638<span></span>
</td>
<td class="nump">57,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_ProceedsFromReceiptOfGrantFunding', window );">Receipt of grant funding</a></td>
<td class="nump">2,693<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets', window );">Long-term investments and other assets</a></td>
<td class="num">(34,735)<span></span>
</td>
<td class="num">(11,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investment in and loans to equity accounted investees</a></td>
<td class="num">(4,469)<span></span>
</td>
<td class="num">(8,335)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(149,609)<span></span>
</td>
<td class="num">(26,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration', window );">Payment of liability for in-licensing agreement and contingent consideration</a></td>
<td class="num">(948)<span></span>
</td>
<td class="num">(5,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_ProceedsFromDebtAndExerciseOfStockOptions', window );">Proceeds from long-term debt and exercise of stock options</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(458)<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(194,343)<span></span>
</td>
<td class="nump">70,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">414,650<span></span>
</td>
<td class="nump">501,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">220,307<span></span>
</td>
<td class="nump">571,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown on the balance sheet</a></td>
<td class="nump">218,017<span></span>
</td>
<td class="nump">570,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable', window );">Property and equipment in accounts payable</a></td>
<td class="nump">8,918<span></span>
</td>
<td class="nump">2,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation', window );">Right-of-use assets obtained in exchange for operating lease obligation</a></td>
<td class="nump">$ 2,124<span></span>
</td>
<td class="nump">$ 658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued royalties receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_IncreaseDecreaseInDeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_IncreaseDecreaseInDeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash or part non cash acquisition property and equipment purchases in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire long-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_ProceedsFromDebtAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from debt and exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_ProceedsFromDebtAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_ProceedsFromReceiptOfGrantFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from receipt of grant funding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_ProceedsFromReceiptOfGrantFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of long-term debt and contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118819456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of operations</a></td>
<td class="text">Nature of operationsAbCellera Biologics Inc.&#8217;s (the &#8220;Company&#8221;) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741122284048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of presentation</a></td>
<td class="text">Basis of presentation<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March&#160;31, 2022 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to &#8220;$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; and &#8220;CAD&#8221; are to Canadian dollars.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118677216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text">Significant accounting policies <div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741119640592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net earnings (loss) per share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net earnings (loss) per share</a></td>
<td class="text">Net earnings (loss) per share<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) attributable to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,895,020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287,767,136</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net earnings (loss) per share attributable to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(0.14)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) attributable to common shareholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,895,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287,767,136</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,586,997</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">311,482,017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287,767,136</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net earnings (loss) per share attributable to common shareholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(0.14)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potentially dilutive securities, which include stock options and restricted share units (&#8220;RSUs&#8221;), have been excluded from the computation of diluted net loss per share for the three months ended March&#160;31, 2023 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March&#160;31, 2023 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded 2,974,052 and 50,844,425 potential common shares for the three months ended March&#160;31, 2022 and March&#160;31, 2023, respectively, from the computation of diluted net earnings (loss) per share attributable to common shareholders because including them would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741122212112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text">Property and equipment, net<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,405</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,493</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,936</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,800</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,356</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">235,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254,520</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,475)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,333)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and March&#160;31, 2023, leasehold improvements include tenant improvements in progress that have not commenced depreciation in the amount of $25.6 million and $38.9 million, respectively.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Depreciation expense on property and equipment for the three months ended March&#160;31, 2022, and 2023 was $1.4 million and $2.9 million, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118845408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible assets</a></td>
<td class="text">Intangible assets<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118677216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in and loans to equity accounted investees, and other long-term assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in and loans to equity accounted investees, and other long-term assets</a></td>
<td class="text">Investments in and loans to equity accounted investees, and other long-term assets<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of future office and laboratory headquarters. To date, the Company has recorded immaterial amounts of proportionate income or loss with respect to either venture.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dayhu JV</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). As of March&#160;31, 2023, the equity investment balance was $41.3&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March, 2021, the Company made a commitment of up to CAD $82.7&#160;million ($61.2&#160;million at March&#160;31, 2023) to the Dayhu JV (Dayhu JV Loan) to fund the construction at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loan is secured by the underlying land and future assets of the Dayhu JV. At December&#160;31, 2022, and March&#160;31, 2023, the outstanding related party loan balance was $38.1&#160;million and nil, respectively, to the Dayhu JV.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, the Company entered into an agreement of up to CAD $46.0&#160;million ($34.0&#160;million at March&#160;31, 2023) with Dayhu (New Dayhu Loan) to replace Dayhu&#8217;s portion of the outstanding Dayhu JV Loan balance as at January 1, 2023, at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement. The agreement has a maturity of December 31, 2025, with a call provision, callable by the Company after September 30, 2023, including customary make whole provisions. The loan is secured by the underlying land and existing and future assets of the Dayhu JV. In January 2023, the Company issued CAD $46.0&#160;million ($34.0&#160;million at March&#160;31, 2023) to Dayhu from the New Dayhu loan, which was used to repay, in part, Dayhu&#8217;s 50% portion of the Dayhu JV Loan. At March&#160;31, 2023, the loan balance was $34.0&#160;million and is included in other long-term assets. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beedie JV</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March, 2021, the Company entered into the Beedie joint venture (Beedie JV). As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the equity investment balance was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.3&#160;million. </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, the Company made a commitment to our partner Beedie for a land loan of up to CAD $7.5&#160;million (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$5.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> at March&#160;31, 2023) plus a construction loan for up to 80% of Beedie&#8217;s share of construction costs. The commitment is at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement of the construction loan and</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the Beedie JV. The loan receivable balance, which was solely related to the land loan to date, was CAD $7.5&#160;million (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$5.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> as at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and is included in other long-term assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741206247888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_CurrentAssetsAndLiabilitiesTextBlock', window );">Current assets and liabilities</a></td>
<td class="text">Current assets and liabilities<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax deposits and receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,155&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of deferred grant funding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_CurrentAssetsAndLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_CurrentAssetsAndLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118739024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' equity</a></td>
<td class="text">Shareholders&#8217; equity<div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity under the Pre-IPO Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average&#160;Exercise<br/>Price&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,694,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,087,171)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,606,979</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,079,568</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity under the 2020 Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,322,933</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,617,638</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(136,180)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,804,391</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,881,278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.61&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSU activity under the 2020 Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,946,985</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,065,110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and settled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(487,748)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(91,292)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,433,055</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the number of shares available for issuance under the 2020 Plan was 33,217,073, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation:</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:71.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741122286512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaggregated revenue categories are presented on the face of the condensed consolidated statements of income (loss) and comprehensive income (loss).</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue outstanding in each respective period is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022 and 2023, the Company recognized $2.7&#160;million and $4.8 million, respectively, of revenue that had been included in deferred revenue in the previous year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118838096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial instruments</a></td>
<td class="text">Financial instruments <div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, loans to equity accounted investees, accounts payable and accrued liabilities and royalties payable, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, royalties payable, lo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ans receivable, and loans to equity accounted investees approximate their fair values, and primarily classified as level 2. At March&#160;31, 2023, the Company also held non-marketable securities included in other long term assets of $29.7&#160;million (December&#160;31, 2022 - $18.5&#160;million). </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the liability for contingent consideration:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>beginning of<br/>the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase (decrease) in fair<br/>value of liability for contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>end of the<br/>period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni (i)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TetraGenetics (ii)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>beginning of<br/>the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase (decrease) in fair<br/>value of liability for contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>end of the<br/>period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni (i)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TetraGenetics (ii)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.9pt">The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.13pt">The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 10.7%, the rate that measures the risks inherent in the future cash flows.</span></div><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company&#8217;s current operations.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at March 31, 2023:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118788336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">Commitments and contingencies<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three months ended March&#160;31, 2022 and March&#160;31, 2023, $44.6&#160;million and nil was expensed related to such obligations, and $19.3&#160;million and $3.1&#160;million was included in current liabilities as of December&#160;31, 2022 and March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred expenditures of $46.1&#160;million and $38.8&#160;million under phase 1 and 2, respectively, under the Canadian government&#8217;s Strategic Innovation Fund, or SIF. Spending under phase 1 of the agreement and such amounts are not repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of March&#160;31, 2023, no amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118292944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">Basis of presentation<div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March&#160;31, 2022 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2022.</span></div>All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to &#8220;$&#8221; are to U.S. dollars and references to &#8220;C$&#8221; and &#8220;CAD&#8221; are to Canadian dollars<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements not yet adopted</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741119640592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net earnings (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) attributable to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,895,020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287,767,136</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net earnings (loss) per share attributable to common shareholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(0.14)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net earnings (loss) attributable to common shareholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283,895,020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287,767,136</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,586,997</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">311,482,017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287,767,136</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net earnings (loss) per share attributable to common shareholders - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">0.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(0.14)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741120986048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,405</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,493</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,936</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,800</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,356</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">235,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254,520</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,475)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,333)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217,255&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233,187&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118965840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net book<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,845&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Amortization Expense on Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization<br/>Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118727376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax deposits and receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,155&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Other Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of deferred grant funding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741116841216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity under the Pre-IPO Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average&#160;Exercise<br/>Price&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,694,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,087,171)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,606,979</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,079,568</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.73&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity under the 2020 Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,322,933</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,617,638</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(136,180)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,804,391</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,881,278</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.61&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Share Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s RSU activity under the 2020 Plan since December&#160;31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average Grant<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,946,985</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,065,110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and settled</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(487,748)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(91,292)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,433,055</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:71.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,291&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741119225872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Deferred Revenue Outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue outstanding in each respective period is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118727504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Fair Value of Liability for Contingent Consideration</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the liability for contingent consideration:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>beginning of<br/>the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase (decrease) in fair<br/>value of liability for contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>end of the<br/>period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni (i)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TetraGenetics (ii)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>beginning of<br/>the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Increase (decrease) in fair<br/>value of liability for contingent<br/>consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability at<br/>end of the<br/>period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trianni (i)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,602)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TetraGenetics (ii)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.9pt">The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.13pt">The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 10.7%, the rate that measures the risks inherent in the future cash flows.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at March 31, 2023:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government agencies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">603,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741113764000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net earnings (loss) per share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net earnings (loss) attributable to common shareholders - basic</a></td>
<td class="num">$ (40,110)<span></span>
</td>
<td class="nump">$ 168,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">287,767,136<span></span>
</td>
<td class="nump">283,895,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net earnings (loss) attributable to common shareholders - diluted</a></td>
<td class="num">$ (40,110)<span></span>
</td>
<td class="nump">$ 168,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">287,767,136<span></span>
</td>
<td class="nump">283,895,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and RSUs (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,586,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">287,767,136<span></span>
</td>
<td class="nump">311,482,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118677744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net earnings (loss) per share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded</a></td>
<td class="nump">2,974,052<span></span>
</td>
<td class="nump">50,844,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118456832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 254,520<span></span>
</td>
<td class="nump">$ 235,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(21,333)<span></span>
</td>
<td class="num">(18,475)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">233,187<span></span>
</td>
<td class="nump">217,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">8,530<span></span>
</td>
<td class="nump">8,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">53,405<span></span>
</td>
<td class="nump">53,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">17,493<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">45,936<span></span>
</td>
<td class="nump">41,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">47,800<span></span>
</td>
<td class="nump">40,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_OperatingLeaseRightOfUseAssetsMember', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 81,356<span></span>
</td>
<td class="nump">$ 80,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_OperatingLeaseRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abcl_OperatingLeaseRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741119178912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements include tenant improvements</a></td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense on property and equipment</a></td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741112566832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 154,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">25,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net book value</a></td>
<td class="nump">128,845<span></span>
</td>
<td class="nump">$ 131,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abcl_LicenseBasedIntangibleAssetsMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">37,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">19,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net book value</a></td>
<td class="nump">18,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">52,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">5,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net book value</a></td>
<td class="nump">46,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">64,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net book value</a></td>
<td class="nump">$ 64,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abcl_LicenseBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=abcl_LicenseBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741112708192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 10,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets amortization expense</a></td>
<td class="nump">$ 27,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741117215280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in and loans to equity accounted investees, and other long-term assets - Additional Information (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>jointVenture</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($) </div>
<div>jointVenture</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_NumberOfJointVentures', window );">Number of joint ventures | jointVenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember', window );">Dayhu JV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments, ownership percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Equity investment balance, contributions made in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember', window );">Dayhu JV | Daylu JV Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan', window );">Equity method investment, outstanding related party loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember', window );">Dayhu JV | New Daylu Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_EquityMethodInvestmentCommitmentAmount', window );">Equity method investment, commitment amount</a></td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_PercentageOfConstructionLoan', window );">Percentage of construction loan</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember', window );">Dayhu JV | Maximum | Daylu JV Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_EquityMethodInvestmentCommitmentAmount', window );">Equity method investment, commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.2<span></span>
</td>
<td class="nump">$ 82.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember', window );">Dayhu JV | Maximum | New Daylu Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_EquityMethodInvestmentCommitmentAmount', window );">Equity method investment, commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember', window );">Dayhu JV | Minimum | New Daylu Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_EquityMethodInvestmentCommitmentAmount', window );">Equity method investment, commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_BeedieJointVentureMember', window );">Beedie JV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investments, ownership percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Equity investment balance, contributions made in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_BeedieJointVentureMember', window );">Beedie JV | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_EquityMethodInvestmentCommitmentAmount', window );">Equity method investment, commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_PercentageOfConstructionLoan', window );">Percentage of construction loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_EquityMethodInvestmentCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_EquityMethodInvestmentCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity method investment, outstanding related party loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_NumberOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of joint ventures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_NumberOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_PercentageOfConstructionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of construction loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_PercentageOfConstructionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_DayhuJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abcl_DayluJVLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abcl_DayluJVLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abcl_NewDayluLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abcl_NewDayluLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_BeedieJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abcl_BeedieJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741113802288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current assets and liabilities - Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Tax deposits and receivables</a></td>
<td class="nump">$ 79,566<span></span>
</td>
<td class="nump">$ 64,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_PrepaidExpenseAndOtherCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">18,142<span></span>
</td>
<td class="nump">9,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_MaterialsAndSuppliesCurrent', window );">Materials and supplies</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 99,155<span></span>
</td>
<td class="nump">$ 75,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_MaterialsAndSuppliesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Materials And Supplies Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_MaterialsAndSuppliesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_PrepaidExpenseAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expense And Other Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_PrepaidExpenseAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741112566704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current assets and liabilities - Schedule of Accounts Payable and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 17,569<span></span>
</td>
<td class="nump">$ 14,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="nump">5,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll liabilities</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">6,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_DeferredGrantFundingCurrent', window );">Current portion of deferred grant funding</a></td>
<td class="nump">6,585<span></span>
</td>
<td class="nump">6,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accounts payable and other liabilities</a></td>
<td class="nump">$ 31,814<span></span>
</td>
<td class="nump">$ 33,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred grant funding current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741116893120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abcl_PreInitialPublicOfferingPlanMember', window );">Pre-IPO Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">33,694,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised (in shares) | shares</a></td>
<td class="num">(1,087,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">32,606,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options exercisable as of March 31, 2022 (in shares) | shares</a></td>
<td class="nump">24,079,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercisable as of March 31, 2023 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember', window );">2020 Share Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">12,322,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted (in shares) | shares</a></td>
<td class="nump">1,617,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, forfeited (in shares) | shares</a></td>
<td class="num">(136,180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">13,804,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options exercisable as of March 31, 2022 (in shares) | shares</a></td>
<td class="nump">2,881,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">13.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">14.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercisable as of March 31, 2023 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abcl_PreInitialPublicOfferingPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abcl_PreInitialPublicOfferingPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741116884560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Summary of Restricted Share Units Activity (Details) - 2020 Share Option and Incentive Plan - Restricted Share Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Beginning Balance (in shares) | shares</a></td>
<td class="nump">3,946,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted (in shares) | shares</a></td>
<td class="nump">1,065,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested and settled (in shares) | shares</a></td>
<td class="num">(487,748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited (in shares) | shares</a></td>
<td class="num">(91,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Ending Balance (in shares) | shares</a></td>
<td class="nump">4,433,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested and settled (in dollars per share) | $ / shares</a></td>
<td class="nump">14.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">13.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118207152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember', window );">2020 Share Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for issuance (in shares)</a></td>
<td class="nump">33,217,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118231808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' equity - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 15,474<span></span>
</td>
<td class="nump">$ 12,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,496<span></span>
</td>
<td class="nump">5,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,707<span></span>
</td>
<td class="nump">$ 5,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741119642672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue - Summary of Deferred Revenue Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 37,223<span></span>
</td>
<td class="nump">$ 41,128<span></span>
</td>
<td class="nump">$ 35,861<span></span>
</td>
<td class="nump">$ 34,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741117034320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 37,223<span></span>
</td>
<td class="nump">$ 35,861<span></span>
</td>
<td class="nump">$ 41,128<span></span>
</td>
<td class="nump">$ 34,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability, revenue recognized</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741113753904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Non-marketable securities</a></td>
<td class="nump">$ 29.7<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741113736256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abcl_TrianniMember', window );">Trianni | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abcl_TetraGeneticMember', window );">TetraGenetics | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=abcl_ContingentConsiderationMember', window );">Contingent Consideration | Level 3 | Trianni</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 23,505<span></span>
</td>
<td class="nump">$ 22,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase (decrease) in fair value of liability for contingent consideration</a></td>
<td class="num">(2,602)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability at end of the period</a></td>
<td class="nump">20,903<span></span>
</td>
<td class="nump">22,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=abcl_ContingentConsiderationMember', window );">Contingent Consideration | Level 3 | TetraGenetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability at beginning of the period</a></td>
<td class="nump">36,760<span></span>
</td>
<td class="nump">35,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Increase (decrease) in fair value of liability for contingent consideration</a></td>
<td class="nump">946<span></span>
</td>
<td class="num">(698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Liability at end of the period</a></td>
<td class="nump">$ 37,706<span></span>
</td>
<td class="nump">$ 35,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abcl_TrianniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abcl_TrianniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abcl_TetraGeneticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abcl_TetraGeneticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=abcl_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=abcl_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741112933136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value Measurements on Recurring Basis - Marketable Securities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 603,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">108,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">260,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">68,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">21,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">108,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">108,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificate of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">495,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificate of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">260,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">68,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">21,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | US Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificate of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">144,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">144,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=abcl_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=abcl_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139741118312768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_CommitmentsContingenciesAndOtherLineItems', window );"><strong>Commitments Contingencies And Other [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 44,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseOneMember', window );">Phase 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_CommitmentsContingenciesAndOtherLineItems', window );"><strong>Commitments Contingencies And Other [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_StrategicInnovationFundEligibleExpenditure', window );">Strategic innovation fund eligible expenditure</a></td>
<td class="nump">46,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseTwoMember', window );">Phase 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_CommitmentsContingenciesAndOtherLineItems', window );"><strong>Commitments Contingencies And Other [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_StrategicInnovationFundEligibleExpenditure', window );">Strategic innovation fund eligible expenditure</a></td>
<td class="nump">38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=abcl_AccruedRoyaltiesPayableMember', window );">Accrued Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_abcl_CommitmentsContingenciesAndOtherLineItems', window );"><strong>Commitments Contingencies And Other [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty fees</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_CommitmentsContingenciesAndOtherLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments Contingencies And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_CommitmentsContingenciesAndOtherLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abcl_StrategicInnovationFundEligibleExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic innovation fund eligible expenditure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abcl_StrategicInnovationFundEligibleExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abcl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abcl_PhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=abcl_AccruedRoyaltiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=abcl_AccruedRoyaltiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>abcl-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abcl="http://www.abcellera.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abcl-20230331.xsd" xlink:type="simple"/>
    <context id="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia1073262526243f4a574de999c567cbb_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i737052aafe7343188b2138b8a10bd9ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iafcf79187f5d43869ccc9becf7aeccc4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:ResearchFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5c835c1ffc64e5f833ad6c4e166b620_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:ResearchFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i483c9c91d20d4152999b9b47124960fa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf11690d32474d71aec19ceb33d3618d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab73ed844c554fa19226ae861475ca07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5bf0bf68b36f4153b40b11c6cbdcbeb0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abcl:MilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5b1eb70ee5544c889039a3a33f6a3ca1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic70268a9464e4e829f619d4233df421f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbafe87c3597488486483c87064dca70_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i248effdeb0124e28aff3eb04055b2003_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac2aa801be5c4f8790c550d3f085d3f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2795c9a5ca65468f89a3330586c261c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8f8fc50fe69495fbd3d33c5d2974485_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9aa34c517e046d7ab19dbcb1dd308f2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i780148e6ee1845b8ae18bb190fa364c0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iba57c3ec41b7436fa87687bff535045e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i78911cd59bb34e02911e888b48446aaa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb4c8a76d406402399f79719acbd035e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d27bab226214438b0d7f573c20ee26e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idea9ff625cec4672a5d93fbfed8791f3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i96ea95c9d57e45c98f3caedf608c417f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0decdf41be2e4a30ae97c1a91fa5b593_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d6682fd53d24996a9444b260c02f16e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95249fd386d947d39d33c4ef4a83d14e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i861d96426dca41259dd492868210425f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6732b5466cb84d3c9b86f94b68a032d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ae52bf585f2406684f9101c92e3ed0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i82fb29d006754942a2f5913a08541ed7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i91864d811230449ab2c770081bffde09_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a2304c602314a149a3829e4bb16839d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i63526f8d447e49f5851992c00795cb56_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c1534cce0324615ba2ea393852c6c61_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9615a195ad1a4b138c452ec64af6a8b7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e59f6941600414cacd5ce35743135eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4889d91d341e4ab8b818801f569b0d96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42a0bae74c9743ff8ff66ad8ff963146_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6139469318d432e82d6baefdf566dce_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i12e371e7d54148dbba3063693fd8a2d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e470366e74a442c8d52acc2a9f1b5f5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iabf93e4e7dd64c7e839faca3ad8410d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i406b6a1622cd4dff99832c9462b6e4a7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e1c38a1157c413c866c668dd92b9a77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d27a736c37340be83efab3ba99a8bc0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic9c66215525a40069a548e7bd3025c84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a403b1fa38d47ada5644a9f4c1fff58_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i853afd911efa4258a08a6952094096cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7d0ae58e07dc4eb983249c3c61c1ad45_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abcl:OperatingLeaseRightOfUseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if039c44ad3504f63aa1ec431499bafec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">abcl:LicenseBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5caae842c49f4155ad44dff34efdb797_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia507651da5b4472a9bda28dcdad3b575_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0148f1e33c6b4510b7104f707a9f1015_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i73a7c5f735ad47f2ad483da48085449d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic7dd7959a16f4e469b26e2d1a0a91144_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6bfea07b5a744d6596d3882f182d5906_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f5e482b7eb34446b5095f10b3fbcd1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47a8affab5e347a4b46782717c4df146_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:DayluJVLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifcee6e4ab663465bac83ebdfecfc71e5_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:NewDayluLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:NewDayluLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9d3ffacd78e54c008bb62a070d409d8e_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:DayhuJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abcl:NewDayluLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="ib925185cbb614e71b24a62dc39dc9707_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4bb8630f96284448a0ad62c00db72975_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9a27eee6bb20488893688edd304543db_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abcl:BeedieJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i21720092b1fd485a91d701040dc8eaf4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:PreInitialPublicOfferingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:PreInitialPublicOfferingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7615a3703fc444c5bf358dc8748655b8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:PreInitialPublicOfferingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89a61c2a4c454272afe77744cf55c9ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2858e48f05f04827941d142a021d6fad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2f5814bf79942159d756fd4d496dc6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01e64126d887401289c5b361c74b08f7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b5c3602feb942b29d99d1347ccefffa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abcl:TwoThousandTwentyShareOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib4cf5d989e9741afb07a70513b1e2a5b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c4fd149aa8c46f3800472cd46fa49e2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7d7c7469d9e04930b97b96e58ef2f063_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if605d90125084846a2a1044b2692e5de_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic528446a6c1c4f6d8b57c3c9e62fb472_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3bf8dcc696b24c26bf569ab099f74655_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib84a76c6a7d040048417a102641bdd98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22756f6454b64f73afb36c0c807ea9d5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5df4d4b94b884162a2e0a0a1c655b8a8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29a81d06f8df44d5835bbc3c04f6a927_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5b507a22fd14249969fb3270137dd02_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i974a95ee817c4dfaa7fe8e4fd9971189_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i38c6977e90834eb3bd8b3526452e9e35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1de9aa8ab44841868c7d65c602095235_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i87414b0fe0f34080ae5ec5e948eafda6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia2d15a4aeba64cd299c7371834bb7abf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i441987f8eb1e43f5b29f11eb02f70403_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie9ad3bc7b19842bea7e2bec41c9cce9d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">abcl:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2f397da2a35b4cce8dcf8e1c494f9789_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TrianniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4cae519cf0de46818efc75457121e175_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abcl:TetraGeneticMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3827504d1bb4416a966243425ee8a0f6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id80012107add40658f9e2fb319a4e721_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6c929c76a9ad4321bf79186a9b2ab1dc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c4ad46a8dd94eaa84a356553b207755_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8aad9e0f529743d0a71e223bfe29146f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibfb27a06184e4e31aef700c5aeb48dca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide7ef1452afe4c4580b20216f9d426d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i35bb901c7d87467e8fac6a7c4651c882_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifa9fc66c28764293b5cdc58bd4e86731_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie292ab553fbb4ec4855d3b8096d93cc7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06261a683538461bbd86190f85931bf5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie5785a70c9934456af3fe1177ffc0ee5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i303bc5d507cc4c54a23fba781ae5f340_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icac73633a71d4e618363eb56e2a3a253_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6594a7d2aa24288ab622eea92cdeba3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieb33227ca5de4db4a6b3eb5329ce0367_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i886bb35d7ce64dcb868325a77ed5372c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifea3fcbfe06448049f8dbed1665c5eac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1548cfd0b12440e2824883003e410515_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i820f7b961f97462e883d5674468dcf5b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ied7de4ead6ad466a85824c3b11e8d10c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9b8461fe0bdb4ab585ffcc851e599cee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iabc26d6dc7a2499380b2727bb7a926fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb56c4d8b7ae4aaca71bb026b154f0b8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">abcl:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5f895582ef4c48da9ac1da31b476fc7f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abcl:AccruedRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib92c33e75ce64416b44d79aa0e9d2f2a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">abcl:AccruedRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if4d9776d15fb44e9aa31ce79baa8cec0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abcl:PhaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic267a77a490446c98ef71777d2d5ff57_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001703057</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abcl:PhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="jointventure">
        <measure>abcl:jointVenture</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF8yLTEtMS0xLTYyNQ_b2b453e9-0c10-47bf-96a7-544e598e5e19">0001703057</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF8zLTEtMS0xLTYyNQ_b7bf18f5-7b0b-48ad-a5df-a2c93ad3a5d4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF80LTEtMS0xLTYyNQ_fdbc682c-f528-4104-9c05-390df847fc71">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF81LTEtMS0xLTYyNQ_19964943-ceda-47f0-a707-0f5b8653709b">2023</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80L2ZyYWc6Y2NhNGY2ZTYwMWU0NDRiZGEyZmYwMjQxZjRiMzAzMTEvdGFibGU6YTAyOWI3YTI1MmM3NDk1YjlmZTBmNTZiNGI5OTE2MGQvdGFibGVyYW5nZTphMDI5YjdhMjUyYzc0OTViOWZlMGY1NmI0Yjk5MTYwZF82LTEtMS0xLTYyNQ_114cdad7-b9c9-467d-8d57-f9eb840ecad5">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE1_5b45b7bc-860b-4bcc-97f0-43a3a4460617">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6NjNkNDg2OGQ2ZWRhNGYwMWEwYWI2ZTQyNWI5ZDBkOWEvdGFibGVyYW5nZTo2M2Q0ODY4ZDZlZGE0ZjAxYTBhYjZlNDI1YjlkMGQ5YV8wLTAtMS0xLTYyNQ_1e3383b3-6555-49df-920b-2493c83221b6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yNDk_718873a8-bb64-4971-867c-60d18c9ca4eb">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6M2M4N2JlNWVmNzllNDM3YTkwZThjZDA2YTk0N2E5NzcvdGFibGVyYW5nZTozYzg3YmU1ZWY3OWU0MzdhOTBlOGNkMDZhOTQ3YTk3N18wLTAtMS0xLTYyNQ_9b25f04d-4cbf-4b5e-926d-3f55070b0356">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE2_38c692a2-10e2-41be-9d19-eaf25b3fb71f">001-39781</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE3_c7c29ff3-2075-4428-9b04-a4d196e136f3">AbCellera Biologics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8wLTAtMS0xLTYyNQ_3e6eb76b-498e-4de3-b677-f1e9daf5b653">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTAtMS0xLTYyNS90ZXh0cmVnaW9uOmExODQ0ZGE0NTc3NDRlZWU4YjM4NjVlZDFiMjAzMDU5XzQ_ba197f2f-16ba-4af8-83ec-fedd033f221f">2215 Yukon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTAtMS0xLTYyNS90ZXh0cmVnaW9uOmExODQ0ZGE0NTc3NDRlZWU4YjM4NjVlZDFiMjAzMDU5Xzc_27c22b4d-f530-43b1-ac1d-c53e099c0ded">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTAtMS0xLTYyNS90ZXh0cmVnaW9uOmExODQ0ZGE0NTc3NDRlZWU4YjM4NjVlZDFiMjAzMDU5XzEx_d3a3c69a-640f-4a62-b427-30eff0d84f14">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6ZGI1NTRlMjJmMGExNGViMzg2ODMzZWMxYzIwN2U5ODIvdGFibGVyYW5nZTpkYjU1NGUyMmYwYTE0ZWIzODY4MzNlYzFjMjA3ZTk4Ml8yLTEtMS0xLTYyNQ_eae27411-50d0-4348-8110-840ab8d2d517">V5Y 0A1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N181OTY_d9c3bfc9-cffc-4ee1-95e9-7154b726f9b9">604</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N182MDA_dd9d44e5-bf67-4224-8bd5-b29edbfa2185">559-9005</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OWEzYzlhYzIyYWZjNGFiMGE0NWVjMWI1NjA3MTFkZGUvdGFibGVyYW5nZTo5YTNjOWFjMjJhZmM0YWIwYTQ1ZWMxYjU2MDcxMWRkZV8xLTAtMS0xLTYyNQ_ab2eaccb-1710-46ba-8702-6bf6c210ecbf">Common shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OWEzYzlhYzIyYWZjNGFiMGE0NWVjMWI1NjA3MTFkZGUvdGFibGVyYW5nZTo5YTNjOWFjMjJhZmM0YWIwYTQ1ZWMxYjU2MDcxMWRkZV8xLTItMS0xLTYyNQ_4e5eee13-ca07-458f-82b6-894278fb8912">ABCL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OWEzYzlhYzIyYWZjNGFiMGE0NWVjMWI1NjA3MTFkZGUvdGFibGVyYW5nZTo5YTNjOWFjMjJhZmM0YWIwYTQ1ZWMxYjU2MDcxMWRkZV8xLTQtMS0xLTYyNQ_6dfecf6b-99bd-44bd-a741-e50659c2ad93">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE4_c08931df-369e-4889-8d72-95aad4088170">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMjE5_0005fa26-89d8-4de2-a6dd-b78b2e71ac65">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OTliZWY2MmE0ZWZjNDQzYjk0YjI0ZWNiOTFkYzQ0NjQvdGFibGVyYW5nZTo5OWJlZjYyYTRlZmM0NDNiOTRiMjRlY2I5MWRjNDQ2NF8wLTAtMS0xLTYyNQ_64fe6f41-0b74-4e20-b964-cb847a34a916">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OTliZWY2MmE0ZWZjNDQzYjk0YjI0ZWNiOTFkYzQ0NjQvdGFibGVyYW5nZTo5OWJlZjYyYTRlZmM0NDNiOTRiMjRlY2I5MWRjNDQ2NF8yLTQtMS0xLTYyNQ_dcc8d324-dc54-4e18-bb90-b5b07b103590">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGFibGU6OTliZWY2MmE0ZWZjNDQzYjk0YjI0ZWNiOTFkYzQ0NjQvdGFibGVyYW5nZTo5OWJlZjYyYTRlZmM0NDNiOTRiMjRlY2I5MWRjNDQ2NF80LTEtMS0xLTYyNQ_55e2041c-14ff-49a5-87ab-fd1d71124d16">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18zODQ4MjkwNjk5NTA1_870d3e27-57ad-4ef7-9d50-8f9e5875fb5b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia1073262526243f4a574de999c567cbb_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xL2ZyYWc6YjFlYWYwZGZkNzRmNGE4YmEzYTJmNGQxOTUwZDkzNjcvdGV4dHJlZ2lvbjpiMWVhZjBkZmQ3NGY0YThiYTNhMmY0ZDE5NTBkOTM2N18yMTU3_9a781f27-76e5-4ea7-8d2c-8bb35743a5c4"
      unitRef="shares">288728094</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMy0xLTEtMS02MjU_0e58cdc8-330a-46a7-ba20-e2ee3c9a16f5"
      unitRef="usd">386535000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMy0zLTEtMS02MjU_12d79a0b-7bab-4a1d-b43b-0b140936c32a"
      unitRef="usd">193017000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNC0xLTEtMS02MjU_d80ab5ce-0408-4686-8c1c-babb33c3e580"
      unitRef="usd">499950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNC0zLTEtMS02MjU_cf018f7f-e8aa-4dfc-b48b-9d526f0b4c22"
      unitRef="usd">603478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <abcl:CashCashEquivalentsAndMarketableSecurities
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNS0xLTEtMS02MjU_39a91533-fb46-43b2-95b4-88d49ec8aa2d"
      unitRef="usd">886485000</abcl:CashCashEquivalentsAndMarketableSecurities>
    <abcl:CashCashEquivalentsAndMarketableSecurities
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNS0zLTEtMS02MjU_ac271066-30c2-45f9-992d-d6d8b68f078e"
      unitRef="usd">796495000</abcl:CashCashEquivalentsAndMarketableSecurities>
    <abcl:AccountsAndAccruedReceivableCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNi0xLTEtMS02MjU_ab3a7b97-c6c2-45e3-9023-7204a663e8cc"
      unitRef="usd">38593000</abcl:AccountsAndAccruedReceivableCurrent>
    <abcl:AccountsAndAccruedReceivableCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNi0zLTEtMS02MjU_a4bc73f7-694e-4688-b370-4b00448540d3"
      unitRef="usd">20003000</abcl:AccountsAndAccruedReceivableCurrent>
    <us-gaap:RestrictedCash
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNy0xLTEtMS02MjU_419536ad-a200-4352-9185-6488e1bc9db1"
      unitRef="usd">25000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNy0zLTEtMS02MjU_0da087ef-22c3-42c7-93ee-82cd41524ead"
      unitRef="usd">25000000</us-gaap:RestrictedCash>
    <us-gaap:OtherAssetsCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOC0xLTEtMS02MjU_fa7fa2bf-4fdf-426e-99d7-32c26393d560"
      unitRef="usd">75413000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOC0zLTEtMS02MjU_fbd6a14c-5198-42dd-b562-f82e911b6ed9"
      unitRef="usd">99155000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOS0xLTEtMS02MjU_d30a375b-af10-4a60-96dd-3a4e5db7d5c7"
      unitRef="usd">1025491000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfOS0zLTEtMS02MjU_b43eabbd-12cc-4c51-9a14-e0253ba8ad3c"
      unitRef="usd">940653000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTEtMS0xLTEtNjI1_b9d384b5-de7b-4a81-9fdf-d4d014afe829"
      unitRef="usd">217255000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTEtMy0xLTEtNjI1_1778a8a9-2c42-4b1b-9dc6-cda366d8924d"
      unitRef="usd">233187000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTItMS0xLTEtNjI1_8cb7eff9-b5f4-4fb0-9fae-7e20078f2937"
      unitRef="usd">131502000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTItMy0xLTEtNjI1_0396c864-5b0a-41be-bce6-03804c66e14b"
      unitRef="usd">128845000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTMtMS0xLTEtNjI1_84347aff-4ebf-404e-8101-849393567df3"
      unitRef="usd">47806000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTMtMy0xLTEtNjI1_b102d6ea-2601-4c96-ab01-897ff156125d"
      unitRef="usd">47806000</us-gaap:Goodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTQtMS0xLTEtNjI1_a6c5f204-905f-42c5-85ce-96f5bce7a06b"
      unitRef="usd">72522000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTQtMy0xLTEtNjI1_48afe048-d9aa-4ef0-a191-8df1fe803c8c"
      unitRef="usd">57583000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTUtMS0xLTEtNjI1_db21ba93-a88b-4c6a-a784-2b23ddb9dc5a"
      unitRef="usd">46331000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTUtMy0xLTEtNjI1_6e3a1949-09bd-431c-84a4-89d5c5c4f7ae"
      unitRef="usd">89845000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTYtMS0xLTEtNjI1_6eea3e16-304f-4df4-a990-3dae7c1657f6"
      unitRef="usd">515416000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTYtMy0xLTEtNjI1_2b524ce1-38f3-4c78-b1a3-fc407b261925"
      unitRef="usd">557266000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTctMS0xLTEtNjI1_98919697-e5b4-4d15-ad0b-0670baf1ab71"
      unitRef="usd">1540907000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMTctMy0xLTEtNjI1_f7d24a67-b034-4133-88fd-88d005a2ad8e"
      unitRef="usd">1497919000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjAtMS0xLTEtNjI1_f6844eee-eb19-408b-9560-51c0a78c268c"
      unitRef="usd">33150000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjAtMy0xLTEtNjI1_115372f9-fe9e-4c18-b8a7-52d544869747"
      unitRef="usd">31814000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjEtMS0xLTEtNjI1_9dae4a5d-a3f2-4984-9880-32d36f848fec"
      unitRef="usd">44211000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjEtMy0xLTEtNjI1_ce8d693f-d291-4f5e-bac2-3d3a9e4347f7"
      unitRef="usd">42876000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjMtMS0xLTEtNjI1_dc09315c-f4c7-48d9-a1b5-92001aaa1f52"
      unitRef="usd">19347000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjMtMy0xLTEtNjI1_0a67d608-1cce-4dd1-941b-8f086ab2742b"
      unitRef="usd">3094000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjQtMS0xLTEtNjI1_ed733309-04d8-4e76-8ef5-739d19fe0f6c"
      unitRef="usd">21612000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjQtMy0xLTEtNjI1_ebacd8e5-1e8e-4ddb-8e9f-8f03758025b1"
      unitRef="usd">11807000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjUtMS0xLTEtNjI1_28d00cf4-aa68-4993-846d-579775117fbd"
      unitRef="usd">118320000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjUtMy0xLTEtNjI1_bb6ddbf7-e295-4715-8a9f-4152f7697341"
      unitRef="usd">89591000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjctMS0xLTEtNjI1_e7c6d6dc-40a1-4686-835e-d99e2d941d0f"
      unitRef="usd">76675000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjctMy0xLTEtNjI1_92534478-23a9-4ec3-8d46-b987959aa60b"
      unitRef="usd">77265000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjgtMS0xLTEtNjI1_d967712f-656a-4d72-a188-44bfd509b35a"
      unitRef="usd">19516000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjgtMy0xLTEtNjI1_9b3d020d-c863-4152-b42d-e84012336c56"
      unitRef="usd">25416000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <abcl:DeferredGrantsFundingNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjktMS0xLTEtNjI1_49cab5ed-b9e4-4e1f-a6a9-9d362cfefbe6"
      unitRef="usd">40801000</abcl:DeferredGrantsFundingNoncurrent>
    <abcl:DeferredGrantsFundingNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMjktMy0xLTEtNjI1_b20c8aba-337b-45a8-994e-582f069c91cf"
      unitRef="usd">45026000</abcl:DeferredGrantsFundingNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzAtMS0xLTEtNjI1_c2fda527-00a2-42b3-8cde-397d6ff59a49"
      unitRef="usd">16054000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzAtMy0xLTEtNjI1_5de7e296-10c8-4bcb-9b76-6b152870229c"
      unitRef="usd">15733000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzEtMS0xLTEtNjI1_2e99db13-2978-48bf-9505-f3cb2bee2873"
      unitRef="usd">33178000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzEtMy0xLTEtNjI1_58d7c1b2-fe7d-4ecb-9a9f-5e74f5450ee8"
      unitRef="usd">33426000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzItMS0xLTEtNjI1_9f77d2c7-1877-477a-8ab1-bfa7778bb05f"
      unitRef="usd">3086000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzItMy0xLTEtNjI1_6be13418-bf5c-4cf8-9bf6-12c148c164f4"
      unitRef="usd">2962000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzMtMS0xLTEtNjI1_94480b82-7fee-487b-993c-c87370b01ed1"
      unitRef="usd">189310000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzMtMy0xLTEtNjI1_4ae6d5b5-26f7-43dc-8ea4-ee020dca22c8"
      unitRef="usd">199828000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzQtMS0xLTEtNjI1_02559a2d-f448-40f5-ad39-50ab5076cab4"
      unitRef="usd">307630000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzQtMy0xLTEtNjI1_95faedd3-4170-4c16-98d3-a7fa5eee5e57"
      unitRef="usd">289419000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzUtMS0xLTEtNDY3Mw_4fc660bb-dacb-4bc3-a9b0-58793f405f9c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzUtMy0xLTEtNDY3Mw_93ff381f-2943-43e7-af0e-770ac7470da1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MjM0_884a9f86-0396-4948-8c45-2629c662dc38"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MjM0_c2d7fd58-55d4-4f9c-9855-1430d7c93975"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTYz_a4669c9b-bb03-4b2f-b241-d879dcd4d34a"
      unitRef="shares">286851595</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTYz_b10a30c7-9e7e-4ee6-8ac8-0f2a53ab9a81"
      unitRef="shares">286851595</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTc5_1a371ae5-813d-4b75-9227-a9f9a84eab6f"
      unitRef="shares">288426514</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMC0xLTEtNjI1L3RleHRyZWdpb246NzcxNTViNGNlOWY0NGRmYmIxMjQwZTEwODUwNDcwYTZfNTQ5NzU1ODE0MTc5_1f87a6a4-c2e3-47dd-b753-7c52b82db2cf"
      unitRef="shares">288426514</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMS0xLTEtNjI1_bd6e2ad0-7df0-4b2b-8631-88827e0b19e2"
      unitRef="usd">734365000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzctMy0xLTEtNjI1_1fdad94b-1233-48a3-82ed-b254e9dcdba9"
      unitRef="usd">742816000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzgtMS0xLTEtNjI1_60593a9d-9e16-43ea-a1ca-00cb03b553d8"
      unitRef="usd">74118000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzgtMy0xLTEtNjI1_c3a40283-dc65-45a2-bbc2-585da673d93d"
      unitRef="usd">81630000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzktMS0xLTEtNjI1_6f6e83f0-0326-40dd-803b-3033d88e24bd"
      unitRef="usd">-1391000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfMzktMy0xLTEtNjI1_c20ba869-7abc-4396-9cfe-9e88fa62c51c"
      unitRef="usd">-2021000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDAtMS0xLTEtNjI1_15fca4f0-ef8c-4dd8-96cb-3fbe1a4e5019"
      unitRef="usd">426185000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDAtMy0xLTEtNjI1_9eedcebd-7fe7-49e7-90a0-b0734a268b3b"
      unitRef="usd">386075000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDEtMS0xLTEtNjI1_46afdf34-f475-476e-8be4-017ca5d95a2d"
      unitRef="usd">1233277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDEtMy0xLTEtNjI1_9ee26a98-16b8-49b9-958f-47dcf5393dae"
      unitRef="usd">1208500000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDItMS0xLTEtNDY2MQ_de5ec490-f127-4ed1-a67f-233434edf517"
      unitRef="usd">1540907000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8xOS9mcmFnOjczOTQ4YmRhODIzZTRmZTJhMzE0MGE4NmQyMTQ0MjYwL3RhYmxlOmI0ZmNjNThlZTk0ZjQxNzY4NzgxMWRiYTg4NDdhYTc4L3RhYmxlcmFuZ2U6YjRmY2M1OGVlOTRmNDE3Njg3ODExZGJhODg0N2FhNzhfNDItMy0xLTEtNDY2MQ_50126fff-a672-432e-ac39-c9bfd55bbeee"
      unitRef="usd">1497919000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafcf79187f5d43869ccc9becf7aeccc4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMy0yLTEtMS01Mjcy_fac34c1e-6792-4ee5-8c73-ab347c7876a5"
      unitRef="usd">9333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5c835c1ffc64e5f833ad6c4e166b620_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMy00LTEtMS01Mjcy_9d298a08-2321-41c1-8cc1-cba6a8897629"
      unitRef="usd">10570000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i483c9c91d20d4152999b9b47124960fa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNC0yLTEtMS01Mjcy_0c803a73-d319-4751-84c8-b016f2e94986"
      unitRef="usd">231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf11690d32474d71aec19ceb33d3618d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNC00LTEtMS01Mjcy_85f4c81e-01c6-4334-a66b-b24d731849ed"
      unitRef="usd">372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab73ed844c554fa19226ae861475ca07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNS0yLTEtMS01Mjcy_580c00e0-2738-4500-8d2e-aefc42647351"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bf0bf68b36f4153b40b11c6cbdcbeb0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNS00LTEtMS01Mjcy_c1529981-9048-4cb8-b0f1-0be74315ebc0"
      unitRef="usd">1250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b1eb70ee5544c889039a3a33f6a3ca1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNi0yLTEtMS01Mjcy_aeb439c2-526e-4044-bfac-3efd249e33f9"
      unitRef="usd">307017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic70268a9464e4e829f619d4233df421f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNi00LTEtMS01Mjcy_7c90228e-27f0-4ff2-b754-a8a2a31d166f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNy0yLTEtMS01Mjcy_31dd9b27-476a-488c-8b30-29f8be70c58e"
      unitRef="usd">316581000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfNy00LTEtMS01Mjcy_865a47b4-3d5e-4a2f-9224-885558a818f8"
      unitRef="usd">12192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RoyaltyExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfOS0yLTEtMS01Mjcy_580a4899-995b-4cbe-9180-131d7e30725c"
      unitRef="usd">44637000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfOS00LTEtMS01Mjcy_914d9c64-c2aa-41ca-8597-d81236d63383"
      unitRef="usd">0</us-gaap:RoyaltyExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtMi0xLTEtNTI3Mg_92991d6a-4576-4aff-9f76-c58a694b9f37"
      unitRef="usd">26366000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtNC0xLTEtNTI3Mg_48bb8f30-f569-41ba-a070-20906208da85"
      unitRef="usd">52647000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtMi0xLTEtNTI3Mg_03186103-5cfd-49b5-b43a-ec82449b0862"
      unitRef="usd">2370000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtNC0xLTEtNTI3Mg_8f017ef4-53a5-4490-b845-0a1c9b225309"
      unitRef="usd">3771000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItMi0xLTEtNTI3Mg_c3cf669d-13d6-4d81-b4c7-ba4c94b8ed6e"
      unitRef="usd">14268000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItNC0xLTEtNTI3Mg_24f5017c-e041-4c75-9d3a-f8174654d497"
      unitRef="usd">15134000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTMtMi0xLTEtNTI3Mg_fd98afbe-e5b5-4c56-9469-f232f76bca34"
      unitRef="usd">3990000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTMtNC0xLTEtNTI3Mg_c1b5dffc-577f-4e3a-ab33-9ddebed239f0"
      unitRef="usd">5514000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTQtMi0xLTEtNTI3Mg_741da06d-7c78-4b0f-937b-6be104dd2da0"
      unitRef="usd">91631000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTQtNC0xLTEtNTI3Mg_3f015d6b-50a8-4f8c-b84b-bd92296f9ea9"
      unitRef="usd">77066000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTUtMi0xLTEtNTI3Mg_335d98f2-f460-4c58-b733-d9745c6046db"
      unitRef="usd">224950000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTUtNC0xLTEtNTI3Mg_c2648e79-b689-48f0-902f-66ab5ae3715e"
      unitRef="usd">-64874000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctMi0xLTEtNzg1Mw_63a204c8-6df4-48b0-b854-9cdd01098186"
      unitRef="usd">665000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctNC0xLTEtNzg1Mw_da44feac-0401-4550-9175-9a1bd9610cd9"
      unitRef="usd">9759000</us-gaap:InvestmentIncomeInterest>
    <abcl:GrantsAndIncentives
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctMi0xLTEtNTI3Mg_917abbf7-cbc2-4d11-a3d5-1f3d8674021e"
      unitRef="usd">5194000</abcl:GrantsAndIncentives>
    <abcl:GrantsAndIncentives
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTctNC0xLTEtNTI3Mg_bc90a314-8457-473d-a14b-1bf426d4ad45"
      unitRef="usd">3374000</abcl:GrantsAndIncentives>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTgtMi0xLTEtNTI3Mg_b66f382e-7053-4b27-b17f-2a892a75535d"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTgtNC0xLTEtNTI3Mg_8a14ab24-714e-4264-8fa3-7f89fb937b04"
      unitRef="usd">3593000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTktMi0xLTEtNTI3Mg_12183add-9808-48de-bbd8-1c1eba3a0dc7"
      unitRef="usd">5859000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTktNC0xLTEtNTI3Mg_c2954735-6486-452c-8cc0-736df7d5e06a"
      unitRef="usd">16726000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjAtMi0xLTEtNTI3Mg_531ad2af-6dc0-4582-a1d5-20c5d1e3821e"
      unitRef="usd">230809000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjAtNC0xLTEtNTI3Mg_fe0f1eb6-0cc7-419e-bb65-49a749f5cc06"
      unitRef="usd">-48148000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjEtMi0xLTEtNTI3Mg_c5f64262-8d88-4ad0-9d04-780cadc53594"
      unitRef="usd">62236000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjEtNC0xLTEtNTI3Mg_666e06ce-0a89-4758-8349-dc7a72602340"
      unitRef="usd">-8038000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjItMi0xLTEtNTI3Mg_68c90130-cb7c-4558-966a-df057cf07255"
      unitRef="usd">168573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjItNC0xLTEtNTI3Mg_80790802-1b8e-4cac-ab86-e1d999ffb554"
      unitRef="usd">-40110000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjMtMi0xLTEtNTI3Mg_d2adac40-4760-4e85-b366-3d237b7a1e24"
      unitRef="usd">507000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjMtNC0xLTEtNTI3Mg_fdc81f18-eda5-4c29-9dc7-84fd6a11e230"
      unitRef="usd">-630000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjQtMi0xLTEtNTI3Mg_0c82c9c7-480c-49a0-a801-a9f3e62dc9a6"
      unitRef="usd">169080000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjQtNC0xLTEtNTI3Mg_750eca68-203e-4687-8e7b-80b84b27ae3f"
      unitRef="usd">-40740000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjctMi0xLTEtNTI3Mg_741c8e7b-2aef-4dd9-8069-ace3f33dca84"
      unitRef="usdPerShare">0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjctNC0xLTEtNTI3Mg_9d7bfd9e-dd6b-4296-bcae-0d54e3350fe9"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjgtMi0xLTEtNTI3Mg_1083b138-72f2-4143-9701-f826959d786b"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMjgtNC0xLTEtNTI3Mg_0783ae2e-4a34-41d4-bd46-a286880e7411"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzAtMi0xLTEtNTI3Mg_c19ad758-6c4d-4167-92bf-bbe195f7e674"
      unitRef="shares">283895020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzAtNC0xLTEtNTI3Mg_39aae419-e13d-4a91-adc3-686f3515b118"
      unitRef="shares">287767136</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzEtMi0xLTEtNTI3Mg_b77023ed-a45d-49db-a37d-09fecac467d2"
      unitRef="shares">311482017</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMzEtNC0xLTEtNTI3Mg_0b3a069a-8e4a-4a52-ac17-3243269f80fb"
      unitRef="shares">287767136</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i248effdeb0124e28aff3eb04055b2003_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtMi0xLTEtNTA5NQ_00015d0f-d349-487d-89f7-b17f9f8f4e6b"
      unitRef="shares">286851595</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i248effdeb0124e28aff3eb04055b2003_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtNC0xLTEtNTA5NQ_956d748d-c756-4b44-bdfc-e6396cd8ef26"
      unitRef="usd">734365000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac2aa801be5c4f8790c550d3f085d3f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtNi0xLTEtNTA5NQ_9962425e-d8f7-4b74-8533-02c58d8149f5"
      unitRef="usd">74118000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2795c9a5ca65468f89a3330586c261c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtOC0xLTEtNTA5NQ_97eadc34-f9b2-4f6b-9b40-9ab5b89c2769"
      unitRef="usd">426185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8f8fc50fe69495fbd3d33c5d2974485_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtMTAtMS0xLTUwOTU_feb06ef7-06fc-447c-add5-d26c4e642eda"
      unitRef="usd">-1391000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjEtMTItMS0xLTUwOTU_1d49f7ea-4aa8-43a9-acb2-0565b99817e3"
      unitRef="usd">1233277000</us-gaap:StockholdersEquity>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised
      contextRef="id9aa34c517e046d7ab19dbcb1dd308f2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItMi0xLTEtNTA5NQ_95499721-6522-450f-876a-337a7180ac80"
      unitRef="shares">1574919</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
      contextRef="id9aa34c517e046d7ab19dbcb1dd308f2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItNC0xLTEtNTA5NQ_b793a583-b87b-42c5-bbe8-1acfcb31f3b0"
      unitRef="usd">8451000</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
      contextRef="i780148e6ee1845b8ae18bb190fa364c0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItNi0xLTEtNTA5NQ_cc04ec0c-aa8e-4545-8ed8-51b6d1168067"
      unitRef="usd">-7962000</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjItMTItMS0xLTUwOTU_68226ed1-6045-445d-8e18-bd2a7dde9a6a"
      unitRef="usd">489000</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i780148e6ee1845b8ae18bb190fa364c0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjMtNi0xLTEtNTA5NQ_e329166b-4baf-41b4-9a0d-ec7ab780e61b"
      unitRef="usd">15474000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjMtMTItMS0xLTUwOTU_f10c763e-f066-4831-a82e-2eec1599c73b"
      unitRef="usd">15474000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iba57c3ec41b7436fa87687bff535045e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjQtMTAtMS0xLTUwOTU_c7a105c1-503c-428f-9d49-cb9e3272e74d"
      unitRef="usd">-630000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjQtMTItMS0xLTUwOTU_b7862502-325e-412b-a675-d46ed7448e2e"
      unitRef="usd">-630000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i78911cd59bb34e02911e888b48446aaa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjUtOC0xLTEtNTA5NQ_a4ea3288-b306-4426-ab9f-1b7a564bc1cc"
      unitRef="usd">-40110000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjUtMTItMS0xLTUwOTU_0c246bb7-9ac2-4f97-92d7-8c3046f02296"
      unitRef="usd">-40110000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifb4c8a76d406402399f79719acbd035e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtMi0xLTEtNTA5NQ_d34aa2da-74a7-4142-8d14-83aaca52ac4d"
      unitRef="shares">288426514</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifb4c8a76d406402399f79719acbd035e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtNC0xLTEtNTA5NQ_8ce9b8fe-68fa-4d87-a0cd-d9e36b514026"
      unitRef="usd">742816000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d27bab226214438b0d7f573c20ee26e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtNi0xLTEtNTA5NQ_c25760bf-8c75-43a8-82d1-4f65856d83d8"
      unitRef="usd">81630000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idea9ff625cec4672a5d93fbfed8791f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtOC0xLTEtNTA5NQ_03c5b956-4f4e-46de-82bd-527dedb044fe"
      unitRef="usd">386075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96ea95c9d57e45c98f3caedf608c417f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtMTAtMS0xLTUwOTU_ebadc842-1836-496b-8ebf-f3169c09c2f7"
      unitRef="usd">-2021000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOjgzNTQ3M2ZhODI3ZDQ1ZWM5N2IxOTVmMzlmZWNlYjcyL3RhYmxlcmFuZ2U6ODM1NDczZmE4MjdkNDVlYzk3YjE5NWYzOWZlY2ViNzJfMjYtMTItMS0xLTUwOTU_84133b7c-b0e8-4727-8d5c-66eb2e0c96e0"
      unitRef="usd">1208500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0decdf41be2e4a30ae97c1a91fa5b593_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi0yLTEtMS01MTA4_d1ec81e9-7577-4824-8bef-cd30184d2f2a"
      unitRef="shares">283257104</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0decdf41be2e4a30ae97c1a91fa5b593_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi00LTEtMS01MTA4_3ad03130-ea9a-412f-a7f4-df557e1176dd"
      unitRef="usd">722430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d6682fd53d24996a9444b260c02f16e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi02LTEtMS01MTA4_1bb021cf-6cd0-42ca-959d-c03c5ae63495"
      unitRef="usd">35357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95249fd386d947d39d33c4ef4a83d14e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi04LTEtMS01MTA4_4587e078-2731-490b-8c6e-261ec46b87e5"
      unitRef="usd">267666000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i861d96426dca41259dd492868210425f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi0xMC0xLTEtNTEwOA_901123e7-72e2-4c64-adf4-72a815bc6856"
      unitRef="usd">280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6732b5466cb84d3c9b86f94b68a032d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMi0xMi0xLTEtNTEwOA_bbbd6444-c277-49bd-8ead-2084b5212966"
      unitRef="usd">1025733000</us-gaap:StockholdersEquity>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised
      contextRef="i7ae52bf585f2406684f9101c92e3ed0d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy0yLTEtMS01MTA4_8e11c86b-0457-406f-8805-87d473c51f84"
      unitRef="shares">1264077</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
      contextRef="i7ae52bf585f2406684f9101c92e3ed0d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy00LTEtMS01MTA4_b493a189-09bf-4058-8b45-52379676a7f7"
      unitRef="usd">3325000</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
      contextRef="i82fb29d006754942a2f5913a08541ed7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy02LTEtMS01MTA4_4ded0605-2a5c-40bb-bc2a-993b901f7024"
      unitRef="usd">-2922000</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised>
    <abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfMy0xMi0xLTEtNTEwOA_3050f03d-9ee2-415c-8363-6d1644d15877"
      unitRef="usd">403000</abcl:StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i82fb29d006754942a2f5913a08541ed7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNC02LTEtMS01MTA4_dcadffff-0754-4c0c-81db-7b78ff0f66b5"
      unitRef="usd">12291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNC0xMi0xLTEtNTEwOA_07b36a4c-f021-4b77-9f1f-32d1cf41ffaa"
      unitRef="usd">12291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i91864d811230449ab2c770081bffde09_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNS0xMC0xLTEtNTEwOA_b140cb8f-b3ef-440a-9ca5-f202a9418671"
      unitRef="usd">507000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNS0xMi0xLTEtNTEwOA_83a6326c-964c-48d1-879c-35d99bb34172"
      unitRef="usd">507000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i4a2304c602314a149a3829e4bb16839d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNi04LTEtMS01MTA4_433731b5-6a60-46fa-9820-2272b047190b"
      unitRef="usd">168573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNi0xMi0xLTEtNTEwOA_f0a5445b-bcc6-4af7-9239-f719332d3c09"
      unitRef="usd">168573000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i63526f8d447e49f5851992c00795cb56_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy0yLTEtMS01MTA4_53cb90d8-7256-4853-ae23-7a2032e4e3b7"
      unitRef="shares">284521181</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i63526f8d447e49f5851992c00795cb56_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy00LTEtMS01MTA4_d0454f4a-f3a7-4979-987e-a0df4165883b"
      unitRef="usd">725755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c1534cce0324615ba2ea393852c6c61_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy02LTEtMS01MTA4_79beccd9-83c8-4a08-8e6b-51cde3836814"
      unitRef="usd">44726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9615a195ad1a4b138c452ec64af6a8b7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy04LTEtMS01MTA4_e4c40fdc-ba9e-4c0e-9249-d73b0eed61eb"
      unitRef="usd">436239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e59f6941600414cacd5ce35743135eb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy0xMC0xLTEtNTEwOA_8e399c1f-5089-4637-af33-bc5298a2df43"
      unitRef="usd">787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yOC9mcmFnOjI5ZTY2NDY5NGYwNDQ0Zjc4NTgxYjA2Nzk1NWFkMGUxL3RhYmxlOmJhZDY4ZTA3M2ZmMjRjZThhOWQ4MDEzYjAyMTNkMTM1L3RhYmxlcmFuZ2U6YmFkNjhlMDczZmYyNGNlOGE5ZDgwMTNiMDIxM2QxMzVfNy0xMi0xLTEtNTEwOA_c44b100b-1414-486a-8dd0-17485ca39672"
      unitRef="usd">1207507000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMy0xLTEtMS02MjU_c4e660bd-a726-46a7-91e8-b11a6916b51c"
      unitRef="usd">168573000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMy0zLTEtMS02MjU_216e7466-f84c-4b1f-bf6f-fb0cc0aaeaa4"
      unitRef="usd">-40110000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNS0xLTEtMS02MjU_3c729061-b185-430e-9d43-3d4e3718bda7"
      unitRef="usd">1391000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNS0zLTEtMS02MjU_71f11bcc-0aa7-4d2e-86f3-6d07d823d638"
      unitRef="usd">2858000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNi0xLTEtMS02MjU_0951a2ef-fc54-4a4e-a6df-723c0a943a1a"
      unitRef="usd">2606000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNi0zLTEtMS02MjU_48f36aa5-c4a3-4be9-b493-e1ce64c3a6b5"
      unitRef="usd">2656000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNy0xLTEtMS02MjU_d7a44ff8-b475-4222-a55d-c8a7021ba4c2"
      unitRef="usd">976000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNy0zLTEtMS02MjU_bab6f005-62df-45aa-b450-dd2c3f66b1c5"
      unitRef="usd">1606000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOC0xLTEtMS02MjU_85e0ee5c-334f-4d62-842c-5137352a54b8"
      unitRef="usd">12291000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOC0zLTEtMS02MjU_fbefb337-241d-4414-8fdd-7764a98bef93"
      unitRef="usd">15474000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOS0xLTEtMS02MjU_15b3f7dd-26fb-4de2-a404-d667aa0fa27a"
      unitRef="usd">592000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfOS0zLTEtMS02MjU_49c4b145-b2f5-4fa7-932d-1749b2add5bc"
      unitRef="usd">3634000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTEtMS0xLTEtNjI1_e064a210-1179-49d4-a500-487f5ef834f2"
      unitRef="usd">8751000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTEtMy0xLTEtNjI1_722ab953-eeea-472d-8c45-0e58a651fe2b"
      unitRef="usd">-7915000</us-gaap:IncreaseDecreaseInReceivables>
    <abcl:IncreaseDecreaseInAccruedRoyaltiesReceivable
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTItMS0xLTEtNjI1_27189963-2eb4-4bc2-8d6a-376098e4018a"
      unitRef="usd">167914000</abcl:IncreaseDecreaseInAccruedRoyaltiesReceivable>
    <abcl:IncreaseDecreaseInAccruedRoyaltiesReceivable
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTItMy0xLTEtNjI1_c3c8a1d8-bd71-4285-98b9-84055efef09e"
      unitRef="usd">-9260000</abcl:IncreaseDecreaseInAccruedRoyaltiesReceivable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTMtMS0xLTEtNjI1_9bfdd45e-59ba-4ff3-99e2-4594620c48f5"
      unitRef="usd">69965000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTMtMy0xLTEtNjI1_204a3701-cbd9-4d5e-8bc3-bc412b118521"
      unitRef="usd">-12614000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <abcl:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTQtMS0xLTEtNjI1_59e93c70-b9ad-4e3d-99b6-72f1dbce6d8c"
      unitRef="usd">751000</abcl:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable>
    <abcl:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTQtMy0xLTEtNjI1_c3ef8e9e-67da-4dd1-963f-b2b1fc231681"
      unitRef="usd">-5778000</abcl:IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTUtMS0xLTEtNjI1_db4dcd6d-edc6-48cd-b12f-9218e2dd03aa"
      unitRef="usd">941000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTUtMy0xLTEtNjI1_a49b0e2c-8947-49dc-bd14-3896b150ccf1"
      unitRef="usd">-3905000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTYtMS0xLTEtNjI1_dd256105-fa1e-4d15-8da5-41868f5a5e2f"
      unitRef="usd">22857000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTYtMy0xLTEtNjI1_35699047-1b97-4d5b-8f00-86c55a46a76b"
      unitRef="usd">-16253000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <abcl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTctMS0xLTEtNjI1_e177446f-2f62-4ad8-a3ba-416b1d4b8a46"
      unitRef="usd">-4682000</abcl:IncreaseDecreaseInDeferredGrantIncome>
    <abcl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTctMy0xLTEtNjI1_8f81397e-3991-4bc2-a440-9d658678187e"
      unitRef="usd">-4525000</abcl:IncreaseDecreaseInDeferredGrantIncome>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTgtMS0xLTEtNjI1_3d4f5b9b-5b6f-4885-991b-857b2b505b5e"
      unitRef="usd">7557000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTgtMy0xLTEtNjI1_dee06f5c-8bf7-450b-a85d-fae88c97e05c"
      unitRef="usd">6063000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTktMS0xLTEtNjI1_cc414dab-35c6-4533-8aa6-c38bc7201e5c"
      unitRef="usd">100219000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMTktMy0xLTEtNjI1_7ae5921f-9380-4afd-9a0e-e5f61989842e"
      unitRef="usd">-44063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjEtMS0xLTEtNjI1_25391f64-c261-4d46-ba1c-b70a43c9dcc9"
      unitRef="usd">14495000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjEtMy0xLTEtNjI1_4e05b55b-1e79-4b2a-a4cc-6d440db08ba3"
      unitRef="usd">14984000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjMtMS0xLTEtNjI1_d261cccc-af19-41a9-8122-c6cebaad37a3"
      unitRef="usd">51774000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjMtMy0xLTEtNjI1_c092a485-8d1d-4ac7-98a4-25bca85b116b"
      unitRef="usd">360752000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjQtMS0xLTEtNjI1_315781dd-dcfa-43d7-a244-c1acb37a70e5"
      unitRef="usd">57294000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjQtMy0xLTEtNjI1_7b7e02fb-1353-4749-814d-14962815fa80"
      unitRef="usd">262638000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <abcl:ProceedsFromReceiptOfGrantFunding
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjUtMS0xLTEtNjI1_e80059e0-81ab-4839-adc9-8f0d9b519bbc"
      unitRef="usd">2596000</abcl:ProceedsFromReceiptOfGrantFunding>
    <abcl:ProceedsFromReceiptOfGrantFunding
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjUtMy0xLTEtNjI1_561dfb18-26cc-4625-adde-9b722c9b9b86"
      unitRef="usd">2693000</abcl:ProceedsFromReceiptOfGrantFunding>
    <abcl:PaymentsToAcquireLongTermInvestmentsAndOtherAssets
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjctMS0xLTEtNjI1_ae859b19-4794-44d6-9236-58625aaf8a2d"
      unitRef="usd">11657000</abcl:PaymentsToAcquireLongTermInvestmentsAndOtherAssets>
    <abcl:PaymentsToAcquireLongTermInvestmentsAndOtherAssets
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjctMy0xLTEtNjI1_b1b02070-16e3-40b4-ade0-54745bbf2ba8"
      unitRef="usd">34735000</abcl:PaymentsToAcquireLongTermInvestmentsAndOtherAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjgtMS0xLTEtNjI1_eb9ba837-cf72-42e8-9ffe-b54b9b87eaa2"
      unitRef="usd">8335000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjgtMy0xLTEtNjI1_e4714443-2c2d-4c18-b348-976d3217c36b"
      unitRef="usd">4469000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjktMS0xLTEtNjI1_4d30e305-2fb4-4aa2-9360-856ba8240abe"
      unitRef="usd">-26371000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMjktMy0xLTEtNjI1_382845c1-30fb-46d4-b7e9-79cccc53bc3f"
      unitRef="usd">-149609000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <abcl:RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzEtMS0xLTEtNjI1_5e45a1aa-784e-4fba-9517-2332483fdd60"
      unitRef="usd">5072000</abcl:RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration>
    <abcl:RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzEtMy0xLTEtNjI1_176b183c-7f3c-47f5-a578-9359883088f3"
      unitRef="usd">948000</abcl:RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration>
    <abcl:ProceedsFromDebtAndExerciseOfStockOptions
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzItMS0xLTEtNjI1_72f279c0-3fad-4fed-8f1f-bc494536a697"
      unitRef="usd">1941000</abcl:ProceedsFromDebtAndExerciseOfStockOptions>
    <abcl:ProceedsFromDebtAndExerciseOfStockOptions
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzItMy0xLTEtNjI1_88e06f69-b51e-49db-adfe-ce9ef76bfa79"
      unitRef="usd">490000</abcl:ProceedsFromDebtAndExerciseOfStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzQtMS0xLTEtNjI1_78397500-ad96-451d-b241-acebe410c722"
      unitRef="usd">-3131000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzQtMy0xLTEtNjI1_4911af8c-cd98-423d-bf0f-9b193a66262f"
      unitRef="usd">-458000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzUtMS0xLTEtNjI1_905abf7c-da2f-4129-924c-3c246be3033f"
      unitRef="usd">-204000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzUtMy0xLTEtNjI1_ec218818-38ce-4850-9ea5-2e80d739cdc1"
      unitRef="usd">-213000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzYtMS0xLTEtNjI1_69ebb4d3-349d-4039-ba80-af74b7bddb8d"
      unitRef="usd">70513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzYtMy0xLTEtNjI1_bbd1380f-723a-4c73-8914-423ab40b89bc"
      unitRef="usd">-194343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i6732b5466cb84d3c9b86f94b68a032d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzctMS0xLTEtNjI1_d2b8b55c-8c0b-4e59-bffb-e5c974271755"
      unitRef="usd">501142000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzctMy0xLTEtNjI1_c8a88987-691d-426d-be69-c1ebfc541504"
      unitRef="usd">414650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzgtMS0xLTEtNjI1_7b682147-d468-40b5-8be8-a3a23ad250cb"
      unitRef="usd">571655000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzgtMy0xLTEtNjI1_30e18b31-000e-4302-9e7c-bfe5cd696415"
      unitRef="usd">220307000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzktMS0xLTEtNjI1_4393103d-13f5-48de-a655-675209fbee03"
      unitRef="usd">937000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfMzktMy0xLTEtNjI1_b2762747-f5f0-4850-9d4b-426d5e54afed"
      unitRef="usd">2290000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDAtMS0xLTEtNjI1_140d6117-e5f7-4c46-9b9a-1b1ee722a216"
      unitRef="usd">570718000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDAtMy0xLTEtNjI1_feeeaa7e-a034-4cbe-8959-6ec4903b8dd6"
      unitRef="usd">218017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <abcl:NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDItMS0xLTEtNjI1_1f729a3f-a860-4b8c-a83f-d2effd93b701"
      unitRef="usd">2353000</abcl:NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable>
    <abcl:NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDItMy0xLTEtNjI1_a6a63557-b5ff-4ecd-a40c-c994f98577aa"
      unitRef="usd">8918000</abcl:NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable>
    <abcl:NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDMtMS0xLTEtNjI1_a12ee269-5f56-4137-b1d4-1eb9197566f3"
      unitRef="usd">658000</abcl:NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation>
    <abcl:NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zMS9mcmFnOjgzY2NhMWM5NTJmNzQ1NTE5YmFlNzFjZGU3OTJmOWJjL3RhYmxlOmQ0NWU5YzA5NmRjNDQyZmJiY2IxYjk0YjdmZTU2NWVhL3RhYmxlcmFuZ2U6ZDQ1ZTljMDk2ZGM0NDJmYmJjYjFiOTRiN2ZlNTY1ZWFfNDMtMy0xLTEtNjI1_ed0623eb-c565-4c4c-bfdc-6dfc56c5c149"
      unitRef="usd">2124000</abcl:NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation>
    <us-gaap:NatureOfOperations
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8zNy9mcmFnOjQ5NTQzMmFjZjg5MTRhNTViOWFmZDg1MmViZjEzNWY3L3RleHRyZWdpb246NDk1NDMyYWNmODkxNGE1NWI5YWZkODUyZWJmMTM1ZjdfNzk3_7de70934-0892-49db-84c8-6d0a64ac55ac">Nature of operationsAbCellera Biologics Inc.&#x2019;s (the &#x201c;Company&#x201d;) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80MC9mcmFnOmFlNzgxNjc0YzExODRhODM4MTk4ZGI3ODVlMDVhYjU3L3RleHRyZWdpb246YWU3ODE2NzRjMTE4NGE4MzgxOThkYjc4NWUwNWFiNTdfMTcwOQ_d318e63d-fcd1-4252-927f-24c7cba36a41">Basis of presentation&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March&#160;31, 2022 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to &#x201c;$&#x201d; are to U.S. dollars and references to &#x201c;C$&#x201d; and &#x201c;CAD&#x201d; are to Canadian dollars</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80MC9mcmFnOmFlNzgxNjc0YzExODRhODM4MTk4ZGI3ODVlMDVhYjU3L3RleHRyZWdpb246YWU3ODE2NzRjMTE4NGE4MzgxOThkYjc4NWUwNWFiNTdfMTcxMA_50da4510-9250-45c5-917d-0cab76d0386a">Basis of presentation&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three months ended March&#160;31, 2022 and 2023 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to &#x201c;$&#x201d; are to U.S. dollars and references to &#x201c;C$&#x201d; and &#x201c;CAD&#x201d; are to Canadian dollars.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80My9mcmFnOjMwYzBlMTIyMTIxMDRhNDhiOTQ3ZDk4MmJmZjllOWJjL3RleHRyZWdpb246MzBjMGUxMjIxMjEwNGE0OGI5NDdkOTgyYmZmOWU5YmNfMjM5Mg_569d273e-8cf8-4c26-9b6e-67756cfdf112">Significant accounting policies &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80My9mcmFnOjMwYzBlMTIyMTIxMDRhNDhiOTQ3ZDk4MmJmZjllOWJjL3RleHRyZWdpb246MzBjMGUxMjIxMjEwNGE0OGI5NDdkOTgyYmZmOWU5YmNfMjM5Mw_53290967-7aa3-487c-a9f3-4656271d2cbf">&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including evaluating whether contractual obligations represent distinct performance obligations, determining whether an option for additional goods or services represents a material right, allocating the transaction price to performance obligations within a contract, and assessing the recognition and possible future reversal of variable consideration, the fair value of acquired intangible assets, contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80My9mcmFnOjMwYzBlMTIyMTIxMDRhNDhiOTQ3ZDk4MmJmZjllOWJjL3RleHRyZWdpb246MzBjMGUxMjIxMjEwNGE0OGI5NDdkOTgyYmZmOWU5YmNfMjM5NQ_1ce23d4d-e903-4899-8092-bb183eaf7089">&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or that there was no material impact or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfODkw_b3357734-0795-43f6-931a-3d23fc3be481">Net earnings (loss) per share&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net earnings (loss) attributable to common shareholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283,895,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287,767,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net earnings (loss) per share attributable to common shareholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Diluted earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net earnings (loss) attributable to common shareholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283,895,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287,767,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,586,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;311,482,017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287,767,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net earnings (loss) per share attributable to common shareholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s potentially dilutive securities, which include stock options and restricted share units (&#x201c;RSUs&#x201d;), have been excluded from the computation of diluted net loss per share for the three months ended March&#160;31, 2023 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three months ended March&#160;31, 2023 used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded 2,974,052 and 50,844,425 potential common shares for the three months ended March&#160;31, 2022 and March&#160;31, 2023, respectively, from the computation of diluted net earnings (loss) per share attributable to common shareholders because including them would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfODkx_497d52af-673a-4d0b-b161-804558f7dbe6">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net earnings (loss) per share attributable to common shareholders was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net earnings (loss) attributable to common shareholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283,895,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287,767,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net earnings (loss) per share attributable to common shareholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Diluted earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net earnings (loss) attributable to common shareholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(40,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283,895,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287,767,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,586,997&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;311,482,017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;287,767,136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net earnings (loss) per share attributable to common shareholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;0.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMy0yLTEtMS0yMjE5_12b4956f-895d-4d95-a5ff-e91d442d7e29"
      unitRef="usd">168573000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMy00LTEtMS0yMjE5_7ee4042c-297b-4e82-bda2-ff3800a9c3cd"
      unitRef="usd">-40110000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNC0yLTEtMS0yMjE5_bf04131d-1348-4c75-adf8-095fcbce33c1"
      unitRef="shares">283895020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNC00LTEtMS0yMjE5_d5f4d7ae-684b-450c-a442-f9e3178bfc71"
      unitRef="shares">287767136</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNS0yLTEtMS0yMjE5_20b843fc-a215-4e2c-8cfe-33fffd951b48"
      unitRef="usdPerShare">0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfNS00LTEtMS0yMjE5_17bd2a71-6063-4134-9a13-26cc8776c903"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOC0yLTEtMS0yMjE5_b31dfe7f-3f0b-4275-990f-afbc125ecbf1"
      unitRef="usd">168573000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOC00LTEtMS0yMjE5_5078e38f-7e19-44e4-9cc3-33a0c2178731"
      unitRef="usd">-40110000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOS0yLTEtMS0yMjE5_afc359c7-01b7-415c-a6e8-d5c4e4b984f2"
      unitRef="shares">283895020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfOS00LTEtMS0yMjE5_61eceea3-d49a-4fee-8556-a2f3b9877bbf"
      unitRef="shares">287767136</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTAtMi0xLTEtMjIxOQ_924df33b-26a7-4791-9735-7775c9e0a4de"
      unitRef="shares">27586997</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTAtNC0xLTEtMjIxOQ_1f6f0bf2-a184-41a1-a076-7c0735081e77"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTEtMi0xLTEtMjIxOQ_5cd5e37a-cbc6-4728-944d-aff8acf1063f"
      unitRef="shares">311482017</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTEtNC0xLTEtMjIxOQ_3bb01e3e-8502-44a8-9114-f00b118f7491"
      unitRef="shares">287767136</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTItMi0xLTEtMjIxOQ_8d558a0b-4417-4376-b63f-6d3ad92c42f3"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RhYmxlOjkwNTI5OWE3M2JkOTQwYmI5OThlM2I0MWQxYWNhMjg5L3RhYmxlcmFuZ2U6OTA1Mjk5YTczYmQ5NDBiYjk5OGUzYjQxZDFhY2EyODlfMTItNC0xLTEtMjIxOQ_3d18a495-604e-4ec1-929d-3e3c323e1c34"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfNjQ4_0943225a-86cc-49ab-8805-b583e01116b5"
      unitRef="shares">2974052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80Ni9mcmFnOmQ2M2I1YjM1MTQyODRiNmZhMjAxZDE0Yzk1MTIzZTAxL3RleHRyZWdpb246ZDYzYjViMzUxNDI4NGI2ZmEyMDFkMTRjOTUxMjNlMDFfNjU1_7a3b2fda-7a7e-48c5-88c2-12a2b3b7ee91"
      unitRef="shares">50844425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfNDEy_e9f16ed1-6d9a-4fa9-8522-e88d7af65225">Property and equipment, net&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,405&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,493&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,936&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,356&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;235,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;254,520&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,333)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and March&#160;31, 2023, leasehold improvements include tenant improvements in progress that have not commenced depreciation in the amount of $25.6 million and $38.9 million, respectively.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Depreciation expense on property and equipment for the three months ended March&#160;31, 2022, and 2023 was $1.4 million and $2.9 million, respectively.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfNDEz_5c51a121-8c3c-460e-a793-d026f5bdf221">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,405&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,493&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,936&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,356&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;235,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;254,520&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,333)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;217,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i42a0bae74c9743ff8ff66ad8ff963146_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMS0yLTEtMS0yNDkw_7cf58152-8025-4ab2-96c4-04df64587e80"
      unitRef="usd">8303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie6139469318d432e82d6baefdf566dce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMS00LTEtMS0yNDkw_29d44714-095c-4bc0-aa3d-d7b2c6a919cf"
      unitRef="usd">8530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i12e371e7d54148dbba3063693fd8a2d9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMi0yLTEtMS0yNDkw_b85f9669-4d31-4bc2-b279-df2ad0d18c67"
      unitRef="usd">53405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0e470366e74a442c8d52acc2a9f1b5f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMi00LTEtMS0yNDkw_29adf264-b1a2-4dc3-b58d-437817483880"
      unitRef="usd">53405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iabf93e4e7dd64c7e839faca3ad8410d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMy0yLTEtMS0yNDkw_3fc5f6a8-e4ea-48dd-a1c7-03c4ea3b5db5"
      unitRef="usd">11361000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i406b6a1622cd4dff99832c9462b6e4a7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfMy00LTEtMS0yNDkw_f65d33e3-6d9a-4096-b244-3dc906f3db18"
      unitRef="usd">17493000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4e1c38a1157c413c866c668dd92b9a77_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNC0yLTEtMS0yNDkw_270f5a9a-6319-4d06-9f2c-6297edc048a5"
      unitRef="usd">41256000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2d27a736c37340be83efab3ba99a8bc0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNC00LTEtMS0yNDkw_40d74c5e-1f6b-475a-a108-cd12ec9840dc"
      unitRef="usd">45936000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic9c66215525a40069a548e7bd3025c84_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNS0yLTEtMS0yNDkw_1618111e-07d9-461c-a506-5b980d705c07"
      unitRef="usd">40567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a403b1fa38d47ada5644a9f4c1fff58_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNS00LTEtMS0yNDkw_bc4d80cc-d75f-4678-90a4-663446ff8f99"
      unitRef="usd">47800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i853afd911efa4258a08a6952094096cb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNi0yLTEtMS0yNDkw_00351683-4019-4873-a274-2e0dd07572a3"
      unitRef="usd">80838000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7d0ae58e07dc4eb983249c3c61c1ad45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNi00LTEtMS0yNDkw_583792b4-0252-4209-85b2-0ccf880d7a0c"
      unitRef="usd">81356000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNy0yLTEtMS0yNDkw_1a8b98dc-61a3-48c6-a0db-e0e1ce2b4429"
      unitRef="usd">235730000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfNy00LTEtMS0yNDkw_472390c4-2f70-4389-b935-639c887d2180"
      unitRef="usd">254520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOC0yLTEtMS0yNDkw_d3fd6ca2-c3ea-4b4a-96ab-a9305ec9dac8"
      unitRef="usd">18475000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOC00LTEtMS0yNDkw_86d1b103-9523-446b-a4de-cfef8e580a1f"
      unitRef="usd">21333000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOS0yLTEtMS0yNDkw_db4e5e1e-1bec-4266-8ecc-1bb237cef6d1"
      unitRef="usd">217255000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RhYmxlOjdlMDk1OTBhMjk2YzQyY2I4OTUzYTk4M2E1OGQ1NjQ0L3RhYmxlcmFuZ2U6N2UwOTU5MGEyOTZjNDJjYjg5NTNhOTgzYTU4ZDU2NDRfOS00LTEtMS0yNDkw_81e7cd7e-02ce-485f-a250-b9501f533e05"
      unitRef="usd">233187000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMjI4_e18106e8-ed96-4330-b908-58736ec70ad6"
      unitRef="usd">25600000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMjM1_540e526d-a907-4d71-b77f-c1982f874045"
      unitRef="usd">38900000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:Depreciation
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMzMx_33176d30-fd79-430d-812c-4e14e859992c"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF80OS9mcmFnOjU1NmYyYzljMmViZjQ4NDU4MDE3NzJlMDM3OTVhNTk4L3RleHRyZWdpb246NTU2ZjJjOWMyZWJmNDg0NTgwMTc3MmUwMzc5NWE1OThfMTY0OTI2NzQ0MjE3Mw_b823eef4-cff4-4e2b-bbbb-e37d6a6e5610"
      unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RleHRyZWdpb246YWJhNmY5YTUwNmQ2NDg3Y2FiNGU3NTM1NjM5ZjVlMGRfMTg5_98b86125-521f-4f78-a771-9d6450c51b47">Intangible assets&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net book&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RleHRyZWdpb246YWJhNmY5YTUwNmQ2NDg3Y2FiNGU3NTM1NjM5ZjVlMGRfMTkw_b6eae308-301b-4758-b9b0-05ea4b097395">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net book&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;128,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if039c44ad3504f63aa1ec431499bafec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMi0xLTEtMS02MjU_385b46a8-b269-468a-b8d5-5b813a28ddaa"
      unitRef="usd">37873000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if039c44ad3504f63aa1ec431499bafec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMi0zLTEtMS02MjU_ba9d0fd4-f784-4850-8e9f-8e469becb29f"
      unitRef="usd">19857000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if039c44ad3504f63aa1ec431499bafec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMi01LTEtMS02MjU_ed5fabc3-d786-488e-83bc-1c33018ec530"
      unitRef="usd">18016000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5caae842c49f4155ad44dff34efdb797_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMy0xLTEtMS02MjU_c5b3c8de-2864-4a1e-adf9-a2871433a671"
      unitRef="usd">52700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5caae842c49f4155ad44dff34efdb797_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMy0zLTEtMS02MjU_705af3bc-8140-4f3f-a960-3248cc3df519"
      unitRef="usd">5881000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5caae842c49f4155ad44dff34efdb797_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfMy01LTEtMS02MjU_685cd937-7939-40e7-a16d-0523d8e795e6"
      unitRef="usd">46819000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNC0xLTEtMS02MjU_34e18e74-fb90-4104-8029-188c87597904"
      unitRef="usd">64010000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNC0zLTEtMS02MjU_4bbd5202-1b40-4502-880f-e3012a84cf7c"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia8e7f4505e53420ca35f8e4f84fc7a19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNC01LTEtMS02MjU_7f8354e8-47e6-4f7b-847a-7cac97724cb5"
      unitRef="usd">64010000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNS0xLTEtMS02MjU_31002a91-8340-464f-9195-559871c5db26"
      unitRef="usd">154583000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNS0zLTEtMS02MjU_89dfb6cf-96d9-4cb9-a275-46c07eb90077"
      unitRef="usd">25738000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOjk2MTA5ODgxZmRjMTQxMzk4ZTQ0MmY3OTE3YTBmODQzL3RhYmxlcmFuZ2U6OTYxMDk4ODFmZGMxNDEzOThlNDQyZjc5MTdhMGY4NDNfNS01LTEtMS02MjU_9daf18e7-6373-492f-b33a-328ee23f3484"
      unitRef="usd">128845000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RleHRyZWdpb246YWJhNmY5YTUwNmQ2NDg3Y2FiNGU3NTM1NjM5ZjVlMGRfMTg4_7120713f-bbb5-4259-a91c-0c3593ee4d32">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended March&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization&lt;br/&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfMS0xLTEtMS02MjU_38ee0934-f949-4ac8-87f9-a39df71b1536"
      unitRef="usd">10599000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfMi0xLTEtMS02MjU_66317600-0d53-4ac9-a7f6-58c32daf0571"
      unitRef="usd">4241000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfMy0xLTEtMS02MjU_8c35d384-e5df-4ac7-a14d-d0456cf436c9"
      unitRef="usd">4241000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfNC0xLTEtMS02MjU_b2fb21da-14b2-4886-a654-5724fdfaae63"
      unitRef="usd">4241000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfNS0xLTEtMS02MjU_3b671b78-8745-4f11-b803-5f8befc7b631"
      unitRef="usd">4241000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81Mi9mcmFnOmFiYTZmOWE1MDZkNjQ4N2NhYjRlNzUzNTYzOWY1ZTBkL3RhYmxlOmQzNzc2ZTE1YmQ0NTQ0OGI5OWI0N2NhZmUwZDc0Mjg3L3RhYmxlcmFuZ2U6ZDM3NzZlMTViZDQ1NDQ4Yjk5YjQ3Y2FmZTBkNzQyODdfNi0xLTEtMS02MjU_4eb8e594-a6e3-4bea-b8d3-bed9cd2e3d34"
      unitRef="usd">27563000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMjUxNg_dc451fa3-28f6-4b0c-8b78-3b22e544bce3">Investments in and loans to equity accounted investees, and other long-term assets&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of future office and laboratory headquarters. To date, the Company has recorded immaterial amounts of proportionate income or loss with respect to either venture.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Dayhu JV&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During 2020, the Company entered into a joint venture with Dayhu (Dayhu JV). As of March&#160;31, 2023, the equity investment balance was $41.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March, 2021, the Company made a commitment of up to CAD $82.7&#160;million ($61.2&#160;million at March&#160;31, 2023) to the Dayhu JV (Dayhu JV Loan) to fund the construction at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement and September 1, 2023, or upon the trigger of certain liquidity events as defined in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The loan is secured by the underlying land and future assets of the Dayhu JV. At December&#160;31, 2022, and March&#160;31, 2023, the outstanding related party loan balance was $38.1&#160;million and nil, respectively, to the Dayhu JV.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2022, the Company entered into an agreement of up to CAD $46.0&#160;million ($34.0&#160;million at March&#160;31, 2023) with Dayhu (New Dayhu Loan) to replace Dayhu&#x2019;s portion of the outstanding Dayhu JV Loan balance as at January 1, 2023, at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement. The agreement has a maturity of December 31, 2025, with a call provision, callable by the Company after September 30, 2023, including customary make whole provisions. The loan is secured by the underlying land and existing and future assets of the Dayhu JV. In January 2023, the Company issued CAD $46.0&#160;million ($34.0&#160;million at March&#160;31, 2023) to Dayhu from the New Dayhu loan, which was used to repay, in part, Dayhu&#x2019;s 50% portion of the Dayhu JV Loan. At March&#160;31, 2023, the loan balance was $34.0&#160;million and is included in other long-term assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Beedie JV&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March, 2021, the Company entered into the Beedie joint venture (Beedie JV). As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the equity investment balance was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2022, the Company made a commitment to our partner Beedie for a land loan of up to CAD $7.5&#160;million (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$5.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; at March&#160;31, 2023) plus a construction loan for up to 80% of Beedie&#x2019;s share of construction costs. The commitment is at a rate referenced to a Canadian bank prime rate adjusted for applicable margins as defined in the agreement, and repayment on the earlier of thirty months from the date of initial advancement of the construction loan and&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;five years from the initial advancement of the land loan, or upon the triggering of certain repayment events as defined in the agreement. The loan is secured by the underlying land and existing and future assets of the Beedie JV. The loan receivable balance, which was solely related to the land loan to date, was CAD $7.5&#160;million (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$5.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; as at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;) and is included in other long-term assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <abcl:NumberOfJointVentures
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTA2OA_5b01c7c1-c448-494b-a56a-f4e27fbf4df6"
      unitRef="jointventure">2</abcl:NumberOfJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia507651da5b4472a9bda28dcdad3b575_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMTc_06221a24-77b2-43e5-af76-b80df547adf5"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0148f1e33c6b4510b7104f707a9f1015_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMTc_5fcce713-38ef-41ec-b2df-ec6bc10810ec"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i73a7c5f735ad47f2ad483da48085449d_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTY0MDAwNA_1611971b-adc5-466d-8fd6-3e4a65c6b151"
      unitRef="usd">41300000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="ic7dd7959a16f4e469b26e2d1a0a91144_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTA4MQ_4c18dd27-b96d-4039-8fcb-abc0238f3650"
      unitRef="cad">82700000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="ic7dd7959a16f4e469b26e2d1a0a91144_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTMwNQ_dc442f69-47c8-4d43-a427-33660ecbfb67"
      unitRef="usd">61200000</abcl:EquityMethodInvestmentCommitmentAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i6bfea07b5a744d6596d3882f182d5906_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMjc_b32b1213-29d5-4b22-b8f3-05131ee57749">P30M</us-gaap:DebtInstrumentTerm>
    <abcl:EquityMethodInvestmentOutstandingRelatedPartyLoan
      contextRef="i1f5e482b7eb34446b5095f10b3fbcd1c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTYzNzg1MA_298ef85d-a91e-45c3-b292-5791f2c0e4c8"
      unitRef="usd">38100000</abcl:EquityMethodInvestmentOutstandingRelatedPartyLoan>
    <abcl:EquityMethodInvestmentOutstandingRelatedPartyLoan
      contextRef="i47a8affab5e347a4b46782717c4df146_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM3Ng_dd62d795-a82c-4179-8456-9df0ef70fa5e"
      unitRef="usd">0</abcl:EquityMethodInvestmentOutstandingRelatedPartyLoan>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="ifcee6e4ab663465bac83ebdfecfc71e5_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTA5Ng_895e93a0-fd67-49e1-92be-6ce74ca79be8"
      unitRef="cad">46000000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM1Mg_e063125c-14e4-497f-a62f-f400e530fbfe"
      unitRef="usd">34000000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i9d3ffacd78e54c008bb62a070d409d8e_D20230101-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTExMQ_49a84486-4d88-419d-8e8e-a2e03d6b9301"
      unitRef="cad">46000000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTY0MDA5Ng_e063125c-14e4-497f-a62f-f400e530fbfe"
      unitRef="usd">34000000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:PercentageOfConstructionLoan
      contextRef="i9d3ffacd78e54c008bb62a070d409d8e_D20230101-20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMjM_017736a4-4419-440a-844e-a51b1288431b"
      unitRef="number">0.50</abcl:PercentageOfConstructionLoan>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i891eff8eba8c4b7095d0a052343b35de_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNTQ5NzU1ODI5OTM5_e063125c-14e4-497f-a62f-f400e530fbfe"
      unitRef="usd">34000000</abcl:EquityMethodInvestmentCommitmentAmount>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ib925185cbb614e71b24a62dc39dc9707_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM1OQ_ed14f65c-c086-42fa-ab58-18ca3b5c067d"
      unitRef="usd">16300000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfNDk0NzgwMjMzNTE0MQ_533e954f-abc6-4137-8eb0-98c1c90b5e53"
      unitRef="cad">7500000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM2Ng_3e42710d-209c-493f-b23b-a8ad2298a11d"
      unitRef="usd">5500000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:PercentageOfConstructionLoan
      contextRef="i4bb8630f96284448a0ad62c00db72975_D20220601-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMjk_97817886-7682-4e5d-8c0c-c95bd76fafcc"
      unitRef="number">0.80</abcl:PercentageOfConstructionLoan>
    <us-gaap:DebtInstrumentTerm
      contextRef="i9a27eee6bb20488893688edd304543db_D20220601-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMzM_e4f951f1-7f98-442d-b9b7-f589fad74ea3">P30M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4bb8630f96284448a0ad62c00db72975_D20220601-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTQ4NDM0MDY5ODUzMzQ_ec280c1d-cf1c-481b-a789-eee3539d5713">P5Y</us-gaap:DebtInstrumentTerm>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTA5OTUxMTY0MzIyMw_533e954f-abc6-4137-8eb0-98c1c90b5e53"
      unitRef="cad">7500000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:EquityMethodInvestmentCommitmentAmount
      contextRef="i2634cd416c7c4f2e93a5953686fb4618_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81NS9mcmFnOjA0OWRiNjI0YTNjODRmMDJiMTdjMjRkMmY3MGY2YjllL3RleHRyZWdpb246MDQ5ZGI2MjRhM2M4NGYwMmIxN2MyNGQyZjcwZjZiOWVfMTY0OTI2NzQ1MTM3Mg_e94fe3f0-ffb6-42ef-bc19-329d9dbfa0c8"
      unitRef="usd">5500000</abcl:EquityMethodInvestmentCommitmentAmount>
    <abcl:CurrentAssetsAndLiabilitiesTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RleHRyZWdpb246NTg5M2Q2ZTU4MzA3NGU0MmJiMDIxNjVkOWMyMTM1ZWJfMTE1_5d1ea021-e2af-4d33-8def-a8a69487e38a">Current assets and liabilities&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax deposits and receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts payable and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payroll liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of deferred grant funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts payable and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</abcl:CurrentAssetsAndLiabilitiesTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RleHRyZWdpb246NTg5M2Q2ZTU4MzA3NGU0MmJiMDIxNjVkOWMyMTM1ZWJfMjM2Mzk0OTk5OTc5MTk_769b0f96-0dbc-487a-bc7a-572f4c64b84f">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax deposits and receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMS0yLTEtMS0xMzE4NA_86d89d19-ba8f-4bc8-9567-f89220179672"
      unitRef="usd">64817000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMS00LTEtMS0xMzE4NA_49363819-34bb-4dba-af59-de1a1ddbdfdd"
      unitRef="usd">79566000</us-gaap:IncomeTaxesReceivable>
    <abcl:PrepaidExpenseAndOtherCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMi0yLTEtMS0xMzE4NA_59f56d4d-3e71-4541-baa2-e6925dd52c8b"
      unitRef="usd">9064000</abcl:PrepaidExpenseAndOtherCurrent>
    <abcl:PrepaidExpenseAndOtherCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMi00LTEtMS0xMzE4NA_7009a802-e4af-4135-8f18-d3cccb1b714a"
      unitRef="usd">18142000</abcl:PrepaidExpenseAndOtherCurrent>
    <abcl:MaterialsAndSuppliesCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMy0yLTEtMS0xMzE4NA_0b62e365-6fd0-4f20-8662-e33c0efe7501"
      unitRef="usd">1532000</abcl:MaterialsAndSuppliesCurrent>
    <abcl:MaterialsAndSuppliesCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfMy00LTEtMS0xMzE4NA_649650a3-6c95-4f04-9f29-e34b9dfc5433"
      unitRef="usd">1447000</abcl:MaterialsAndSuppliesCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfNC0yLTEtMS0xMzE4NA_db812a49-c224-4b57-a473-4ac8bc921fc2"
      unitRef="usd">75413000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjJiNzZjMTliZTk4NjRmMGRhN2U0ZjI2OGM2N2E1ZDk3L3RhYmxlcmFuZ2U6MmI3NmMxOWJlOTg2NGYwZGE3ZTRmMjY4YzY3YTVkOTdfNC00LTEtMS0xMzE4NA_9c19b318-07e7-4f4d-bad1-43f5aa7a6e5f"
      unitRef="usd">99155000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RleHRyZWdpb246NTg5M2Q2ZTU4MzA3NGU0MmJiMDIxNjVkOWMyMTM1ZWJfMTE2_a5c1db11-fb63-435c-a34d-625c06d0ae6a">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts payable and other liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payroll liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of deferred grant funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts payable and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMS0yLTEtMS00MDY5_ef14acf2-3883-41a1-a0d9-dbccf3cc6f7f"
      unitRef="usd">14828000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMS00LTEtMS00MDY5_155817cf-463e-49f5-b585-60e165f26e1c"
      unitRef="usd">17569000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMy0yLTEtMS00MDY5_6ef00fd3-0519-414a-a9e3-396f4cbc36d6"
      unitRef="usd">5583000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfMy00LTEtMS00MDY5_5fb641c3-81cd-4c61-a580-7bdb64e77e7a"
      unitRef="usd">5868000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNC0yLTEtMS00MDY5_7339e0c6-47a0-4fd3-b7eb-b05a397046cd"
      unitRef="usd">6454000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNC00LTEtMS00MDY5_a8b7a186-bf2c-4b0b-8599-5ca47b000c2d"
      unitRef="usd">1792000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <abcl:DeferredGrantFundingCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNS0yLTEtMS00MDY5_c9126646-a476-42d1-81f8-ecbd72641915"
      unitRef="usd">6285000</abcl:DeferredGrantFundingCurrent>
    <abcl:DeferredGrantFundingCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNS00LTEtMS00MDY5_3d2f6e08-684a-4896-adb6-e7da191031dc"
      unitRef="usd">6585000</abcl:DeferredGrantFundingCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNi0yLTEtMS00MDY5_4750047c-91bc-4fbb-b30f-97c3759be0b0"
      unitRef="usd">33150000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF81OC9mcmFnOjU4OTNkNmU1ODMwNzRlNDJiYjAyMTY1ZDljMjEzNWViL3RhYmxlOjcyODk3Y2NhNGM4OTRhMzFhNGE1ZGE3ZTQyMDg5OTBlL3RhYmxlcmFuZ2U6NzI4OTdjY2E0Yzg5NGEzMWE0YTVkYTdlNDIwODk5MGVfNi00LTEtMS00MDY5_1a35e9fb-089d-4eff-909d-00a3b10aade0"
      unitRef="usd">31814000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxNw_6704d1c9-c6b2-499b-91dd-fbcad0023861">Shareholders&#x2019; equity&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity under the Pre-IPO Plan since December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,694,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,087,171)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,606,979&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,079,568&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity under the 2020 Plan since December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,322,933&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,617,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(136,180)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,804,391&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,881,278&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSU activity under the 2020 Plan since December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,946,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,065,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(487,748)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(91,292)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,433,055&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the number of shares available for issuance under the 2020 Plan was 33,217,073, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxMw_67913442-5a45-4901-ad7e-c9866fda889d">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity under the Pre-IPO Plan since December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,694,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,087,171)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,606,979&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,079,568&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity under the 2020 Plan since December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,322,933&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,617,638&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(136,180)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,804,391&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,881,278&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i21720092b1fd485a91d701040dc8eaf4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMS0xLTEtMS02MjU_2a02b57d-769b-4fbf-9a54-84791e1e4b04"
      unitRef="shares">33694150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i21720092b1fd485a91d701040dc8eaf4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMS0zLTEtMS02MjU_16f557f7-06a0-4c2a-beb4-f12d84498f4d"
      unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMi0xLTEtMS02MjU_2e9f40ef-f64f-46eb-818e-39f76e41a602"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMi0zLTEtMS02MjU_8e0ce59a-e5ac-4daa-b099-2c880ca2ac0c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMy0xLTEtMS02MjU_a9fd076b-6581-4458-92ae-01adcae9e935"
      unitRef="shares">1087171</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfMy0zLTEtMS02MjU_60af87be-2c34-4bd0-8230-b7ee04ac5340"
      unitRef="usdPerShare">0.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNC0xLTEtMS02MjU_4b2efc65-157c-4343-a655-3feff7936527"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia6b300c0700b4d10bb1a516fc5507c86_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNC0zLTEtMS02MjU_7c105370-b576-4c5a-935b-7b7c296e3735"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNS0xLTEtMS02MjU_3ee8db9f-6fdd-4a25-8d72-e172398c9ecd"
      unitRef="shares">32606979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNS0zLTEtMS02MjU_909f5b3f-5b19-4c04-bcd3-ed5552c1560e"
      unitRef="usdPerShare">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNi0xLTEtMS02MjU_4d2dabf4-d602-44ac-a790-60726bbfc163"
      unitRef="shares">24079568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7615a3703fc444c5bf358dc8748655b8_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOmFlYWY4YWE1OGZhYzQ5YTU4YTMwMWQ4ZGFjM2Q4OTEzL3RhYmxlcmFuZ2U6YWVhZjhhYTU4ZmFjNDlhNThhMzAxZDhkYWMzZDg5MTNfNi0zLTEtMS02MjU_daf1c1e3-bd28-4097-92fa-3b42bce05b85"
      unitRef="usdPerShare">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i89a61c2a4c454272afe77744cf55c9ec_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMS0xLTEtMS02MjU_422a49b5-bcbc-4e2d-86a2-a1f75a073802"
      unitRef="shares">12322933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i89a61c2a4c454272afe77744cf55c9ec_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMS0zLTEtMS02MjU_287a7f32-c42b-46b1-8825-fd5bc7c02d9a"
      unitRef="usdPerShare">14.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMi0xLTEtMS02MjU_44bf5d1e-2d07-424d-a6d6-5b7672cc498d"
      unitRef="shares">1617638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMi0zLTEtMS02MjU_b7e6f913-5c61-4a29-b5d9-0348c2ffa0b8"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMy0xLTEtMS02MjU_a401fa96-023d-4fcd-b3da-59a89a8fffbf"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfMy0zLTEtMS02MjU_bb1d41d2-33db-479e-8317-552c59926145"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNC0xLTEtMS02MjU_9337c1bb-aa2b-4522-ae26-285cbcd12617"
      unitRef="shares">136180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1dc399d422c24f6eb63f12c95ec3558c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNC0zLTEtMS02MjU_667c24de-ca88-4f68-8c6a-dd8f9a2c2e5c"
      unitRef="usdPerShare">13.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2858e48f05f04827941d142a021d6fad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNS0xLTEtMS02MjU_9cac7b5b-4fab-4edb-a386-c5756fc319d6"
      unitRef="shares">13804391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2858e48f05f04827941d142a021d6fad_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNS0zLTEtMS02MjU_660d76c9-33a4-499d-a6b5-2a1a66e87e7a"
      unitRef="usdPerShare">14.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2858e48f05f04827941d142a021d6fad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNi0xLTEtMS02MjU_612388aa-895f-4a18-b433-51c1cd5ce87f"
      unitRef="shares">2881278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2858e48f05f04827941d142a021d6fad_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjRmN2Q0YjJhNzFmYTQ3NzY4N2JjYTMzNjRlYmExMjZmL3RhYmxlcmFuZ2U6NGY3ZDRiMmE3MWZhNDc3Njg3YmNhMzM2NGViYTEyNmZfNi0zLTEtMS02MjU_8f9b7e9d-8a9a-408b-b20b-63e86b252345"
      unitRef="usdPerShare">17.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxNQ_dbd703b2-a885-497f-af89-f4472b1891e1">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s RSU activity under the 2020 Plan since December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,946,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,065,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(487,748)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(91,292)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,433,055&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic2f5814bf79942159d756fd4d496dc6c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMS0xLTEtMS02MjU_ea7d7a43-e94f-4d86-878b-21c97ebcf141"
      unitRef="shares">3946985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic2f5814bf79942159d756fd4d496dc6c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMS0zLTEtMS02MjU_772e8158-d009-4cb5-96b1-b925a0b4f8b6"
      unitRef="usdPerShare">13.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMi0xLTEtMS02MjU_8f962a23-fd7b-4e88-a88b-336276a6ebff"
      unitRef="shares">1065110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMi0zLTEtMS02MjU_e19660ec-ffa9-4223-8c46-0ae84353ffd5"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMy0xLTEtMS02MjU_f8b748ae-7d1d-4ba3-ae5a-7154f131c81c"
      unitRef="shares">487748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfMy0zLTEtMS02MjU_944a880f-fd14-45c9-b91a-911cbe8547d8"
      unitRef="usdPerShare">14.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNC0xLTEtMS02MjU_281c31b7-2ad4-4bef-9678-42fc3ed7cf49"
      unitRef="shares">91292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i01e64126d887401289c5b361c74b08f7_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNC0zLTEtMS02MjU_25650130-547f-4473-8994-28a4a87c5b6c"
      unitRef="usdPerShare">13.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6b5c3602feb942b29d99d1347ccefffa_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNS0xLTEtMS02MjU_ecff5f34-616f-475b-8125-a0c2033fc5ae"
      unitRef="shares">4433055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6b5c3602feb942b29d99d1347ccefffa_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjc5NDFmMGQyMWM1MzRlNTdiZGE0NTA2ZmZiM2Y3ZDI2L3RhYmxlcmFuZ2U6Nzk0MWYwZDIxYzUzNGU1N2JkYTQ1MDZmZmIzZjdkMjZfNS0zLTEtMS02MjU_fc3d025d-1837-42ca-97fe-1f3cd3fe5a1f"
      unitRef="usdPerShare">12.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2858e48f05f04827941d142a021d6fad_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfNTQ5NzU1ODE1OTk1_e483adf2-f555-43f0-8497-b6b4cf9526df"
      unitRef="shares">33217073</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RleHRyZWdpb246YjEzNzE1MDk5Nzk5NDBiNjlmYjJlY2IyOTY4MWY2NGRfMTMxNg_a213500c-eb3a-48d0-8677-d2b8db3530fd">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of income (loss) and comprehensive income (loss) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib4cf5d989e9741afb07a70513b1e2a5b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMi0xLTEtMS02MjU_ce666e14-a896-47b9-bb03-173a94c58cbc"
      unitRef="usd">5937000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c4fd149aa8c46f3800472cd46fa49e2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMi0zLTEtMS02MjU_fea60933-f517-4520-af12-d0487912c324"
      unitRef="usd">7496000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d7c7469d9e04930b97b96e58ef2f063_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMy0xLTEtMS02MjU_8f63eb9e-746f-44ce-a725-f1af19d4f449"
      unitRef="usd">994000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if605d90125084846a2a1044b2692e5de_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfMy0zLTEtMS02MjU_55c21d0e-2cc3-4954-b272-214a8b5a4268"
      unitRef="usd">1271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic528446a6c1c4f6d8b57c3c9e62fb472_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNC0xLTEtMS02MjU_10ecd52b-89de-49fc-999f-551d54642b81"
      unitRef="usd">5360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3bf8dcc696b24c26bf569ab099f74655_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNC0zLTEtMS02MjU_1c61a6e7-3dd5-4af9-aba2-dff9666c5cbe"
      unitRef="usd">6707000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNS0xLTEtMS02MjU_9d4d6244-b62e-481b-8473-a54f96a30bd3"
      unitRef="usd">12291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82MS9mcmFnOmIxMzcxNTA5OTc5OTQwYjY5ZmIyZWNiMjk2ODFmNjRkL3RhYmxlOjQyYWZkY2Y1ODA3YzRmNTNiOTJmYmM1NTgxZGYyMjdhL3RhYmxlcmFuZ2U6NDJhZmRjZjU4MDdjNGY1M2I5MmZiYzU1ODFkZjIyN2FfNS0zLTEtMS02MjU_79153030-5b34-4c57-af40-6180f9294030"
      unitRef="usd">15474000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTk3Mw_27077583-11a2-4dde-8c09-f2ad0acdd270">Revenue&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The disaggregated revenue categories are presented on the face of the condensed consolidated statements of income (loss) and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue represents payments received for performance obligations not yet satisfied and are presented as current or long-term in the accompanying balance sheets based on the expected timing of satisfaction of the underlying goods and/or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue outstanding in each respective period is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022 and 2023, the Company recognized $2.7&#160;million and $4.8 million, respectively, of revenue that had been included in deferred revenue in the previous year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTk3NA_aa302abf-08e9-47b1-8a8d-42e50039addc">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue outstanding in each respective period is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6732b5466cb84d3c9b86f94b68a032d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS0xLTEtMS02MjU_2fc2c0c1-50bb-45ad-84b2-036a7087d29f"
      unitRef="usd">34954000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4889d91d341e4ab8b818801f569b0d96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS0zLTEtMS02MjU_bebecae0-e6be-482a-96ac-bd946d8b8112"
      unitRef="usd">35861000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS01LTEtMS02MjU_8d9d7c63-2ca3-418a-9182-0cd2f4806219"
      unitRef="usd">41128000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RhYmxlOjcxYzg4YjE5MmJlMDRhNTE5ZjQwYzY0Y2RiZjZlNWE5L3RhYmxlcmFuZ2U6NzFjODhiMTkyYmUwNGE1MTlmNDBjNjRjZGJmNmU1YTlfMS03LTEtMS02MjU_d886bb01-3e94-4086-a52d-6c8c9640d5e2"
      unitRef="usd">37223000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTY0OTI2NzQ0Mzc3MA_9ba9ea57-5ef6-40fc-8afb-41863f68ab05"
      unitRef="usd">2700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82NC9mcmFnOmU4MTFmMjUzMTI0ZTRkOTc4N2MyOTIxZTBiODUzMmY5L3RleHRyZWdpb246ZTgxMWYyNTMxMjRlNGQ5Nzg3YzI5MjFlMGI4NTMyZjlfMTY0OTI2NzQ0NDA2OA_7d2c1892-9057-4b49-a2cb-8dbfc55db7a3"
      unitRef="usd">4800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMzUxNQ_ac96d829-5291-4a10-bc94-d96b24c9d740">Financial instruments &lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, loans to equity accounted investees, accounts payable and accrued liabilities and royalties payable, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, royalties payable, lo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ans receivable, and loans to equity accounted investees approximate their fair values, and primarily classified as level 2. At March&#160;31, 2023, the Company also held non-marketable securities included in other long term assets of $29.7&#160;million (December&#160;31, 2022 - $18.5&#160;million). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the liability for contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;beginning of&lt;br/&gt;the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Increase (decrease) in fair&lt;br/&gt;value of liability for contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;end of the&lt;br/&gt;period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trianni (i)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TetraGenetics (ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;beginning of&lt;br/&gt;the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Increase (decrease) in fair&lt;br/&gt;value of liability for contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;end of the&lt;br/&gt;period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trianni (i)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TetraGenetics (ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.9pt"&gt;The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.13pt"&gt;The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 10.7%, the rate that measures the risks inherent in the future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Company&#x2019;s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company&#x2019;s current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at March 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMTA5OTUxMTYzOTAwOQ_9da41746-7bc0-4b86-b019-cd5af1e6f390"
      unitRef="usd">29700000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i737052aafe7343188b2138b8a10bd9ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMTA5OTUxMTYzOTAyMQ_ae1c9c14-7aa9-4130-bddb-78abd37fdb65"
      unitRef="usd">18500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMzUxNw_fdc4047e-124f-4304-9a6b-fe083572ec06">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the liability for contingent consideration:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;beginning of&lt;br/&gt;the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Increase (decrease) in fair&lt;br/&gt;value of liability for contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;end of the&lt;br/&gt;period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trianni (i)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TetraGenetics (ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;beginning of&lt;br/&gt;the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Increase (decrease) in fair&lt;br/&gt;value of liability for contingent&lt;br/&gt;consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability at&lt;br/&gt;end of the&lt;br/&gt;period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trianni (i)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TetraGenetics (ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.9pt"&gt;The estimated fair value of the earn-out payments relates to a specific customer license ending on April 9, 2024, was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions include the amount and timing of projected future net revenues received by us from the specific customer license, discounted at 22%, the rate that measures the risks inherent in the future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.13pt"&gt;The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 10.7%, the rate that measures the risks inherent in the future cash flows.&lt;/span&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib84a76c6a7d040048417a102641bdd98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMS0yLTEtMS0xMzI0OA_9aa47fec-d1ca-42dd-ac94-2413bd04de1c"
      unitRef="usd">22934000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i22756f6454b64f73afb36c0c807ea9d5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMS00LTEtMS0xMzI0OA_becba53c-fc32-474b-aada-2e9b15c90d18"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5df4d4b94b884162a2e0a0a1c655b8a8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMS02LTEtMS0xMzI0OA_a0fbcf01-75ef-4e80-beff-2f7763486f45"
      unitRef="usd">22934000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i29a81d06f8df44d5835bbc3c04f6a927_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMi0yLTEtMS0xMzI0OA_f29913a7-83a5-48d9-ac35-2eaab7ad9e16"
      unitRef="usd">35886000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="ie5b507a22fd14249969fb3270137dd02_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMi00LTEtMS0xMzI0OA_54762e9d-cdc7-4e04-b001-09384838f28f"
      unitRef="usd">-698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i974a95ee817c4dfaa7fe8e4fd9971189_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOjk5ZWMyNTQxMTYxMzQwYzE5YmMwNjE5N2E1MjQ4NzA3L3RhYmxlcmFuZ2U6OTllYzI1NDExNjEzNDBjMTliYzA2MTk3YTUyNDg3MDdfMi02LTEtMS0xMzI0OA_53825f8b-114f-4988-b58c-86b27699301f"
      unitRef="usd">35188000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i38c6977e90834eb3bd8b3526452e9e35_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMS0xLTEtMS02MjU_f0beccfb-b283-4d04-ade5-d02fa642a06b"
      unitRef="usd">23505000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i1de9aa8ab44841868c7d65c602095235_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMS0zLTEtMS02MjU_52b3e500-dd66-458f-89d5-98cc2d55bb73"
      unitRef="usd">-2602000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i87414b0fe0f34080ae5ec5e948eafda6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMS01LTEtMS02MjU_ff8fe21f-89c2-4e2b-ad47-b7e00199fb38"
      unitRef="usd">20903000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia2d15a4aeba64cd299c7371834bb7abf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMi0xLTEtMS02MjU_f3981558-7385-4d2c-b177-ebf6a3dc2841"
      unitRef="usd">36760000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="i441987f8eb1e43f5b29f11eb02f70403_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMi0zLTEtMS02MjU_8aa380a1-cdd7-4b89-9687-4daec542c557"
      unitRef="usd">946000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie9ad3bc7b19842bea7e2bec41c9cce9d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmI4YzA2Yzk5ZWNlMTRhYWI4NTEwZmM0Y2ZhMTAxNzAwL3RhYmxlcmFuZ2U6YjhjMDZjOTllY2UxNGFhYjg1MTBmYzRjZmExMDE3MDBfMi01LTEtMS02MjU_f0ee34ec-e667-4308-9385-25d60cac99c8"
      unitRef="usd">37706000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i2f397da2a35b4cce8dcf8e1c494f9789_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMjI5Nw_f67467ec-2cab-4035-a595-5c74fbe6a65e"
      unitRef="number">22</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i4cae519cf0de46818efc75457121e175_I20230331"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMjcyMw_784c87db-a305-4b65-b788-7c2b855f867b"
      unitRef="number">10.7</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RleHRyZWdpb246Yjg5OTZmNzk4ZTg0NDYxOTk2ODNjNGE3NWNhYWZjOWZfMzUxOA_e1be9cfa-8339-49de-af17-131060afe422">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at March 31, 2023:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;260,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;144,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;603,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3827504d1bb4416a966243425ee8a0f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy0xLTEtMS02MjU_b95853dc-6ba0-4b87-aa81-e072ded9558a"
      unitRef="usd">108117000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id80012107add40658f9e2fb319a4e721_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy0zLTEtMS02MjU_8a190ac4-78f2-4e84-a29f-c745b76951d4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c929c76a9ad4321bf79186a9b2ab1dc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy01LTEtMS02MjU_5f2d70fb-e7ff-4808-b10e-022fdfa1bae0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8c4ad46a8dd94eaa84a356553b207755_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfMy03LTEtMS02MjU_f852feb3-1c1b-4c72-b406-6a9aed154e06"
      unitRef="usd">108117000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8aad9e0f529743d0a71e223bfe29146f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC0xLTEtMS02MjU_e80c617e-1086-41b9-8998-7c46243624ca"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfb27a06184e4e31aef700c5aeb48dca_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC0zLTEtMS02MjU_45cbaa3e-e818-44f2-ba74-e5ea2ab7f2ab"
      unitRef="usd">260756000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide7ef1452afe4c4580b20216f9d426d3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC01LTEtMS02MjU_dc0ad9d5-b708-4c02-86d2-710d9af83462"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i35bb901c7d87467e8fac6a7c4651c882_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNC03LTEtMS02MjU_073ec3f4-466c-46c1-af3a-3f31483ee9d6"
      unitRef="usd">260756000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa9fc66c28764293b5cdc58bd4e86731_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS0xLTEtMS02MjU_f9d82d8f-4c7c-4e5e-9df5-441336aaa408"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie292ab553fbb4ec4855d3b8096d93cc7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS0zLTEtMS02MjU_af245b41-ebae-4389-9227-69a0cb2e1802"
      unitRef="usd">68129000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i06261a683538461bbd86190f85931bf5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS01LTEtMS02MjU_121efd39-d474-47fd-920a-ddb3089c5e30"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie5785a70c9934456af3fe1177ffc0ee5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNS03LTEtMS02MjU_cff04a05-78c8-482e-adc0-c5637a28b45c"
      unitRef="usd">68129000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i303bc5d507cc4c54a23fba781ae5f340_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi0xLTEtMS02MjU_e07b800d-7587-4b8e-b65a-41da8d62b134"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icac73633a71d4e618363eb56e2a3a253_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi0zLTEtMS02MjU_22dafbee-60ec-4364-826d-fe41eed55c9f"
      unitRef="usd">144526000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if6594a7d2aa24288ab622eea92cdeba3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi01LTEtMS02MjU_b3d7a30b-11e9-4360-bb9c-3ba59e7940b7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb33227ca5de4db4a6b3eb5329ce0367_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNi03LTEtMS02MjU_ba5065d3-bbeb-44a9-9ce3-fa587e2647e4"
      unitRef="usd">144526000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i886bb35d7ce64dcb868325a77ed5372c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy0xLTEtMS02MjU_35adef48-240d-4fea-98e6-2aa044be11ec"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifea3fcbfe06448049f8dbed1665c5eac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy0zLTEtMS02MjU_837e9d4a-96f9-4319-af70-50057da7eef3"
      unitRef="usd">21950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1548cfd0b12440e2824883003e410515_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy01LTEtMS02MjU_a6a0427b-8bc4-4ccb-b859-c8a1375270b7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i820f7b961f97462e883d5674468dcf5b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfNy03LTEtMS02MjU_3f55a9f5-6d6b-4056-8110-f14edf88bd46"
      unitRef="usd">21950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ied7de4ead6ad466a85824c3b11e8d10c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC0xLTEtMS02MjU_8f52e50a-dcb4-47a3-b602-4282f43d8bcd"
      unitRef="usd">108117000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b8461fe0bdb4ab585ffcc851e599cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC0zLTEtMS02MjU_b19e11e0-30e4-424b-8233-49c2d803a77d"
      unitRef="usd">495361000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iabc26d6dc7a2499380b2727bb7a926fc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC01LTEtMS02MjU_c7e12f50-2335-4e33-ba5d-0f7068b268b6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idb56c4d8b7ae4aaca71bb026b154f0b8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF82Ny9mcmFnOmI4OTk2Zjc5OGU4NDQ2MTk5NjgzYzRhNzVjYWFmYzlmL3RhYmxlOmM0Y2QzMmU2YzUzMDQyNjE5ZDdkNDVhMTc1YjdiODExL3RhYmxlcmFuZ2U6YzRjZDMyZTZjNTMwNDI2MTlkN2Q0NWExNzViN2I4MTFfOC03LTEtMS02MjU_c4f1c0aa-0b52-4fe4-b997-db4ad80947b9"
      unitRef="usd">603478000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMjM0MQ_e9603aa9-c979-40cf-a4cb-fd147c4d87dd">Commitments and contingencies&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. During the three months ended March&#160;31, 2022 and March&#160;31, 2023, $44.6&#160;million and nil was expensed related to such obligations, and $19.3&#160;million and $3.1&#160;million was included in current liabilities as of December&#160;31, 2022 and March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has incurred expenditures of $46.1&#160;million and $38.8&#160;million under phase 1 and 2, respectively, under the Canadian government&#x2019;s Strategic Innovation Fund, or SIF. Spending under phase 1 of the agreement and such amounts are not repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of March&#160;31, 2023, no amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="ibbafe87c3597488486483c87064dca70_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTY0Mzg3Mg_f7c9a73d-92f0-4528-971d-19e936560d05"
      unitRef="usd">44600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfNDk0NzgwMjMzMjUxNA_16d8c450-b66c-4eab-b0cf-30e2ffa093eb"
      unitRef="usd">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i5f895582ef4c48da9ac1da31b476fc7f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfNTQ5NzU1ODI5NjE3_6a479c0e-8d3b-45df-8a0f-cd6132430e33"
      unitRef="usd">19300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ib92c33e75ce64416b44d79aa0e9d2f2a_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTYzNDYyNA_d4554663-010b-4461-ae9e-94ae4143cf79"
      unitRef="usd">3100000</us-gaap:RoyaltyExpense>
    <abcl:StrategicInnovationFundEligibleExpenditure
      contextRef="if4d9776d15fb44e9aa31ce79baa8cec0_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTYzMDE5NA_e614fceb-25cc-46a5-a76b-991f46712402"
      unitRef="usd">46100000</abcl:StrategicInnovationFundEligibleExpenditure>
    <abcl:StrategicInnovationFundEligibleExpenditure
      contextRef="ic267a77a490446c98ef71777d2d5ff57_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF83MC9mcmFnOjI3NDhkMmIwYTc0OTQwNjM5YTZhMGUwNmIwMjU0NWE3L3RleHRyZWdpb246Mjc0OGQyYjBhNzQ5NDA2MzlhNmEwZTA2YjAyNTQ1YTdfMTA5OTUxMTYzMDIwMg_89d07dfa-aa21-4014-b780-60d7f11bab30"
      unitRef="usd">38800000</abcl:StrategicInnovationFundEligibleExpenditure>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItNC0xLTEtNTI3Mg_24f5017c-e041-4c75-9d3a-f8174654d497"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItNC0xLTEtNTI3Mg_24f5017c-e041-4c75-9d3a-f8174654d497"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtNC0xLTEtNTI3Mg_8f017ef4-53a5-4490-b845-0a1c9b225309"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtNC0xLTEtNTI3Mg_8f017ef4-53a5-4490-b845-0a1c9b225309"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtNC0xLTEtNTI3Mg_48bb8f30-f569-41ba-a070-20906208da85"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtNC0xLTEtNTI3Mg_48bb8f30-f569-41ba-a070-20906208da85"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtMi0xLTEtNTI3Mg_92991d6a-4576-4aff-9f76-c58a694b9f37"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtMi0xLTEtNTI3Mg_92991d6a-4576-4aff-9f76-c58a694b9f37"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtMi0xLTEtNTI3Mg_03186103-5cfd-49b5-b43a-ec82449b0862"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtMi0xLTEtNTI3Mg_03186103-5cfd-49b5-b43a-ec82449b0862"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItMi0xLTEtNTI3Mg_c3cf669d-13d6-4d81-b4c7-ba4c94b8ed6e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItMi0xLTEtNTI3Mg_c3cf669d-13d6-4d81-b4c7-ba4c94b8ed6e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Exclusive of depreciation and amortization</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItNC0xLTEtNTI3Mg_24f5017c-e041-4c75-9d3a-f8174654d497"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtNC0xLTEtNTI3Mg_8f017ef4-53a5-4490-b845-0a1c9b225309"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtNC0xLTEtNTI3Mg_48bb8f30-f569-41ba-a070-20906208da85"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTAtMi0xLTEtNTI3Mg_92991d6a-4576-4aff-9f76-c58a694b9f37"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTEtMi0xLTEtNTI3Mg_03186103-5cfd-49b5-b43a-ec82449b0862"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RhYmxlOmEwMGI5ZTlhZDE4YTQ1YTlhY2IyMWJhOGEwZjA1ZTU0L3RhYmxlcmFuZ2U6YTAwYjllOWFkMThhNDVhOWFjYjIxYmE4YTBmMDVlNTRfMTItMi0xLTEtNTI3Mg_c3cf669d-13d6-4d81-b4c7-ba4c94b8ed6e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjI1ZDI2NzM2YmE2ZTRiMDk4OWNjYzk4NGY4YTc0ODc4L3NlYzoyNWQyNjczNmJhNmU0YjA5ODljY2M5ODRmOGE3NDg3OF8yNS9mcmFnOmYwYzBmYTc1ZWRkODQ4NjU5NTVkOTFhY2M2ZTFlYTM3L3RleHRyZWdpb246ZjBjMGZhNzVlZGQ4NDg2NTk1NWQ5MWFjYzZlMWVhMzdfMzY1_ad8f2420-e232-44aa-8ec5-a9b4ddb773c0"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKQVV!TJLJO?_=T(ID54_EYS!$KTT@.L+(=3^H+Q!_<W)]%]02P,$%     @
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MXSVKEUGL\^DUS(Y=+Q/R+Y",)N%PG-'J0QZ'21(?P3??RU@>LSO4=#4]03!
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MD6LZGY1/SM!N0WYNN3*47^.>0'85X)>AZ2GBCD&';AX[.L";Q>4>[&X$XR^
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M.VK]85C36XO&&]#^1FMWF/@#CJ_W\A]02P,$%     @ -(>D5@6G6?_U @
M? 8  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULC57?;]LV$/Y7#FK1
M)S7Z;2NN;<!IUC; .@1IMST,>Z"EL\65(E62JI/]]3M2LN(BB;$7Z8Z\[^-W
M1]UI>5#ZFVD0+=RW0II5T%C;+:+(5 VVS%RH#B7M[)1NF257[R/3:62U![4B
M2N-X%K6,RV"]]&NW>KU4O15<XJT&T[<MTP]7*-1A%23!<>&.[QOK%J+ULF-[
M_(+V]^Y6DQ=-+#5O41JN)&C<K8)-LKC*7;P/^(/CP9S8X#+9*O7-.3?U*HB=
M(!186<? Z/4#WZ,0CHAD?!\Y@^E(!SRUC^P??.Z4RY89?*_$G[RVS2HH ZAQ
MQWIA[]3A$X[Y%(ZO4L+X)QR&V"(+H.J-5>T()@4ME\.;W8]U. &4\0N = 2D
M7O=PD%=YS2Q;+[4Z@';1Q.8,GZI'DS@NW:5\L9IV.>'L^D9:)O=\*Q"8,6C-
M,K)$ZS:C:J2X&BC2%R@R^*RD;0S\(FNL?\9')&?2E!XU7:5G"3\S?0%9$D(:
MI]D9OFS*,?-\V0M\'Y6J#UP(8+*&DX0W/F&XYJ82RO0:X:_-UEA-7\K?SY5A
M."5__A37/0O3L0I7 ;6'0?T#@_6;5\DL?G<FAWS*(3_'_O_NZ2S%\P*?\,+3
ME4I1#QJ+-:@=V 9AIP0U,Y?[!=!=5<UT6?!1*V-@4U5]VPOF(+_18'%-";_R
MBGH9X35D\["<9V0DEV%9S)U1AG$R@Z]8-5()M7^ (@WG<0Q%6)8)Y+.P3"[A
MYO;N#6N[=]<PRRD^AK='@QB*/"Q*1YH6X3PKW5):AF5>P*95VO)_F9\">-]Y
M%63R)XF:?OL/30NP"M@IB!M 8WGK$Z+-K4.,57!O#<BH"F-U)-Y;V-&L@0=D
MFJ"N+:9"+7[60U7+G=8X+"XOG5= 'J9YXLS9HSE_-,O1I$SG83'+X+FO*SJ9
M""WJO9][[B9[:8?A,*U.HW4S3)3'\&$ND_ ]EP8$[@@:7\R+ /0PZP;'JL[/
MEZVR-*V\V=#O ;4+H/V=4O;HN .F'\[Z/U!+ P04    "  TAZ16!EZE5]<%
M  !T$0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6S=6-N.VS80_17"
MV08)X,K7O2#976 O+9I%MPB2-'TH^D!+8XM92E1(RH[_OF=(698WWDW2HGGH
M0[*B1)Z9.7-F1O+IRM@[EQ-Y\:G0I3OKY=Y7+P8#E^942)>8BDH\F1M;2(^E
M70Q<94EFX5"A!^/A\&A02%7VSD_#O=?V_-347JN27EOAZJ*0=GU)VJS.>J/>
MYL8;M<@]WQB<GU9R06_)_UZ]ME@-6I1,%50Z94IA:7[6NQB]N)SR_K#AO:*5
MZUP+CF1FS!TO7F5GO2$[1)I2SP@2?Y9T15HS$-SXV&#V6I-\L'N]0?\YQ(Y8
M9M+1E=%_J,SG9[V3GLAH+FOMWYC5+]3$<\AXJ=$N_"]6S=YA3Z2U\Z9H#L.#
M0I7QK_S4\/ U!\;-@7'P.QH*7EY++\]/K5D)R[N!QA<AU' :SJF2D_+66SQ5
M..?/7Y5+<AXL>R<42"HSH8TLG?!&T,=:^36(2TU=>LJP@3<3N7[8:'Q.%MO+
MQ8^>;"&D<^3=Z<##+T8?I(T/E]&'\0,^3,2M*7WNQ$]E1MGN^0'B:8,:;X*Z
M'#\*>"MM(B:COA@/QY-'\"8M29. -WD [Z=(Q"WYW&2B2QG3<&-4Z<5[K&M+
M3OQY,7/>0FU_[6,B&IKN-\05^,)5,J6S'DK,D5U2[_SID]'1\.4C84S;,*:/
MH7^G7']O'\2[G,25*2I9KD4NG0 VV7 :F'YEA*-*6NE)' Y_$!]"MI9-MOKB
M6J[S6MR\#Q8NB3)%6,&@$SCEA9D+F!6I*9'5.K82W)O7?!Y7<Y52#$/.#*P8
M"R_0'3_6.$W6)>*=$1FL]P-.UU%+J;$9>XJ&B+U*:B$+CMVQB<J:RE@VR+ZK
M,C4%##(!SJ%+^!P KD)W"]RI0$X35[(-Z[JVJEQP)0QW/=BA2>[R$N$CQK,-
MU/-$7 3'4%YIWM971&URI]KTHE=J68*;%2(]F(Z2"=J7UH@F005%C  PVG6K
MD!GX!-]%H2(0+-85QWAU<2T.3L;)\09)/#LX&B7C=BG]/=^>\S%&;^EHHQ&_
M0G;A^;Q&]C[+,;"D"*K!F !1""43@:DK6<I,R1(1EG?($F94W"BS#VC8V(99
M*615:97*F2:$9!<*$@<1F!<H""8]6)0+2\1!1H%;"'4=8X[/25JMD-8@0F5!
M<!$[Y=R:(NQ@9?%C52H?]),MF?4 PI!OJ?)4S(#1I@O.U55CP%NU6$0#*5F/
M(2ZT0BHS3B8M8X][V.TD%!\7L% .=9;6K*C9.NP"K63UFM6GV17^UY1-4[E-
M;6U2 GUY<4UI]+?)X3A2LT]S>,=P'@_9@B4MF7JNV77T:$> DY-DM-4) $NE
M^YL"PGN!7O?O:R7H]*;6Z\:-AXNGW#)R3ZW3HV384>MDVEGN46NW['[#&TV\
M;)4*?6@,AWC[Z9.3\>CX)=I4;!(;-KNL[(B])01\P/:-+-&BUEM=?%_%1^EL
M>>.&*'$0^F#M(9C[2CCL1W[0'*36W!Z7BM\-^V$=[#;*VV1)SI&E3@E,AIM8
MT4UU'2B*[UA,1"'O();< *?%=M^L</JDG.<[7R%WUE>3A:VJ-\XKYVJ8^B<R
M0M*BD;9-;,7$H8#(7.$$5T;M8I9#[V%B0@GU[VF,)^<]G>UH*Y3NOAK=4XD[
MSH,DY9IT1)7LG_+)=C8_.CYVAS\>-,=VQ]NS%NS?#+71T;VA=E.7M*=9?#[2
MX)NI;6"Z1+"--Z&(HI(";;NMY#@YW$I '!QVEGLD4.G:!9N=D19 YZ'],^H)
M<@H3T7B;:9?+\%ZS>S0USC>UT E#N?_#F-SWAA>H"A6,V2#6,- !>P2D3=[>
M,<MMH3-IMW'\!Y/VRWVHK8$.-EY)22UC+XU2[_8*A]Z(<;B9M4V%;07K-V^Z
MO/F+HG6?ZU8\_X:.L.^+:-#Y$B[(+L+WOA/A@R)^%+=WVY\4+N*7]'9[_#WB
MMI&CICF.#I/CPYZP\1L_+KRIPG?US'A,D'#)+_YD>0.>SXWQFP4;:']H.?\;
M4$L#!!0    ( #2'I%8*^S&U_ (   P'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;)U52V_;, S^*X17[&34;\?ID@!];-@.Q8*VVP[##HK-Q$)E
MRY/D)OWWHVS'2X<T&W:1*8G\^/$A>K:5ZE&7B 9VE:CUW"F-:2X\3^<E5DR?
MRP9KNEE+53%#6[7Q=*.0%9U1);S0]U.O8KQV%K/N;*D6,]D:P6M<*M!M53'U
M?(5";N=.X.P/[OBF-/; 6\P:ML%[-%^:I:*=-Z(4O,):<UF#PO7<N0PNKF*K
MWRE\Y;C5!S+82%92/MK-IV+N^)80"LR-16#T><)K%,("$8V? Z8SNK2&A_(>
M_4,7.\6R8AJOI?C&"U/.G<R! M>L%>9.;C_B$$]B\7(I=+?"MM>-(@?R5AM9
M#<;$H.)U_V6[(0\'!IG_BD$X&(0=[]Y1Q_*&&;:8*;D%9;4)S0I=J)TUD>.U
M+<J]473+R<XLKENEL#; M$:C@=4%",Y67'##4<\\0SZLII</>%<]7O@*7@2W
MLC:EAO=U@<5+>X^XC03#/<&K\"3@+5/G$ 4NA'X8G<"+QH"C#B]Z!6_)GME*
M8!_J99ZKE@D-WR]7VBAJD1_'0NX1X^.(]ME<Z(;E.'?H76A43^@LWKX)4O_=
M";[QR#<^A?X?!3J)=YSM:2?PV92HJ!M?*-U@CM6*SH?BA$"ERLNQ5O# =O0^
M&JGY *G(@C_UV3^#-':S8$+"9.HF:0I+A0WC!>".!HX>"B0[SU/73V,(,C>(
MK1>#BMNB607=-HVP' ,WB4):XW@"#](P,=C^P9K<)6X<1"1,IVZ0)+8'9%O3
M5=-WQH'?PQS\-=RC.,PV&+[,YAD$%'J866%"H4]AG_Y&JFY4R370U%7,\'H#
M FGHC #/D+A)%M&:I1E0,RLIQ OXU(T32I8[F8;'@&EB(1T6L%&,;M9M75@O
MJ1MF":T)K7WZV+_EY0RBB/+H6R&@BL9PK.F]@PE5H=IT<UA#YZ$?5N/I..HO
M^PGW6[W_3U#:-[S6E)<UF?KGD\0!U<_>?F-DT\V[E30T/3NQI-\5*JM ]VLI
MS7YC'8P_P,4O4$L#!!0    ( #2'I%8X (@N=@0  !@+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;+U6;6_;-A#^*P>UZ!J L45)UDN:&$C:;NN'
M+D:\MA^&?:"ELT5$$EV2CI/]^ATIQ757QQT&= @04^3=<W?/W9%WOE7ZUM2(
M%N[;IC,706WM^FP\-F6-K3 CM<:.3I9*M\+2IUZ-S5JCJ+Q2VXRC,$S'K9!=
M,#WW>S,]/5<;V\@.9QK,IFV%?KC"1FTO AX\;MS(56W=QGAZOA8KG*/]L)YI
M^AKO4"K98F>DZD#C\B*XY&=7B9/W A\E;LW>&EPD"Z5NW<>[ZB((G4/88&D=
M@J"?.WR-3>. R(W/ V:P,^D4]]>/Z#_[V"F6A3#X6C6?9&7KBR /H,*EV#3V
M1FU_Q2&>B<,K56/\?]CVLDD<0+DQ5K6#,GG0RJ[_%?<##WL*>?B$0C0H1-[O
MWI#W\HVP8GJNU1:TDR8TM_"A>FUR3G8N*7.KZ522GIW.:Z&Q5DV%VKQXED<\
M>P7X>2/MP_G8$KZ3&I<#UE6/%3V!%<-[U=G:P-NNPNIK_3'YM7,N>G3N*CH*
M^%[H$<2<011&\1&\>!=L[/'B8\&>7E$2*YB)!ZHM"Y=:BVZ%?OW'Y<)8387R
MYZ'@>^SD,+9KGC.S%B5>!-0=!O4=!M,7SW@:OCKB>;+S/#F&_E6:?CJ2H*,H
MAWU\N@+@]QIAJ1IJ7-FMP(I%@T/WRK_0@*7CUZI=B^YA4#1 !5O>@EI_:3D'
MM*&"T%Y^1@EX-[N&62,Z,+(K$=Y@B>V"SH=,1V?PV\9OJ"5\\FV%U2E<;ZRQ
MHJN<*\*XLV\4(8Y96B2,3T)X#N&H".$7RBZIPRG]O;U'74J7_)><A7G&>,9/
M2"Q)@#I\B?)1\%M35(EEO2M%B".6ABDKLJ*WP^':1VP >QN>JH.J4<+"K&"3
M-/>J6?PC6"9+X0^BF$<LCB)6Q#'YSY-1SG<<<Y;RC*5Q#CP<I>D>WX[4+Q2_
MY''*>!Z> (]'>?A]NGG,\C!A,?'L;9+M?\\WRW/.HLS1S;-1RO\+WS?S#_\S
MS3$K$BJP?.+<CD?9/LMA.F&<AP/+']&X;<(#@]8VCN"$BCM+\A-'5CK9I[X@
M+HK(,U]$WV<^80GU5#CQ;D2C/(/+ V+,L]'M0C7N2C$@[H1L/+TT/( T9B,<
M2X?XVY)U,D1L4W<0WK:6A$^D-IO*(6V%K@RL!@I<K&K/]2>N%UL+"^2),S_$
M+Y:6)'=T\] '$(Y@[CKJ=.&?AI*R3V.'<!5V]N0)E9Y;H_>];(0Q<BE)1G;>
MDU*14UVOU!G5R$HX!\AGZQ\;3R,%J%J$EXTRYL2'Y2S0=>RFGCO\Y[D9ZM:<
M41%K1&C[]Q;=>_MU3J(^?S=TR_MMAUWA'0UA:__4/8<)]7!&OQE+BA3FHG$\
MDQ3UP2U:1VM1).!:AVH/.]2B\>>BHC%$NG?2S5,$$Z<AI"P+,U\C5%Z^2R<L
MR1(X]/2-]Z:5%O7*SV1$H=ITMA]<=KN[L>^RGW:^B/<S(X6\DG0+-+@D5;I-
M)P'H?@[K/ZQ:^]EGH2Q-4GY9T^B*V@G0^5(I^_CA#.R&X>G?4$L#!!0    (
M #2'I%:A4CMZ?P,  +\'   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;(U5WV_C-@S^5PBO&#8@BQ,G;;,N"=#F-FP/!Q2]_7@8]J#8M"V<+'FBG#3[
MZX^4G5QZ[05[L46*_/B1$JGEWOF/5",&>&Z,I552A]#>I2GE-3:*QJY%RSNE
M\XT*+/HJI=:C*J)38])L,KE)&Z5MLEY&W:-?+UT7C+;XZ(&ZIE'^\(#&[5?)
M-#DJGG15!U&DZV6K*OR X8_VT;.4GE *W: E[2QX+%?)_?3N82[VT>!/C7LZ
M6X-DLG7NHPB_%:MD(H308!X$0?%OAQLT1H"8QK\#9G(**8[GZR/Z+S%WSF6K
M"#?._*6+4*^210(%EJHSX<GM?\4AGVO!RYVA^(5];SN_32#O*+AF<&8&C;;]
M7ST/=3AS6$R^XI -#EGDW0>*+-^IH-9+[_;@Q9K19!%3C=Y,3ELYE _!\ZYF
MO[!^PAW:#I=I8#!1I?G@^- [9E]QG,%[9T--\+,ML'CIGS*)$Y/LR.0ANPCX
M7ODQS*8CR";9[ +>[)39+.+-+F<&I7<-;)BKYQO U0TU;&)=T</?]UN*^G_>
M*D"//W\;7[KECEJ5XRKA=B#T.TS6WWXSO9G\=(']_,1^?@G]TKG\+T?XO48H
M-*FJ\EBI@ 6W4+^3LU0YKY% >81(WHH!-TE@KY)S E?&=>[X="WQ)J_(&5U$
M* K\X]8,)(;:YEQ-^,XXHN]!63%N&+:6WMWAR_TQO,,2O3\C]$KA<2!%T*I#
M'\=CC@Q6  \B:-''>62%Z=9H3I!;G,"Z  >>9,0RE9JMA<W++!5Q7W$X&X"1
MC+/5#P%]PRQCQBH7\LH>M*VXWTV,$?N+8ON?RH3/+4\6EH-NQ)8+T8=5_;P9
M*MAQ ;V):)5S!0FCE /+A=$YTAOUX-G)!;:%^# K5'G->R3AI)R<O'8%:))4
M2F=XKM(=H^38;/E.#RTT!6XH=AS$[)5!]M)@]IK'%<SFHQ^OY[*X'BUNIKR8
M3T?3;"&:VU$F3IT7FI)IJ#TB-/U40)D*7U*0PY!0HVB_Z>LL)^LJJ_]C^ZML
M?,M3SI@XL-GZ:CY>'!6CLR*8PT@*?&0::A6@5@5L$:W<-]-)>"Y>\652PS'S
M?=AIUQ%?%YX[;S5L>C94>594\>G@N^,Z&_KY>M*>7J?[?BA_-N^?-BY#I?EZ
M&BS9=3*^O4[ ]\]%+P37QA&]=8$'4US6_,*B%P/>+YT+1T$"G-[L]2=02P,$
M%     @ -(>D5@ZDN3 I"   [Q4  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&ULK5A;;]M&%OXK S5;) "M"W6Q[-@&'+?I!JBQ09-V'Q;[,")'XC0D
MAYD96E9__7[G#$E1CF1W@;S8H[F<^_G..;S:&OO%94IY\5CDI;L>9-Y7EZ.1
M2S)52#<TE2IQLC:VD!X_[6;D*JMDRH^*?!2/QXM1(74YN+GBO8_VYLK4/M>E
M^FB%JXM"VMT[E9OM]6 R:#=^TYO,T\;HYJJ2&_5)^=^KCQ:_1AV55!>J=-J4
MPJKU]>!V<OEN1O?YPA]:;5UO+4B3E3%?Z,>']'HP)H%4KA)/%"3^/:@[E>=$
M"&)\;6@..I;TL+]NJ;]GW:'+2CIU9_)_Z]1GUX/E0*1J+>O<_V:V_U2-/G.B
MEYC<\5^Q#7=GBX%(:N=-T3R&!(4NPW_YV-BA]V Y/O$@;A[$+'=@Q%+^)+V\
MN;)F*RS=!C5:L*K\&L+IDISRR5N<:KSS-^]U*<M$RUSHTGE;P][>78T\2-.%
M4=*0>1?(Q"?(3,6]*7WFQ,]EJM+#]R.(U,D5MW*]BY\E>"_M4$PGD8C'\?09
M>M-.SRG3FYZ@]Z%\4,ZS=I&XS7/Q+Y\I*WK;XC^W*U@ 8?+?8_H'\K/CY"EU
M+ETE$W4]0&XX91_4X.;''R:+\=MGA)]UPL^>H_[WG?0LF>-"'J4MWDMMQ1\R
MKY6X5]+55H7]SYD2=Z:H9+D3B?1J8ZS^2SFA<;;N*$GG%#9DF8I<RY7.M=>X
M5 1*J9!>K(G! S/0I3=""I]9I<YR]:!RD6EEI4VRG8!WY"K7"/!4K';B]^&G
MH?CE]O8CKH-*934$\"R"SXPC8E4-UJ!(Q"5GOE=)5NJO-2[5#G1PV(C2%X-R
M.Q5T'3JF:@-IZ.8VTTE&>SLA\<"LR&X020W9&"RU8*F=,&M^W".Z5X0>2QC)
MY,!!=RE^944GK<!T_+4V'B) J81,VD(6TMU^(7L"@H5.X0>=G#3RVX9PW!".
MA.% A[G*;Q@D>8UL!>+X#-P:B:(G>C);4HL9"OQHV<$[FHFGV@)D\QT=ZK+]
M]99E"U2G?3U+X_OT=3!YT'+8#[$??UC&D_.W_=#J!VEB4!N<)[,GTF7,CA?J
M:ZUA_Y#LB'0/A4EQ.HP:1LS:J:2V;#=HG22F)K*07FD6+1*YD>6Q'00&,8$)
MFF>@KAE+U &M2NZ8$8F&35NKPY2@?6MV,N=?S>TH: ) U>4&2@1%4T02AW-S
M*U@JD=;N<"W$F_M_;7%4Z;\K?71,]!RY_,1D'*(OFTW(JK+F4:/44EXI)-$^
MDUP@@]"%^S1"+<D1CWJM"4Y<2$ 1#\6M%_>4<%WMB#BX6LR2N3,B4WF*("S/
MCD;"/B\0F"%Y<@,#>V6+-NE@Y5?QQ? <%3G/R2>O?X*^Q0IW&[ZQ.!.O)LOA
MO+WR9@@A.H_>'7CT[I2KK<JE#XBUJAW@W,%*"2SH-)U#5K:TL>DWJ-H 6>^V
M2,FP[,OT3W06 >TD$:BMI1@"!.H ,PG@8A- B*&]HPLM]D=/P(YB[Y0F_:!/
M)&GFT#>)M35%GYDD<-,5*XV0"GG.L=R[X]!!XCS5CF-(5 IE(&V2"4\=I\:^
M&!#FU.4IQ D6L1QRZ B-5;W*QL%U"&%,')>VBJ&LDPP^(J)'R@YS:&3A A3X
MNP/C%?TR"U<G![X+R1Z*!WDJ!"U7<;I/C'L6.O0)'>XAF[U[PDN7X$+EK B]
MG*)>[C"=8O%K1PGQ]J%,, E D=>I"JLW'?^#BY^MEF6IQ6O]1KP2<1Q=3&=8
MG.U_?%;HO7Y1I4( .-SCB]-YM%PNL'B]N%@V&Y/E\D4QI]]'S&DT'\^)>QPM
MQC%OC:.+\?2$L(OH?#'&XF)&(D_/H_/Q0N"(7 >(8V!+CSA'25N>86#:1WS(
M>XXI*5RE$@!=THP#A$>HWR74@>84#(BU6P!C+BY8^5DDMHC:5!%B 3.X<6KX
M<^R )3@1PU: 1[!@V6I/71'T"L5C3;T*)9Q!\6V B!Z<%BFM;<MCKQ;G9PAA
MIS<EO42BAT2N&B +H!LPJ^"TIJR!T*SA&K%N_OQ&2(O,+*GLA7(35*U=@)5G
M!8TZ^ C(&<?_")7"ANJ#K28C0W99[;Z0E)3ZD*T%OR#*WE9#H5]P>(46#-F'
M5J9Y[.H$W9A;USF5"CPS9>L?][(CG[KNN-NHPPM^[[CO>9$-&UC[CN[9"Q*Q
M\?9%AQ#H 47<D*/0XAK;TB=:(+1J,Q)T&^L\===D/#S_3@Z[WS<!G_9-P"VU
M-+;+D*<-*1,H9"DWC-B"!D?4C-UAMY&9'&4ITYM, '92[=&!2];L>.?!6O"@
M\"!USJ=(.%=7E8$H1^5 Y2;^IFH@' JU \"I[N;TC,(EK9N#FFFAJ9+-T-
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M[L3/'Q]A1:*&V)TJ/7340W(G%KD64B?/?8E[(^:#W'-K3O5C*&_D^K4=WN*
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M)U;TU*%V!G2^4<KN%1=@?#R7/P%02P,$%     @ -(>D5O:S,[8M P  M <
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M7U1<:[$4)",:E]]"4JJ;5JG1LA(EMR029<:]:HXQRKRL$4XJJ?6I2X.U0".
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MG/#CAT[?^]*FVGN21>]$MJ=HMU&T>X@]_ [8+E*1)83EA11K,$HJ?,5Q5B9
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M;6^;.A3'OXK%G:9-V@J&\) N0>H:;;=2-U5]N'LQ[84+3F(-<*YMDO5^^ME
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M"$5>SJ#^_IAE\O5)V<'N!RN6_P-02P,$%     @ -(>D5MI8('>S @  (0<
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M0J^RN37);NAX;E-")D8%2;L*OF*E1W;ECX0A)D'3TC0B2,X4P1<K]"J03;G
M7B=L"KO107*F#IY9ZE7FM_0;.QW?;P W0D?:A>[UZSVR^\>P:5<:G2/M_PE?
MO]:K +8#[G::EKH1-=(N:C^IWJLHMO&]3I/"N4;AW':%^]\+OHIO:P<''?^_
M.]C>..',@$^+<UR!(K;(97G86;^MSXIORA-2T[P\:%;<*OL(E,)$=575I5K*
MO#R[+1\DFQ?GI6,F)<N*VQE056SI!NK[A#&Y?M &ZA/TX;]02P,$%     @
M-(>D5F^M.7FC P  W0L  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
MK59;;]I*$/XK([>J$BG!-[ A!21(;Y%.6Q24].'H/&SL :S:NW1W@4;JCS^S
M:\?0@T$E)R_>B^?R?;,SN]/?"/E=+1 U_"QRK@;.0NOEE>NJ9($%4RVQ1$Y_
M9D(63--2SEVUE,A2JU3D;N!YD5NPC#O#OMV;R&%?K'2><9Q(4*NB8/)QC+G8
M#!S?>=JXS>8+;3;<87_)YCA%?;><2%JYM94T*Y"K3'"0.!LX(_]J[(=&P4K<
M9[A1.W,P5!Z$^&X6-^G \0PBS#'1Q@2C88W7F.?&$N'X41EU:I]&<7?^9/V#
M)4]D'IC":Y%_RU*]&#A=!U*<L56N;\7F$U:$.L9>(G)EO["I9#T'DI72HJB4
M"4&1\7)D/ZM ["B$P0&%H%((+.[2D47YCFDV[$NQ 6FDR9J96*I6F\!EW)S*
M5$OZFY&>'DX73.)"Y"E*]>95-_#CMX _5IE^A$N8ED<%8@:WJ+3,$HTI6!6X
MXYE6,#)!-<)G[U"S+%?GI!9X@5=)?5V6L><IW/ $N3D"F.2,D]@!DV>WTSMU
MWG<UL3,8W:1B,BZ9! >8A/!9<+U0\)ZGF/ZN[U)4ZM $3Z$9!T<-?F:R!:%_
M8?B$\!I<4 :FJH8C'L(Z^*'U$!X+/HPIJ5*X%@55FF(V7B,I&9\C9;^&\2/L
MRDW8H]T>;9A,X>^_R"3<:"S4/TTA*_VWF_V;BK]22Y;@P*&25BC7Z S?O/(C
M[^T1=NV:7?N8]>&75?& TB3/M(S;UY56FE(AX_,+&.,\XYRFQ(OR(4$XRW@5
MVG/XU1CDDE/IM6.]FDMG/0Q[[:C7[?3==0/<3@VW<Q+<"_A(AV"R\T^!=?:
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MH78.=+Y1RAX,-VC#,YG]!5!+ P04    "  TAZ16KU]NP6X#  "$#@  &0
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M/N/!7#7-XET_GH'C0MH3A#PM9N3XZ(0<(97<"RD18%/F,"NOS?(V@]LF@_A
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M'#C%_9RZ4GJK=$F+A3IQ?Z0_0V@_@&U\@'XE[P..'.#(0_U*?NQ7QI0R?,*
MX, F[F?3?X3@3A.>^R+\N4+; V3C S0J>2]W339NFPR^;[*S4<D!3?P;=TV>
M4$/K#QK^7*&= ;#Q 3J4O \P<@ C#W4H^;%#Z3M!),"EY%OW3[9+HM6&\.<*
M;$\"5$L&:% F?7 R 4XFH09E'<@])XAQXVF0\LF:CT(_I(5!F5R[F.A-XO2D
M]P^K[#>LVE8/B"R4M2JO7FZD6$E=[N ^7RMEOVZ4SYP<'AF:_P-02P,$%
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ -(>D5AMA[>7C P  5AX   \
M  !X;"]W;W)K8F]O:RYX;6S%F5MOTS 4@/^*E1<V"6ASV8!IG02;@$H(T(IX
M15Y\LEHX=K&=CO'K.4Y6YD!WQ(N7IS:.ZW[QY7SVR>F-L=^OC/G.?K9*NT6V
M]GYS,INY>@TM=\_-!C3>:8QMN<=+>SUS&PM<N#6 ;]6LF,^/9RV7.CL[W;7U
MV<[B"^.A]M)H+ P%7R7<N/O[X9)MI9-74DE_N\CZ[PHRUDHM6_D+Q"*;9\RM
MS<U[8^4OHSU7J]H:I199/MSX"M;+^I_B58#\PJ]<7^+YU25'D$5V/,<&&VF=
M[VOT[7-DW )6'JXZ;]Y*Y<%>< _OK.DV4E^'9O I9M%C]/VP^QPZ\<3^3S>:
MII$U7)BZ:T'[H1\MJ "HW5IN7,8T;V&1G9LMV/ \^ =+,3R;1ZBHI^R)Q!MV
M*7J\E"A:@'8@&'YS1DF!'(*]X8KK&E@$61"0Q820WXH(LB0@RTD@5P$'?QI!
M5@1D-2'DJ">/",BC*2'+"/*8@#Q."_F1^\X",PW#5NQP/R)[09"]2$OVACOI
M AA&=8=5^QH1VDL"[65:M)6\UA+K<NTQ.M>FTQYC,-O@&-<2XOY[14"^2CRR
MV"YPJY',L0-EG#MD.,3(QBW$47M.A>UY6DAT,#+Y6\:U8/"CDYOP@Z=,@X\1
M2;,D5LL2IYZ^#G_*N'.HU!B,LDF>6"=+O07G0R7'I.Y[4!FN'?,F=&6,2?DD
M3RV4SEH("Z7OO %3\GY/-5XK.264/+%15F%5K(T28-VW?B;ZVYB-\DB>6"27
ML 7=C=8L98P\L3+>2HW[%<D5SCKG;5]]-(Z4-/+$UC@W;2OO%D68:K7I8S/H
MOP)S3NDCG](?H^U+3@DDG](@["#>5%,.*:9S"#OXPF-,RB/%8WLDP.&5.XP)
MR>-)ZO,)&:E'ARA**$5BH>P+U7O[DO))D=@G=S%[+Q?EDB*Q2_8&[[V4E&**
MU*<2,O(\BS$IV12)94-BCN)X0>FF2*P;*D ^8ZL8D])-D5@W-.;K.#U"Z:9,
MK)M_XSCV(;8K.A7.T3$FI9ORT74388Z3391SRBD/,6-,,BDVY2%FC$E9ITR=
M%R,QXY1324FH3"RAO0;'Z=FU+;>W\4:CI"Q4)K80B3D>=,I"96(+/8#Y6@CY
M5\JLI"Q4IC[T1)A/Z$&G+%0FMM!NXW9/9AIV 0W@RA+L,LY_4Q:J$EOH'G,W
MSKBE6^JA+6EB3,I"56(+[=]N_H&.,2D+58DM]!#F^1H=.LH;5)2%JL06>@CS
M;J;&F.3+F>1O9X@<S"AO4%$6JGH+S7;O,04T4H/XB'_AL+SFJOYL6?@8,K'5
M44B6-)U2YUCV27\P7.Q>B^Y>Z9[]!E!+ P04    "  TAZ16N#;$W*D!   N
M&P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=F[;L) $(7A5T%^
M ):966X14*6AC7@!"Y:+,-CR;A1X^R HX%@ITJ ]E;6V//X;?[+6LZ]0E>E0
MG^/^T,3>Y52=X[S8I]1\.!?7^W J8[]NPOEV95NWIS+=ENW.->7Z6.Z"T\%@
MY-K7&<5B]CJSM[HVX3\3Z^WVL Z?]?K[%,[IC\'NIVZ/<1]"*GJKLMV%-"_<
MI7J>CNY^D/YM<M%;;N9%N]Q(X7('*01I_B"#(,L?Y"'(YP\:0M P?] (@D;Y
M@\80-,X?-(&@2?Z@*01-\P?) &4<$"1UL";06I!K(?!:$&PA$%N0;"$P6Q!M
M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!;.Q_;!'HKZJT$>BOJ
MK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMG
MLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;X]Z>P*]/>KM"?3V
MJ+<GT-NCWIY ;]_9[";0VZ/>_IUZQW2M0GSV/-;X_'=2G6[WAN?C[\O'R<X+
M=<?9P>^QQ2]02P,$%     @ -(>D5E/9*RFR 0  4QL  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULS9G-;L(P$(1?!>6*B+&=TA\!E[;7ED-?P$TV)"*)+=M0
M>/LZX4=J1:,B*G4NL1+OSHR]TG?)]&UGR VV==6X651X;QX8<VE!M7*Q-M2$
MG5S;6OGP:I?,J'2EEL3$>#QAJ6X\-7[D6XUH/GVB7*TK/WC>AL^NU,TLLE2Y
M:/"X+VR]9I$RIBI3Y<,^VS39-Y?1P2$.G5V-*TKCAJ$@8F<=VIV?#0Y]KQNR
MMLQHL%#6OZ@Z5+%MQ9S?5>3B?HDS&76>EREE.EW7H25VQI+*7$'DZRK>BP[[
MG7VX8=H_^=7^G4R?8:A<6&U<F)BER^V.(VF[1R8(D?5E_Q%/CD'ZZO-1.^V,
MLE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A <MR Y)B Y+@%R7$'DN,>
M) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(6N"0M8$A:P)"ED3%+(F*&1-_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"
M% ,4    "  TAZ16!T%-8H$   "Q    $               @ $     9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #2'I%8(?P?F[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #2'
MI%:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ -(>D5DW10CRG!0  VAT  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #2'
MI%99;*&";0<   ,A   8              " @>H-  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    "  TAZ16.EFBX%T"  #S!0  &
M        @(&-%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ -(>D5FC9X:SJ!@  ?R(  !@              ("!(!@  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #2'I%9 ?G :! 8  ,8E   8
M              " @4 ?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    "  TAZ16G8C5[\L'  !<(@  &               @(%Z)0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ -(>D5I H("Z& P
MJ0<  !@              ("!>RT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( #2'I%;AJ@ELBP0  ,L+   8              " @3<Q
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  TAZ16K7.\
M+^8$  !\"P  &               @('X-0  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ -(>D5GLCU;/Y P  / L  !D
M ("!%#L  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  T
MAZ16) 7Z(V@#  #)!P  &0              @(%$/P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #2'I%8%IUG_]0(  'P&   9
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M970Q-BYX;6Q02P$"% ,4    "  TAZ16#J2Y,"D(  #O%0  &0
M    @(&S5P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M #2'I%9R*\::@@4  +P,   9              " @1-@  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ -(>D5J;=7WW(!@  *!(  !D
M             ("!S&4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    "  TAZ16=-NO900#   I"   &0              @('+;   >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #2'I%;/^ZHV_ (
M '0&   9              " @09P  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ -(>D5DUA;( > P  2 <  !D              ("!
M.7,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  TAZ16
M]K,SMBT#  "T!P  &0              @(&.=@  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( #2'I%92[PHR9P0  (H+   9
M      " @?)Y  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ -(>D5@025*EN @  A04  !D              ("!D'X  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  TAZ165*$#\#\%   W#0
M&0              @($U@0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( #2'I%;GM27)G0,  #D-   9              " @:N&  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ -(>D5LAEX==P
M @  S@4  !D              ("!?XH  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    "  TAZ16G)P0VQ\$  !E%@  &0
M@($FC0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #2'
MI%:*ATIVR@(    (   9              " @7R1  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ -(>D5BK?\HJU P  RA,  !D
M         ("!?90  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    "  TAZ16?GN5@HD"  "N!@  &0              @(%IF   >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #2'I%:W>G0.6P@  +QB
M   9              " @2F;  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ -(>D5MI8('>S @  (0<  !D              ("!NZ,
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  TAZ16Q&&^
M ^D"   A"   &0              @(&EI@  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( #2'I%;DL,Q'M 0  $T7   9
M  " @<6I  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M-(>D5F^M.7FC P  W0L  !D              ("!L*X  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    "  TAZ16FK?KZ5T"   R!0  &0
M            @(&*L@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( #2'I%:O7V[!;@,  (0.   9              " @1ZU  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ -(>D5EC*<OMI @
M\08  !D              ("!P[@  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    "  TAZ16'\H+O-("  #?"   &0              @(%C
MNP  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #2'I%:3
M5]TF1 (  "T%   9              " @6R^  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ -(>D5DX:@;U'!   SA,  !D
M     ("!Y\   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M"  TAZ16HXI.:1@&   ^-   &0              @(%EQ0  >&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #2'I%::0C12B0,  !$2   9
M              " @;3+  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!
M A0#%     @ -(>D5J5A4$\M P  YA(   T              ( !=,\  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  TAZ16EXJ[',     3 @  "P
M        @ ',T@  7W)E;',O+G)E;'-02P$"% ,4    "  TAZ16&V'MY>,#
M  !6'@  #P              @ &UTP  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ -(>D5K@VQ-RI 0  +AL  !H              ( !Q=<  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ -(>D5E/9*RFR 0
M4QL  !,              ( !IMD  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #4 -0!J#@  B=L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>125</ContextCount>
  <ElementCount>207</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Nature of operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Natureofoperations</Role>
      <ShortName>Nature of operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Basisofpresentation</Role>
      <ShortName>Basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Significantaccountingpolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Net earnings (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Netearningslosspershare</Role>
      <ShortName>Net earnings (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Propertyandequipmentnet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Investments in and loans to equity accounted investees, and other long-term assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets</Role>
      <ShortName>Investments in and loans to equity accounted investees, and other long-term assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Current assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Currentassetsandliabilities</Role>
      <ShortName>Current assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Shareholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Shareholdersequity</Role>
      <ShortName>Shareholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Financialinstruments</Role>
      <ShortName>Financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net earnings (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/NetearningslosspershareTables</Role>
      <ShortName>Net earnings (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Netearningslosspershare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/PropertyandequipmentnetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Propertyandequipmentnet</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Intangibleassets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Current assets and liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CurrentassetsandliabilitiesTables</Role>
      <ShortName>Current assets and liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Currentassetsandliabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Shareholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/ShareholdersequityTables</Role>
      <ShortName>Shareholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Shareholdersequity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Revenue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/FinancialinstrumentsTables</Role>
      <ShortName>Financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Financialinstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Net earnings (loss) per share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails</Role>
      <ShortName>Net earnings (loss) per share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/NetearningslosspershareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Net earnings (loss) per share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/NetearningslosspershareAdditionalInformationDetails</Role>
      <ShortName>Net earnings (loss) per share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/NetearningslosspershareTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Property and equipment, net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Property and equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails</Role>
      <ShortName>Property and equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Intangible assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Investments in and loans to equity accounted investees, and other long-term assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails</Role>
      <ShortName>Investments in and loans to equity accounted investees, and other long-term assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Current assets and liabilities - Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails</Role>
      <ShortName>Current assets and liabilities - Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Current assets and liabilities - Schedule of Accounts Payable and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails</Role>
      <ShortName>Current assets and liabilities - Schedule of Accounts Payable and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Shareholders??? equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails</Role>
      <ShortName>Shareholders??? equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Shareholders??? equity - Summary of Restricted Share Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails</Role>
      <ShortName>Shareholders??? equity - Summary of Restricted Share Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Shareholders??? equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails</Role>
      <ShortName>Shareholders??? equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Shareholders' equity - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Shareholders' equity - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/RevenueSummaryofDeferredRevenueOutstandingDetails</Role>
      <ShortName>Revenue - Summary of Deferred Revenue Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/FinancialinstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails</Role>
      <ShortName>Financial instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="abcl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abcellera.com/role/CommitmentsandcontingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abcellera.com/role/Commitmentsandcontingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0547-EntityTaxIdentificationNumber-Missing] Submission type 10-Q should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. abcl-20230331.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="abcl-20230331.htm">abcl-20230331.htm</File>
    <File>abcl-20230331.xsd</File>
    <File>abcl-20230331_cal.xml</File>
    <File>abcl-20230331_def.xml</File>
    <File>abcl-20230331_lab.xml</File>
    <File>abcl-20230331_pre.xml</File>
    <File>abcl-20230331xexx311.htm</File>
    <File>abcl-20230331xexx312.htm</File>
    <File>abcl-20230331xexx321.htm</File>
    <File>abcl-20230331xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>abcl-20230331_g1.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="396">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "abcl-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 396,
    "http://xbrl.sec.gov/dei/2022": 28
   },
   "contextCount": 125,
   "dts": {
    "calculationLink": {
     "local": [
      "abcl-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abcl-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "abcl-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abcl-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abcl-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abcl-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 344,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 24,
   "keyStandard": 183,
   "memberCustom": 18,
   "memberStandard": 28,
   "nsprefix": "abcl",
   "nsuri": "http://www.abcellera.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.abcellera.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Net earnings (loss) per share",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.abcellera.com/role/Netearningslosspershare",
     "shortName": "Net earnings (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Property and equipment, net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.abcellera.com/role/Propertyandequipmentnet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Intangible assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.abcellera.com/role/Intangibleassets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Investments in and loans to equity accounted investees, and other long-term assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.abcellera.com/role/Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets",
     "shortName": "Investments in and loans to equity accounted investees, and other long-term assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abcl:CurrentAssetsAndLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Current assets and liabilities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.abcellera.com/role/Currentassetsandliabilities",
     "shortName": "Current assets and liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abcl:CurrentAssetsAndLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Shareholders\u2019 equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.abcellera.com/role/Shareholdersequity",
     "shortName": "Shareholders\u2019 equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.abcellera.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Financial instruments",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.abcellera.com/role/Financialinstruments",
     "shortName": "Financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.abcellera.com/role/Commitmentsandcontingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies",
     "shortName": "Significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net earnings (loss) per share (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.abcellera.com/role/NetearningslosspershareTables",
     "shortName": "Net earnings (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Property and equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.abcellera.com/role/PropertyandequipmentnetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Intangible assets (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.abcellera.com/role/IntangibleassetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Current assets and liabilities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.abcellera.com/role/CurrentassetsandliabilitiesTables",
     "shortName": "Current assets and liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Shareholders\u2019 equity (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.abcellera.com/role/ShareholdersequityTables",
     "shortName": "Shareholders\u2019 equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Revenue (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.abcellera.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Financial instruments (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.abcellera.com/role/FinancialinstrumentsTables",
     "shortName": "Financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Net earnings (loss) per share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails",
     "shortName": "Net earnings (loss) per share - Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Net earnings (loss) per share - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.abcellera.com/role/NetearningslosspershareAdditionalInformationDetails",
     "shortName": "Net earnings (loss) per share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Property and equipment, net - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Property and equipment, net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseholdImprovementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Property and equipment, net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails",
     "shortName": "Property and equipment, net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseholdImprovementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Intangible assets - Schedule of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible assets - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails",
     "shortName": "Intangible assets - Schedule of Estimated Amortization Expense on Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abcl:NumberOfJointVentures",
      "reportCount": 1,
      "unitRef": "jointventure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Investments in and loans to equity accounted investees, and other long-term assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails",
     "shortName": "Investments in and loans to equity accounted investees, and other long-term assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquityMethodInvestmentOwnershipPercentage",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i0148f1e33c6b4510b7104f707a9f1015_I20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Current assets and liabilities - Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails",
     "shortName": "Current assets and liabilities - Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Current assets and liabilities - Schedule of Accounts Payable and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails",
     "shortName": "Current assets and liabilities - Schedule of Accounts Payable and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21720092b1fd485a91d701040dc8eaf4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Shareholders\u2019 equity - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails",
     "shortName": "Shareholders\u2019 equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21720092b1fd485a91d701040dc8eaf4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "ic2f5814bf79942159d756fd4d496dc6c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Shareholders\u2019 equity - Summary of Restricted Share Units Activity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails",
     "shortName": "Shareholders\u2019 equity - Summary of Restricted Share Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "ic2f5814bf79942159d756fd4d496dc6c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i2858e48f05f04827941d142a021d6fad_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Shareholders\u2019 equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails",
     "shortName": "Shareholders\u2019 equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i2858e48f05f04827941d142a021d6fad_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Shareholders' equity - Summary of Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails",
     "shortName": "Shareholders' equity - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Revenue - Summary of Deferred Revenue Outstanding (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.abcellera.com/role/RevenueSummaryofDeferredRevenueOutstandingDetails",
     "shortName": "Revenue - Summary of Deferred Revenue Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Revenue - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.abcellera.com/role/RevenueAdditionalInformationDetails",
     "shortName": "Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.abcellera.com/role/FinancialinstrumentsAdditionalInformationDetails",
     "shortName": "Financial instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i7306d677d41b4ccb95b7c5763ff0fc4a_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i2f397da2a35b4cce8dcf8e1c494f9789_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AlternativeInvestmentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails",
     "shortName": "Financial instruments - Changes in Fair Value of Liability for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i2f397da2a35b4cce8dcf8e1c494f9789_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AlternativeInvestmentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "idb56c4d8b7ae4aaca71bb026b154f0b8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial instruments - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "idb56c4d8b7ae4aaca71bb026b154f0b8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Commitments and contingencies (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails",
     "shortName": "Commitments and contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "if4d9776d15fb44e9aa31ce79baa8cec0_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "abcl:StrategicInnovationFundEligibleExpenditure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i0decdf41be2e4a30ae97c1a91fa5b593_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i0decdf41be2e4a30ae97c1a91fa5b593_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Nature of operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.abcellera.com/role/Natureofoperations",
     "shortName": "Nature of operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.abcellera.com/role/Basisofpresentation",
     "shortName": "Basis of presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Significant accounting policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.abcellera.com/role/Significantaccountingpolicies",
     "shortName": "Significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abcl-20230331.htm",
      "contextRef": "i21e8fde38826446494eebbcf2a22f7c5_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "abcl_AccountsAndAccruedReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts and accrued receivable, current.",
        "label": "Accounts And Accrued Receivable Current",
        "terseLabel": "Accounts and accrued receivable"
       }
      }
     },
     "localname": "AccountsAndAccruedReceivableCurrent",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_AccruedRoyaltiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Royalties Payable",
        "label": "Accrued Royalties Payable [Member]",
        "terseLabel": "Accrued Royalties Payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesPayableMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_BeedieJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beedie joint venture.",
        "label": "Beedie Joint Venture [Member]",
        "terseLabel": "Beedie JV"
       }
      }
     },
     "localname": "BeedieJointVentureMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_CashCashEquivalentsAndMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash Equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities",
        "totalLabel": "Total cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_CommitmentsContingenciesAndOtherLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Contingencies And Other",
        "label": "Commitments Contingencies And Other [Line Items]",
        "terseLabel": "Commitments Contingencies And Other [Line Items]"
       }
      }
     },
     "localname": "CommitmentsContingenciesAndOtherLineItems",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abcl_CommitmentsContingenciesAndOtherTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments Contingencies And Other",
        "label": "Commitments Contingencies And Other [Table]",
        "terseLabel": "Commitments Contingencies And Other [Table]"
       }
      }
     },
     "localname": "CommitmentsContingenciesAndOtherTable",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abcl_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_CurrentAssetsAndLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Assets And Liabilities",
        "label": "Current Assets And Liabilities [Text Block]",
        "terseLabel": "Current assets and liabilities"
       }
      }
     },
     "localname": "CurrentAssetsAndLiabilitiesTextBlock",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/Currentassetsandliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abcl_DayhuJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dayhu joint venture.",
        "label": "Dayhu Joint Venture [Member]",
        "terseLabel": "Dayhu JV"
       }
      }
     },
     "localname": "DayhuJointVentureMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_DayluJVLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daylu JV Loan",
        "label": "Daylu JV Loan [Member]",
        "terseLabel": "Daylu JV Loan"
       }
      }
     },
     "localname": "DayluJVLoanMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred grant funding current.",
        "label": "Deferred Grant Funding Current",
        "terseLabel": "Current portion of deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_DeferredGrantsFundingNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grants Funding Noncurrent",
        "label": "Deferred Grants Funding Noncurrent",
        "terseLabel": "Deferred grant funding"
       }
      }
     },
     "localname": "DeferredGrantsFundingNoncurrent",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_EquityMethodInvestmentCommitmentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, commitment amount.",
        "label": "Equity Method Investment Commitment Amount",
        "terseLabel": "Equity method investment, commitment amount"
       }
      }
     },
     "localname": "EquityMethodInvestmentCommitmentAmount",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_EquityMethodInvestmentOutstandingRelatedPartyLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment, outstanding related party loan.",
        "label": "Equity Method Investment Outstanding Related Party Loan",
        "terseLabel": "Equity method investment, outstanding related party loan"
       }
      }
     },
     "localname": "EquityMethodInvestmentOutstandingRelatedPartyLoan",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_GrantsAndIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants and Incentives.",
        "label": "Grants And Incentives",
        "negatedLabel": "Grants and incentives"
       }
      }
     },
     "localname": "GrantsAndIncentives",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accounts payable and accrued liabilities excluding royalties payable.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Royalties Payable",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesExcludingRoyaltiesPayable",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_IncreaseDecreaseInAccruedRoyaltiesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued royalties receivable.",
        "label": "Increase Decrease In Accrued Royalties Receivable",
        "negatedLabel": "Accrued royalties receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedRoyaltiesReceivable",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_IncreaseDecreaseInDeferredGrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deferred grant income.",
        "label": "Increase Decrease In Deferred Grant Income",
        "negatedLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredGrantIncome",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_LicenseBasedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License based intangible assets.",
        "label": "License Based Intangible Assets [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseBasedIntangibleAssetsMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_MaterialsAndSuppliesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materials And Supplies Current",
        "label": "Materials And Supplies Current",
        "terseLabel": "Materials and supplies"
       }
      }
     },
     "localname": "MaterialsAndSuppliesCurrent",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments [Member]",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_NewDayluLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Daylu Loan",
        "label": "New Daylu Loan [Member]",
        "terseLabel": "New Daylu Loan"
       }
      }
     },
     "localname": "NewDayluLoanMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash or part non cash acquisition property and equipment purchases in accounts payable.",
        "label": "Non Cash Or Part Non Cash Acquisition Property And Equipment Purchases In Accounts Payable",
        "terseLabel": "Property and equipment in accounts payable"
       }
      }
     },
     "localname": "NonCashOrPartNonCashAcquisitionPropertyAndEquipmentPurchasesInAccountsPayable",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Acquisition Right-of-use assets obtained in exchange for operating lease obligation.",
        "label": "Noncash Or Part Noncash Acquisition Right Of Use Assets Obtained In Exchange For Operating Lease Obligation",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionRightOfUseAssetsObtainedInExchangeForOperatingLeaseObligation",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_NumberOfJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of joint ventures.",
        "label": "Number Of Joint Ventures",
        "terseLabel": "Number of joint ventures"
       }
      }
     },
     "localname": "NumberOfJointVentures",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abcl_OperatingLeaseRightOfUseAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right-of-use assets.",
        "label": "Operating Lease Right Of Use Assets [Member]",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_PaymentsToAcquireLongTermInvestmentsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire long-term investments and other assets.",
        "label": "Payments To Acquire Long Term Investments And Other Assets",
        "negatedLabel": "Long-term investments and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireLongTermInvestmentsAndOtherAssets",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_PercentageOfConstructionLoan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of construction loan.",
        "label": "Percentage Of Construction Loan",
        "terseLabel": "Percentage of construction loan"
       }
      }
     },
     "localname": "PercentageOfConstructionLoan",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abcl_PhaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1.",
        "label": "Phase One [Member]",
        "terseLabel": "Phase 1"
       }
      }
     },
     "localname": "PhaseOneMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_PhaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 2.",
        "label": "Phase Two [Member]",
        "terseLabel": "Phase 2"
       }
      }
     },
     "localname": "PhaseTwoMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_PreInitialPublicOfferingPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-initial public offering plan.",
        "label": "Pre Initial Public Offering Plan [Member]",
        "terseLabel": "Pre-IPO Plan"
       }
      }
     },
     "localname": "PreInitialPublicOfferingPlanMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_PrepaidExpenseAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expense And Other Current",
        "label": "Prepaid Expense And Other Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherCurrent",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_ProceedsFromDebtAndExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from debt and exercise of stock options.",
        "label": "Proceeds From Debt And Exercise Of Stock Options",
        "terseLabel": "Proceeds from long-term debt and exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromDebtAndExerciseOfStockOptions",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_ProceedsFromReceiptOfGrantFunding": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from receipt of grant funding.",
        "label": "Proceeds From Receipt Of Grant Funding",
        "terseLabel": "Receipt of grant funding"
       }
      }
     },
     "localname": "ProceedsFromReceiptOfGrantFunding",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of long-term debt and contingent consideration.",
        "label": "Repayment Of Liability For In Licensing Agreement And Contingent Consideration",
        "negatedLabel": "Payment of liability for in-licensing agreement and contingent consideration"
       }
      }
     },
     "localname": "RepaymentOfLiabilityForInLicensingAgreementAndContingentConsideration",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_ResearchFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research fees.",
        "label": "Research Fees [Member]",
        "terseLabel": "Research fees"
       }
      }
     },
     "localname": "ResearchFeesMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued and Restricted Stock Units vested during period shares stock options exercised.",
        "label": "Stock Issued And Restricted Stock Units Vested During Period Shares Stock Options Exercised",
        "terseLabel": "Shares issued and restricted stock units (\"RSUs\") vested under stock option plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedAndRestrictedStockUnitsVestedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "abcl_StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued and Restricted Stock Units vested during period value stock options exercised.",
        "label": "Stock Issued And Restricted Stock Units Vested During Period Value Stock Options Exercised",
        "terseLabel": "Shares issued and restricted stock units (\"RSUs\") vested under stock option plan"
       }
      }
     },
     "localname": "StockIssuedAndRestrictedStockUnitsVestedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_StrategicInnovationFundEligibleExpenditure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic innovation fund eligible expenditure.",
        "label": "Strategic Innovation Fund Eligible Expenditure",
        "terseLabel": "Strategic innovation fund eligible expenditure"
       }
      }
     },
     "localname": "StrategicInnovationFundEligibleExpenditure",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abcl_TetraGeneticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TetraGenetics.",
        "label": "Tetra Genetic [Member]",
        "terseLabel": "TetraGenetics"
       }
      }
     },
     "localname": "TetraGeneticMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_TrianniMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trianni.",
        "label": "Trianni [Member]",
        "terseLabel": "Trianni"
       }
      }
     },
     "localname": "TrianniMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abcl_TwoThousandTwentyShareOptionAndIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Share option and incentive plan.",
        "label": "Two Thousand Twenty Share Option And Incentive Plan [Member]",
        "terseLabel": "2020 Share Option and Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyShareOptionAndIncentivePlanMember",
     "nsuri": "http://www.abcellera.com/20230331",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.abcellera.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r277",
      "r352",
      "r366",
      "r393",
      "r394",
      "r408",
      "r415",
      "r420",
      "r451",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r277",
      "r352",
      "r366",
      "r393",
      "r394",
      "r408",
      "r415",
      "r420",
      "r451",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r204",
      "r353",
      "r409",
      "r419",
      "r446",
      "r447",
      "r453",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r204",
      "r353",
      "r409",
      "r419",
      "r446",
      "r447",
      "r453",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r270",
      "r277",
      "r304",
      "r305",
      "r306",
      "r351",
      "r352",
      "r366",
      "r393",
      "r394",
      "r408",
      "r415",
      "r420",
      "r445",
      "r451",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r270",
      "r277",
      "r304",
      "r305",
      "r306",
      "r351",
      "r352",
      "r366",
      "r393",
      "r394",
      "r408",
      "r415",
      "r420",
      "r445",
      "r451",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "totalLabel": "Total accounts payable and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r17",
      "r396"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66",
      "r127"
     ],
     "calculation": {
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r132",
      "r362",
      "r371",
      "r372"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r92",
      "r347",
      "r367",
      "r368",
      "r430",
      "r431",
      "r432",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r437",
      "r438",
      "r439",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r78",
      "r79",
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r42",
      "r57",
      "r62"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potential common shares excluded"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r410",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset Backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r112",
      "r131",
      "r147",
      "r195",
      "r198",
      "r202",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r321",
      "r325",
      "r337",
      "r418",
      "r449",
      "r450",
      "r484"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r123",
      "r134",
      "r147",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r321",
      "r325",
      "r337",
      "r418",
      "r449",
      "r450",
      "r484"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r147",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r321",
      "r325",
      "r337",
      "r449",
      "r450",
      "r484"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Long-term assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r53",
      "r207",
      "r213",
      "r357"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "abcl_CashCashEquivalentsAndMarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r319",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r319",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Basisofpresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r125",
      "r395"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "abcl_CashCashEquivalentsAndMarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "terseLabel": "Total cash, cash equivalents and restricted cash shown on the balance sheet"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r39",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r100"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r107",
      "r116"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r222",
      "r223",
      "r389",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Commitmentsandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r437",
      "r438",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock, no par value (USD per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r418"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares: no par value, unlimited authorized shares at December\u00a031, 2022 and March\u00a031, 2023: 286,851,595 and 288,426,514 shares issued and outstanding at December\u00a031, 2022 and March\u00a031, 2023, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r136",
      "r138",
      "r142",
      "r358",
      "r363"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Deferred Revenue Outstanding"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r254",
      "r255",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/RevenueAdditionalInformationDetails",
      "http://www.abcellera.com/role/RevenueSummaryofDeferredRevenueOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r266"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r254",
      "r255",
      "r266"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract with customer liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/RevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r103",
      "r104",
      "r111",
      "r149",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r345",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r149",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r345",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r42",
      "r64"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment",
        "verboseLabel": "Depreciation expense on property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r42",
      "r64"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r143",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r163",
      "r166",
      "r176",
      "r177",
      "r178",
      "r182",
      "r328",
      "r329",
      "r359",
      "r364",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r143",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r176",
      "r177",
      "r178",
      "r182",
      "r328",
      "r329",
      "r359",
      "r364",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Netearningslosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r121",
      "r139",
      "r140",
      "r141",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r184",
      "r212",
      "r253",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r327",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investments, ownership percent"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in and loans to equity accounted investees, and other long-term assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Investmentsinandloanstoequityaccountedinvesteesandotherlongtermassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Non-marketable securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r95",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r331",
      "r348",
      "r349",
      "r350",
      "r404",
      "r405",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails",
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r330",
      "r331",
      "r333",
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r245",
      "r271",
      "r276",
      "r331",
      "r348",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r245",
      "r271",
      "r276",
      "r331",
      "r349",
      "r404",
      "r405",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r331",
      "r350",
      "r404",
      "r405",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails",
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails",
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails",
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in Fair Value of Liability for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in fair value of liability for contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Liability at end of the period",
        "periodStartLabel": "Liability at beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r245",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r348",
      "r349",
      "r350",
      "r404",
      "r405",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails",
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements on Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Financialinstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r129",
      "r217"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Amortization Expense on Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r61",
      "r355"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r61",
      "r354"
     ],
     "calculation": {
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite lived intangible assets amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofEstimatedAmortizationExpenseonIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r128",
      "r214",
      "r356",
      "r402",
      "r418",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r29",
      "r101",
      "r108",
      "r119",
      "r195",
      "r197",
      "r201",
      "r203",
      "r360",
      "r401"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net earnings (loss) before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r148",
      "r161",
      "r162",
      "r194",
      "r314",
      "r317",
      "r318",
      "r365"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax (recovery) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r106",
      "r117",
      "r429"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Tax deposits and receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Accounts and accrued research fees receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.",
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Accrued royalties payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r178",
      "r281"
     ],
     "calculation": {
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Stock options and RSUs (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Intangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r56",
      "r59"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net book value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r34",
      "r193"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest (income)"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in and loans to equity accounted investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements include tenant improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r147",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r322",
      "r325",
      "r326",
      "r337",
      "r400",
      "r449",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r105",
      "r114",
      "r418",
      "r436",
      "r442",
      "r483"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r124",
      "r147",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r322",
      "r325",
      "r326",
      "r337",
      "r418",
      "r449",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r6",
      "r7",
      "r147",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r322",
      "r325",
      "r326",
      "r337",
      "r449",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenue"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsChangesinFairValueofLiabilityforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r185",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Natureofoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r43",
      "r109",
      "r118",
      "r122",
      "r135",
      "r137",
      "r141",
      "r147",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r174",
      "r195",
      "r197",
      "r201",
      "r203",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r329",
      "r337",
      "r401",
      "r449"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net earnings (loss)",
        "totalLabel": "Net earnings (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r163",
      "r164",
      "r175",
      "r178",
      "r195",
      "r197",
      "r201",
      "r203",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net earnings (loss) attributable to common shareholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r165",
      "r170",
      "r171",
      "r172",
      "r173",
      "r175",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net earnings (loss) attributable to common shareholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r195",
      "r197",
      "r201",
      "r203",
      "r401"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r133",
      "r418"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Investment in and loans to equity accounted investees"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Equity investment balance, contributions made in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r122",
      "r135",
      "r137",
      "r144",
      "r147",
      "r153",
      "r161",
      "r162",
      "r195",
      "r197",
      "r201",
      "r203",
      "r210",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r320",
      "r323",
      "r324",
      "r329",
      "r337",
      "r360",
      "r401",
      "r416",
      "r417",
      "r432",
      "r449"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r390",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Propertyandequipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r65",
      "r126"
     ],
     "calculation": {
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r67",
      "r115",
      "r361",
      "r418"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r81",
      "r120",
      "r492"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r427",
      "r434",
      "r493",
      "r495"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r44",
      "r45",
      "r388"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included in other assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r72",
      "r113",
      "r370",
      "r372",
      "r418"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r121",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r212",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r327",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r196",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r264",
      "r265",
      "r353"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty fees"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CommitmentsandcontingenciesDetails",
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Earnings Per Share Attributable to Common Shareholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/NetearningslosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r55",
      "r122",
      "r147",
      "r210",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/InvestmentsinandloanstoequityaccountedinvesteesandotherlongtermassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r58",
      "r60",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r58",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CurrentassetsandliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r278",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Share Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested and settled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested and settled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequityAdditionalInformationDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockBasedCompensationExpenseDetails",
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options exercisable as of March 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options exercisable as of March 31, 2023 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares outstanding, ending balance (in shares)",
        "periodStartLabel": "Number of shares outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofRestrictedShareUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r73",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Shareholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balances (in shares)",
        "periodStartLabel": "Beginning balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/Significantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r71",
      "r121",
      "r139",
      "r140",
      "r141",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r184",
      "r212",
      "r253",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r327",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r184",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r71",
      "r72",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/ShareholdersequitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r51",
      "r418",
      "r436",
      "r442",
      "r483"
     ],
     "calculation": {
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balances",
        "periodStartLabel": "Beginning balances",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/IntangibleassetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r398",
      "r410",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/FinancialinstrumentsSummaryofFinancialAssetsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r186",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r165",
      "r178"
     ],
     "calculation": {
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r163",
      "r178"
     ],
     "calculation": {
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.abcellera.com/role/CondensedConsolidatedStatementsofIncomeLossandComprehensiveIncomeLoss",
      "http://www.abcellera.com/role/NetearningslosspershareScheduleofBasicandDilutedNetEarningsPerShareAttributabletoCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r426": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001703057-23-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001703057-23-000008-xbrl.zip
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MYWRBEM*DO/BT57:%8(*NQZACV_G1L7B^W8'^76S"Z_1L:Z<3XOG_C1<KM2)
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M^'(EV.K%+X->J?)"J/)<ZIU38S4).)]$DC@/0C/A'-#Z7#K)&JHJ/C!+[8Q
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M-&S%].78=$_NKPT?H>'<>/]KP(COI0@/@(EOA[8'YMNZV(LGW=Y@I9:CO'8
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MT*]M-DO'^,L0Z"\&""M+Y'CQ^Z\-SZG9'_>\1CJT4 1V[A ,,#*N_@0LZ=W
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MK?8.[==^^U__1:3Z@S*Z-KYAT"SZT&-[DI/PYXVAH_Y>06/L__X P'=C)/-
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MQ\N=QD9C<V?C]72ASMN*>D]YR)5_&0?Z:+NKQE4K[SQ=Z0[+O.<+FW]Y8;E
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MN<=4]N+ 0C_"]GC$;TAA*Z;"%]7V^)F!5V/K5HUS(I*W'*A)3!K *P2-C/1
M39*+Q/(H,#$KZWEEE>B?7MFI@BJ+;,VS":I4UOS UCRU733&X*,+N<*-0MS
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M1H%,$FSW1L!VHJ6KR.OBAK'R!8,+!JT2!C6:O!8TNAD:S=%7K#2SD4;$+>.
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MS*DM7^.?WSIA=  O40'5U+?&HL7G7[$.1G RNOPK#9AJ(F!,;'8JIO_-HZT
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M;;0VQT+B-B&+7=P?I+W8DCA_C3%\730<9NZ<_C>%Y-\EE:^$377#1;T5CP<
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MN/;'[!*$]3<>$,_5 2^;K^FEJJM]JAZV&\#]+GB%R[_Z *O\8L?SIGL>NUT
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MA27@39>_,2PMT:]*S47K#ZY+3AS#?-02B&/M,MK>U*IS;[(8A6:KBNOG*9E
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M6T]U;GW?,TH3E0L+*:DIXE$$I#T&*FJ$"THFF[Q?6=/3G%NPMPYVW1MW9O_
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MR,G=AN5WTSQF*!A)2RA\"85?AE#XT5WEYUO'8L>&/W.<_-N9J/<<1#\5XNV
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M5 2&33A966-UPV7=:%%.I<JIU.MX/QX'6O/S?LP.66->D6HOS]MXWL6K3;P
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MD5$I(I*8#RQ%84D^[Z:K6LTWP.>I[..Y.E,N<>/!]5N>.)( P^I5LLSQ=2Y
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MH@9*)HSB&BQ=R37S6F')@[<*%WZVZ#@^WOXT\" I!^-64N!GF@!3R\F]5G
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MHABKZE0VMA*TY:AHYAO8?W_)%9['SIJ9:K*ENXE0N(?GUUC>"23NM=P4!VD
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ML]WA7\I^]TYK./^FIQ8IKSIZDND@@<6E7DLKX)^5D[G?;\Z_H3OZ$?=Y?K&
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MS8DX5W7/5%5R;5'KLE;W#FOSGJ/>4GOZ#FOKGJO>Q\Z^]@,8WUGK?'8UT2R
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M[@%Q@<.Y_W].A 8R( D #EA+JUHH5T< JKC8HW*J']5BZPA '0%XD@B 4X<
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MGSLN[;MT0R;%S&(0>AG41H#.$VPJ NK@I00I78')+H!A!4%\%VTB56P('Z"
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MI")194CEY.C"0;;:DGME?&"I--?&.7?QG^,0T:4ZV6UZ.WN)DM7*QU:V_[B
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MWM2'U2S$=*7D:I1TG7:8;J''^E%Z-=/:_L=<[_./?8&NZH^-NMO.2)=N0_E
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M6:@N,5HSF)@>D TN2//PAY8.[!TOLLP -737B$-MF0\=J#5)#U\7P#+IOVC
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M]H#,C$#M+BX#^X6\^$9 )OG*D^:+R<B/K!*D#>::Q*%9$JKG'&=*8- S,-,
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M/](,9.X^T5P#*^A7U-((UVJ)L47[QJC$-ND#5]JH(=ZG((YSCA95#\?%:V8
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M5UZ8+$2_7 82+<)M&B G<>+,11=[$*JL(<&HK7,ZC"UQ5$F%\R[6: ,@Y F
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MM8])B<V"G+I;*%O.!Q =WAL+?@\$TO<>1Q&:Z54:->@U'Y/3]!T8S5/X_,A
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MD8BGF09"TZTI&F&A1\,2^F7ZS-8(1U!]G*R;YH%9%VZ@(MRAB&XE&TE^%"I
MIB;@*UN3,@9CYN<' I)+1()> 5LX!\/!-HJYL\5J&>,S;S/)K\[OD8IU73?9
MGPSA$.M;$<*K4/#P,478E57_UM1#P<M(J*?Y90_2+BHH$X&0SF9I+L_RDG%0
M>!MR+&]G$I<YBS]_V7(;P)X(4&O3SQ%Y:X**T?-(UQ#%&2WK.\E9W+;I=>J1
M:YKF2O2L^PN5A29;#$@3>]^1H8[*0SE+'L4GU6P0,>AD&Z=FY5HDN7BN*2(9
MI<LT BO,.*/Y(]"L%(?Q(P!'5C_+=8FF!H5_(2)45JA6 N&L\W7F22YM<;X)
M1K57B#9Q:K0;0I0 ]S8ZEDW'^"9=@NB?.FNR8-<3VN<*,6=E<[1""<;@;T=J
M*-:< )\OGBCG[R<'L%NUD#4<&DH]I;M0>P#I*3U;_&<?<S_[M !7IT+ZFJ*D
M-57/-J;Y(;D/V*;5##1/+3W1U#9I:UWS\H6DXURE GF7[=@@ETOJ#,<!G='&
MPCXT(++O]VT7RQW+M@^'WJ9MMFO?Y2)TYK8Z*';J,*<A9DLY&M70+:$3+U'2
M]Z5#?O6DK._FA_L<4Z\ DHBHF_@=Z8?4P!Y.7UR>P87;BDM7RY,@AC3,"!Y-
M!(Z\Z[;^@(!%86@%I1H\ *@*L)^';.E^: [NTL0OG5OZ9>48N)5K"P/FY^,>
M%,N\$L%T'\<#4?<T[<20(2Z\];;+G''Y)(L-#,[FFG>Q.*L(-HK3@S+9M&9;
M#[YOMQ<(A'@Q2KG3DP)ZECN14FZ8Z)73H%1,)4#[!]GJQ?/?4Z+Z^6?G< @(
M.MMA/' ; E0\K 2)>10K1QHGI)#6'K;.4<'/H#*^I/!%J8"';L.%J;DZYOE[
M/%M\RXDCRKA-WHVU2NC;?VGJF]/5ZQVE(EZDXR-=>?&J8SG+%ZM#I>2KLY\U
M70W6L38VX\E=GE<S&]!%A!7*Q"_)H\;S@+?E%B^.[=))6\$M^J53[(,YN<_\
MJ H!\OS(@N(_'&=RA&\%@I3.58X!LMU+$_7HI4/DDO''>&5ZW''^>76E4OYA
MT=\S[4NOUQWU!#IHG0N6Z2Z]"5HJ-$['&8U<0WAC-HFC92)1$5YS[H'A,?I-
MKP[2". +2_&+PQN2%]P6O98J-)D>X9I(\KWY!6$;HBV_#\^G,O?/#-*SQ>L6
M;8"/!'1PW-=K7!I.#!:QZ3:<#$@F=\-P8>#V\8P(*S$!^DR#,')2LI>;7%Q<
M*6C2%+H6G, B]/)=(_DC6S]R-E+/I-2M9X$.H:=XBE- 0Z$L1"=6C8Z:+TU.
MB^;/96T=#^68+NT\>3-O\+BB+NVJ8\9]&CN#LQ@X>,9W]=P4.=]Z43S&S8)S
M/4G)('8$R2PGB^%6L(ETVS$>EX*4X!B5#CN07_7!9JR%(,L"2JNNL[!%]"ZD
MS1;6^W @&D-QE2P]9]LO[72^?KV&5\6%UQ2K':Y0KXA)TIA$"-\8&HK]J]G2
MZK_"_9]?'_ ]D3MKQO?]:/<^" ^/0#.&]C8 9'E8GRV^<%J">D%^9W(Z;\5V
M)1]196EIB_-DQ<PUHLTA<FR=^65F.E4P<,6QI0-H^-R3&D\X9,C*5,6)R:=3
M!(AIY80?8B4<;^5#QX**]I;Q=T"<3ZD1OJ$!KW&*"8D$FE'J7;C)G0M]A"OG
M;V*G.!V&;**?BL16)/ZWIR+Q.V]LTN3A2B46^;J5U@IL*6C;P$V,+8*R?197
MHM&!HT/2\*)LXWLA-^1A*8?\?(Q<>1<88FO);=U>KK5U'XIH*.$VQ5,!;<DE
MK+H[W/MV.0)K_D"FU!TE2BAK!^7!T'%@+.Q<58I4*\K^2<#, 05CS< 5T#(O
M!B,BORIJBI/D,%M)#NIW4GO&VWH[S.SE<A1 T9OT+OI=#J^>T>NJ[I'WHA='
MU>+RW+6LFRF6VK0#1>B=. U\3SZS'?.>!%LTSQ9_%=E$/M.BMS(-'5X?]Q25
M<FY5NAZ05 5!]ZH=N190N(?6 _GN&51V\_$P??YBZB/Z;:%-7)% J%$GIAT*
M#XR?*-O^"]&W7K4<$RW2L</"D.EXK"L3#-S?-%V?%CQ'GY0,3<^-#QN MA;-
MSS7M49X??MST-#?M/MF2PQV9$Q]Y4V<#-;GI/U/@-'QL*&>J%(W-]K89L]S5
M=_2P:#*Z8R6"3BBZR/#D#T:N<'P=FO^BECG77>_D3%F5+ZPFZWA2J#5)6LA(
ML2CRI+F[H?H#UU3'YGPV&4:]:*,26<!U'C-J?6#:^T-%K1"QA>)L42@;K?@I
M&C+LZ\P !$9#FZAQ*\$7%YCD?Y4CLRP5\F[Z<-SJ=Z[)CPY./S(O+EE/@;+F
M-++03SJST_H7A"]Z@7L^K"4)1[N_8K-7A0#2DN*R<I\M7D_1/>> #1^Y72Y7
MX,?S.!]C6=E3^QIV'>5O*..QUP.D"M$5G:%DS$2Q^4,.37_-R-0B]TDPOQ 0
MXK!)=I$$EV<A2(L'($A<'>%6?;([$VA* 5%Z=V01+IVV]'K7>/=:N#T7]Y'5
MT48DJLHHA\;C^]:B(/*VJ84I\!$8H >%\3+'*-0J'=4S7^1P_UQHW+P8W5PS
M74G<KY-Q%9WOY&* +39'%VUZS5-)D7T<"<$A-;QP96:1*BZ=IZKBF]#9+34X
M]@1>;;)0@W.H5"=MB&2'E7J+1RB>8.;=0E?VEN@?:ZK]U^-!<&?PI)OAIMZ/
MT@AW%OS5G7,D'EHOY;QN\I(CA=1I8UUS^3'<,8JLQ;5\ML\1 J[4:=X1-B\O
M<QQ\1L%!I.5L.@S637"W!;NZW=;+7LCZ@'OE_+X8Z<I*F05$J)D#\0K8[O("
ME:+O#'W'=&IN<Z-W/PU&WC)I;O_C5LYW$"?VDGD,(I02%QDN2F;3]J(8$;[R
M)MTV^:77Z<E3N"""NOR(X2+5.W7-G@5'T, <3GN"6FX%-DT//MXTJFV&WL6?
MVQU#G)[_^R(9F\/-6-9=8/: #A:Q.+H67^%<JYVTX]6CNZX_SI1D=FA8RS,B
M686&P7)%/<6!:4V]NGE,MXD@U-[]_B@+S5U1LJ)C?#+%H6G;X!2()AD)&+.Y
MKETO+92K\B$[,Q,MG/VNB7'#K<X/P"581T1>,.ZG$D_:#N9NHKZ]!T%7"'VY
MN)C>WS2VZGOFZ/+LT)L^&0<2&Z)(A;->T%,(VHJ^-(P@1I'&'*@S4:@"<<27
MRRLZ\R6)@"2>K011KF);#YY E.R]ZPJ>A^MRHG."9N:M'FX1 WT \WRQ"TKP
MNN6J@($-SE;N; OZ(*KG-UL,S0YOJQ5F" .&.6WF#";Y3MC!MY*0"H/H 4OV
MLG@)Z]C&[@&)C31>DE *F%C8J(-FG$>N'0,Z((R7< _ND)IM"RAY<D1<"SX^
MQDQ3@G VTYP&JL*LEMJ/EH8@!F4<9L@7:Y;XXM(*@3G+,\"CD0-F+4^ 5L#/
MY/%D'Z#*>_\EK-7$\'::(5+)[Y +4G^KW9%;*!B:1[H1>L<@CH2F_8SC@+F/
M=6&U&^?BJ4DKM@JP:]$4%=PU.WG!LX]L8O'TL;83'" FX#M#>M.20N*^-\+8
M+%5G)S(/L77J!ZW7"\O*B,"X'7[U8NA/]?9PNEHV]1!R(_Z2WHJ>[ TM'CD,
M2OEQ-B8P-Y" M0[N_\O>NW:Y;619HG^%J^[MN5(O9#H?>EIK/LB25:4>VU)+
MJO9\ZP428"8L$F !1*:R?_V-\XP3@0#)E)V2:+/7FBE+(L% /$Z<QSY[!\UK
MJT53^3QIV+VA@,,(FL*DWF"[6RS%XAH:-DLWFI_<JSHC0$WD0@*(_)0R"GDQ
M/$W.9D+L5MAW,LW_8SX&L6GAR*ZQOKU<NB@0I$_<"S7( X]@::!D\7#,DE]%
M1/\4,Q&><.Y<@56!/@;NB!&2A2PX;3%+(1\'('2KR$#8S-APXR(^77JIKT.^
M>TB:\%'SL^?MT:%^[>O73_:U?OWU+)#9@^@CR484I\7L<K?EG9V^*!$5E]CM
M&B$V+@"\\":^]U!HW!W@AT(EXR(7]=2@130SM&0FBB(@+.NDB%$Q!;<-@?CM
M@V\JQ=DAKB5&1*)1TT'I+5F#^#*.M*&\@GESD488)R$+"E(IY^*-YZTT\ !+
MN&,NPU9O:7%5!T+1PC1%<@MZGZ"F*3FS372MO@Y#<T/B$Y+ :$4^(SZ7LB;#
MV1K,IVUZ="/4%47$CYA@13,'%7H9FMX+[*A&\[5KD/>5CMS/SAMOD#U,'2TL
M%H*SE>3'\_S4&I#U*T@=YDNS2@?)]B^AV!74__E0,J6#P>H;JQIRYOH^F"/Q
MJHC<[*"D=Z=+QERP:F^,'RL<Q5V_A&I$(#LC>)L9:58PMV1)$6&:4A;77ZZM
MB;#*$?EU8);]J=;=<M@$=WMN,:4NIM2SD>D)Y?-,YYA8<K4:<E4&GH(%QAP.
M[]VM&_EK['8&GJ6WMHEX"N,HC)XT!IMT[HO=_(9]B.1##PMYIP?0XDGHV(5>
MLE9?X-] ,^OHLKGF)+(F^.%!2& \@<*[$!.HAD_**G,9U0<31#.K4*Q0O>NP
M!>YP"]CZ1="F-B1\VD.B XB35JQP9/E'F.U?*;?[-F'*J'?Y:&C-LF1!D1!;
MA6>?P,*!R2U#CF,&==CQGQNQG/0#:X_J]EBMA.03LLC YY:TFF6A@4TVH=J5
MI'.U!CGX8=\V[Y[37'&P@\GB1 ?]#NH@.R:, 7HB_!]F\J&@(B,OK/[)H/YI
MU""N*NVJ7!,KMJ%9R@*1$PWD(K)=G'BE6C6T3$!A53)(G=X]: X?\!0'M:M\
MVI7<PAJ%+)A/X V!<Y#:?2H[P=ZOO.)H2D,SQ^QUH=N;2"PD2@L$-=&* A<6
M9>]KB8+'.O8Y(G)6G%J:-V8%+ *HB]Z%D3;\CJ?%CKXUPT8%=$MND0#FL /F
M!*C,L5M$>.J%2XI>B@K<_-MP[S%P0M+6RZ8 &F#*N>OC;1*IHO<)6?9X@],*
MTH'S6#;16Q"*)51)]=SDG);6CS,JQ@S.SS5A!#D, J- <F2'QHA;-$8T0;Y/
M4IQ6MWHW^!EN-TN<W'>$I:N;^LCG+Y%QDBOQZ(]Y;$'P04O]&Y+VTTGG\C,8
M+0,80_3_@+4YEJ\RMC%#6G7,15HJCJ['ONV6'M6@NS<O6WFQ$&""8$;T\-:1
MFH^;,R/HXU-QT0W+FAF(<:,$9]K@<<6^\P7[:+[SFJ13/&METN01;#,!W:O:
M"713K3.]YE&KP8M<!+H=5U4CJ6YC#;7[FS95#&S@_<6;*B@(K"_C"RJ_,3==
M/B9=EC._IL9HD=DG1&Y'2EL&+T(BB[W*IH406NZ^ILX%MO@,>\4*:J8L%)BH
M#O+49'I$/B7,IN-H<"AN,O&#EAXQSL@B/KGS:!7X8C8B#+K[GB=^17GQ<%1&
M*XH!F7L(IB"$!#,IL"*H 93%!8Y Y*VV=/I<IFB9SD+\K^W^-6VZH?,1B0N$
M_B2TX,2*<T*J&U&;2C2I< _=TP#XWL.>D==168[=0%$BV Z$#3B,5(Q(/!GU
MM<'.%B7W-T')35@L4@HTQOL?() W+9;"IISOVURO%=$9@'-(FTG(21/X%-ZX
MF8T5./N 30Y)D1CK6 ?LAUY#UE_.SI%:K<.-3IA.NJ&#6E $NK -7QO]<\".
MAJ3/+;0(DI['%3("D"A=!R,A,*_'B>,=X(*,'B6(G#D5C]-,B!SPG<'2<KO!
MP[WLR9K08U?X3&4GT/KLZ/#8T4SR6A/H#TK;) I+ERR<"W<7YBLP:.H#DU\I
M(FZ!ID:*(--]747=XUM6QX=OZMY]5L*PE#PG-_>!. A]#7<>[_J\0W]^Q&0>
M3WYDBI]PMZ%@EFRS;$,D%(9/8''=J:^5F,'>> ._PC*,+OKEZLC%#?!0MK/R
M7^!I0CK"E^V70)6T;D!I65R"+@?VI"M ,7$9F"!1"%B4[].'/J\+8W@:IY&C
M&][F%[C]W.\<@#8*M'EZ -K<]C*UV9^<E #9F406D[1Q#(,)A=$0\)^O4>-+
MU2[:7J-(E.YO@Z(;:<1DXB^E(JL@WBEZE#'+\4KE*Y0N('OG>-I]Q7;$-(@[
M7#E"VV4-.+XA,"W!/8-<,<%-D_ ?[4V3P#&.7RUC(E/F-[0=6^AQ=I]>;Y<Y
M=(LEH?T+--&XN9P!0D-COBKS"\?8SB@0$B@CV3/!#^&V$V;ONOC,$./;RJ$$
MR7>4:N(,_!^10M\M61YEO%/YU&&F^PZSV\$_<JXFF=G&(&EQ0TG^E#&"2$LD
M[FZ1ZK[VJ;\HIXW<W&UYT;N;LH'K&SK%K@ \-V=O7?+>6>C6#\2]F9;P-EG&
ME !N]H?D'I\KHA@I(WBRU4</<R%$:PM=DES(+*'FX3]O<H%CR93&"SJ/H.IA
MS@'ZKQZD(B'*X0]$83+09-;,KL'QKEBEH;9A ]J"74,L_CX- A]RJ\*.K+^E
M:NHQ;TM \2$8*LX^829LGE\UK0^)\(V)*HU;4YO4>PPG*DR_>._9DX./@'IB
M.D;WA;(@*9'"N7DWU)K67%935I284]_-]H@!9K#&.V9)MB,F_)4&E&A5CO?-
M./^*/+K7$#*2K.&LM(V*H(\-8.-NUE93MP_ 0E9U(O>6*"!Y5F<F:K4)2^H)
M!&^"G"[*C391BBD*$8RUYW 7\\FI4\:Y'ST"T-G5KON:8L!]6R4S"^*=YM/F
MBM<GVRV$-WD=DQUCX7J\;KWYD<,Z<O!\IC?*HQHX,K2^8QO*$@I2*[ 25=EV
MXJUJ _4PP^_O;$//$^8A$2>HHRW2X\PLO2ZEYP< :[/7=RW%'T_>7ZK@NA^Y
M\&CPK2U 8/^!5$:4VP63\"EC<]'=SBU0$KDRV%<U]6.M\-K)X4(,W"\T\/@J
MF5K?0UD[$CUO8C]#[R?B;AIVTW&>==].'7=I#NL5.N&TG#L@[8V6J4#F>>>9
M/59($^"V;:T:=N@#D"XQ#@P75F(-'K7005-51MVCX=%#\-5@VV;# C-X[I=N
M"V#WUIMD9GW8/\G'<-"%GV-GK 1.RN";>>%9,W>?,5OL7F*==.]VX)N!;60N
MO$5%";>0[[4&QRYG[]5C9 784KOS6Q>I1EGA$\_7B=5AJCAGVEG=V8>U05UZ
M:UO@M>V/PR HA;7!-_0 Q*'D\$B^)'BZD7$T8;G8\H"DB.N90=5/2D8V7J*]
MS7@?_@=@,T@*O-]\F<BGVRWTV<=M__LC/F^-;&,WTG&/&*?0%IFF.)]ALA'B
MIJH0MO6#/Y!(3O']W*E@D W\J[!3P;L-[AHF[O^H)\PD$:"?2V%OY'5;:%'"
M8_-I!DZK):D'/2Q.\E*MT/)1D62,G,\B.3Q10<W@  K2;/A*9XEO)RWG7DN,
M8LAX-1?C%;F<8_;2$\7"W ,+1%^M95[Z-LCPU8:LPT]A'8>U EWA">U'Q$2]
M@.%&2K'?D<#8.VA!.G]K59:VQ"T8/S0]D_^#%OG>U>I?87]EYCU#5 (IC :I
MGK%Z1ZZ[KIFO@?@JDTZI#.;FXWS17.N6T<8H=#.]]$9J3CU!N^1*"%0&S>XU
MU=WD/MQ<O9;HSTM#C<GSX -)7USH8C"CI*PJX(O4G! 8Y;VB!T0Y C2(S/[2
M$5M>6T)ZS0^K:$1'&#?BYDUH:D'<K,8L&ALH9G1LH:O>BN?A&>6P!0UL/]Y-
MOA[\6U]4:".PS@W[H49R[D4<13!^=,,;L ^TR&<?B6Z!Y76 W:I(3R[2^K9-
MS@'@;HJ_7!Z7"VA,GUO);S1 \??!H9(KE=R')X=*[FU-;5&!N$1/D 02D,9C
M-K"X)DJ&SXF!B!2D7[C_7SRTL3K?AMSF"LN8,\EJFR8JL9-PR@+CO(NYS$@6
MVOV <V!%&HD2Y4$T@D)1?9?^><*UBX!-R%S*5ED]OFA64KU+4V=:+A#.?L1K
M/<?_>\9_.L/_N\M+MFF_JHB,4K,;0+%<#>_ZKJMR=X'4,^_4A2Q,T'J^J+C6
M-EOS!J(O6FB0#TW8A8WJZ13(?@#&][KB&NBL;>:+OG(+Z,4,+1_4-%\N\KJZ
MJI;YU#1#\-EAX:KA1I#V!>.8O3"Q,O9(=%%FD(]E^!RZ%J7$"\=+:8D2ZKS>
M[^?$Z76MKS7HM1#J=:PRP&GA+^D9L9!1. QEV\+PJ2W$#FLP$A*"LU<Q]Y(#
M4,I%,6!R.@%B;_%>"#-G%B<6F"1\A $!4&7U3<CE[;D,-GH";, T*4951ZO*
MXVU:N=10AY(=(PAU;\%PMN#CO9MS#7F1+PN\)<L5HU21F.I1?P)^:L&*@<3)
M9S$=0B3(A"(!C=X2 CH_%"\C'U-6>W780#@]!0?WGI?[+/!5D7-D_AJSO^[0
M-MS<1>&D#B-0T_!OBO.$(RP!EKXL"_RLC1Q-SB(MJ>KUZNB7\?T'SFXV1HGZ
M'79CA9HI#4T"DQ9"M7_9=[A?4':2>3'DXF =;&<^+GKLVG@]'W47!S]&@ ?[
MU%G3 FL8RSG<Z&X=Z'#'1N79,/) 0F6SW;W\!#BF,X1)HQXC_ZB.!/>U3WA[
M)W9$*KQHRFZW49(A:.SFV+N\W,]TQ 001BT9XKV[1;2\DVZFW(0O-WMBV^+)
M$=<, =?(.RY<(>X\+#V+_2#4PY2.-082/MF4]28+:DU_('!#2SJJ'A.?Z8^H
MY*F>*L)X"2S1K>E6<W=VAX";E3O] CZAH7$7D:F;;ID_WQQLDH"1#(2719==
M.7EKJ4^;H/82@0='5F@[RRQN Z 47 ?]V)B=7:^Y^]S3_<4$[SZ;QLFY/F!%
MA1PL5,;AX]3 8Y6V&D/Y@[(R;=M<<VIXS'Z9!\)^8F;CC*%@E!]LKIJ/910*
M$#X<7E,$ /C*,:A1 4E X,QY24Y<^MI]!< %E!T2\AJJ9]/?%N:QOI]">FA]
M\I8O&A&IE1QU9DVESVNZ*5F6[J37%]@_FF3=9>\&U'80=(J'TDLE36]8[FF;
M&X3_.<S4&/'.J!*M+)'<.68,\[Q)6-^DLM@(+T4D+A01!MCCL/'\Q2ZR^#A5
MK:.V>-.0M%<6P?1'*,O&AI;'Z])VX6BI;>]2QZ\W32P;=:FL5,C76[200(2
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M6RQG-]%MT+X#6%%77E#&[Z)MKNG2&B8Y,ZYT(2(7:BCN\T@45<$9'0G7)E-
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MR2*K!3 *M29C&(O5RCHQ]*XHX>>'GD#P26UJ-NP%8ZG&!!CE):3E.[V5N2Z
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MW>2]=&:56FJ1-EE9O^-U\JU$YFC29>5KBD7%Z2?F^N4_9MQWNN F G%0-2S
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M6W!V\HQ- ORU1Y.>G3Y#2'QTM76;TP46U).SQD0.(-0@C9 :M8PG& B67J/
M&:J6%%A13.SUJ1<YX+/F(68.6^,]8*-;8\,.(Y>0F(6@-GR*&"5XT>88*Z+4
M/9=97Y6%BY07DW?]@LK%+ZJK:C%Y"]6T AY_>G9O>G_B_(<S FD\B@U_$%-;
MD0U._$!).(=H-GP%A#V;4+W5S826FB:CW!9R0]^69)KLXP%HIL@*F# "9\,U
MG'=5-[A_PIP!DXQMR.)#W;EDYO#TAJC'%G]S.&3K\'82H*V7TCI[::D\VBZ9
MXA3%5X-61=CXT"T%^!T233%^3'LGXT<*NMXWS2-T$7P202 %@N3N;\J!\HY7
M0:=-.4?V%*E3!\KH$V?W9H#17ZYRHG*+M5*8! T[\SW[10 92A5(18Z9FQ>Q
MX=%B1Z6@YDZK8#_\O"%6(GXJL]<S>H.?*M^-G\LM &OWWA>@Q"$ZRRE DC)J
M>=A07-[E'&0T-U9*Q[95!<"LMESU:RW_ S0+1'Z0Y@1C(Z*0(Y8L]!O&!WH]
M')ZRG_\9"N\S-.)Q^5VZPNZT[KYG97>;(R6:T@4BKG+;HYS+A#)<4@,Z.!H_
MTNWK/O8?S67M)YE@X%)$$DV=DC22ZIQ()L%.'1%>*:>^.%/]%A@:V"RW2.ZT
M**/4R_;8N6SM8O(/]^YEG=DO_G_=Y,6/;\@?DQ'##4RC=F?^S6S=2!BGX('W
M/0BNRSV>R"A,[OU7#LC9*VPK#)T]4EWN6"./\#IPHA9562B"#OG!V\EO#7P#
M[@(B""/N$GBAX?S!W](;3HRBB?Y<RLWGWZ8(5+F$^)/WP&$\RQX]?)@]/#T=
MO :8VLYL?77\O.P,K:=<^;#_PSP[MYM[73\;3"[='ETOQ)ZY0;O;'LAC6#V'
M_1$!)$/:W:(&W38H%_.):=Q>W.R?M7J]#<K*%S?&V532Z)!WT.)G/=4(.XO$
M-8FAGVJK2NQ8 ?MANZ2OK:"S2.0P]@XD]%. @*.]..3X(C0%E7G2]Y]@&TLF
MR)<P7.#X2-B2X3UA%X(1D$GZ>R+&)1="V6_Y.HIH\/&&1\FYVRS6),G9'X#4
MI>GH[2U[9CH71><JL@IO=("O*'SET0&^<MMCRLUNB_)3(L&.'3]&:VBBY+,8
MI6N"D5O-S6ESG[V %@AJK"<#>.PN[EE,56Z- 9G3\"G*=(;<L>3)(6Y6#C.'
M0]1,JZ96*8[F3<1%XBE H:KKCB2WP@-$KA,"V(J5=M%<5],^8@\-NI7XU8$T
ML8)?\'>RZ68S=%/@I/:S]8#G+9H,YUC\JZ>+<_(^:'_P[4=;;8,TEH__S$Y+
M3%:K:G5-_3N&UYNE+C:=X66Q+0K#CN_?![L>^87!_E+.]5"G''6U@C 9H^2H
M,^L+-LK<;2N,C\'=\Z$!(Z24/2@P;Q?P&K2Z*)C)I@G:0)!Y-\4.:M' /D3D
MZ0^I_@-Q<_B+WTEJNF>.Y8>PYS0DFC#6,?/S^3D\W.,9&6E0_+FIX8?@PWTM
MS' E,8!OS#T!&85($$Z\>,/QY!6:.EAQ0$>Y_\5:DV35G&>ZN/F?,GY/R?,F
M:<JS25I 1)YI]V;$K>]E%4+483B!=*/PM'DW>J3+]1_--1"62:*N7'5:3 -R
MGSI.L"7HSFV3,%^18R_2A7)9?]QKI'N5H:#@QIW8"]1V#.Q%ELJ,WM^//=MA
MSY'4B.7Q*'.H$5/;^%9+(U.S_28TKA7(-1*_\;!7=?\R_)L4^. 5^R[>3H;P
M)46_W\K:"T4*D[AD1*$@&7G+Q<]-P0DF?V)O4F;))-]6[E-EJ4XE4MOTD@<A
M9K4R*&U)0FW=+@RO'+GV3+^'WH"!M0F),H,W"9.58>K7O$CX$NG29Z*@.4;K
M&\G)FE(.><MQFF('&H50GG [Q;+7M$CV9V?"HL8$5^+Q2ZEH=9.@X:%5TEN/
M9)$]+VW,PY#J/2<+8\(%99H,#DIXF>PF.E@0!HR,:Q@V?&F!O]=U0"D U)M"
M8;:K"<T0K@#Y9V+[FV,H#/7M9H5SXY6L;D0O1ON=#0_GFCF,W-L)(DA)EC:>
M2=Z[,]7G#6C<)UCS14=>)>UE>\?M]A--ZNOV,M#J+:.INLD85:D2)?AYPKYG
M' E[O+ O=<_NKNP9J@!8AF:U0(R((GXI@D09C<TB*.":-(#9^MN$]G0G2+Q-
M+UPMU4A0G[X0B\5YXS075!!:PU;>PQ#I#;)R2+PB<NWB58NFD;> )-?3,1_U
M:E$A;T6@0:=F=R5P#T"[-+,>S;VS.  _X([E4G7)+$-+L";0^\@Q\06<H!K^
M&M:6[_J+TJV!TN D!ZUVEMPDTJ('Z$:-NV:.2D;U4?Q"E/ZU@]F[".RM^UH#
MW:"XLF5-+"/(=N2\E?(:^M%9,[;NP>71AB%935J18.;Q,XV6PX;*-,N&0"Q&
MJJ235M:(5'NQ@'4I5(!@E5>^B0O%$.U@-FT 5<OA0QP-"^IP5PA*ZM8D(J=J
MZ=6\1%,02%JD!PQW<8MTAXT>EE"O:80_'!TKRC\2P2(\"M-62!)0NKU8L$,+
MK@IMO;G*^0)L&YTQ*$/*BPJ%$ 4 BQNY=^7?X7)PGL3PF3+?L.D- $ZGDFSV
M</KU\QO70<A)XN.4&[%',0WYPIN&'%2'C$4P!D&86%&!#&V'!:8,IUOXD4AR
M$HGC&>@AW)3SJEU&RG7S$LV2\WR1YJM<K&!!\"UN,JZ>$J<MW(6X,!#@@>M#
MV?A\U2EWG@L'R&89V<4<N3OQ%8%^2[C<2-RN0J(LM[D"^V,I-5L TX6!><MM
MB=6Z]QN4[NO(H,&PO-N73]WK-/62J1YIY*&B2Y)5/A*WQ,P.9<^I,@&HF882
M5Z$P#'NA2KQH477'DU_"L2*D*R ]V3[R?..X!3=JX8U,[HPX<:P(@!]K-%61
M_DR[ =% (-K/+3S,K5E7M9GFZ>1Y0(<%1"C*<P>7'YI&J$7*QB<WEP30:WK[
MC)V?M$B[-3Z1Q4HS,L-QU3O=)I\LN_WFB@56"RTRC3B-^& "1P%FMV?D=2D7
M5T*9P7",^>M:9%VAH[!JW;P0_0]CJFX7;QQHXTVA]?&^%EJ_*3>9D>%(4NA9
M8VU6T^9"+=A3MHQL4G,@L%FU]KE17Y8":[-_OB8?9#ZL HT&]PJ&H_R8@6-&
MC(_."XP=5+S88!Z@(3FO6,.LAH*E,P"&#]@:?V<]"+ZY0"@TD\]C3 ^!IOO3
MH@* -3HQ:,7%H0"WEK1XJ"7XO]CE0<HT\CC$($K!6O0]R(.TXPB(!R4(<78_
MG[LE+^"=.YD>'^J*'0R,]3;V[LC$YDH4#\TO3<W5=H4+S$DA'6>/VV-$9F9%
M*7V+AB>X*Z<Y7\]O/R#K#>)$0C=X)#?R';)47O0+@KI33T^FLR$3^#GS@6 =
M;)>G%Q:%16#9N6Q:Y+4 :R?L#KXX;RB*0[):-QE+Y)\7J'@F2KD,05;2H5@.
M6,L0HJ+;JZ:0XA&\3A3V:!:E2 2,45X2!^C@I9.W,O7#[66.HF^U4@?;E/*1
M[G_F:\322BI,ZN=QH03YE1+DG>R1(;L"AUXB,63+ZWMFAG\M:;)2,Y7 -B34
MAF F&1,/II8/%A-7NG,*[FLV>5$NJMX=AA>JAX$..W*I,RQY9 P4WE>)G+A*
M-L,=DC&>)"BRSO.9;Z64YDHO"K9IF\BKV9C4?E!ZH?&2CPZY3=8;0@Y-86*@
M1_! '!O:JVO%)\])0,0(1U&V(SE.B*;D&>Z.VCYD?'T:-,&/4D]5JEW/'2I"
MX0J="LZ43P2F'@>'!:0K9@N%JI341MNJ_B+6U^A[LZ8H):W#(RF5I,8_--I
M[J9T^_LC&K@>QHXQ4FH\4CS_:#7S\/<L02<E^C !G&$FN7!'[(J8'H%Q6!/
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M"7I(0B-O!NYA\PX?L/@1#]QGIV7D57U%72:=043WJ'"5FV\>A0=3K_X\%J>
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MZNG7,\>?91:%#B  >W,<>LF:N.;VTC:#\6L,CM\0($(6#G1QKEB[%^&(>^A
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M1 #(Q+L9=N?P5LZH3!NR\$+^PO^[%7 689*ROL39](-U^[%<=JKVA>45%W&
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M"U:7)1 %((,R.4:<59,6]75JW?4'@3N)5]H]7D\#[WL1V"*.,_H&+?V"37;
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MK:])^A7)^DC'K,!-CY>%6]*.,[[8,8[Q!WZ-O30/,<!M CPW*GN@AT4RZ/!
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MU:AWO"X7A^6XN]NLKIM>C5<41=@D:H8=:>OR(J(&SB:_-154=MT#1.Y9N+W
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MX"(O34H9L\#2N =B.T(<)/MOQ KBO&MREC:057^FV'Z!I>' &\8T*6IO":R
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MDCH RER=FUR[OB=WGY47">;>R6A%D<Q)IVCV,13X<IJ"K*- .,5:YMB<^ZW
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M;1VP?;N/ZP#=NRO8S.)K[!RW-=>.#D]6@T87BM)1L60],ATL9Y"S9,D4F8(
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MOX]I&?X^=SX-YP[J47K6NC"=I6<@!&<\2!U-4)GTT-^.R2I8/_9.>C!?GVW
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M[OA+A6DM-4;JG3V55[4JR]>%6 6"PZ-D6D5VQ8E_1[_3-BBG(X-2<C%2C^"
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MF!@M;C:#LN[E)*%Y\UDH:/M>]8PM>30&.L23.?%O]*U'&D<&_^BO7$;\-3
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M+78%;D@MYW(SKHK$ +!$W(1^Y<=HAN*>:?_5^ OWKFI]MYU;>Q,'*W.76/
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M"6J1,FK/!]%&90ID)FJ;>!.4TL@Z7+U4=\NTR"7-JT&^\/[+/K4TW%Y!>"#
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M,LR([%DX$)%.PZ:[1H,/Z14R87%AD<Q&D@8M$KG,3%/8-)X/5\ 5T+>OY-S
M&D#.!TP!YRRXZYRW%%# [8RX1,!14-J"?L&Y%=PG4 S&9!S&_^S/ =W/ SW&
M!&W&!UW&"0W0!JW0 EW0#XW0"PW1#<W0$AW1#GW1%8W1%#W1%LW1&=W1&^W1
M(^TCRS$8+7+( 'N?*,&;7^J37]'-WNQ6["::+]$\]YL25UE$*?T248F=3J(/
MRD*9,EU3G7-/W4=U 0S/[(S. ^S([NS.#(RX4;W4CKRWD4>KM?\(&+.6?F/H
M9:',R[DLUF%-UKY<UF-MUFF-UFM]UFVMUF[-UF\MUW%-UW!=NGR2O7T!BMQ;
MS"@1#3B=$H8RHT0]6#D:$U&GOBE!J33GQT,)5G3J)#%:F(1M4<1S?!UX$)=,
MR5)=P$[MP)IMU05\QFDH+H"1'KLDNNAIJRQ&-*BF(Z_MVID49P#"&;4]VVYS
M,O4#(+2=2;*]V[CMVK>=V\']V\-MV\4=V[J=<,!]W,MMW+[MW,D=W;QMW,(M
MW;!-W<0=W;4-W;#-W<KMW;T-WG'VW=/-W-U-WN)MWL\]WMG=W.%=W<A=WMA]
MWNU=W^M]W=8]W_JMWO3-WOB]W_+=W_S_'=_;/> "7N#PK=T*_M[IG> .ON 0
MWN#NC=X4;M__[=_YC>#&87@F'1A?(:HGX:\I$:-?BI0\3=ENU:8.$!-,N"PU
M?8=9B>(MD:=J8<Q(8F@XD-<I[D_I$Q4"<SO+H R3[-E,;<F;+<E2[;=+O0%%
M\'BSQB."D79=W1$E\1!0%+IWL;D6PE46@A=109E7<\%<;N6=BQ5COCFS]V7C
MU3.NY.56CN7!W.6A"^8F(>; [.%?5A)G_GAI7N974>8SF1F=ZU^!/N<S6>=P
M/I.E78MZOG&A"Q*$#FR![N:B6^ARCN=?[NB>,^92\N=[WN9]+NF 'LR53NAQ
MWC.'KNF=R^EX_][H9A[JD:[FDU[J)V+IJ.[II;WJ8>[GC/[IC[[HKC;KI![J
M@Z[FN&[2NO[HO![LGBX:L\?GLO[G;!ZZQ@[G89[K;Y[HK>[KSP[JD"[LTT[I
MMG[JV)[LVK[I=][MCA[MX?[LU"[H;WX<=I[M=)[NO4[FW@[L:#[J\&[JQV[N
MJK[L=H[OSL[NL>[N:S[NUC[OA@[,L[<]^VM5) $88!&G*M&]*A$6*EJ1X\OC
M%B6@0FG3RX( .BJ8I-K8*G&0AI+-^S'9AA8#+?_QVZ0/A<IQ=Z,,5AW:2\ZW
MYAS/3;VW3,[93KVWRF!\Q?%B?Y&YI[WG/83T'MSG5S-^)X(571;UAO]W6ZLD
M)4AF0K8N]6UD]5T_]5I/]6*.9&,/]EQ_]EF?]IMQ]5Z/]56O]FZ/]G+O]F+/
M]G9O]G2?]ZD^]U_O.60?]FL?^&V_]X#_]7J?YH2?^'Y_]XP?]XY_^%A?^(K_
M]G4O^8O/]Y6?^9??]UO_^)O?^* _^7!?]J2O^8@?^:CO^9S/^GCO^F6?^I0_
M^K+?^K4_^**_^K8/^[C_][2_^[FO^J?/^Y!/_,(/_,?_^Z8O^,M_*EJQ+E1O
M'$T?YW_!A?@J'03*AT?4?U!H<=H_\T^%D'8,$T,$QZ!91-)CS4'8UYG('9/
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MF>="EZU(+_90'X]+(@M;'KR@#S%R(%X!(\ 8H$ $$6\:BJ__8$1(PB]-[+8
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M-)B$-YB$-'#I3+ T&8CIF/^>Z9>64$U(XQM( S]<AAJI7<XJ"=31:9B>A$S
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MRHD(S@NA6Y4B6_//OO-P+&<T!Y >SK$VWV0I !A Y[^/<U!,<\;_"M_9MO.
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MYM%>;)VV&E &^94B4WZ=B%*45TTD7&.-[4,40C-Y=-Q*"/%VTW%7_[E$5$.
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M39!$[X]HD4&*(+E61D+F_\X[TBDMXFF",D/!#F7+]$6#7J\53<6\#@5?% <
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M&]KA)I%962?4(6XRRDP:94\"RTC>CL/T9&ZTWJ6(+<I''O "/_#SXZH6Y"J
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M'=330B,T(#X1D1;,**EJ0AQ\0G_A)BD4CZ\C'AS<DO$)DB7+0'V2N%91PMX
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M+DB<I2\EPC/_^A+WDAQFBI0L!9!%\C$O!B9"&1"\04$(?)L@KN(AAF'],.)
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M8>PFX!G"43TY8K5 O%E#KC-.AW*O;]H/D5W;AJJ.]X$<%-:ZI5FI4EU+A[-
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M\91$0S[</47H !Z@Q\&.63 5OYS>B5RAG>581I5)[AT-H-1:<8K)&NE#&L1
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MU>IB3T2">(Q)Q/I*D_"@#34<4D<4A[,1-YBP++')#*]DZ3SAKMRNI1-ABC%
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M?E]+FXSY?%V9E!+_*$\EM=$,BF RK.BE*H"R(0U!IM8FTO\@1VZ[D]U\#IA
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ML"Z]8@MK O 8 P)3"3+8RY$*<[_LDI&^H@(\%2P68S\%TZ2VQ3*<;?H<Y)K
MY(^0 Z_\L('TT3,F[0X')4#V0>\^DX+V@1(7L3^*XS%0D\?Z*"$<T<6PU&ET
MPU@T 95^95"2+ :@9C^(07,RP6EXA6XDTCO2(+3P1CL8I)HL)2!%!UWW81)
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M8]=*Q^P:ILEPBJ',$I>']T=>$*,,\V(L8I )FC ,F0!#O((#TT$R^_ L..#
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M:I:CGRZB"MAP@9V7I\_\W.PS;<]J]2*%="U6)K6<[7?3F" #"]K* L07LK]
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MSF1!IX0I?L1ZRF0<9D&A^=5'>FDE8H,HI\RB"V0L44G+%JN57=K4+_FKF,#
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MO'I@K !X4V@=BPB**8CY:IC_&4])DREQTR/&L@)-(+;M-85[FW]FU!X*)<9
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MXXI^:HBDE#K.6&F-!NWDWISV)8CIH422^6.&G@)ZH);_47FEE3S9%\*RS(8
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M#KGHN&#JC6/2.!<,@>/0I?P:IEU:#K$!@6=J+QYDN, !PKW1)?HBOBF+M,2
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M[M@5-"H*;^0UYP.B<FD^IA&WXT,XHS"]='.DTG.T"UJ+9"&CCW$>8=L);:E
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M@>-MI[5_2=:,_$88EJR$[2^?A2I[@RO]=1)M7_%Y;PMG-UF>X%X+CC26% L
M%D#IOP7%((*]&(74UM9;O]#Z2&,T0OA5[ I?)=AK?8K(I'&/K!=="M43=V01
MOOJ4.=!:-)6DI8EYZLUZ=FT5<4I*M%7YQFJCI9;9*@:"$GN$QF0-I/F_&&0;
MWW<^F+H M'8%B'W0ZD';5V_?OF7[Z"%4:+"AOF@'#4:C%RVAOGW*!$ZLEW'C
M07W_]2YN%'E18D:% PN.%)F1H$:$(0\Z9+ARX3Z3.#=*++@19T2+(F465#CT
MH<1]25T^E,G18(BH2T*<B&K5*HBJ(;)>C:IU:XBI7<-J%4O6ZM>P8T^(_6K6
MZENI)J32'0MW+M:Z=N'N[=LUXLB8 TGF/.BQ(E&E$Q$R;NSX,>3(DB=3KFSY
M,N;,FC=S[NSY,^C0HD>3+FWZ-.K4JE>S=EP'%"@[H#[)C@W;SJ?;L%_#CIV[
M-F[;OFW+IJV;=W!0I34PW]#\.70-SJ5'=V[]^77JT[-OEUY9)<R*%PN>I,=<
M.W;TU-=W1]^^>_;UVA/&C!91Z?UE&5OS)TU,S TRX! @3H$X_-0?@@DJN""#
M#3KX((012C@AA8WIP]YY[:EW'7?L43!=!>F%J!T%S6T@V4 Q*;21?BMBM(PR
MU'V87H?1A3A==1M"=^-S17"T$D$'I?\HH4,O(6011N(]Q) ^#ADUT0TQZ!?3
M0T/>!)Y,]G6DV)$Y.>211S$QU!22B#6I%)4'*0G30"]EA.28%"WIU$5C!G:8
M4!TE-:=!/CGEI6+V?5D0DOI=I)"=:+946)=G(G938 J)]]*>3S*V49LX<124
MED8>]65A*?WX4&!(AF3HF'L*21^K4X9DIF)^TM>3IJ6&6NMX$TDZ$TM!-?3G
M3)R2>FA]-BU6Z)$7!6OF1&?FQ"A&I!9V**=-BGJ4L<32]RF7?;:*IJO3 J5F
MGV'J^M1"@F9$JU#A LF2N!.U*^=@YN)GKI9_,D3K8H8NBJQ.$FEYD4Q&ILNJ
MKH!-6ZV7&3G_VM*D:NK3%0AJ476566^)999;6&G@ PXQ$"AR#!;GQ5>4)),<
M)<LBM\RR#V-ML+(,+XLL \TWL$P$51M3+%7'9%6\1%5F(<34GOL&-B2681Y8
M(=112STUU55;?37663=FFW%<!\>';:74!O9KIM2VQVVF@%)V;:789G9N:LL&
M=VDS=LBA>QB^)]_>&:IG&4_U 498-.KIF#?>&.:M^-W,Y91K3R.%IS5_F@R(
M PYI$*-,)FG$D ;EH8L^.NFEFWXZZIM%LW>'(_;-.G2PHT>$9!O9GJY'+@:I
MT>L:S+CXW?"5V+MS=FL@GIH,M4AEA/7*FFA]V\*$Y$8QX$"GJ? :_Y11BIFV
M-.6\2_F[YZ2[#H62IJ@F9ABUE8YJ4ZPX@?<1L'Y62VU3UB(&U+:@UDI_Q!2F
MDEEU25F,R12WVF2F^65I5F,"%6$&PQ2>V(I,]L$)2O)5I3!!ZDW/^HF_?F6O
MF# E4KXBUDFF1Q&F("M:0N*@8!#6,,3$Z3"GDM[@1%(4+M'** KYH<)B^"0C
M&9!*X]L>3A2XJ<+(BHDX45I1 *A"@JG/2(-IRH'N!!CM)>M,.I0AH1Z20_T$
MIB3?$]8#?>4F5C')5G8BE)+&-\$EVA!8^Y/<K;[4J7V@I2L^LTM<AM:5$Q !
M9#' V<A"%K*@%>TJUL-!S01D/4E",D"*C/]DS( 6 B(HTGJ3)% D.UE)&6A@
M+VW!RBG]$I6')=%6YVLC0G:8NEG2LI:VO"4N<PD:Y,P&-V:[36ZZ]AIA]G(W
MQ5Q;,8.#'.-TC32%@T_LH@F\X37'>-#< .LJ SFE(,E/T5#&-9_S.QR1$W'1
MK%'BG%-&_(Q'(-'2I6:(<8.09>(Q3X,G/O.ISWWRLY^IB1&'J*D!'C'N.00M
MYW5<EQ[MG$@RB(I<FUIT)F@L T/CC!TU%5J\A8831Q@JPD%NMSR+Q.E!!X&E
MG,!3D'%1\4\APY2Y5@H3"J)+4G'RG[&XY+ [>I";@!+841;%)GO9;TM)P1>T
M]*B_B:@*B3,%8Z3_ /5%GLRK2W(ZC*=RI[!V<2MBT*H@$,?ETR^:JH!:/-A-
M?B(PI\;O)WB47Z#49"]K<41=*1WK"ITFUGL)2J>NZBM"0.*4+PZ)7-X,TY3.
M%R:EW:HDVUN*N:38RO8Q:4I4\B KZR0GF@;6A6C:'V-QY9)P ;5(>.HB8I^U
M*LXREF$2T^SYTN?3/P7*8$=4&L'*E">$Y4NQ!ERK4<JW+A(JB88#HT]= NE'
M56(L!!2HF?6B)$I/ K*/(0C0S4 IW>QZDD"9O,K,IJM=Z'92NCRC6%KBHA>3
M@24$\G+GET2%/DG%1*_^O"]^\ZO?_>83F+\4#B^%XS7="*<XM2DP,!%,_YO2
M@*B:#98.-3<PS@@;3D8UTE%E)AJ]*Y)'1]:$,-[0Z;L'2Y@Z//H=CY1$GOK
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M35I4>(0E Y+4-R%PVEQ)*5FW?3'(H)EF766''&C+;,CD2@9-YV"I?L\W&6&
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M$97AX"XA ,'2YA("!YBS"'QYV@F\LC2WU8UA7)$:5>;R37Z:)2Y/,PQ'$--
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M&H1&TF!'C 3UA<AY(O]GSB4Z??;,"8(G4)Y#>2(MBG0ITZ9+CS[EN5.H4Z!
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M*2GKEE=8RQ.FZX!H@A\16_BYS76K6]2R'@UM6, AR41;<2HR 2-ZQ!ZA!5?
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M6>D1:F#.BIH21*6-+2^VV6V6R,\",::5S-^-7?2P"OZ 2.IB3VF6BQF;:[+
M:?0(6..%5$K1)9G)TZ4YZJBR5.H6*KN$#VFAI5*1SU@-F T5)EJ$6-[ESP(5
MV7#R(?[,#[3PCMC%R5*MZ@?QY4[=FYEA(A."V:):&A=R&JT(%4WTW$$-GO(
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MKY2 "2-68]@P FR*Z9U@J_S8;<0B V@X)&<(T#8@XN!$0G ([H\*<!K![6^
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M#Y8D+UD9, W[EB5;D"F9H[[G?-]0NM@D@YZJ\AW;SEBW[>[ME-*YS5%,LV^
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M1M ^2.YXI))#:MGDC44VV>261PZY9)=G:K37E);55>&;#4ZBWSZ:H'%>>FC
M!^>>?/;IYY^ !BKHH(06:NBA"$:3)9!:9MGEEXQ&FJ.-BW99A'A$92IE1PX%
MY6F7.T+J9)E,.EJJI(_:>.E$8JFU_UFA"'EF4% ^O302252-=!Y; WFD&$L1
M+561L"99.=5 >J$4K$,T#609KAA1]I59$"%5TK6:]2IM3SP1A5BU2F7ZT4<8
MV042LN'>-1&QV_FE%D=X1971L"!%!F];!1665&$:D?56LUFYZYE*915%%;-5
M)337N]J5]->S28'%';E6=J6LJ_TR9.5#.F7V*[(:UVO3=8 E?)EBU>X%4[!2
MDK36O$D13"S%8PT&%W8NC5N082ZEU6MC4^GE;<9IS4L4K<Y:V=9&X'Y5<6,@
MA=MO6\.ZA1U'.0<,+DOT)J0RU8V92U%$<*T,&,=$O^KLSQY[E?.\;Y'-5F^B
M 3<;W773YO^;<JQ!=QMRJ2F!]W#0L69;=+&UMMIMB8?VG&M]\RV:X*TAM-*R
M>"U6TG9$1801HA2YAUY_WI'>G3YWIE$Z>C%,!?KKL,<N^^RTUVZ[GRS*^*&+
M)9*HH8D;:KBB[\$7;Z(I'[8(2AT.;K"EDS>*";WTJ$IJ?9?_1:OF6"WE-#VE
MJ7X9/O2D@IHJF*ER#91C&-_^IACIB:'??*SC@(;K[N>O__[\]^___P"D$)%
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MG#FJV3/-##$OR1)W?#OD*$A4VR?0_#+6BC,9,0P52YHF\Q)C.HS%Y)#\H#D
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MVM*W&ZC:GU &MZIBV5+:P_7B+P9CE)32QE)23BDV3=D#(ZW) ^1:Q%*V%1I
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MZ-%'((((AF?@?0D>A9!1,47C4' 56G@AAAEJN"&''7KX(8@ABHA:- TBR."
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M4D]IY'&86A&1B)+#$\:N= M,5+S@N5-Y0:I9E,,A3V8E,8;0)'7H7)3A7@I
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M7;Z_&1-=K^B;/R73]6U!RVC(B[N8@I:,9.>";+SN3SO C;/& Y5TRV44B*]
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MT9[F:SN3QR+SRT6&1)^ $A$<K(EE!V?F=+X"BRISLFDB920]^U(K>&EBF&J
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M!&8M?7F,1XI"UX)H9L9XG>E0< K9NM(TL0W"L(I/Q%*/-G:S'*T)(C'<$;#
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MPNQ;LQ=M%6$G8Z2.FOO:C]1(6I2!5"4'%B\5E9*Y;=1M8Q#<PT9JUK4$M=1
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M7]JM%C&42>RB\PRF*_P715F43WG.*U(2SHRR(I*7Q-LQ5@E$86R55X%$#O-
M5+J2'6,[PJ*6(RH95\(4FQL]Q-P2LL1.6P'8:*FPB!47.TDN0G'#W5HY;'*G
MX#+"H1/%[ARZFDVBFC/&[I03!XTES'K.?#4C=3U+/YHB-;(M?^--B&LB=_)
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MQ0&^1Z%ZS4^5KV3=+OKR7?%9,[N5S@N#&&EVH&X8E?:@DFY,1?'I)?XUZX*
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MZ*V#[:DT4C-RXP,QADU[N3^/8.T23(H;9;>>;G]WTV_46RWC=_.6Y?IAC7/
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M;#)4XZ. 0JHEJ<I&3Z  [6)?9V%<!V]%YT#IB#R]XDY)4I($ZM,&S\[ZRL\
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MM861>[JG*CT^"X4,;A1M+<O:VH9'N]4.]J@=1J4=#"V/3!['@2P21IN="M-
M1>E\[,]^[0<>%#7:_&#DPR7:\VEN\(CUPZ#DUP^RM05']+C;_8CU7.X3S,0T
M(4/ES/L/RIOC("G+NOA(@*"W;R#!@@8/(DRH\&"]?=$:-MPG<-^R@0*AU=-'
M<9^^AC%N1+,835_%?1$KALQH<F#'E- D#BQ);V0]FC'W8=384=]#F"9[.JQ)
M\F8T@2UY[H2I;&##AR]7%MTH,:5%CLLT1JSW<NG_P*4889+D*53E4JXE3^)D
M2K7CRGU<A59DNW)GU)])&VJ<R58NQJ]56TYEBA6H2J-:W3(-.O+J1HR+L3K4
M6U+J3)]9%]^4VW1B39,:41X&?'FEX\:'(TJ=FC=DQ:4]'WX.RC%CT9!O9U/%
M##GJRZM A_IMN!3PU<YX:<-\&9&SP[">TS:EN'KV8*G+:=K>"-3POA#>OX,/
M'_X$"/$A3H1?XGT)>O7?VYL/7QZ\^_/UP<_WKN0[^_SFT<='WW?[B0>@?^C)
MAMMS)3DE76ZT=0::<AH-=YQLI6TD6F^SY:0:8Q9"AAALB-T54H?7=;2A:X5!
MU1ESM0T%TT,IA31192,:_R7A3PDNU*.//P+9E1@XW$!,03?(<$./0\80I)-/
M0AFEE%-26:655V*9I99;<NED':#8 0J8H'P2IBEDVF%*F9^8\B4H>XAIQR=C
MTEFFF'2&B>:<<H)IIRE90J/!!AH(2NB@A18ZJ***)MHHHX\Z&NF@6QJJ006-
M1HKHH9MBN@$%A5Y:*06<:IJE/I46.BJAEQYJ*:J<0@JII)5RZF-MAXUTZTLC
M8=HIJ)J^*FJOGM**:J-I[8J34+FBUJ6SST(;K;334ENMM==BFZVVVW)+;33%
M(BKHIXP6VRJIC:I*JKJ"9OFMI[$"FVZFBGX*K*_DUIJ04S7-E%%<5P'L%KJ'
MLO]Z+ZJJBLHIP@47S&@14PG4FDD==NM@BLIN&!90<74&C0Q-0BC88\EU5IMJ
M$4XW5F0V$8472GHAQIUS$WVX(TH3DUC3894%)AE/J<'8%F(XSSA70XY%5"%/
M>C7$-%(5;2727CJZMN-PBBE+E79:151;9?\.U%>&B)6VHM2,3=239C$MG9C8
ME35UF%=)*^C;46BSEI=:)+]T$8I984R6;&=I!)9*,EF5(&=+IT3A@LJ*91GC
M;7F5V(@NB]5X3W"MK-FN$(UD68U8YSCY9H*!51'4W0D8 GNNK^<=@.[=%WN
M_/D7 A3?1?&>>[W+7E[MM<,NWO#GP2Z\[<67!Z!](2C_7[ST(9"LN72&"[8S
M2ZE#5AKG4<68T>$I5[>U6D/E;7*.>T,M/MLFGU2X3R@Y!UC4;0D$OO:8&<X:
MZF-=C"L5,X@^-#$,4! C$VG  0YBH(F"1$,&.!!#CQ9X@\D,,(,:W" '.^C!
MA.3I2W8:4YY*&*<X[4E,=DKAFD#AIB^9D$YHTM*Z9'4N> $+7K!R%*76M;!B
M-<Q>.[S7N,0UJ2P1S%?@VE2Z$(:O(IJK7(GZ4:Z:<[/L+".*^")4#N>U1"%*
M,50SXERR5O?!,Z(QC6I<(QO;Z,8W;C!4.[2AKX(HKV$%"U$/PU(][.4J)8)Q
MAT$D5@T+M4>$<"TL7+L58K2R_XQ &NN)CG+B%]>EJ7Z1C6L;&B!$$B.ROT6.
M+3' @6Y\ Y'8+,<GMZ'+<6)3N*,E,C J&4WFAH:RH+PD*48A3$A"Y"^1X(]#
MLVS06Y3#D>1D""^V;)S5]I;*DI@E*'HS6B[CACW>: \K?OD+XK(2N<3(97)M
MR8[?'E.7SMRF9RSSYL:FJ3+*$(5I#J$<4S8I-T^.#IEZ*5J#:/.UU: /;E;Y
MYN7FF3\'L9,YE<O?::1F'*3@I2Z^61SX7F83'(5D.UW!#?INR99Z+,]YX)E=
M@4!P/.\ SSNYNQWQ;I?2$Q"OI;LSCWM$VKSZU,YY^2%I"%QY&KF !C,A,4W1
M-K.6AO^*QG%YVQ%#^Y:6THF,.3B32>@X8Z+#4%-&B\P943[*$E/6:*B>T=J*
MJHJQZW5&:!W4Q T:2*11BN$I!!D&DM#0HTR,TDA3*@MB^.K7O@+VKX(-+&$'
M:]C"(O:PBDTL8Q?KV,9"]K&2C2QE)VO9RF+VLII%K-@8X\(3ZBFT?/HLGE)(
M0M"&4(5A^@0?]C1"CL HMON<;:[@%B@Z*I%<70Q7%/-8JL1IS%]#F4F_PE*1
M?BECBU[,8\&,R%M(OLHSPIG8=!<9L>'.2!F0U"%T\QBK(A:17>*+"M?<LHR9
M*$,9CH0&/901C;+<]H^"#%9XWY7;3,F1BXJB!S26@1'W*F-(&<KH[R;A:. #
M(SC!"EXP@QM\)>TF\;[/-=BPDC@HAA4*4+-*%0Z5ZV']_BK"BE+(4 *V%.+J
M2BO+A92\"KE%+7ZQ"%Z#344T_SE N\'(E"F;Y_=N$ .7$627UXN:_W!FMC(>
M4V+;!(U&B(D;"YTLE#KSG]KL-EVQ)<Y#6,/E;-Q&-] DKL@ +-I$<D;D+O=2
M)?SL*%/3PF3K9"ZM**9,^BKC,Y,QDD,Q(PC'AAH_&4EFHP296\:&UCFZ*95%
M=KDG0O5FS$P&]$&+'DSX=N--TJ05<Z9AB_XV^A4GTY/3/..8<C!SNA:5&IZ+
MSIC@X!>Z5"9%._O(77ZB=SO^Q"=ZKRO>?0@$/5S;CGC^V37R6CJ@6QL[/<H.
MSXBH:D6 'N=$Q[R(3_:)Z=&Q>C<3N9IQ5O8^NHDME>3-SMK NB.YB(ZKF62F
M;0]3X__[#=,ZY[.Q #=(#+>.,M\XT.M V#K!NR;I@5+*A%N3)$%]&QS?.$@X
MPI&D<(87W.$-/WC$*3Y*B%]<XA5_N,8S;O&%=QSD'\>XR#D^\I"3/.4H7_G)
M6V[RET\<YAN/.<UG;G./RQSG-=?YS4NN;[>ZU>%(&CIH1QBFU.(IM*98+9]:
M^,([I:FT>*HYQ*O>UH_(@,.&"N^L+JSU%F^8CEB_.I$,3O:A)RGH9L=!%UV\
MVP\S4;>R6OLHAZ[VLZ>][J-\,7V9",8FVK"^G:* W>N>=R*5'?$95_N+!3_'
M+T[2[9B28.&)) :#9T)^#MX\YSOO^<^#/O18^I:DH#@PYQ;_4@-WE+ &#FFE
M+"**DO<=U \M^6%[N?X@PV$,6(O;FD/)7L1@Q*.XI)@HT_]R*0 ;2K.ZU33+
M'12;=YG-*.F,,K2TTM 1B8U &.K+J"7EN%X^IFL$6N7M&>:;$'G*9282'+VE
MZ#(:<__V#T<=?X9Y?7XY2_9HDM3[^]]3R89A3(@MZ<16B8^4@1/_&0U6U!):
M! VI00Z9_<_*,$?XB815A<]V4)EA'!5!L)GV0(5<.(T -LA<I ]=_--S[!/=
M[,C^">!8O4B@.8B-)%D]D89659-#*955:=5:?-*Z:4?ZL<[S\-IWF-2Q30]Y
M!$^RC12P+=NO/:&O3<^OU<=\I%05_^*.ZXC4\L14%X*'3S4.6KP@:IA;3[Q,
M8@B0:(P5.BF+;#2(WPC&ASR:BPA5_NB-DSG@R3@9N<5/S5R,VGC2+J$(QVC$
MVVC-<ZR1,J3!U0F<6R1)#O3()+05OXG>)6)B)D(+TRT=FI")U(F0U)E0#"&=
M")G0G'R)E@1+AWG7\!&2\74*I6@=?NV6UL&*X'G1$6$)N#@1+K*B<C47W+&+
ME(A51H'8[*G>$,WB*[JB? TC0H1.1FGB-%)C-5KC-6*C*O:6IM0+;H68%-F7
M[0G*!I@*B.$0HN07,A:?,#Z*0BB?= 2,G>T+A#5*$&W7<X4C.G)1.FX*$835
M5 @78U3,G/_!""Q9QCRM3D7<P &07]C,$D1-#H/X3)])DVG4848A1[C5T@56
M5.*4E0PR2PU&8R$J!N:<TTT8U?7<B%0@SJ*QC8>(1:IA4]'X!1I&!FP9!_\X
M2&K018985(S 9-$PF3\%X"GAC#59QH9(FQ4AI(*8QK15U>BPDE2V3VGL$G&8
MH/GIS$N*3V],WVO,TH;TA!Q>S-14ARG=Q%(VU%3Y)*7MB/W!CS/-4X5()83T
MT\_ T@$*91$&"!B^!Q1*#^V(%.T<R'HXS^S 1^L )DLA#TH99H#4C@DLINT0
MR((HE9G!!%Q\AM[ #*<Y!V+\"U*H#>!<C _"$OMICM-H5&*\6?S_%,WUK(T&
M"N3WG-*,!!JV=1M"[8UJF P&I1$QI%WA+$-;4=!"+% ,R%4V*N=R:J)IF58)
M/2>=N G3?2*?\ F<)%V?@$DG@@(-90HW*LP-G1XWVF*Q;(FLA(HSOHKIP5@N
MZJ.A>&?;N>>JM"(>B:,&4)%[$9AL+8:KR)U[6MB*^:=Z0HIHZN=[<5F],>>"
M,FB#.NB#?M C&<RC^"(>\6-],@H1M$N'L>?Q36@R"JBZ:*A"))+JQ)]C5$9R
M$1\MKB.("J. REB_H&C>^&:W"(1Q&)-7@L]*Y$\,R "<10@<PEIQ>%)Y326Z
MS4T>/M]-P,0_,=+Y[:% S05TJ&&8-> ;_Z(:B11E;$B73C!&=I2:<S @9SB5
M5.P$W5 ;S; $5N$?6Y330[TDS21:D 7@C:"&&RIE7HI(C#!4YQ!I4I2?+6%-
M=-@I,[T9ZH!9-L%I-D$,43Q.'+[A55$'1KK9W@A0A?!@,YT(O.DE5]+$YTP3
MH479V 056+CD-YDH=4B$$BZ/]*04[2AF8T[F7VIA%>;.84HA3AGAK>4'K)['
M?, 4KH$ 3TGA=V!I,C%I8[0%1?;96HI?EG523(J(_.&-7%Q-.IU%LO 5_$$J
M"]*(9M996EZI5Q)$*Q%.)N%@A1A3]K51(\I )A!$W2T)DD!HO=JK&U$GTY6"
M=E+GG)"6=8("=XUR)W22EIMHYYBH(GC^RH>R(R0%(WYJ23<"*(A.J.F!2WI"
M2NY5B3.*X^.QXG<.DJ%H[$$$QSQ1&47$%^JI7JKX4<=BJ'W*V@ABI%C=:\W:
M[,WB;,X2A+L 7B3))R4-4>/9$#EB"3TZWM:]'7DJUX#*D>.Y(VC&'XVU!'J9
M8SU6+=^U9] :WP9<5WF=&%#_=$O ?"H*0IG.[(I -)"7XJ6C%0:EAI7& %-+
M\E6+!*!M9HULA,BDPF5GS)^I>1I:J""EUF"725.0PH;)( W; $ZZ^4V>9L96
M9<=-QHWIR)+_;(A1! 9=HA4SS6W<#%7IU(71%&F:;13XA&Y$E$9+&MFD"L1;
MP)\AWL2*.!K=MN%%]8M8*0T\<5HKT<U8OF&TS4]U5$U3M,VR?A-"C:$K(4Y'
MY5-;3*Y*-N2,[&Y%Z<36A(3QR,ZMX8?VYBKT\%1,(5OKY-1*A8"O)6&K(B'Z
MAF_V0D_<=$C[,(Z;0LZDO22D,650A@Q8%*1<PJ!(7DR3%D100:"[20V:<4=%
MMMI&_]#-W/A9@1'E_)Q/;[J1)C10&A $&B2))1H$-"R<7>GL!X.PM)R6T9G6
M=I+0F4QG:)FB:V5GF!@LGZAB.KZLNE1H=\'*>:HC=R',?5WHA2;LPG[8#ST7
M% 6?$(67K>!$-$1-Y52.R\[+'8DGW$ELJ]B-;WBEW81P%FOQ%G/Q@O71A&DM
M[4E>@/H*)8THEM!1ZI&*Q7HLY!W*R!+$5_3%= 5,3CS2!M >/K9H,V(LP])G
MABV?Q,BH!G%:[=IE_71-/7R$O-G3M^E2@OS2B 34SI9@&C89[^8IAL#I^CCO
M0)U3F?*?<W!;N";3COE$V]Q-YLR,ULS2_);$F6H3\>:OM?\1X?;Y#\?@[>FP
MH:<9CCW%) &+C>8*4+?MRR9A[D_2;G00L/]$&@F*634YSN/X1=3&T]WB#4)^
MT]>,%9OUTY8VU&DZ+_@]1]6@3>EF7S,7Y(,4F0=.DW7@R+0]H4H%YGRHAV3Z
M#ONZ!X'4U&+FA_D"&[&YSDJ]:GA08:VJAU\FS_1<8;'9CJJ^LT:Y;4/M"Y-Z
M[K9YDBP]H'#&[VD$8#K9X1#JSR&RR%$T%/VX;_4 Z=.,[L4(SBJYR$ YK^8M
M(EP11"8DB04GA":,$KQV<4_[M(^$(M*M5FOQ25"C4 N?$ L5-=2-4'>.7KEX
M;'CE%RN"'>3!,3$>8^/=XPY!\8?_/J.5N$N\-.SQX9887VRY^$AY59%0H6S8
M>36C8-@8*RPYXAD>SNQ/XW5>Z_5>.PLT/%Y7)VV+WM#1\A"60 /83;%\+@KD
M76C7?;5!*%\S%T=4M,;5-N/$$LN _I%F*TH1Q(@I.0:Z<<LD>U^6J2G\[D,#
MX2;?&""5113/8.Y+DQ/[3)/XH4\P954YT5G?9JE=,,;<)(@E_]E'/G# /*7H
MOJ4Y,5IHE"J#:)4Y_Z!%&B6E';)B7$RX)7,/ENNK6=HYK7*L 6^J,D>'^ U+
MP]]+TQ-5GF5:HC?\. XK(6KA1FF:Z01AH+)L[Z3%3,8^:4:#+&^0&LTM=UE_
M!Y"J1M-7_U3ER8AE9S2FL.VS^*;'K7)O/#,T$^(:0L<'\8C4?G3A[[#48 :(
MK#$4YQ9NF>+?5T&;<(JKV0S%5$H5X((9;\+W]+&9]7(I;9SI3;YE58B-UC2N
M5ETRG]TM 6MJ:F20@AJ$3N. !SN$PRD$DR Y7TOY!T.=)_[KG21="_&!)Z[0
M:HW)"&WY=KYPF7AG%&?UUB9,;H%=P>"P6;MY?9HC8:MQI61)'ST>?>8CY&TU
MT (+$BNQV7:,F_EL(-5P>S;7A>)+DXG(AF#QE#OZHT/ZE)->&O\QI9LYI6/*
M54/)I)NC62\CU\$8UAZC')TQ(GW%U_[2C*JH)+5Q?JV>UL[GC/^UKG1@U0!%
MGYJV6FS;IH_B9'. K46/<^*8)+]@AT^06W1SA?3B.&B;SVA&\^*>>"R1(8M(
MF[)#!J""$SN)&F: GTJ@#E0(U"/#\N':8.2D7SN-4:H%;[QIN_[XLL4T!+.G
MS4KF)#QF\PWZ=U<ILS4?$[A:2%$Y56FN:3ZM9;<1&7=8+HX&Z0,_KYU5:5L8
M%VNB,@IJ<^"VN$H 1OFMT_DX&^IV\J^K*CUXH>TXCQ-*CU_ZJNX$VZQN+W^@
M!Q7J:H./A_&0[^O<!SW+JGGH#>R:C8R .Z4F+DN*Q7DWX/G5!7_2.)''.PY:
M5#(%/%(1<,E8=$[$I701F1E6!;F;%4ROM^FE;1#!:7!!H$$#/>(^4&(,X+1!
MX!4.I'VDN[V]RDF:&)V8/!W DB)JQ<G <KF7Q[V8_$F6%!&&54K(!DMCTXMX
MTLJ66&RXE-YBPSJ%&C&C:*,>2YY\-M=EMV./.$<51<WJ,.TWNMU4)^WM)<IA
M;(CI<]G;J_[JL_Z]VCFA%#&C[+"G4Z@X]G%A7\GK$U]96VT><_4WQF)"_)7$
MF-A4J&A@]];2_F(S;D 15!=EE__8D=]D_A#BYV+S,>V#C[W&C0H3_Z"EVO"/
MMP<3; RPJDH[)%=D>4\KC?0M4 K03]JE.Z\R4;%DI6+WY;R:Y0 6J+%%Z@+$
MOFCUH@FLMP_:P7W*# Y$N&^9P7WZ%N[;1V_B/H+ZZNF+F)#BP((8.4*#J%&?
M2(T6,28L>'#C28L'HV%$V?%B-(HV5^J,*)(C19P,@](D&7%B1Z $5W+TN5,G
M3:8K7:)<6I AR*@L)9JDM]4B0XL[)SK,&53EP80F+R*LE]#BQ&4I.5J,^%$A
MSJ\R%>Y5N3>O09-9^[ZDR'"H6XIK3ZH,\?@QB,<G(%=^O 0R9LB2,U_V'-DR
M9,JA-7__+EW:,NH0)BR/UHP:-67-G"M'"5T9\XG2&G563)O4Y%RE-H]RU6I3
M*=./OM4R10X79<^354F^!1Y=K%[#*JDR5>B5Y4N)&@<SG^GV^$N3@6N:=2L0
M8LJ]8N/6MW\??W[]^#7=D'%C$K;JRP2'&'"P+YH"<4##/@(-I&^_""6<D,(*
M+;P0PPPUW)###CW\$,0019S0#E! *?%$4SY!L8X3373QDQ-CM"/&%FL$9<48
M0;$111=-['%'4$3<0 ,-B"R2R"2-+'))))?<@((CE9S2R2<UJ,#)(T>4,DLC
ME6R22R:QY%+)*+,T$TPD1732S###Q'+),:ULTDHRYSQ2 PD+_UHF.+<**BBX
M-*ML$LXO!>6RT$&)E%-.(E.:#J$_K4-JQ$HMO1333#7=E--./?T4U%!%'954
M$*/I\DY4J322@D.+3-1./#4H(L13X^SRRUBKU-7.-+FD53_$:JK(NK<ZNFM7
M)I5L%$U=KTP63V>+?&HNO#RBJ-3SVMKN(*B<D^ND90Q,*J5)XU+HVN@P<JC;
MG[[ZRB.!UDVW)>4RBF_8:X=MR*J^KO,7N[ >XNE;M.!5***Z%)ZK+87-8FC=
M^'C3%R.%*EJ)O(VZ'8[<A^,BZ:3#P$WXIV+AV[;;G*9+.:+$JFJ7+II*LFX^
M?G/::*YA]9H)J_%^NCAA@@K6N$^,D?_26&3H#DY*7FU;[I.B>/,J+V.5  U
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M0CZYB3]V5"D@FUUCE(JVV)^<<@/3(Y]@U%U*)RSO&G6HJ%]0D%TORT?[V9X
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M0- EOC-<AG:ZF1ER672$/; F!KF" -\10QQ'A[B2*[JZKLWCQI*U'5K5 &(
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M^6254V9Y99=;AOEEF6.F>6:;:\;Y9IUSYOEC^<#:Z^"#SXT((V^//MAHA36
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MA^"ST%>#\'3..D/],]DST_0G@2P-C-':R3HU,$0TD<NR4BLQU=*9(;ELD4L
MKKW04'62J3)%9T;%T:@013512!!A*U)%,AD8]\@K:8FW@!&UN?*9@B/>)>BA
MBSXZZ5)]!M=:I:5^&&FL[U79Z0 +0/2_AL%>6F1U&,?7:'*-EKM?=NU>.U^3
M>79[7+0+KSM;?#0F_!ZXS^69\GY!AI9Q.7Z7HHQ1T@=>CRR^=N!UYF%O??;7
MXV9=D+]5;R+YV_](97GIG^C_GP9:A12-V@M%51!0+;ZO ?U.1!WHR&<#N8D2
M4/)&H,81J'0BR@2W_N6P"'W,@1:\( 8SJ,$-<K"#!XJ&<.C3O0+^R$G]>=)J
MH/$DUY#G/@ DGP#EUYP*A \[57&<05J"DJ)DR4;3H1\+@?2;\P@P1C6$$:X$
M8I$DN0ET2Q1325(6$P.MZ67[8-"KV*0DRVWD<G K"4<F9R=T#0H->1O82)3!
M,6#Y21]D=%"G5.:F960B#8F2%\?$<))@R2 &%5K<F#+WGI[LXP";JE!*7K(,
M92QM5F \" 07-8E(;FMQ)EE0I>(X$8QQ<BI"24.Z*!2GG P.7%>4%H46U:FE
MC,2*_SIY2#(<5#1-MDU.4,280L3PL#VA@1A2*5@,',"K./XD!NF*04<4,C!S
M(6I0#9#!)RI6H)(<H)$@T5)"WN"NC^E#$[N,P1OH)">,/:6<+]$$KR0$+;5M
M4B1QJZ,NB_:O&T3%36P+&,8D\JF!+6Z.%CO3FMH9E9YE36L]$YK4#+HUK3W-
M!Y(JF@PHX ,?2'2B/G#7#22J 9J%#6A?H]F_Q(:UKEU-; EEJ-9XMM"9V:E?
M!N)(4%A&D:)XY$PEV5_E!B0F977NB2,QD"F78KF^%<6?S#H<1?ZD-UMJ"9"/
M1)--1X:M@L2-E2.!2$YC8J\U$=4F'OPJ6,/ZH=:AAG:H.?^-\-+:E\?PQ3AF
M1<MFG)<8LQ:O+Z&QC.S\0CNWXNXPLE/+\R##.[9&YB[1^RORYE(C*%VOALU9
MT?7D5\3TK$8[ Q0@_)KDHQ66\#N\V4!EI72;\XB0M)IEK&2_HY7"":@]"8P&
MDZ1#/_\UUH@DM.V.X".RG0P.*6+]+7"#*]SA$K>XQEW-_X(3)?;)I[F;->*0
M,"/:*;U0>T!<+G710X2KV"20N*)JWY11HN9BUH@!/&)O8'/=#= (*.&*FR5!
MAS=2AFE46F0F41I4Q9&P<DT+F=Q.9^I5 R5*5CA@BN$(-,%%(>M5?$H7*%#6
M.3=)K(X+ABB]$,6P6[EM)/8,D(;_I34)A[S$0!-;(SW'U!%YH:%2377(B0>%
M2"DVY"!LPE7FVG6ICWV*E2_=1QH@.BT,9^XG#;GGP+P9H0E5:'#D HJ])/*>
M4JW1C^*,BC:E18PR.>1?:%+)0EB)@SX.RI=JZ]NF#A P/S5+R!&+FY ;\9'W
MS#E,WW)(5-!9*3TBKFYK1MQ"B)&)-\1*R!3ZLA8KMZ2=GNF?C]/<4YZ,N+*%
M( ID.ZG-ND;2L-6, O*T%(H-K:>5KO2DK'I:U&9&4E+KS-($7>BJ13HS@8%9
M2T:N6-R.O-29U!B*)($<1NQY,3?M;:F)>\HRNVBFQ^&-;7-"G)&2V)'!T=3/
M6_IO@1A7_ZU2T@UP=U(93L,,X LJ(Q.".@"#TN!+K)@;!^C&P23B>]QY8S T
MGGGK\E#G.[T"S]YW4<UJV-(9VA'F+=&K@RDJ4YBTE,(PIC L6^(*"N7%Y>%M
MX<-:B,<ZR=@5+?BV]UWU(KS2)-P.Z^/>8V&H'!+6-HC,A0WX)JO>EC-6..@Y
M[X]64P_GCM;FYH,A_+S#G-MHA7_\4ERD#<+9[KG\N4N7+77A9Q( +=!R]+XZ
MUK.N]:USO>M:649M7>B^'0U=MC+/SV*;/L+,TM;G\KGNB:X"KB7I\R@$0=)#
ME"M"FO=\B#/GN8G>ZY0LR;M+CXLBVK"]%"C70U$ZW2U4I[KXD?]EQ$ IB\8;
M&P2M__I6(F\49H/J":IX/HP8@ .5Y3[5$6(X+%WKCA1$#]SHP3D+#9E8MSY;
MG"XTA$EP"X+0,QMFE*:"<E'!JI"'U2BM!B^KGSJE8C0FX:Z(?0DC>UO(,%@U
MJ K:\]F[K4>[@F5ZCEA5;HA_2)XJ]0:)'"XB:!!RI\:D#P1\DW#5QY@N@Z6)
M977QBIOR5-Y('_"EFU%@7CK)0)\HD<J$A$7(C4-0V0W07PQ RS_-'@-]1'NP
MR3*D7SJ-6"(ERT@P"[#Q&HG]4[E(T^#0@T)QU*49U-/@C N.S4<YE*$M#!\U
MS(/(VM@,#2KI3$*%C=1@FJK-#*?%( O_AD!+/=I5$4A#W,_G1)NXI0I]1<X_
M.=M, %B<))NJ1 4I-<6A+!%/,."7B8Q#T)T8*@7EZ$\R*5%)X(U(#%()7I.1
M3-C*.(4;6E",$4W#(!]5Y"&?- P.\*'7#:*&M$XIC%Q?J)7T)"(CND5=[-5J
M$!Q9F<9<,2)=6<;J] [L0$9<\)7 42)B!)9EV$%AJ,7##9Q<]=LBKD9\ )T)
MZ=UKX%QYN5!T!48KOLC9X580N2(LND8MFD5LV$?-D1=G[:)M\4@%_*)5O 1[
M2(X3!F,1,9?UX$AUN8A\D)9_^(9N19D3JAXA?B,XAJ,XCB,Y!D9L 0G[K,AR
M (<LHMS_7(\R*XX%"&'7;16CCFC/.DI'/';$_C3A=VD@-I5(8T'6/?[<9277
M=!0!;PW>F7#_">CL4Z39U]W8#;,TB.;45R+!21;]%SZAH8^%F+K4W99D @X:
MS/K1"4$4VH1\ MQ !1K0"QJ%RS[H&<<,BSZPGKMDBA)]A!B0F:*X2DD0@RQU
MC#+<R\@\V*",&!>NWL)@V'UAS)A-2 PH0T^43$X(VDYJ"9"9I#Z!"ARJC*G(
M2J90X=YD&TWL@U!VS)[H9 +A4 +U1)D@I8-L64<HSH5)ROY-G9 =P#;^&LG<
M43K%GRLIQ*<!S-V!RE:FRXA]!.Q=2I.A9%& PIO]V4RZ2Y\ 4IAX51HD@U1!
M&IZ9BJLTVGLTH1<M6S+%% 9NFQK.Q-24U$F%31$&S:N%  7@$2JQ_TH,<,ML
MEE18:DW.O" 1RN#8J)1!=<U'S8P)T(RK+0'0" SJK68*$@4AO5AJ>E\=!IL<
M@8I31(Y7 1(#T=2XM-'40<X^*=ZCC4Q]"0S_4!$3DMB:/1XV01I2(46B(=BV
MU5K<E Y)4E F* ,Q!!F$"*)#$$/#W, 8].=_;HN EB.#=H6_K<XI@D+S$ 9B
M'.):'%S)?4*$3J@=-!Q<U46$WLXB[MLD)E:_42(B*J+&Y4XI@D+",=PG^I59
M?<:+EFA:2)QB(=?;3:-CO4]JE0]UQ%R,$!%]J./>O<@,A9")&$=YU98U"MW+
M&6/[$%U6!(@:AJ=,Y-V4HD_0 9[YR!QL9/\.>.G$>Y!3@YXIFJ:IFJXI6!EC
M-+I0S8T=,::/SDGC;<C0.Z860=JI^EC%%CF%VAP)2=@(DMK6?1 DS1UIE;0&
M$=B8H#IJ$X7.WBQ+3]T)XF +I2@@-JDG0(G)RW!D.X&,1I">GKR!)$Q"&DS"
M&P"FH4%+=Y5$6'9*%_5D( ZJE]"#DDT(3.W*M$A3-/S>MM0J1>S)PZ3!3;F'
M-KF+4R40'D%(GU3;0F!2.IE12R35@C!(O'F8KD!4Q(#@L>V$CM%?T20@3Z&G
M/S)0^#V,:B .4GE8R>B3,4E+I^ =HNP*#OC2Z:63@UP5F'%)YEE94?1?;LH*
M)QTF* 4+LHP,@4K_X)Y,JDB$7R_)5#1061DQ#JA0#BC)P!LX'TG4@_+I2874
M!+,0$A7>RT] &E;A4W^-4T,<H=@<Y]A@6A"*U E<E,$TJY YJ]!X%'.R6DC%
MV@Y"#7"VYF\69TF)31(2B',JT.&$Y[3]T^*46*I4B\FHF,HN;3_=$H6-B4[A
MUZ^A80DN&AAN#OF1(79*Y*AHFQ2"8-SDA%>A3%+!1.G@Y+U.1?A-A3(\V(A)
M123-"YO^;68@CUT]3VH0[K\9KE\A[EJU57;\#F%QXO*8J"/V%>1*C[Z97"3R
MA87>VUDQ1NO\3EQ4+F'Q6]I-UW*9B-B1$)SZCW@8AP_18\I=(Y!FEX\:_U!H
MG>[8Q2YPM)UM(>IJ%8437NE#J-#N"F-YF=#384]N497?W(]6 B[T1J_T3B_U
M?L5X]2C/\6*7YB,)[6-8$.\!24=IW8CJ"E"+?(?W*M.?[E#DU)A SNZ3FE?Y
M4"/4<>^)V EWAF=^=@D@A6UT<D3F(-5"2 KTK<RBI<1&K@QXF43WY0GH/8B>
M2 IN-FRC/<6_SNM">%.#G(HO;8XFH(N$X$#AI"5$^0"^Z@,PN9CJT631C('H
MZ9D\(4M9:@Z _DLFG&M&Y.VFB &^1H0R_"OOO4>DI,OZ"1*V00Y#U* ,2$*8
M6,Y,Y.? @,+&= M%-J#80EFTV"!5XMG[L<I88O_$IB#3KT4;4Q0?1-U>)DR"
M)*")@SR3?F4F1DBKA"PF1OQKK<:$,J2PGE!E2:"3K%#+G< 75!1H;O;2Z4%%
M8SH(%]::F3 0*_4OR@Q%KI5@RBR./EP-SP;MT<(:JA54S,QL;4J0!!G2MBS9
M"A9AU42(S;C:"NXFT+:R)],,K8G$4WK5$GHJMZE,B3U;W+;-Y$F3D9T>F%C>
MX,!)W#*>67[@)D&;_^83W>C6FV31KY&G FOAC4&5,A<>Z'2Q)DE%&CA,-T=2
M!4F%DE%@]3;H(K*5.N<;Y#[BB(8NZE"B[(@H9$1/Q8&&/-OHXXZBZY#H8:QH
M8&U<8JU%9S0BP3E/BV;_8HYB1I+^B-@-'31FUI;*QX'8[W4@*O+BHCV*D'&T
M(T;':9.2G4':CT!LT>4A!$*\HY(.9'CHXGHQ5P(M%9EFZ3G7M$W?-$Z+8S2(
MT/'6;T.CB#OVG(G8D%G,HT,K+]\AI)TJ%U:$23TY=8)AR=*!J?BZ2/A =.[6
M#]?BW;C(K:2RX4_%%.6)YBF]992U$^5]X$:@3<#HS;_*$P*&&H2( 5+8746T
MWJ#TDQH)&8.(@5^WWJ(@'T74\)[UY#?=0 >C!)#QJ@R(@0_TT:Z8<[0A!8$V
M$H/T[QA+JZ70'P[X]3?MR;HQQ!M\VMZ*Q$:TY9ET\=+( , A%9@MGKG<Y 'B
M_^4M16>VT:?[&1H.H,$DM)@2RRI'5-.B6*6FULDD"-/"X* /J(R^6N04?=*F
MA!/<*(/&]#5@G[$XA9^#F)%-C6>B\+6@H(N[F-'8.MO@6)U2Q!2_Q+;*.* /
M'FVL 6T0QIK-SE.$4,H\08@#O++62&6#G/(FB]1)#?BK)532,N^;F(Q_V5)G
M9B8[I<RV?>?4W9H#PO&Q^A,I,> 11V?F\),"+EJ[,C""FU*'DTS?B.&)HPVS
MX,U7B@KI*!EW4P65\:'R)6!5",H-[&].$^+QD&+B+F[A^M59K0Y>32Y;>.+A
M7JYE<,;G3L;N5.[A"BZ2"W3KJ,Z-&@9;(4:$PK.1AWYN[=PN/?:T2ENUV_U/
M19=0-*((X(7T9#%IH;9T,$KT,,+/^3+6[TX=_]CJ0>#I4/M=+C[IGLJY+T+S
M3#_*CA\ZHB>ZHG_5+19OU-7'1V_T?-#&=F'&S@$URP5'V_D=C_8= ,&&]V:)
MHS@*-BG$^R[JE'86D"JUTPD)WBWEXFC_<XB<MT"!M4]\K4X8T[1EH(ES&RDQ
MA>0$#*62GF5?]ZY(]Z8^!0=:BB:\Q\1\=@2["[78'4/(Y<VN485T$<;HGK$4
MN]^*K7M&RPU""Z!<4V6&<0BCV+J]AQXWB+&2X4> :A_;ZPW8WQEI*AKE*G[7
MZO.!3-NXS$S>9@19MH2$+$;,-C(]SI_B&<-,,05"!*L4\ZNT^\&(+%J69 27
MY-)DNT@(Y9Z%B2!=O&VF>Z7L#S-?CD<L$[+I,J6J-8[9E ZB5( 3I]BP<LS7
MC-+LD@-L,G!V#:NX+*O)/- D5-1T5'!V,A$*C8$ 6[*P]Y^$H1>!:N'\&-\D
MFE=*_3;FTVL'_VRGVN=$BB$NI4TT+ZWU247EE&'EM)3\:14.G0W^WO+U?8[H
ME%O=5@4H8&M'M,LXVVV$E/:B;QUB9"):G$;N!+Z7_Q4_5SF5 T; 17F06]Q@
M,6)!+X;E?N)>8"YFQ"B_/0]=)49:+?G%4?E:V%OUX%SJ;B]ZB7G<K4^APFGR
M<F_X&F]0_P=R999*)VEVN2./W"G,9050J.'E$0@(&21M=#I5U^[\N$9KC2E\
MZ-3?/S_T1[_T(PBAJMU^H$]&A[F34E9@#/\K9G]6$Q#Q$_54W!A4%QO[D1AU
M_-UCO;F7@K^,6(S@(=WH>*2].Q4V=QD.=/5I<PE U(.VK]X^??N4[?_;MVQ?
M-'H$%3)<J"^:OF5H9-R(@6-C1XXR.(;<F"FA0(7U#I84P_%&1AF:#*(DAH.E
M2XT?6^84$ZVAPGT#E:V,D=.F31R9"%(L^)#AI 8V/79L*>;DR8'0"B[,%)4C
MS($%'48\F DJ#J)<$V+E2>]-C*A((5J,J<\DPX,B.<9 RG#@0[H*$R+\6<^A
M)J(YB>WSZ[!BUHG1LJ+<AS$GUXUBE'&=M-#@/JDN3_*4W)#PPS26S<;8>;#>
M ;PQ0A\T?7.HC#=9[>Z;69NVC,\MD:(DO"]338U4J\KEJ2P-[<-E-Y:D6W$9
MQ8<$OT9L^) >3\BLJ9/N?#TIQ!#GEYP/<>+_/ CU(=R'6!)?_OOS4>S;9Y^?
M?Y'#&_=K+ST-?/"!@@(1S.@S!!GT@3\3U ,A/?LF5*_"]2A$[SSKO#-I.,7$
M"NLOR)(3[#O.L%*+KNE A&PMTOKR":7J7/S+I,4XXVLXB7"SCC,2Z<HN1<&$
M%*BNP11R$2+!#K*KH(/D4DNAZVCLCK63P/-)RRVY[-+++\$,<Q_#9(!KGY5N
M2.S+EGP0T\TWX8Q3SCGIK-/..^NT Y1/] 3%CD] \9//0/L<U$]"]SQ444$9
M!:4.1 _E$U [\-SRT4C_=)313.TP15)3^MPCT#I,.;24/OD8%-1 ^2"T5#]+
M";12+2_5T]!"]>SS_U%)-YUTTCW[S!130@%M==!9%=)' PTV6+999I>%=MD*
MH'V6VF>;I:#9#2B0]MEJH;W660V0C6A<<+UEMEMLU=WV7';9!?=;=\N-9EUP
MQ44WWFVUU8#:=*65U]T-L'6SHIZ&I)$P9=SM%]YQW06W7X@#'CC:9O^=MR>&
M&&+LL8/*#5GDD4DNV>2344Y9Y959;MGEEV&.6<YH*J9X7WEKGG=<<>/-MXAR
MH8GXYIO1S3=>G'6.^&<OHTG(:8+"8BBAZI91!F=]L<Z:YVH=OM=B#8J@NDFY
MNB-/9L#$@QK&SDPZ\2'J. (Y,B@]_(DSQ1IK<K"4JCKSM<I2PT$,,3*!J?\\
MPE "<A\?BKIAF!\!$RHDU[@RLVP2%=+D;YO$T"3Q)_GJC!@QGB/J*"(%BZLZ
MA&@+29D1KPN+,V70$$G!P/5*6ZZM1+HAC<<D&TXTO2=Y3ADG25LNM+[W2:;Q
M&#09B*'(!LLNR+O)^H^E27AZ#8W.%BJ]RL'">ANATYZ[3.W68VB ,!MYFN2U
MS;!2:KGB&K\]AC0"X^P@3;B"@^V$)R: :<YK7I,)NW3L+TL*C)56UYV>^*5C
MUZ$@BDQD)?5 2$/U"=!Y/A@?]ERH/N=10@?Y8Y\-\"8C.$BA6:!3NI#DA",:
MD \(3G"A#[9'/_"QT'M(>)XE!2]O%:Q*C1('02S_B:>!,?$.[$#$)-R8*"X0
M&4CJID>W*<4$*&SCR8I,5!"LL"TYTTM.5LHV%]F][WT<.Z.45A<9ZM@OBF>+
MDQBBXQ/0@$DH=O3C'P'IIE^)ZE"7TI2F= 6L7VG*5XL*%J V5:H_A8Q8BNK3
MIH"%*$/5*E&)K&2F=O6G1%+25IY\U"4_T2I+@D*5=HA5*2LY+%C)$A0A\Y;7
MKN:O<P%L:#5+5[-$]LMW78QBTG*8,'4IM)TYRY81PUK/LF8Q=QEM7!.#EI@2
MTC0J2L]N-$.7L[H536).<YB]%"9C*)).R Q$28%TYSOA&4]YSI.>];3G/5M6
MCX<IDVA)6]8QCWFNC(VS_USU&.?$Q,6SB3ULH5QC5T#A]24VKE,PJWM:=\!Y
MM7_Q,IS<PMJ]ADE,A\G%2.&96B ?4C\0_05Y$N210MQ"T6PB#FWE"0Q8GH33
M*1&0)SWQJ6A\ZI.90FF!<>EI3V-D$H1D(@UH:J$8T@ 7JBUQ=?]K:DL:(+@W
MJ(DT2JE*QW3S!J%,Y0UF@H@8ZW:WGR:I1=U!JXR4D0FGDA4NDBF)0232T\.1
M;T5'.@AE7/(]O,[%BG:MWH>X]*0YKI&;-ET(-";A5,&19*=LU4[_CBJC)"EV
M.TO*Q!@"=P,QO"$A3>22!$N;F\Q",8IQO:J"QA!5QY06<2#3ZU[QQL:39$*N
M,/\\3E21!R(=-?:FVA$N$X<SU *^E"! Y,^$+A3="&F(/AD:X75+2 0$CA"$
MY\$= CORFXYL(#_0M1!W?XA"$Z8P!!R2RX@*B$XB#K$QTKN>CH!4D!MM+$LJ
M!=%,N1F\OO D=!T;SMLD8SZ)7+"B[K7+8MOH$["VD;5!.A)A*5Q'!N/S@+]+
MTD8$"*;FR "?)3;QG"[9J$-)$E"ENE0K07$J5P4K5KN",2%A6<MR<7)0O%KE
M(7$U*DT^\I$_/J2.D65(4]3J59(J<J8:N4H^L5A1G*RRG\JUC*M9RV8XVQK.
MNL9E:/5K:<CRYCZ3*4YEZG++R&Q6F2MUYG81<\X XZ5L!AH*9C3#^4MA\8X$
M*[).@\+KR\?\&M'R-5 T7W-VR5/*54X<:4E/FM*5MO2E,9TR:!0-G-@*:,;"
MW&9^25-:?+X3S<QYYVSY4\SF'"BSB/"EZ3QD:A8AJ5KJ8;4UBQIIQ23UP" :
MZZFZ52[]_[/CVQ3L:/(U!(R7XTC?P&AK[-PMP]FDH%?QQAW!& EO!E'>32E"
M;6:32#ACS,H8)0*FX%4VCB?2DF,Z*Q>\2=M*$F6,E3"7Q,&F,2'(]LD8!9/-
M+=WV?20*-%B$:S^OPA>-D,&!_C*AHAWY2-R'L_54U7(=G'Y%-@=/5E!M.R.Q
MB+R!U9G1BL9'T@8.24MZ+<APC20EC7N[MB*7W4PQMR7;4ERU78TYBMX7W]@-
MW"=ZDU(4#9L4^;XWP5]$XV:=[E[U5E<]Z+T/>ZL>1*RK9X6]<Z%S3[ Y[>4$
M 8?1@-;M0Q^K5ST_ <+/>:C'(I/O36VA@V"6S/?T)"KO1^O^#O]8W-K3A^2T
ML0=V8K,G2."N=ELB\I:WWHU+'BN=?$EK;.>3&-]9B A:\2"SYVF>[1-BM$2P
M7^*=63.=^G?JZ5&<+.6O:O6K6_48R$.&9([U%+)<+;*5C;3RK0*%R2-S*OB7
M<CTI:^]D4*RJ]H6$5"B+?^5&07]/S0SIFG7FRWYVV9DB&_4_LP_-7CKSH>$J
M9D&U_\U?M]G.BZ97F+*YV 9[Q]?<Q[.TJ$EJC=Y26J&C*#O#+=U4;P )L  -
M\  1, 'GQ)L4[?KL;_N(1M70#V.>*:0$ALX>I@(CRDN>)N.@YG(2AV&$:6A
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M\6F<L9-MB]V8QC;XS11$D\V6>$'__I>@@$VKX%L[,9!!0,2"^2H=G9K%V&/
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M5X<:#"58A]5JAB""=?N2V8 \K]D2$U5X='.3GHAM Y&/:6<>T_QD!3HU!+Y
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M[(#&";961B U!\TRT?XJ;9-N3OMHIWMNT%!SV$Z%*X" &>9?=M3%%>\^.,1
M;TD.'5;60)?^F]!Q@.&7767W^?542S#9Y-QRRLEG'WM [1=>3FLY)YY9Q5W\
MG7#^40>1P<LM]5-"[E65\D+QQ<7<6<FY%UA7W'6,DJ0KTRNQ86CM7!!Q_#Y\
ML7;[/B828#9=+!>\_LI4F5'P$9>06\]-ZF]8\3$E'T**_=2N95M!Y36_:X4L
M]=@BPXO3OG*!S/5&27-L$TQOKSP2>"+5V]=)=E]T7<Q&MZN?2BMCMEMOJX4
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MI)LG*H>\[Q.D6N>G312+MXBD(N)W$K=$$A1?A.9$"0J*QKM"3 >W_ 2?^;-
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MFU2[=1?25BX-=MI5QFV46V$<.I?_T5O@B3@BB26:>"***:JX(HLMD@A*':"
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M\CF>\WQN9ZIQED<&M!RY_"YGE.E<;OKI.@>!C2:?(8G-FI4YM57N+Q?5VX6
MAIN7+&=Q<BF+6JH6O9+(KZ&EVR;V2MJ3W6PM/0V,S_1*PDW+K"5K%]+;.Z?W
MDMG<AD,P0]Q(_,8ADH8M=>5;2F?$IQIK>H^  54:<"@RSZ$9*"^'>9K9%/J2
MOG"+.>Y1*.]X"D'+.44L*JV:.Q?T5'S";W$$G"EX<F<X!H($,V39T#5S2AW_
MB,I/<3F)"WP0.LFMZ@8U^WF)8T4D/*$IAC*F^21H623#+3&IA*2%88Z&E$(7
MGK!&Y"KMC8K$HQG&,(0M?%()98@C4^"H7%=L9"[!J,0>XA)6NQH7#V-IJ%N=
M$I%3#)0A4T:N5:5*EL6][BMQ>:LYA@NZ#[OBP)+8J>TV<4SE6N8H$X;,,E)1
M6.1BYF\925PG#E>4W#U1U[J%0)P0"E/J?6YY4;9'6.)));4IT/9"J^ %,[C!
M#GXPA"/<W>@Z=[W[ B^KGDLF(OQ+3N@EEG_SR%XLFBIC$S[D'IN;7A]6^+HF
M'E%^.$(6H1"3<<KX+GJCNV+QVDE9!P&FS"[I.(_U_Z8Z&B6<TP;'%X=V:'F$
M71M7$)(TIQ*UG(5%FX6^JCG4*3DF/LD+>0P#/># 3IY+>VM(J(E7WYUY.!_K
M)M.B8C/M8#2!XN&-UH("U &2+B]0]DC_8'H7RAF'.]J2<V1YHIRIQB=Z7/:G
M[9ACEKX=E'1)YLE=P-E9 W7EH?"9*4HN$UEFY75UIVDJSN22M GR;W&<%9M&
M[0(=\@ANIV.K3. LS6D(.KJ;: N06._I8U-#U4)5^RE5B',\@5C$;1G]3>2>
M$Y^V@<Q_>-W+V 2+H4EC9C_]#"NOH;8YJ+9Y,()92K/-MNS/Q,>C$ 7? M'B
M/Z]1ASDE)>EO4/,@P9K3+?\,<K>$%UQ#$XXPA;7UX NM-%LHM3"V-EPA!TL!
M6QNM%H8Q.N$+$8[:A9?KENTMF8B?",0S<KAAKL3PAT?^0Y"C&$WC^B)\WWA'
M4FFQY9%2):\VI5Q;5=%7_SU8,B/EVZ!#:U"T;)2 ?;[R08VK'D6'[AF?#D:9
MK^R/D/06)","#3P6UY%%'ZX5F>BO\Q!E//0+.-K3KO:UL[WM;C?1%U=LJDNI
M?+W951G./^6P6IT\ZM']+WWQ-*Z0?7V-/239;T7,=32:*&8=RX])EI4?PI<2
M["?[N:Q0C/A1%>%CRN -::1Y28QH)ME_LT_TUM/NIH&SV<CY<G9:^K+%('@N
MX\O_[*=SK^U)KS1WD+O.9O[3ZD>CA2*]CKV>)SB_J]!:=>.$#()1(U6\BO,[
MVN/F/1E;ND_KSGK5ZV91?V?NCH'GIY6C'Y1CW"&=]N?<W6=+[1N3FU\KNI_$
M!+:;F\SZ^: %9T'[*7E,AO^Q5728!TITFDR<E#TYSWPXSO0<VD7@VD0U%9UU
M&3D%%3N9!D EWU.AQOBL#SGQ1%,<AOO,S6-DS[FAU.=D5?9@CI3Q17+@%+.9
MVW#07LR,U;E9A/=X#G;D&:LQW_M@&[H]8+"=E>IT2V-MC>G 7M]@(/[]#K,T
MWR!%B&I %3F)36!LAUE\T]ME$I40W,3A2,+)%I/4B!B:_R&-W%"5V,%KE2$.
MF0*6&!QIL=9L99P)+1R-G%>&?9@B14R(3=TI7<Q[H1POS5SFS5P2#:(9*1/4
MI0FB^"'8L9R:**+BE5?*66(A,MZX7,N%R=T2T4O8!9$B+IX5&2(HBERA,)V*
MA%[9C8XQF2+!'-.M0&)Y#0I17,6A$5(%=2$O]J(O_B(P!J.+.$QU71ZT3-TQ
M+9V=;-BXT$..V=S(>1VN$%VL7-&+N0HQPDK (*+EB5S%7&/Y(89&*(2,P4=_
ME K?[:$//>. !1%5N,Q)K$2059+,H =;(,_Z8:!(T!1*\8_BQ!-$%-_[?,6Y
M)8BS]10XF8:?95-4O559Y:.2)?^@G.6;HO79!4XD_BA-#^Y?_]%;]YB/-$&&
MV+B'/@'(L T-[GQ/9WA5!6(;]G$'O8%388UC0!U?4WV/WHP:Y.3,^*V/\#6A
MOQ7/:BA-^I3:^(A&LU5:6;#39=QCN^7%52W'7H4(9PA->-P'^MG>6QS%W #&
M>03ASOC%X7@-\26?ZZ0'<B"@:ZA-1]A,\[W%5D'>-J'@OTV'W4A%[AW$N;G'
M<DA/2-W/Y6C(^&Q%[F':V'0;9"AA\]$/!:F.^<D%U93@4C;;7B':%K8?:T!&
M='@57VE4!,999K:;LFFE76P+S+3EYJ2',,X,"\&6P>56C]PA"#&<:^X(Q*$0
MEQB<'9C @FR2EAMZ4"F(D!I2B0ZIG*]P8^$Y(C(*'G(!F"S%7+[L";4(6-Y]
M"G+"T2=&G1 )EWF97'9)XL4,T72&D8N1"S2(Y[&TV(AAE\CI2<F%"S3H&".)
MD88UDCK&(KZH"3B.B+-$F6%(4+6$6'R5427>$J  #DM\F>*L)H,VJ(,^*(1Z
MDC/RT(C]G'.2BAPURA+]2Q9%(H;27'$!7B/>W'1A7B6&734J48M5I[\%Y#N:
M(]W$YWJM9^6M8QNAB;]T3?M]_XPFR1A@8!O.^!N<10[,L!-C,(UDB45BM-I]
M<,>?J>:RG=6=E2-00J$57A])FJ/FF--8?4^EU1K31-F19LWQ79](# U0G-22
MOE-%+N4.YDU?4%I;1!5T4"92M!64K8ZSP(;DB!OO00YA3H=BS*GP*!M@@%H!
M*HCWT)N48@\26H>0THZX\9OE1,=[Q-A<08Y;L@TE56%![A2:$MOF_ 0UV9N7
M2=[EU 5F%*5SB*EI/.;MW 5&,0^'+ YYQ,2J7@^=?H_^^-Y37IG="*#1+!#;
MP,04<I5,N61F3D[\X:7OU,P]B42>+IMN*"D^ 4]#52!G%2L+#DY</J"_]1IF
MC453-O_(HF7651@D66%E6ZQDA+8+DP0G!_%FCNR!CPQG'="KC-AKC:CA;KD0
M;L40D;P6C;06OT:)PE6)O^*6'4A<C,BK'>+0;/K6<@*8M7S='U8,M30=<BY2
MFS"7#U7CBDU7(QJ=AOK=QV&8,9(LQ 2>-M:=RMZ=J>AA);9<ROB7?;$CB_9)
MAK:L?)8B&6&BRZTB@II/V5%>B-IHA@%=+F6H(-5'@1CKNTXMU5:MU5[M'YVB
MW2T=?8*8<>+1PKP<(2*1=?7<R^K*I+PGN$3#I;Q2K&1LAAJCS*;)?E:;QW0+
MZ=A/,K)GWP'7QUYLP@2B!D!F3TC>+E828-"@-@7-2,XI^XS_&KFIJ4)M1RX&
MU4Y283A23Z2UA780#X/ FF= )+8!(3V-:?XPVNM]1SK=:OGD%%>.7]C !_0%
M)+-^CH+F9#R%U61)B'+LY4KISSVY&4FD#3L%8)_5*H_F4X-,JR")VV9Y6F.^
MS[BB94E]EE+HF:Q^+O29FF.E3>/(A)-.UGS\1:Q6(:HM6_.ICWP<Y?*MQEHB
MZSJUS'^866,N#E3(FU6"[D,L+Z]JSDN(4USVE YB[[,J%,^HCE?MU=\(9%8D
M&'E8Q?G):;*-E$PD#W< UC?I):C*) +&E/=EVO1<*R59)4HHY/J>U%XHWW\$
MZ5!B%66 'Y':WD?I#-:*2VMVD RA_Q .VQ89XC#&T0B60%S!T59KQ>%OUJ81
MMQ:Y.)TQ JUQ69Z)2@R'AFB*MF-]!5<K:4#=@DG<D6>H?.> >IC?(N(6@TD5
M30IU4MT579@34>S87A=[*ET:#ZT421V)_:T3]YP;$8O5)91<>!LQ"JBH'*?+
MFF@M7HSC$=)<GET--[(C/S(DJUT=79'7]2PI?:*BG%&)>IS(<N<6>>)P#5YR
M7K'*S;&(0N.)_-@_F020C:.^X/'?>>..)6T1O$PWA9YF3-,#QU.AP0<(ZF0$
M5]1.Z05),96L\6HV1>#^LN]AS$:K>D6I4>0!^1EOW-GR+$@#X4SPQ$>"&&GW
M64ZL(=4'+O^4JOK545ZI?IBIMDW'?C35K58S DJ5;4A?/$=44/UH+R?/3L!/
M YW=%O8E6Q@;9LCI_-K:?L"@SMBDDMF365+?OY7$Z9P;.0XKEBJ$ O-?:[ 9
MF55O8[9'WB @=ABA^X04ES&K6"Y:0.6>5S$T%UZ--Q.'_D70J0:;2?/-//?-
M/J5K6\"-^:0:]PW?8O1>!&YT[+ O:'K'?)1K63BI@KI/JQ70#=JO#;HK3_Z%
M"$H?--_TH7TP3X^;2+ZI2$E6)'^*;M60EOA(Q"[<EIB6C)QA:N4(P4[<;'YA
M$6M<DS3)DZ@6&7X)<ODL=DDC%/OMGQ R<TJ1(=N1AW[7&1],B5[_IQA_J,4R
M;8B-XHW*<F#?7:,@TM#)G'.9;"@JMB!N8F:39RY=,B]YLB:BR/TAAE(EA!-+
M2R>*,1[I217OR23M#F4DU%CO-F_WMF];D-.!+1S_UW:E[(EN@-KR2C8>B]+2
MJ&!7*-TVMH=::,HADR7CZ(FP,F)L#>39XZ*H)\&$HG8JYQ5IQ+(0I$D<K@4Q
MIO$M&T'F1/AZQK&"JJ^-ZNCJZ;\IH3,=:N[^ZJ"AA-3\M/$NU:1RB-\$V_J%
M:>78S$I2KUA>)=6XA@1NVI7913]=F6IR7Y.98.LYC4,GX)UJ(9]Y%$U+8.O]
MLFG6ZNRM6F5\"*Z=8 GZ5:B=]^II6D"6_T^](16>">:%:'/PDMKY.,;LW.4Q
MYVF$/T8&@O.B71/HO.^$T)5+?/!)G7/L*N^""B9DY9NJ)L_7J)N>J>676F&%
MR_CZZFY]+XYY9(5FVMYM?&I9$J&(?\Y,?$CV1:&"4Q46LB^N7<UE+8[WV%-"
M0IO=&*GZUD7L##1A%EKG!N6$ZQY,ENIOMXA9TZ8&%6P=QE9='S'"QM9MTB%=
MS] 0MU8'== 84IP*33$3$6AXSFU@;PJY*)>-2HO7^?4VTGIWUG'@+O9PY['/
M@I'8*O;?/>+F!:+7MK'8[C'3/O?<12=I(XPMF:+2T1PT'E[B\=S.9D=(=,;3
MME]X!VW".#=TCU V&AE;MD=>-#!RI*>[NJ\[NY^(C#9QKR<M&\DZ>%Z[BW2Q
MYKTL9!_>R2TM%*$ZI8AW,@7+=8?7L+@[*[]$Z!U:?R"MRG:V)#KWLFNQ7-*8
M+_]KT@WJK_.18S7'J@(=!DKNC.<*+Q32C["JX <CJ3SI#%NUE/X$F4_FI$ 7
MZTV(9$VZ=_U.6FBZ69"&*LB[54E/1G&X&?7YHT+5#4\QF^W"*,LS!?9-H47A
ME9#+*F!HN>(,:=(/O0K;I>;DSK_M(V[CE45&CJ!*!_S<N0#%)'UOA^X^,[C&
M:?<=:18&543^,UB@V650IM22>.DP)4)JYF9Y>+_I>,D+(5EF(2Z.QNS(AV%)
M[6I(+F^$O/EI=8=,!6A :]6D3O18&^%'N?F9_4[W#@35?%L!ICZ%B''\99I%
ME3:Y])G.Q;DJE:+S*+A.'U?*&Z"K;F6V^XGTZUFSUI'_& D-04G"(BQN2JR\
MLN&XW):0Z,@9YJN.K+7Q.W\,*6S!!LF3*']?(Y%P>S;WE^QABYQT]U?%>-P8
M<Z=UV79?[]+>1CL6[ZW0;;]V@><APV+ V[N2&%*(Y2S0%3Q :-B@02#!@?L0
M)E2XD&'#@A0&#BPH,2+!B04O5C2XD2(%C!4/-E2H;QG)?='V*=L'K5XT?2B7
M??SHD>+$BA4>ULS(T2!-F2OK03N9<E])E]'HB52ZE&E3IT^A1I4ZE6I5JU>Q
M9M6ZE6M7KU_!AA4[EF&TC3)KZM2YDR!.F3MQ#B32E:=$M!Q]ODW;]J+ O!*+
M<(VYMV-!MVLW0+R;L^[9@8%%_]8C.7G9/GI(@9HDV=BNVHUQ&?LUW+.O6GU!
MB5:^W%(E6:<O]]4#BE*VT,HL]5E&*+GHR9:67<J._3*IR=@H8PL5+AFF;Z'%
M42\W&:TV[Z2Z)P^/C5#E:81(71J]O.\T2Z'#P6-?OEMH]MRMDPJ'OALH]\S
M>WNGCM!V[M[4WR/OM^N$J\P[\HS*C3J7L#/PM^IRRVX[_60;KR3=!$3HPOB"
M>VF][(IK$*'QBJL,. ]IVXXH]48<*BG<)JQLO]-R$^XXW5@ZZ;*7:-PMMQ)5
M;,D[V4YK;K\8 P2/QO0T/,DXV6;\3:4CH8S./^:,2VI*WK8\S[SC=KQ02.EZ
MPRW*'_]W4[+*\#PD3T49=Y2RR2_/5-/-[GB[#343JVLN0AF%*X\H& %%Z3I
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M..E*#AMS#IVG-8[_9'2SPNWDSA<M3$,3U$ K:8^OI1H!;Y @E.Z\)9'U3I$
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MNS*U' Q6(9\K1(OGZUG\N?N3) )*$4]1N2"3(2MO[E[2+BE50ONBUS_U-)#
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MAG&Y&"S4E2UUTF T TYR0I!J&(W6\C13BW<H<:%5IJ:S2#"FUUN*IUPY@8I
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M7*$1C2KIE1G=^$:'+.U@#IM:2?[5*X"%!%P4D2-#N/:19T&-6%#[&D%2%LB
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M.YK5-/@T&0909Q-;G>F&@92I<8YE#XO*;6C"GF&D 0><<YBZG%+$-W'O=CA
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MNVB=^17P!PW'!:Z^^"OKLE2=71!+:K:Y:-\R?\-%T.##\[;) YKOW7R[I-]
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M$0-T*J%[\.#Y0:=-L<Y+1*JA!@=P0DG9%<VDJ%=AH?\A?/KLSP)MT)Y%?L8
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M!#T\<)^51,GPV:2A=^&%^%"F9>06F"EU674?A#M.C.GFW6H68W*L^'(=A:1
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MC:R1TT%U:4RREM6L9_]%:UK5NE:V,F0^H. #-.UC-&8J33"->QR43/$TNOB
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M!"*XX($/#@AA@0Q:F&"$"2[H(($!>O@AB"&*."*))9IX(HHIJJB=1]#D1=-
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M57CT 2CU4=\S86#P :3'E?<V7^>SDVRP^RKE>F-Y0V#U=P3T?"<Q&D0$>\N
M$M<+!LLYD0O*%S?Q:?_EN'8KY5,K WM7\"3T^0W038@W<2:DP2&[=U&S;QI8
M!)'+0 73-9Z#1Y='-I]3L+)$0XN3A(ZOA'TK>D\H)3R?%H)Z>5)2\!A4NI[G
MR#\_18*7^H638JH_.@9K1Z&+]H4ZA)T[!#3 .0[(.04?3J9_^A@\.Y-7N[5?
M.[9GNXH,[=@.:A [L+[*<LC>JT^3L)$/HG7'2!I,0AJ<#3'L,JN7L"7[\FA
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MR\>GS4QJ:;;%.8<9BC$D+!%FLYP*F">(LAQ32E+E0SQ.O4Z->M[,"[%Z6F[
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M)E$DF>90"IL$CF -\QASB"1C",=$4RR#9)^<ZF:A$?@&E"*7<WPK=&\?W<O
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M0+Q2SC."*,CPN3'>Z(,R,"6V]6FEH@*-1E4.JY9.-GM5HY7-]U\=5-V 2K.
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MF'7(8'$#:C3 [8'S0 5(N/7F1<8QT (UKNRCKF@O,BR'2^#+"-%SKV*/ \K
M62NPD;:28&VDN2_O(HM7S[MGS%)>'FG_P=;R[M$^651N4N^656Z#?Q@%OVR4
MO/VJUNQ>O?VFUF)>J _KN5 S)A*5$*(@%M9-(1$YS&/%(2&8L"R/:18[I7QZ
M =FGMEXVLD)6"0M4+2UXM.+>5 &2QO[^?KX$<K58L'6Q<ZWZP7-;-.(WXKB+
MFN;(#[WILAK!*EE#6V_05ASP9]!^L%8>E-K?@%K_&U![AIK/H\+@!C0H@!H&
MT.  2B "[M7&'[U06[L1)1]W)SC^D!QM'%] A!=:,QMAW"B1HYSG2<1AE"D!
M2:HS2(5 ,.(LX7'.$AP[U8A_&?'_="MG\_>)K)U^W\I(R^=@7\"?:07=@O#G
M7$1[C>%4UE$_X?]<2VFO@0F^FO:3HM^":K:YKUGQY<-Z]74NE7SU_&N9R*G.
M\KZ\OS6;Y*_E>?%,192@6$J8\01!HE0*.8]BF&4\)I0HC;3TB;1U[]IK(1LA
M&M>>>@DC.GBJTHP!W<@,V%9HO\7*8QS<%IIAT!UXD;# 6JE!([9=$+[_M4+Y
M![ 5'MQ>AMF;UOT1"T3)'AV/2J?^@!Q288\6>B8#J"Z\3),?5HNYS3BP=86)
M,<\BQ06D3%!#6QA!IA():<)REID?N?8J"W&^JZG9VSM)02-J[QQ''0"[\5$8
MV ;FGYZ(^:<AN A&J-0$YSL:-UW!186/4AA<?J,?51P84[\\V5PD=[JTR(I6
M491=GC2MHU1R#"F2&I(XSR$C-(<Q)AF1*<I1&OL0B*\ 4Z.5HVU\.SJX *N^
M=66\!\:->(:$>V Z.MK15L+;&]=*_'81GQOP9KYXLD\/P5A]40S$8][=C\IN
M?<$YY+S>[?1,BO#PN%@]*_51+<I,*CO?H":;*54:QY&6$''KR6V+_^4IYI#G
MF$1*I#I+O*CO8H]3XSJS.S=]+?S+P[AC[,9B09$;F+8:6>&Z$K;MB7AS,=^N
M?TH$5VA"Y4:XV-^X21)<U3_*EN#\XA4)VEXQ\;N21RD,DR3*"=$15 Q%D.28
MPEQ&' J<9C3&64ZH5WA<1U]3HY2J%'8E:RNK88^L;F>P==R/A4%LZ V9E1(>
M@35 "D@'/$*FBSO3T_@YY+I5/IE8[L(KUR19L?Z(/QE!;=F\^?+)V#IWC\86
M*H_%7RF]6M?^7)_9-U6\_6:L(-/'?,G6S^\VZJ'XQ2AN"^Z9)=N\^FYIYK,J
M-K,D4FF*N((2QQ(29&P9SM(,*AHKQ1-&9)+XG%P/*.L4C[H/\T3Q4CF;#\_Z
MD&[8MSZ97H89:3?NF\CX#<R=>SZ^P$Y_L%,5['1MQK-^OE3W!NRK!QK]0J>G
M&700@J:W&4;2%TB/,RCDI]/K#-ME3U>B\]&S.HYPGL413#A&D&B&C'5JMKU)
M+%0LD/E_G'NY_?QI0I8_G0A1_JNGV\VU4<E_BCCDMI#_TD0AGXY\&.0\;K1P
MY*D$(/N'' \69&RX:JU8H=ZHZL]WRS+LH*:TY7V=<ILK@;',%!2*<4@P9Y Q
ML^6E'&&I<Y8SIMS2)?MU[#1+1DVB7$4@]<E>[@BUL]D7"K[1++A24/!](_(/
MUMND@G,K-@B=)-T/IW!&EDNG8]M+'D"<,'U\W@Z3V'@7%)_Q*$-Y'L$X2RDD
MG B8QUI 1%4>)TE.<^Q4'^]B3U.S83I3&U^7MM@WY4 0S(8^K3^1N'B0/ $7
MP1@H=_$+1?A?5/=2]N)K8_/+%'G-'>)_K.;+S=^--?IDOIV91CK%Q@2!FBAM
M-CA)!G,M*<0BSZ3&2$>)4Z:3\UU,CA2V-^?_:<4$7VLY/5)@GH:RFPC" #0P
M ]38W&E02@C^'@H;CVR@5V,T4O+/<]]1J$R?G3AT)O8\_>9X>3P[)=]+V]G]
M9!^2,^*QXLO=VFRX-_5?;H79\A5S^S5\M%X5=_K7HLZ0=\<W;+ZTCJAOOXDO
MUBO_I]7.+'MO;;4[OIC?5Y]M&E$=*YY"I%()28122"-C5E&SB8NR#.$$.97)
M'%S2J5%NJ0Q<:?A4- 6XP:I6R&YC5*T2T"LSH;:[F46YXUEMU?)AH2&_ Q>B
MG\CH#KU>5)J!N[4]X=J YN\M54&IJUU2C+9-3?M&7_!N"1J-;>J1UE:V5!K<
M36[P?5:RB7P$8RV(]>"O+GT,US-!L#5VA!'J7JJ'%&#$%7\$'/<-AS$Z[!E'
MQZP5<Z=W]UHS13B-;6FI),N)+0TC(+<U\_((2YS)F%.<^1S ''<QM16_DM :
MQZNMC)YA<,<PNIVT7 ?.T OF%I?6K?LPARSG<0@5K';<P;A!:6<5/ H^._^D
MWQR7:CY[N]S,-\\_S1=J_9IMU/UJ_3PC,1$JX@SBG"60I(Q")C"!FF*:1:D6
M"7-*JG2F_:G-[DI$4,H(&B'=IO<Y!+OG=@!<ACX[]8+$>3)?4/S$3"Z4^,O]
MZNN/YLUJ$IL?=G/W7'NC3-P+RC2S]M)CPP9[O6+%7,RHX&G,$C.-B62V&I.&
M'$<4:J9CADF>4>;E]^'5^]2F>RE4F8BE"NSRS+[BASQ&C#$D8Q@;0H4$91QR
ME6,H4LRS+$]CKM7,M,17+XY]6XKAT'</L@,0\#&'RLT>&PS^@1G=,^2N%'_\
M*+L]U$8.L:OZGF1\W1XL?8/K]AL9.TU9^9_/IM?;I?Q@OLQ?S+?Z9O5@]K$S
M8AW7619#9-@2FK_ED-.$0"R4Q%J)7*9^7HD#"#FU1:R4%%A1P6^5A)YY#P89
M23<*?>GQ&9AI?89FQ!1=E[%[\41<'2+^2=)M708Y7%(MA[YZ7#GN'R,>GCS6
MD7A1ICF3/(61R UCHSR#+#8_93B.DP2G7&*G P+G'J=&OW<'9_GKXXL CQL>
M)\P=KNE"(SDP41[>CIVZ6KL8#]D338][K]"HCG1_Y?")AKIW\D&H\_[(J:'Q
M[H%\]-J[S_%Z\=J"8!TE$P_*26&.!2$,09';K+^$)I JP2"74<1TE,8H=O+X
MN$*&J1%YN^C48:G1WI6^W$?$T6 >%N>!:;X-<6=IU[&J>7F#&+R(E[L$+U2[
MRQNB\R6[_)OJ8;5^5ILU^YM:JLU<U"M\GO$T(11#1%-D;-18PSQ/!&0"X12A
M2"'E[MYVW/[4B*PMH8_M>0(Y!TOS.CP&)IQ2.%!+U\>"/(&)A[UX'38C68=[
MGTLH._"\YIU6WXG7QK/QSLN\9]%U/'9-6I R+ORC$FK^U7+A3)O-L\A(#BG.
M(TB40)!AKF!"!%,\1YQ(KPK3)WN9''6Q;T"JQU4QWU2UC]=;4?VC*D^ ZF9D
M70W5P*S6SF(!=A(.D'>L$XF@J2<.^WB!I!%GU#R=[N'<P_THP![X/9D)9F.X
M'RWGUVL-CY&2N680,V%((,(,,F[H(,>:"(122JD7"9SI9VHTT(CI.>?/H>@V
MZP-@,_"\;R0$6Q$'2!)V 89 D_Y<+Z-.^PNJ'D[\2X_WC&XNTS;\K#9?5F97
M]%55I1GO_EB:S__+_/&#,A^/L0'OU0SC3.9)3&QJ4@9)JA"D1"@H&=:1C',J
M,Z]*3<X]3XT>ZE0D#Z7D8+X5O;@!JT9Z&PXMO&OZN@^&&Z<, O' +%.C6PD-
M=E+?@*W<8"=XP-AI7ZQ"Q5([]SMN;+4O'$>QUMX-],R!NBC'5LG3]Y=OO]D?
MU4Q((A6)4Y@S:4,%1 ;S"&&SLV&,I%DFE?#*U>#6[=2HJTS8 WE9^4NT2X2I
M2E[/%*ENT+MQ57A ASY-/E5%;7=;;DNH=6/JGT#5"Z)0N53=.ATWK:H7$$<9
M5OW>[KVE>IA79L'M4E99^>[5TE;9F/$DBU@2:8@2E$ BI(*<&YLJ9Q1E:9Y1
MZ1>VU-'7U BH)6IYP"+:PGIOM\XB[+SE"H';\-NN/<A>.T'69^-U"8QPFZ^S
M/8V] ;ND\HE-V,57_$.?ZD3/STT0I76@FB4)YIAG'$J-*20L%S#'*8*IEHHI
M%B&:2-?8IU,=3(T:&AEW@>M62O?HIY,@=A-!"&B&MC+\4/$*@.I2O5<$U,D&
M1PN!ZE*G'0/5^5S?N,6/ZGYN4U\N-^5WI[ 4298J&]AD-AE(Y)!*L]V@&"41
MH9%.I5/UA7,=3&WRUF%Z.R$])^])$"]/WFNA&?HLPP^5'M&+IU6_(GSQH,&1
MXQ=/JW,<P'CFN8%"22X4$VY%MG26+Y>4\5RK%&IC_T,2<V[H@'*H,HDI9B15
M,9L]EN6(/VW8>N-F_(\DO<^L.M1AN EVL=X]-Q_*TN;\ YR9-X4:I^Y]H"^&
MT2CBF4 PU]A6U<@QY!JG,$&1HA&S.=1%_<6\73IF.)[L]])H\()?BZK"/?^,
MGXK;CG>"@S_B*5U;Y_91G2V!??(TSVI^ VK=;_;C4H_"6!L$0 G!B(%68<=L
MK-BK0%)/*QPK[%!X1V@%[KZ?.?7>-+$L5.W\H'(F4IE(B'%,(<F1@HQH#;,\
M5R+E4<I2KS)T>ZU/;1=4"6>7D+7ZJI9/GO<I^\BY,7IO/ ;FW5JN 3Q$3FH<
MB+7VVQZ56TZJ=<@ IQ_JX:9N)L)J;8%^/O162E&61=*8FSG1QN8T<Q<R+06,
ML4",I=9GW<G-H[N;R<W<K:!E29Y24@\_[?-P=L_B<" -/9UW^'AX?_D Y>'7
M'@2PD=S;3WU8H;S<+^+0Z>Q^_NWQ?-XO:K#G^G[YZ1Y,^)H57^S_;9-?V:*^
MV?F9K7]7996I71'.68X3DN2<PXAE"A*NK">LH<8LCT06BXB83;E+D4O/?KVX
M<H2"E9]M'\!F!KTI_UM^V+4*-^45Y<-6"U!XEM_U'1,'?AT&Z8$)UPH,RO^T
MQ 9&;K 3W+NVL2^X'IP\#,@CD72)LS@$^^R7'(J__3'K)'2/YL9C>'\=]RB_
MQ^O]=JT?UC:A[N;9YB_9F"ZV*\S[^5*5)3)G*8F)(E+"6%)L+&.J(4?<_)2E
M228()YF? _3E+J=F)3<2@U+DDHU:UJ 5&Y1R>V: <L#>;3,<%M&!&;X1]J9&
MD_FCZ;UW=@<HT(;:H<-1=]GN !QNO3W>[,= -J9SS1:FZ5OY,%^6]YN;^5=5
M^R/6VR2=9"S2BL),6NK)909Y8@Q1P4B:B$AQJ;W\F)UZG1H/U4*74X;MB>U'
M/&Z0NW%/<" 'II\VAOL2-X[+ YS=>8$4B(+<^AR5A;Q@."0BOY?[<=''ZOBZ
M*2AN*_K^8[[Y\OJIV*P>U/KM-[%XDG6!3?,_^9E]FZ5)KN,<<XB%K>+$(L-,
MDE.8B)0EF91$$B]FZB'#U'BJVBGWN@OH,P)N1#4PK@/35BT]L),*-/*#/XP"
MH-' 1E[4.H!&"1NM'H[&KH P$*GUD6!4BKL"HD/"NZ:IOO17*//2%\.Q;TSG
MBU5IZ+4N6ALY/J\^J+5>K1]LV1M;>KAX]5PFPOPV+V8,R01S)F">HA@2I+@Q
MU3(&F<AS'FF6".6U7PPBU=0HLE&JM$-::NV'4FTG^F8%:MW*2E:5=C=UCENK
MG^?6,\Q(NQ+OR.,W.!6/-70]"#H@U,$H.X1,(Y-X0!B/:3UDXWVC]-:/]DI)
MO5HMY>XLL=[X"9631&$,M:%Q2 1'D I#Y2R5*:<ZC2E._>+T.GJ;&C%OA07<
M2.L=F]>%JQM=!D-KZ)N:+5!6T-:=S"#941PP"1:FU]77R(%Z#FH?A^JYO-0W
MWN=62O,1%:_-CW?KSZL_EK,HT9RB+(%IJA*S_TVQ(0J$((Y4IB62).?$+^3G
MJ(^I<40=WU++:=9Z^S>SMEM9?6-_C@'MIHE , U,#KT0ZA$'=!:#*T*!CML<
M.1KHK%+' 4'G'^WA$O+)GJBI^[EXMURNOI9WSS\]+>7;Q;Q,&5L>M,FY+7TX
MTZF(,LXTQ#H79M*3S&SO2 2UDAGB491%RLE$\.QW:D2PE1S,MZ(#;60'JA:^
MRC!22>_AK. Q%-UT,2#  U/(#MN=U,"*#1JYP=NAL?5P!!D&XY$<0?R^XU!^
M(/Z0=?J!>#0WGA^(OXY[?B ]7N^=#7=M2R6\4=6?[Y:W0JR?;,KP;=[-#^RY
M3.<::1TKK2644MO]H6"09O8_B<RE2!27V.O&PZ/OJ2T =4[839D3]K&2T3MC
MKC/P;AO(@> <F.X;J<'WC=P_&#(">TEW/UP N$^B75^HPJ7?=>YY[*2\OI"<
M2-7KW40/<[6.]"H^KV[%?SW-U^K]:GG_6:T?=FGWK--<>716E3N8L301,4\8
MS#.MC-DJ8\@I3Z&(4TFBA*=ISF9+=6^S9#D8KOX2.$TX6DVXMAS#S3LK,C14
M^=#.Z%D>;:^LV/ZUM'H,BX,).Q#4([F\U<*;[2^HQ0=6?F 5:.7ZK!R=2QV\
M"N#TQ=W#O!T6_Y',W.TX;%: U>.P</K^0YF\_6'L-'U[-#N>"=Q?YSU3^(IF
M^J<R7"W+U*&OV>-\PQ9515][@;/^JN1/J_5/3];T?E<43S9QPBSG<92F&8."
MQ]852$60,HJ@0(CHE$0D\@OZ]99@:N;QKL1U75V<?67S11E68.]"Y[78_0N,
M^X^1ZR7,@,@/?C%3UG,OA;\!M?A-C?%&@1+_2@70Z! VJ6(O^ *F6O3K?_0$
MC+W@.966L5]#_2AQ6U:Q=KHL;GE1WE7/<!XG#&-C3Z<DM0?"*>0H3B!/N$PB
MAG">.V5MO-C3U"AN5^6SSB5=_-6/PLYCZD9509 :F))V(#5"@M\:,0->$U^$
M(A"]G.]G5!JYJ.XA75Q^H6_J$\;GB_*:^1<C>E4.:?L94\TE89C!!$<$DIPQ
MR&(20QKS6#">Q$KD?JE0.GJ;&CWLMM>+G=B>#-$-KQM+! -M8*9HR7D#=I(.
M0A=.F 3+L-+5U\@95QS4/L[ XO*2OU?)Z]57LUUKOF62)C(56$$BE(9FSV03
M__$8JEAS1G""8N24(?ZHY:G10BF<RT=] ;#NR7\5#(/O4AP1\/(*.:EM+U^0
M_99&\P YJ4#;[^/T _W6[9_8?/UWMGA2[Y:/3YOBO75'Q;6S(HHCG::8PSR)
M(TC23-BIJ&%.:$P9B3D17F<9'7U-;7*6L@'LMTAW8>FV1 =":.!Y:Z4$I9@W
MH!+T!M2 #>#XZ8!)H 6ZJZ=1EV<'E0\79Y=7>E:9*@]2=RO^+,[3+"8:0\64
M6::)C& >91AF.8Y3+1F+S=L.N8#.=>#%!:,E_=E=$OA<AYT%T8T/KH%F8!*H
M1&L;Z &K/9U1.U1=I\/FQZW@=$:YHUI-YY[K-XW?J,>U$O,J;^I2WCZLUIOY
M?U?7?IHGDL@L@5ASZ\JI4\B5-;RS",=4*#/CO:(].OJ:VD+?%K5*JM 2UF^.
M=R'L-MT#X3;PS&]+>0/,WQ9JBUY;Y)(;'M<K^20ZP?2F!P>8 C%%5T^CDH:#
MRH?\X?+*E7N&BJ)^5JQX6BMYM_QH0TW6\^7]*U;,BU^7*V[O(.Q=7VF5F'\V
MVLX7E4ROGLO77R_,>OIF]?^U]VW-C>-8FN_S*_C6U1'&!$"")# /$^'*2VWV
M9E5Z*[-[8J(>%+AFJEN6/)*<59Y?OP O$G4A!9 @S9[=AZZVG21QS@?RP^V<
M[SRRY7J1IYBH3'* <IM'HE0,"%$,Y$+@+"&891+V6G $-G1N)%;8%Q4&1K^5
M)GHF X_6I9[KGE?LJ"GF2ZY]U'^1-!* H5=8H<U\G>792&"WKNW&:L]O&-AM
M]XN?E^OEX_-CM;D!E6!2$0YB21# *2. <H@!U%!@*9.<,>;"VQ=/GAO15L:Y
M<>LE3MUD.,C[D=FKLBO@]DZKMUU48VYJT(SY[4@QE\^;A!-:W:@_XO8+1M&G
M^J+^V/]H#/O'@JL$93"G0'(;CJ$8!!2ET'RC*>9QC"%V^RA]&Y[;-_OK"!I4
M1Y3=YC=C8#?R%^^@-A7]9@V/"LN#*ICX@36-KM2QV3F)25V X:D@=7E_ST*"
MXIN2SROU21?!MV^JP^%BOO+%3DB.7TR6:AHC0H!46@"<0P&HYBF@A%&(%(89
M] H3<V]Z;LQ46VZ#8\N(_\IXK\C_'EW@1EKC #LR;=W"U'!6$7L\"G/Y(Q:J
MY)A[P]-6#?,&Y*+PE_\3>C+8GNT+[:5/^OURS<RZB:T>-KMEL7U6QUJD.949
MA3&@-#4+'<P%X"3)@42((R)8JF(O73N71F?'6K7-]A,[6!W59GM'M'AU@"-S
M!89U;,X:CJ@_57E %(JD7)J<EIX\0+@@)I][^THMO3-3M*_+]=>?MIO?S:1M
M\_C$UB^+G!.%5(8!@PFR*:P$,,EBP',,64K2A,#83V[I:CMS(YY*4*BV-2J-
MC2IK?467KD/;S2\! 1N94GIBU4-^J1.) 1),UY\[L0Q3IW.74DS=E_?<[]F\
ML-7^I2Y1:*8?.,D18$+F &<9 UQF'$B12R@3$N?$26GMZM/G]L%7QO54$3_!
MS7&;IB\:8^_%5$"$#ZZ[ZG&H#9639T^[:W+-K8NMD:L7]=7.J1.0K3SK&RO8
ML]E6I^W5*\A5K)G-C(LSK@&FE &:Z1SD.&."B510@?PD<VXU.;?ON9&E[2N0
M<Q-=MP\\+&8C?_5-48CP)\;N4 23N[G9X,0J-ZX 7(K;.-\Y:,RO4O06<:)C
M&FL%S!!O!OW4C/<$83/?%\AN1B0<QUYA,:>/GQM+U(.=5JZU'5M@\QKS>X Q
MT:!?619\S#_S..R@7S_\-4;],\=:AOWSJ_JH3WUC._5I71?+BC'.\C1A0&+!
M )9( 8X%!CS1*4(ZYUP[?:97GCVW;[2P+D(^TD2G6'5_FP,1&/G#+)TWEO6I
M GZ&@X_\4F\\II)6*E^*8#I)5_WMUD ZO65"?:.KMIYJ%UV_I+\NT?*@=V0/
M=I?KKVHMEFKW=KD3JXT-$//<-/=ZYHP^QX;=10CZB>71T?11MM%[@190X<:]
M[<G5;;QAN:9LX_\0_UC&XQ&C+6QJ-P3VWS;R.,F__*M2OY@7LJA_%*>()()0
M(.*8F%6]D( H:7Y"4"4,I3CA3NGJ0PV9VPSA:/5=9&WT*E$UN%>Z&6]*K"?;
M(W"#V2L\,P1& Z(Y!S4_6?!G")":L:)!GC=8P\<0;B$I]FVS,O?ORD87RBQQ
M8F)C2!,> ZPA I1"!G062\%X%@M"?#)_;S7H16K390(?K2XF'(5J867WGR)5
M6-Y;W><Z\&XSN)!PCLQ;'\\P?->-VA!=GTXHPDO[7&_NM=1].IWO$/CIOL\_
MG.'+EMDZI9]?'OEFM2",$(BS% @N,<"I(H G<0R@IC++!-&".E4/N'CRW&9!
ME7%1:9U[B,(I7-U?_R 01O[,'?WW"CNXZFNO0(/3)TT66G#5@68PP?4+^L80
MO5^N5"G"NT "29:8[TXI;)8H"N5FL<(4($SG>4ZU2J!3GO^UA\_MTZLB8*R!
M46FA;X10 [C;7^ 0.$;^"#V0Z!'_<^GR@*"?QL,FCO2Y=.,RO.?*-7U.#93I
MU_6>?353_#>;]6Z_+?41/F[8>D$I,D.C^4)SQ;GY0A,-:"XSH#BB22+B6&6I
M^QE"1TMS^UR/MMH@6-&P-EH9<WUVV+OP=3EW"(3:V*<01\ ^Z:AI:/0Q(& ^
M!Q2!@)OJN*+[C0MVC.& 2O>A1M<#)CSB</#C],##Y8:^6D9\_Z%X8A&$H;:/
M"Q3'-$NHS3[G9DG!( 0$,PRTUCF,I4Z3Q$MA^+*)N3&FM3!:'DR\BZPXF:]B
MT06.;CL-P] 9F1D+8#XT@/G2!4P/]:$VWX.)#ETT,+'64)N#EQ)#K5?V#:/<
MFYZT90W+#*_C.<\Q>1&G@N.,"Y A(0#6L5F_")P#6W(PUFG*$^*5@^70YMP^
M_:/)O<0(75!VXX' V(U^6'* K4H&;9X.CY(1Z@%0L##+VRU.'&?I#,%EH*7[
MK:%JGI;A8<MCQ4T<9S+&5 *4,+,D8S$"5-O@;2+B%%&"%1Y8ZO2\R;G1356Z
M,=K6=H8J<WJ!M2OKA$1P=-*Y6M3T8/$4%4W;X!FMD.E%@Z]<O[0-@-ME2UOO
M["F=N%PO]^KC\KNMA'I*;DV!QBHX]3\5V[XW;^*"X3PS"T,%E+25$6*[9XL,
M!Y%84HR8P)![I7WU,V-NO&1>Q-Q3YK ?_&ZT-#ZH(U-5Z0 H/(C.)TMW12"Z
MV*MSD5?K2&0]":AF. C)4%J%_8R85HEP$% 7.H/#GM8WE/52E:@^B'YI"*;K
M).,29Q@(F!* $\GMV94&+-%ISO($IVYG5Y[MSHWSWBJMC&&R7U*L*]ANA#<"
MA",SW'4=L[OH8/4X>O:>0 6+#W9K=>+(8"\H+F."_6[O&0C'UK)*T$ARA/*,
M9L 6[P58R!2PF!+ &$D1$1HGU*]RW>'1<V,6:YEGV-H1)C?"Z.?\R)Q@C1HA
ML_[2UU"Q9L<'3QM5=N'01?S8Y15#L^EW]ZM5(?S5_-.AX*Q4DB(M "*PT,')
MK8A@##C'4,<YTE#0?AGU7<W.[;MMF'@7&;LKV;N3[/&>DER._>"Z:Q,:W=%W
M;D( .R QWP6GX,GYG8V^4H*^"Q#M2?I.=P_8/BYB%595'>ZB]O;]?K]=\N=]
MH4^X*?[V(]LI^<!>[,7WVZUYSXK[=@LH$JT@Q""E-B:/20D(Y!!D2 J$(59,
M.(EYA3-I;@17!")'FR>[]BRCQ7_]_-==],-R78;>[_[<8Q]Z6*=Y[%-/UA53
M[&.7SD2E-U'I3M3T)]IOHK?+U?-^^5U%[[16HA U+*X$A9=1Y6;4]#/PYG<0
MS$-NC@\S:/K-\R  7MU<#_/D?FS]CFW7R_77W8/:%LT4+ZJ21W57I!@7, 9Y
M0@P59UH"C@D#,J.4HRS6"'$?*K[1WMQXMC(O4I79T0^KS6[WY^C)3'H*HO6C
MV5MHNW%H0 Q')LC:TLB86A+>751#.L8\T1&90#1VJ[5).<K1]7,"<KTM6"B!
M$FI9E./9+:3,,TRAMB*M%.!$98 G2 -))(=29D(CL5BKK\P8U#N.X-B>TW=!
MR^^BV>JH002;YUJC@=41!6IGV$9\*\2>S&^U_8,#"QK(]XXI\$3S=<,)CL:.
M&DAPB<EX,02-MEX[?.#2;8?(@2LW]2WY4WXE]VOYUM9UWCP5B>"5S!G6A$I,
M)- J1F;68I:2)$TRD"C!-2>Y4-@I9<2IM;G-66IC"U:11W-]J_UT >Q&(,%@
M&YE 3A!K6#J"SIP+(L&*]W2U-7'%'@>W+\OTN-S4\S3+\I%-Y/[P^+3=?"^7
M4C]MS=Q^05',8$P02%(D 29( 9HP!#1*F4Z8>8.DUXJGO:FY$<?!TFC9,-4,
MI6+U+%6T5VMFOHGFOWF>C;6#[GA6%@3*L<_.#B@VK;R+"CL#GJ7=Q"+4V5I[
M0].>M=UT^.+L[?8=_=CCT_8K6U>1/S:-:[-:RKJF](.=OU>)>HTR&(?2&,<C
M(@I5@DA. %4Q!)C:?(U$0D 43(FT7*.\CNJ"6#4W3FHZ=1>=N%6,UDW'3DO%
M''WK?=87II_=N&WRWAN9!J?J.&_B# IT((X-8].D=!P4QG/F#OOPGF'I=87I
MA@10[S+3AWBL9AUXD4,$M50 IU;RAYCU*N<J!DP2&F<JS[GVRJ(9W>*Y#0[6
MX:CP..(OQX!%UXKRK]3M;N/!K#ISY+%B8#_ZQ])/A6VHL/O1[9TV0G\J^"^"
M^2=KN(<&3D/:]T37UPQY1:3.Q^5:?3!#W&XA$Y;GBB. <F(&#Q);47VK.YG+
MC/!8PE0XC1M^S<Z-_)L:UZ?ZUL;T*B[M-VM]5)CO(TCOWA7=7#X>P",3\BRP
M]9#9&07CB31W'+ .)+OCC5*G!H_[TZ83Y/'V\$2=Q__N@2N+8ES9?;2;VW&5
M-(!%G.:$0Y!*I 'F* -<"050DK-<:H9C[75RU='6W B]L"V*>T[7KV#I.=$>
MAM!D4^2[J#3T+JH &R%1PP&3T%/;*RV]SJ2TW>76Z63'+3T+KQ\B_FS!5+7>
ME9L?Q["_'U\N@P)_9UM9BA(?]8=V!7%]^<;6G\I8X9_,(_:[#^L'M5UNY (Q
M$<M40H!HGME2#3%@FB*0T=Q6369IYE<[=2K#Y\9=I03F(:RW..XQ]BK9/R1[
MLG? C2;GV+,C<VXS0KOI=#-,VVY87(WDMJ[?51KN#>6U735[WAO_HPJ ZF6Q
M)ZU1"4+ FO83=UN@86$RLR<=8Z;NC/,!:_+V>\=V[;=+*ZM1I+G\=;W<[W[]
M_-=ZAIS%68QLP&C&",!"I8!BCH&24A)&4@*EE]9=9VMS&V>.QI:L$Q7F1C_8
M[!_/\:4;9;=!(1AV(S-Y$[8B<ZH)VQ@EQ%UP"1?FU='6U&%>M]V^$N;E<)._
MTO^;4O;@_7(GV,H*L[Q;R[=LKQ8YQ#F&9DU-.!, RYB9.6^6@)RI7'-DUMW(
MJ>AX5R-SXXW*SJ@TM-0G>F>#'8VM[C4 6B'M9HM00(V]Z=D'(Z_J += Z%4E
MH/6ADU4+N.56LVK S6N#:\@=-Y1S3>(D);&9*F2YF3D(JUJ)8A#GN<8QRM*8
M>45VNC0Z-R(H;8ZNZYGM>FSJ>_6 XXY<8%S'WIKKDHASA#2D'%S+-OZ8XF\3
M[_7W <%#V"W4/O\O:O]A+3:/ZN-FM[O_SI:K,I^WRO1MU!*KLNX66B6&BC($
M4I1903<D ,-(@URJA#*5V#6.#T-Y6S WNC(.7.3>LK/<>E%FWC=+#D8@DJ5#
M?B3FWV-NC#9J/XQ,;[8+2N.C'SX6'7!PP*)?ZQXT?#CD^(:CN]X !N(^__8G
M)<+>\)RS8O\'!94?6"BB<TQE!A(J(, HUX C0X2(B40J+ C-O4(C6]J9&]W5
MN?'VT$!N5BMFJ.P@->"YO],&+884"YU:[79" 4YS <PZF *E!4J4@C!/X.*[
MVO+-A. VVYMV-#G ZS>NC-I%;H-* -A''CHZY!]&UWP(/ "TM3('C8<V,K]U
M>9AZ-.:C>O>'S1 T3?VTV<C?EROS[C)*888S %5BJVK2') \44#&>::XF=QR
MY5D@XG:C<R/SBXHT=]%:>69A.X'-:)I)@C5(LRP&F%@1?!(G0%"98I@SRN/4
MIP1Y<+ G*$-NJ9UO-O^(OMN C!% =N/DT-"-3- 7NQ5WD07RAX/-46UT^\@V
MN/Y/%T8C%0"ZVN2K5@#J N%6":#.>_N1_%]WZI-^M]LO']E>[18IY'FF20Z8
ME6'$F2V2G#$!$IS:BH*<:*9\Z/ST\7,C;F.=C>11M7U^;'(&G1MO] =D9(:H
ML#B8=A<];%9+\1+]5OW_*"7"KL,1B S.'C[I9W_=L?,/O.6JGDOL(G;C9[7_
MMI%-M=>U_,MFN=[_S?SR;"4'ZW1EG:80D20!2&N[](X)8!(*D)N)A4J)B(5?
M2*!G^W,C@RJ"J[3_1.C89C$7+D2U#[T3S7W[R'&!.![R8R\< X/NOZCL!UVH
MQ:9GZ],N0OM!<[$X[?F8?B1X+__^7+7P97,OY=)&K;'5 UN:QM^PIZ59H11K
M9'X>'?>K,H;NEGOU66V_+X4J(]QL,N#7=?&4(@)\ 5-IUV (Y,P0)M:Q "2-
MS4),XCQ%!&<"0A_6'-O@N=%L&4-;.&,WWHZQMNJ&!-?K=+<; <^I$T=F[/N'
M#V_N;FE:V]252JI1;[;1F\UN'S5\"D??4P$?B.]'-W?2 6(J\,]'E,G:'9CU
M5V6<6T-MR::+1//=::;Y[C0O_9!V7A(129-$*\Q C'%J5N8* Y*+'$"(5"PH
MYH+3Q5/AS^<]V^[=1I]1;/5AJW.+QR.NH]H$VT=<?5VN[9ZY7?/NOZGHJ3L=
M8\J.%B).L9E19(1E]M@. 2*X F9>H52<(HEP4G7TN[6C7/),NKFV=Z).5F8)
M,;ON=9M0O'J'C3R+:&:Y-EPL2Q,VG:QR8*-3-^^B@Y]1X6BCBF'YV!%29,?H
MBM#)M4%M?)VTW#%@;DWH':6QGDJU1ZF:*G9Z05"<(T12@-+4COD)-VM-F0-I
M]^W,\ "A1#[G?9=-S.UT[XMM(ZH*64:KH[V> K276+KQ[C"$1B;-AG%WT9O0
M=5K;70^E+WO9P+2ZLJT.7NC)ME_94T?69E&69WCU^\B90JG2$C!E9O'8RL/R
ME&);>0=K*"'.I=<^TF43<]OY*?.AZV^[C)3PE&F]A)$A16.>,B DB4M]19HD
M F1:2BDDU#%-?"AR((R34>1F###=.'(81"-S9/F2U3$.P4FRW?=0 K&7#4RK
M]MKJX(5T:_N5/43QWK*7;\_- X$J/9G%6N<YC8'@F;93( @(,A^YP!2EFIAU
MLG;*X>QJ9&Y$69@9_>5O'F)K;?!U?]&A0!GYFZ[P:!X&WD[E=L?(0WXN %83
MB<V5F/V]P.Q[:>N_!E*7NP%"IY9<V[W3*<?=L/Y$)^[6M3TUG\0W)9]7ZI.^
M+M-Q+4^^$.>X%_OE=[/:_%*D:J@_]D4TS@+K7$N1(I!G,0<8\Q@P;G/=<Z6Y
M5AE#F9>27&#[YL:NGY\?']GVQ>X,MHALU'YXRC@%[E:WR=@K=M;(K'_SB/&J
MUL?=H?>BWPK7QHE;&PGV4*)*@:V;5CMI'&@O)))&:J9GV,KC9KNOZB!\TN=Q
MOPN=I#A'A &4Q;: )B0VRT*#7.=",YH*[AETTMG<W!B[::VE[>5YOH5GS$@W
MUHX1'\$0'#M>XPR\BTR @,$83IB$"J7H;FS:0 @GQR_"&-SN"I-O:\\KQ *I
MA*(8"J"9S&RY3 EHDIG_<)A2K5/$,Z?5=&<K<Z./PJA1TCA+4%4&F28* 3,/
M-Z!JEIOY=TH BQ%+(9&:4S(LS]8;UG^>+%L^<N>XL?E@P$<F\6OYM86-XV77
MGD P4FYMV<:K9M:>N'DKK_;TXJ&K_Y; Z&)>N< 4,4PR"#)D"QMS0@#G2(%<
M2DYS+CG37C4#W9J=&W775D>?=-2>*E N]#PS,1S[P7<5'@K=L1?7-;";(< .
M6#:[X!1\-=S9Z"LM<EV :%^[.MW=4]1JL]Z8L9C9\ABE5$Q5D?F0G(0Q4WF,
M<C-]%!K@7"I 5)H"2/+8GFJ;E]!KX_%FBW.CI_*PT4Q>K*U_[I?!<!MF-PH*
M"M[([-.T]2 Y59G[YU'2O)S1"24C=;.]:66C7-V_D(EROK''F>_/RY4AK,U:
M5=N[N^I 3D %,2,28%O[#,M4 TH4 S)7,N48*R&)\YEO2R-SHY*#F=%39:?'
MR68;D ZGOP'@&9DLCLC4)O8Y_&V#R./P-P!4$QW^7KY,H<Y^;V#0>?;;=N]T
M9[\WK#\Y^[UUK;].^;OUWLS5[J4T7;VK_N_C<JW0(B-2(F%5DU*% 8:$ TZP
M ERIF,2YP#IS6NQUMC(WQBL-C2H3[^H?(FML]&GMH5;>#FPW 0:#:^S=G[Y(
M>6F6WT2BEVAY^U,G4RV_Z5A3MOSVQ?U64[;.H)TOV2R#-\^&6!YMF<$J?< 2
M $EBGME%E"& G*6 Q%@"Q6%".4MTFFJ?E51G:W,C@K=*J^U6R6BKOJNUKZ97
M-[!N:Z=@<(U,!+6=99I4;6DC]RG<@LD)DD"+I>ZV)ETH.;E]ODARNZGG=K%:
MF7_]>K^6/[/M/Y1=AU4KL 4BF"*D$)",Q0#S3  6FU]Q KGB>9YC/^G%]J;F
MQAB?F9F;%0HQC[6EGIN_[:@Z;O@&P6KL3=[2R *H@YG1NQN[5/Z;NC>Q"+61
MV][0M)NW-QV^V+"]?4=/>F@(=9=[P0N#&F$QU0"+# (L<0*H2"F(E2))GF#$
MB?3)B+ELPHL.)LN(:1XL_RE2A:6>K' )IL0$0JI2 !&7 ,?4@,DE!3EB(B4Q
MX41)?]6%89!.)YGPXT$E@3/S#\(W#?,*H$FJ2"J1!#!5!E#&J)GI*@AR)3*!
M,TFEQK[J!B'@'%^:P+00%$G'@6H0-F,/4 WC_E2?0]Z?Q8T\L+ I7.V(A!JF
M+AN8=GAJ=?!B6&J_LN<JE^V^V?_9AWTWD[2U3:"OXVCM/Y@1\/0/C2L_K"MI
MV[?+W=-FQU8_;3?/3^8.\[MQW0R:STI^*D\C-NO=@F M8DDQR"4WHQU*.>!Y
MQ@$E&L9Y0C,AA#\W3^G"/%G?^E3,&87]01V]*_ZX/4;=VW^_.Y72Z:.S,NE+
MDU%I-Z93(%ANEDH$,D 54T ("AF$D"$L?,>?>;\RXX]LGB],)<LS^U?%<>]H
MIIT_]E94T95%SS?\.4G**2^QK\#9'T_O.& 0U2!$!0K%G4T<HB,0 ?>Y7J'[
M0FV;36GZM+MPK] I%YMZKV&#WZQKM]TO'K8;^2SVG[:5HN']'\O=@L5,<\0P
MR)!( ,ZHF10II #1(H5*QUP)IS#_M@;FMA]8V5@P1F5F])LUU#%"H!7([B$@
M!#PCTW0/9)PI]);[731G[FU0G/GM2&^MCYV$@FXY5=/$S>MZ[N==S45LI+W^
M^'*\I(I,*+(2R^7;A[4AI"+"9%?$)G[YQM:?G@J.>;_9:K4LI+;_0RV_?C.D
M=?_=$-!7]9-Y^-Z69CZHHBUTEG")90Y8FL8V LL02"(5H#%E1*<Y1LKK/'(>
M;LV-MFJ#065Q5)A<E"&/F@*)E8^!:M'-HR]<MZ]F8>R,"+V9%=^$I)D:'_&7
MZP+=%IB[>I^M@4U4!C+O#3I1!<_AK;, W44U1%'GJQIPDVY6_1YJ8W >3DV[
M&3D/G]LV0.=E7=^8P@]K,UPQJTN@S(/901L/DI@AG0$("0989QD@0C) $I@H
MDE!)=>X75GB]H;F-JU6\7,-82U3LIAJ<'[K= UA(S$8>4OK"U2.ZL!N+ 0&&
M+0^>.,:PV[W+,,,;U_<L/[!<F[GB1_-,>:XI<"_$\^/SBEDR:H@/+*!(DHQF
M&.2,I #CE &>Q1(D/,%,)9S$&?.9[ON;,#<*:9@9L8:=G@KR_EWA-BT>%^"1
M^:8T'A367\J16 &G(_;W+MC[2[KWAB^47KN_ =.*L?<&Z$)IO?^3AN;7/VQM
MZMK^Y<&\??O[=3%G>[*3M3*S6P@N>*HU0$EJ9D>)S&Q!%092&.=9@E&F8=(O
MP[Z[X;E173/'OK8\*DR/C.W1P?BA:?8WNL-Q/V $D,??@BT,O:M 95Z@#DBQ
M=T,H>)+]C69?*<W>#8SV1'O'^P?L^I[$X9@6+A:>NZ,V9)JGA,N$ I['RG"7
MR $7B0T"CQ'-$FT(S&O"YFO [#AL>.RG;Q=X[%^.!.P4.XWGP7G%.=+EUJ*5
M"AE%9K,G?"$W['R:GWYKK0<X5S?!^CRG']G5E2'?JO+_/ZP_U0H#5>V^@_(%
M1*G(,PZ!P) !G"(%.*(*$&GUCU@NJ>(^-.?>]-P([LTWNR.YBY;KZ*B<48I?
M%M]DHU+.O_D1GT=WN%'>.""/3':'<J4_U&;_V6)]L#RJ3!]%G,0?L4#\YM'P
MI,SF#\@YI_5X0OC=ML:BMLKV^4_%ME],YYG59X80RI(<9#+'5NA$V6UY"IBD
M.$$HISKV2M[K:<?<>,Z\HEFX/;:N#AB^T18(UM?<;;LKL@'%^4[;760]B0I7
MIMEU<\!R@JVW+BMFL__F )7/)IS+XP;606Z44ZOJ+<I/Z]-*BA>%%T_K+AZ7
M73%,&>)2@C@5J5GYLA@0E0FK.8=B2&&&L9<2^AA&SHU4&Y/'8ZR&#<$_UDPM
MJ[3;P-2O=E?*_+A;RBH\M6?5W)"][DC6K]R78S-Y(R2LX6%=/U=&F_5E6=S+
M6KIGI71'+9,Q9H^$+IT;TL37J9P[ LBMA7/':*N'A.##UCS:6,%6#\]\M12?
MM%;6 +M-6U>0DY1R0170>1Z;$0,K0!/%@(BY3A#/."/*64WP=GMS(W]C,?CP
M\*DX?/#0RW, MIN41X!K](,:RY"%M5%I;E3;6Z#71W;0 48/!<*P<$XD1FA?
MP&4%ZU,)ZZ:&]<E<&4J:T!V<3I5"A\=,)UCH[M.)=J'';?VF]A>94&?Y3]?_
M6KWP&&:4(HU!G@H,<(HSP$G&04:R%+%,,H@RGRG\$&/FQM:'5-KS/,GHM[>;
M1[9<>QZ_#^HHMUGW5/"/S/X#D/>>%H> +-#T=Y IDTYS0X!V/IT-\LR^%+HW
M+Y62=8V1ZIO+848DCP5(,Y4!C&@,>*(I2$@B,WOFC[E7W8_KS<R-]IHA?[6E
MOD1W%4Y7"AL*TLCD5!MX .?V7+0'*76!$(QNKC8R,9%T.7I)$9U7]_OX?WQ>
MKFQZ>/66)H3GE.4Y2%%L/GH50T 210%!PJJ/89U@KQG1Z>/G]K'7UOE]X&>0
MN7W8_8$8^8.N#1OA.[[N<Z#O]^SADWZWUQT[_UY;KII;.O;?S,S#GL8\%"HX
MBP0*)JC@($:V[D6<)X"DJ0+:1B)3"J7FZ6*MOMH1THT#IC+=Z:.BY4?5=&"\
M;^N79]OS]GRC<'!W%Y46%[/[G=KO5U4F=9$]O9M-^O39*^'&<+/JYO]I*=#5
M>V->E8=NL:H9Y3=?[[;99S"?F?T_)$?Y>F=,EX7<TG[?$@:V@&NA&5E-PCC-
M(4II#F#.,JL[G@"62@6@5IISJ6.N/<L6G+4PMZEK:6 UKOC6*3A'SXW@!V$R
M]IY9!8<U;H29;*OKP>H.G#]_XEH#+>Y=UA=HNW!P"=K'I]7F1:E*P*B%B%9%
M5Q55RNT1[M?U\K\-#Q64\F:S:R9%, PSB10!&3<S6(R5F<9RC %1B<ASF4N>
M>E6$',W2N1'+Y^?'1[9]*2:MMI^O36]N"?=/W->.\],Y]."$$]+#1/,X>M_5
M/2>K\X4B_MCZ=6>C+I\/68#CQ.",W@/AR_0&MO.U*ON. W=',>"1&NQ;FL*L
M]8_YO01I)G.> UY44I 4 I8E%" :BT1;\66"O8:&D\?/CL]KZWIF39]BYTBU
MO1$9FQ^=P>@AYG_-YV!"_B</GUC$_YICEP+^5Z^:]V;G;6W +$Y8GD(-%&;:
M<$5F9I"22L!RAO,X%S#W6U?.QK.YT92K F7+!NI\I2A]W[AY;;;^?T%*E]W8
M_TFJE#W[_Y]L6_?_&6W*GMWY6AO#8RE4'F,HBL*N[TT/7*N5>4@P5P03@1("
MD&*Y&?<3 0A$&9"$4D$5CV,A_8*?G-J=VZA<F1W9-S:Z7O/5)0]]4%>X!DX%
M!WCT2*H@V/:(KO)"*EBXE5NK$\=?>4%Q&9#E=[N_J.[;*C'B_SRSK?G>5R^_
MJJ?-=K_ <<82:95(I,TDRF(&"),QR'#*DL2L4 @GKGJZ+6W,C8IJ,Z.#G5%I
MJ+N(;AN:W0P3"*.1V<0?'B_1W!L ]-++;7OF9%*Y-YQJJN3>NK3?;*1,?*_$
M=@\#7EP(<G "&$XDP$()0 7!(!$8<<G,AT^]8C"OMC*WS[LRKU(2\E0.NHZC
MV\1A,#HC?]BU%FT-T!A3@DX, DT KK<QZ7#?Z>;YX-Y]<;_O_:#\\]$J 1TT
M#WXQYE=2[B3E2 NES7!.E1G84PBXX!QP9CB!)VE.$B>A?.<6Y\8#1YVK5:&"
M5<N)>8HHWD;:C1V"XC<R4QRA*XP]2C.\W$5'@\.QAC,V@1CD=GN3LHFS^^?,
MXG[CX.BX7S8/K-I75II@PE(%8D&%F57D%'"%8V#^KH2!6E'J=>IYM96YL4D5
M%K:S5MY%ZTWTQ+;1]T)TYH>_?G[;^[C@.L1NE#(8N)%II!E*9XG#ECT/O7W=
MB4'XF+I&&Z\55W?I9D=LW96+>RB2W NQ?5;RU\T+6UEUE ?V8L]F:S&2.$U3
M'L<@YC;/@^D,<$DTR"5)9)*BE+@IFMYN:FZD4!D;':R-*G,]U#2ZL>TF@K"(
MC;W\: .KCP9)-VH>\B/!T)M(><3_E?-3'''"HU-LI/L)T^F,.'ER(C'B=L>K
M"P>^82MA\\K-C[]N5JOWFZT]'EMDN4:$L 0(E'. *42 IF9N1A43.I.$F0M>
M247PNL5S8_-QM.AL0?F#]]%OUO^H L#SF&O\5\AMVCFK%V/D06M&[\1K"A5V
M]]/\5 M;[/UGE3#LAG]$/<,;#?L-A;:\^*\VRJ,H0X]%QI.8$<#,#V:XLO&0
M&>) YDBG2B,MW$1A3IXZMR'%QK(N=_NE8*N:,LJ8X>YR]1VP=5-T;S!&IM&>
M.#A3WE6_NVC)W-"@)//;D8Y.GS4)95PUO_ZLK_]CSPT]MOMV)OQT(1=U^H?&
ME65<U645 K%ZMN(4[_X0A2;SKVROWFFMBEHG/$X)5H 3E0",H !$, YR%N>(
MLP3G'"[VFSU;.>X43FJ^%YD<G!CO(SK6\Y#->AZB%GDK?E!'ASTW(J=]-1QW
M.&?;X6-OG1I7[BYD^^ZBH[-1>8GM^+,_GMY1HA!=*09S%QVPB&HP(HM&5,(1
M<)/V5;HQU.[OM,9/NZW\*AUSL5_].E;T&T*+HS9;6>S#X]-V\[V8Q]3*?%F6
M"$1Q#EB69@!S% .NI38_40$I2CCWRP?L:&MN,]V#J=&R8:O?$-0%K=MX$0BP
MD<G]B%73S!'$)AS@"$2272U-RF@.+I_3C\LM?63\OYG'?OE]4W,#X[G.,3'8
M)04C($!93$">*D:04#1-G;CARK/GQ@6%=5'L(RE_BI7#J5=_!$;^N$OGC66]
MI/5/<?"1T>^-QU22^>5+$4P9_ZJ_W2KXI[=,J'A_U=93=?OKEPP\:VILM=AT
M@HO-OMWI;M_IUN AG.CZ#&M!\UBC/!9 (!8##"$!%$,)),T4SPV_I0+U.F\:
MT^JY467+FE[;8X?O=4FKU4E)*W$L:24"E+0:]1WQ/%":2\]/>*C4W TM,K8N
M#X]V%Z='%R=.C?C,]O7^""=+4W18Z-.E46U^G1.F*;JA]91IDL;#U"-H2/*_
M57HIEOM%JG6NF20 $JAM[45L%^\0$$)CGF22()@,J4UPV>3<AJ!FG0(5I$[!
M%9C=!H*PX(W,XI?U"WYH0ED9')!UW=$9J;#!E09?M<A!.P"W"AYTW-D_4EYM
MA:U.Q9[4MEJ_*4Q2&1LVR3.;^Z]0 F@F&= L@XE$F'#LE8-SM96Y\<G1R*BP
MTC\>_A)(Q].BH?",?:ASALQ(\K*M$ 0,A[]L8_)P^%8WKX7#MU_<<XGM77WZ
MO;EV(22,88;,'"-6'&#.-> 98V;*035!29)#'7NMF7N9,3?&,&\8\5R]]H/?
M<3DZ.JACKR\+!T#A071T(2I\*)5;B\/BIC=WD74DLIX$7"<.0C+4PJ^?$=.N
MY 8!=;$T&_:TH0+<'<V7TI\\5QKE*3:3(66G13$")(X%X%! I3G-4NHEB>3>
M]-R8K[8\^J2CTO;H^E>[ZZFYZMXI;MPX#M0C\^$!Y4V-<@LWWD9Y@%*U*V#!
MI:=O-OQ*6M*N@+2+0SL_H1^E5>ISNR^;>_%?S\NM^IEM_V%6DN;)G^TN5A%9
MO: TIB0F#%",J9G3F9\XE&:*ER1<<**%$-"OS)53NT[?UZ0UJA[,@XI#/O.9
M/1XLCG8'D_VXRPU]-]H*A^A$A\B5O=%^$U461T>3H\^W(?4F*B^( G&46YN3
MTI,7#.?,Y'>SOXC;N_5^N7]YHZQ"W.K#6JH__K=Z621QD@I;L8CI) 8X5@F@
M7%"SJ.24(2H@UDXJ3ZTMS&W65!H9559&A9F1L=-=O^TZD-U<$@2>D7G#&QDO
MZ;9.[WL)MUU_XF2R;9T.-47;NB\<6$NB%+:U:KB;M66/(L]'921&3,1 0,(!
MQBD'C!$,D)(94BQ5F?*3B^]J;78?>"F>?332*V'*#6#']4XHV,;^\'T1ZU^5
MH@N)T$4JKK;U.C4KNMQN+6'1>5,_VOBP_JYV>_OP#VNQ>51FX:/,F[1?D PA
MG!,(<DTS@"E%@-M?.40X213.D5;U.N2+.W&TM==C_?%EDH"JTCQ;R\&:ZRG'
MU(JN&UT, FL:ICB:&)4VVC2@TLIP9'$+AT \T=K,I!1QR]ES=KAY_<"HSQ]?
M&B$Y[[?JOY[56KP4@Q[/<@6S3($L%X8CE!2 &9( ,B5IGD">"^D5[>+0YMSF
M%LV NX.AO>87+H [GCB%A7%D!NF%8/\8P]N8A(X0[&CQ=>+[;D/0&IWG<&NX
M(//=(;BOBMM(8BV12&.@B-T;)10"FC(K,6_X)H[S-"%.TG ^C<Z-<([1OLU@
MW]T5Y9CA$=P7'>#)/X%@'?M\NQ$_?80P?#"-#RPC1BE?-/GJ0<9M(+C$"+?>
M&SP0QU ?^_MF^V;%=N62/U9:2)%1D"96#C]'!) XM96<8:*QC!,6^RFDN;<]
M.U+J/@;E+U%A?U0XT&]VY-$QCBPU#MQCDU5(I$-&X+1A-G[8S47+<XFU:8/$
M(\"F]1$3UR^M:J*]^\-&/N[L"=190;3J7]3#=BG4 BFBT@PCD EIE0MB#DC.
M(( 9%H1I*#+H%Y(SC=USH]5#[5%6%6]4E;71DS7W+MJ4[M5_+TYSV<Z>F/]L
MWHUO48+N(INY^KJE2#U?'L>M]/F]$B-3?X RHH="H0WOK]0(K1&("@AF4!RT
M7Y^]=NE/3ZO_.0I[]NN*8&4[>S8_- CUIKV[-H/+<$B(,PVSC(%8)A!@K3C@
M.E& <J((A#RF2O2+41UHV=R&O&8(:V%VU$UXN^C'EY,+3QAO:)CKT&YW',I>
MHS/''JP:0;(N ]>N<^0:,Y V$.;!XVR'VO5*8;B!X&R/T@W50 \-IO+\_6>U
M_V9SR^MCMT_/^YU9M5EYN%]5D03ZP+;[EX\;MEX('B?$UC5B2AC>)QH"GL ,
MI#&&$M(DC863+'&_YN=&[E58R6/A0;0\N& 6,D<GHFWIA2V)9"Y>&3\\)(_\
MNZB;H\<'?II0GM+XJ'%<WS _JNR/"@>BCV-#[B%$-2KT$VE5]7WM0XE;]<:P
M4__*_ZG3263U]OA$1:O_4_HM-QK'&H74R1?SF/*D@7"B<:Y!JBD&&#,(&.((
M,$P55TQB#97/ZJ&MH;F-%\W0@++PA;6TU_E!*[9N4_00B$T81^$.EO?$^182
M@>;!K<U,.JV]Y>SY+/7F]?Y)&G6![_?+G6"K(KO6_&6WT)!G@D &H*04X#S-
M (DA DDN<Z(3GJ;<20RDHXVYT<&AE'QI9Y5B;BUU3]5H@[.;!@*!-#(#],#'
M*V'C!@*]4C;:GCE9TL8-IYII&[<NG4+[HUC#?E%_['\T#OQCH3*EF!8*4)@@
M@#.: 9Y#!7A&*14)XRQ/QU, .35F;G31W()ZM]LO']FY2D54^6&#IR[.TL>4
M$#GKQ<$!"T'[YG4C&*[V3[G]%UEWHL*?:6(:G&%]%6V1,U/F$O7@#-HPG9&6
M9_;CX%_4WM:!>-ANOB^EDC^^_'5GC3@41+\7^^7W(MWVGN_V6R;V"X(TI)H+
MP[SF/Q@I!0C/.$"<(H1BE3#E)<;F;\+<^+8H%J-7F]]WD7UAHDUM>L0.MO^;
M'ZOVZ!<W+AT7[9$9U!A?5N:IS;=G)S]8#Z+E^L_1P8GHZ(59!E9^!&3._B &
MXLL>!DS*DOT!.N?& 4_R7W*^6>Y?[K>*O=E(M9 PX=JF]Z2:<3/#5!00,ZD$
M,1><,8IB1)QFF.</GAU[V2U::UQDK7-?4)Z =7L5V1>"D2G%T7NOY>(U5WNM
M$4\>--G"\)KYS=7@U7_O-_WX2:W-=[RZ7\M[^6AF0?8+-M^SJJ8Z"Y+DB%!$
M0:[L*B^V:;B,(Y#&7"NEXIA)Z#/7N-'>W#[-RMRB.!T[,=AO-G$+9K>I0T#P
M1OZHF[B=VEHOK,+-!1Q1"33PWVIMTE'>T?7S(=WUMH%R(!^7:_7!_+A;9"*#
MC&,!(+1!V9!10(4D@$@=YPQ3FOGEJUPV,3?B.%@8_69MC HC^\I^'(%TXXEA
M\(Q,#9[(])?WN' ^M*;'L8'7$?*X<+!5O>/RRGZ?=K4E4B]X:9)3E5(,4A8K
M\UFG C"$&$@32AE+%"6QDU[7]<?/[9/NLS=[!IC;Y]L?AI$_W5I:=(0%_76?
M WVQ9P^?]&N][MCYE]IR5<^O5(C-LRTHRU[L3J49YC_MOZFM^?/V6<FZ4(U9
ML+]YWFX-.RP09:E94U/ <\%LSI0 !+(8H(S$ B6(:4%\JIO[&N#UI4]0G_R+
M;2-BE1?14^E&,9G=6$<.=<R\I4"]N\:1,48$?&Q.J5%^:*!<6!]5YD<-^^^B
MRH. S-,3NU#<Y-O\M.S5$YP+?NO[G(F33<NXNP]KP\/%>?NN,//+-[:NLG]^
MV131>$K^\ES(4G (,QE;71#-"< )1(!0K(%4-$4RQC%-\>*I* EF9F/;O>/Z
M9BK[?8C@W(L13QD*VP[Y&[MFP/!=]*/ZNERO2ZT1<YM018IID5:ZFRJOU/L]
MB:E4N9(0,"TQP%J:%7"<IX#E"8P%@U3DNGI/WJT=U;5G_);4/KS6._*N#&S^
M)WI!'%?V<^SRL3<,AB<?5V'P#?>K*<;> '!,33Y@8'XL4)A!_G'?CGOM#&1O
MN_\Y<I#[=D>P+.3>!O2;2?WXO%NNU6YGK.3+=6'DFT/9YC?-JLV' JCUTH4J
M"C.40Y Q&)LA#^> YKD"7.0P(SDB,?9*/.YORMQVDBJSHB<;6F2(S QB;;6P
MZ\6GW[ UH-?<QJ%I^F+D@:5V(FIX81:8QYXX<>2D-G7P5>AP0 ,1_@!#)F7P
MX8"=4W* )_8, =RL#P%KI9!N?2RL19*J3,2 "5MVE5)#H21/ $H(I8(@2=11
M"=M]?ZZU0:>/\TP*>[+]N'+KK9\:=CO$;GPW#+&)8O,:-E:*V-$/E9D!BS??
MA")4A%UK.],&TMUR]R)>[N8- X_5/^G/^XWXQ[?-RMR\*^>#AQ,FQ*C60DE@
M^($#G- 84)9G@&0XRS.2$DA(KY/VKE;G-K\Z'C';[8&&V7^J5X(.1U@#.L'S
ME#X4M),=W ] M?]QO@M*H4_X.]M\G4-_%QA:XP"<;AXLVG_X\7\M#0]NQ;>7
MC^J[0:?()V=I1I-, 249!1A*;:L!48!XGJ@$\YPPOZPQIV;G1E -)>V#L<7!
MUR_W?QNJX-^%OALQA<=T9&8: N<0.7\'=,(K^G<U^EJB_@Y =.CZN]S=0S+I
M+7M9/?_E;U8=H]*0SQ."I=#*BL$2@'6JS#1)8X"TE!H+DF?::7)T_?%S(YG"
MP.@O?_,5U;G$K9LVAJ,Q,CV< '%;7=\%$0\9H4'(3"03Y/:J^$G_M/K=*>US
M>==TTCVM%I](\[1?%3P)_Z?M9K=;Y)PFB*<Y(+$5^^>< \JQ!!!RI3 E.4=>
M49:W&IP;CQ5&18)MMR]%1N>CC20)EB)?8NPX,0J(W-A3HLY4][NHL'>23/83
M9,;/5B^;FTM&^HGS'EGGI_<%S2PWK;*UN)[!3&&.,@K-ZHP+,T&2YB>"(009
M9VD*"6-I[+5[Y&_"W,CG/+-<UZ8'SRSOZA?'3>I1T1Y[][H[L_S@Q"MEECN
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MLHH7#YV\KF*;6]<**[9>Z_^1?S28KQZ^;=:JUHC$1,?V> UG>0HP3^UWC6(
MD4X)3\TR"#G-9:X]?&X?=6%?5!AX2T/M-G"W/^(A<(S\\7H@X?71MKG<ZV.]
M>-AD'VF;&\V/L_6:0%NM#UNKU+%_>3 =M[]?%]IJ3_:219(HPFE,@8!6NTQA
M83Y9:$9FA&..$RU2@@=NMK8V/K_MU@?SH&]L9V:V&QT]5787$U]5&SUP<[6]
M)WINKPY#]_4V6&N[[Z+"\G(9]^XFRL-W66\"-M8^:WO#K[O3>A.0FWNMMY_0
M)ZM=:;7=*OF3F;#L=^^?"Z';QHY@@@QQ82W-9 -A@#&G@'"5@XQRSK0F,-5.
MQ4%=&IO;Y*,V-_IJ[8UT::]/HO<-<+O)*#1D8Z\N:K1*4Z/*5I==5W_D?!+F
MPR$X5?I\?R0]<^K=H.G.L+_QC GS[=V\.<V^=[RG9XQ.5;?]D[Y^UE^$K50Z
MNU6HT,M90?4T5E!SGH&\T!A)# E3FN2 (A5CSI.4^!5,'&[2W%CZ\_/C(]N^
M'%3$*OWM.CSOQ3,&:'B7N4TQI^V(D;G_9FQ1Z<C=H5.BWPI?HE&VL\-!&RHV
M:;A!T\8Q!0/P(N8IW)-[AA:<:FE^M&H=:4R2&$$()$H5P"DN-LI3$&=)&J=8
MYTHAGWI55]KP(LT))'!/LNM.BMP;X#W#":X@ZD:! W$:F=,^78C??NQ,1?0/
M'6AW/U3,P)46I@T6:'?Q(DJ@X])^G_JO:J>L_)M9*K^U G";8K%<1;=6":!4
M41$K"@$4.0,XMW5T-.: Q!E-H,0Y$5[IN YMSFW^5)M<; W)H]%^+. "MALK
M!(9P9)8X0:]A;QU%/4*RK0= @7C$I<5)><4#@G.>\;FUKU#2[U5].L-F#]O-
MVOPHBGGP[F&S6HJ7\K_'!0/E0E'"4J P-R2D,PXXB0D0B5FC\APFN?242?(S
M8'Z,).P7Q X^V$."AA/1>K./7I2Y0FZ>]DKZZB5Y=H\;;8T)^L@<9DR/CK9'
MI\;?1:7AT6_5_X^R9.N+7C"1),_F)Y9(Z@?.I4!2S^<$5Z*\?[2EBOZ[6&Y4
MU/N+:?7+[VKU7?V\6>^_[18"90C#!)FY&+0*!(@"CK$&-$TIARJ3"?93(!AD
MSMPXTKS".)AHI4MWN+'@=""/S(F=@I=WQ>Q.V C9IE=WT7^:J47T:1TP=RX,
MH./K9+H8,Q<530_@/#0V?9XZ]#CA'=O:BK6[![6M]]&6PLYHEZMG6T3I=$.:
M8LH9I2G(""( PSP'5@(8<)9#J5*F4[N_U><,P<N.N5%H[88].2@,+]=PI>F1
M%9"LW8N,?V4]T M)I3>;Q\?-NOS'J@Y&WP,'OT[U/648K:O&/EIH]-)E?]Q=
MZ;EICA9ZX1G\/,'/BE<Z1.@%5?O)0;_'#4DQ^JS$\[;(7?J/Y?[;YGG_JV)R
MN7IYJVP:S')M6SSH\MP7@N(+(:&$J<) 8YT"S!(%B)0(2)K()&4)CS7SSSCJ
M8<G<:/>7S1H\LNT_5,FANX-'??*(^O2,&W-.@O?(W%EE&1V=B'XOO8@J-Z*F
M']&Q[LU==-\MB]\SQ6@ G$$SCOK8\0H)2 /@NIZ/-.2!/8(+Z[W6]TKMJC,
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M^TD(M> 550SL]Q)D ^I_,_8!#\]RC8;'9%=:\WDV0:$O2D2YO+A^6^F-+?V
M"%=:E,2X(]9%0Z@/P;&,.X1OFPUQ"$!VI6W8&*SWEV*]J*B! VJ#KSNI6!6]
M\4A_YJ7;'$-V J>,<,>-]$D("3V"K:G79/UH_V&(':.*!D!U>0/\SE^42U\4
MV<J96]T&;_ Y<E)':UDFA@N45R[SH1+@.9V,5XF*8'UMC.U,7#.0.PH-MP_(
M7E33 .8NFQL\GYT%/ &*FI[/IJ5/#HJN/& ?H[[6K^!73%XVU!DI!3(8BC%%
MYG@N@#'$*0-$)*&TCX+*7#NK>3BUPYZS/:'R1,IK *:7+V)F%WZR(<61$\*
ML8;D4A@IK<ZE-;0D+N=R49!!Y6WEA <:POM(&386Z,_L'2WV!M!3-D61Q3_&
MR\_/SQ?+V1G,[^R('!/PB$Q0QR614862!K9$4Y19IDKPK0/D#GK$O0-=PR9
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M_9<Q^ET;;(UH8$Z4O*RA.N*.<IY8JAB)N)^LC,XGMJUK\D$/H1ZE:NC'[;V
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MY3&>TQ[=G-H7*#N0U:AU.Q0*.S=C/$PO#4!MY;["_(J5WZ#DC$9>16JSP&-
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M=I'9#U-:&@'/1IX(L\:7(U(33]$%-3ZY,I2*B52[HNI?I:7[8K;'TM(]U-]
MW'&C  [/0IEC9B0X)+L,W, S*"FB-/.),DC)U79A?LC2TGT@L*VT=!]]-(2E
MRP%_R7IMT)D)RM$B!D4\<^AU>1$9IZ4%;.V43K.EI7MI<GMIZ3YB?8)U@]W@
M1V"^] 6-JUGSSGL@1B-QE'I*]6Y-EWNJ&SQ5Z>E>:CZR;G ?F3=@9U:F%C^\
MJMH&H6/$D(X*CH)2)=''RD -%E5$4VMDK-XB:9. 'Z::[XA3ZW"-- "GPP5W
MS?8TW=Z^7&EG(B<FE.G6RACB#.W>"3DE&'6J>A_H/O@8UB0> :MJUP^5=-P
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MDCOFWI1_4/CMVCY@V!J3H$1$&E"@TN&!!!@\0 J&:DHIU.Y8O(6<'R5]M!=
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MDVX\AAZ[+J6]-!VJ\)*P*!!&D>G0T@ Y,PEDO7V2R#_W*1_D1A[TN(FCD='
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M:ZLN-((%D-OM+E^Y(U=\^NMZ[N+@^7\!4$L#!!0    ( #2'I%;94[N'20@
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MTM_;Z_I3]1G;NLNVPK?+I\U5%QH"Y(79[O*-ZV_EI[^)Y^X$7OX;4$L#!!0
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M9ZMJG)_-Z75@OB+F[P'W;/NP9_XM5-4(^:QPO3QHG?1*>X5!3A5:/9-2+Q\
MW9.[OL';V"LX>ZC61<K6L +C(@6G8 +2^P?ORG.;ZY\,^7/]$S)<<I;!^6W#
MFF89Q_'U.?AM+<9<XV[I/O/%I>*(H4 0C^ </5&_[ O@V7;X!,[[YQ>%K$YO
M8L4$-NUK]NA$XX[?MI_Z=TO('$F^UH^7_,DA2'VMSF/LR=#I[U!+ 0(4 Q0
M   ( #2'I%9VAXY3^50" (P%%0 1              "  0    !A8F-L+3(P
M,C,P,S,Q+FAT;5!+ 0(4 Q0    ( #2'I%:%<?]Z;0T  ."%   1
M      "  2A5 @!A8F-L+3(P,C,P,S,Q+GAS9%!+ 0(4 Q0    ( #2'I%85
M3#US]!H  '3\   5              "  <1B @!A8F-L+3(P,C,P,S,Q7V-A
M;"YX;6Q02P$"% ,4    "  TAZ16:]A5#E\O  #&!P( %0
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M,S$R+FAT;5!+ 0(4 Q0    ( #2'I%8*?CWST@0  (L2   8
M  "  4>Y" !A8F-L+3(P,C,P,S,Q>&5X>#,R,2YH=&U02P$"% ,4    "  T
MAZ1640?H-,4$  !T$@  &               @ %/O@@ 86)C;"TR,#(S,#,S
B,7AE>'@S,C(N:'1M4$L%!@     +  L Y (  $K#"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
